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Polycystic ovary syndrome (PCOS) is a common reproductive, endocrine and metabolic 
disorder present in women of reproductive age. Despite the widespread prevalence and 
heritability of PCOS, the heterogeneous and polygenic traits have made the successful 
identification of candidate genes difficult. Animal models have been developed on the 
premise that early exposure to sex steroids can programme epigenetic changes that 
predispose the fetus to the adult features of PCOS. Past research has modelled ovarian 
dysfunction, endocrine abnormalities and metabolic perturbances in rodent, non-human 
primate and sheep PCOS models, through the enhanced neonatal or prenatal exposure to the 
male sex hormone, testosterone. 
 
The modelling of PCOS in a large domestic species such as the sheep is advantageous due to 
similar biological reproductive function as the human. In this regard the sheep has been 
extensively used to model PCOS by the treatment of pregnant ewes from early to mid-
gestation with androgens such as testosterone propionate (TP). These experiments have 
demonstrated the fetal programming effects of androgens on offspring that go on to develop 
PCOS-like characteristics in adulthood. One of the caveats of assessing steroid effects in this 
way is the effect of the placenta in mediating the ransfer of these hormones. TP is an 
aromatisable androgen and thus some of its effects in the fetus may be attributable to 
placental by-products such as estrogens. 
 
This thesis describes the development and assessment of a novel model of prenatal 
androgenisation. Two models were compared: the indirect maternal exposure to TP (the 
current model) and the direct fetal injection of TP. In directly treating the fetus this allowed 
control over the dose of TP administered and avoidance of secondary effects that androgens 
may exert in the mother that could be transferred to the fetus. For the maternal model, 
pregnant Scottish Greyface ewes were administered TP twice weekly from day (d)62-102 of 
a 147 day gestation. For the fetal model, fetuses wre injected twice while the ewe was 
anaesthetised with graded doses of TP during the sam  period of treatment as the maternal 
model. 
 
The effects of prenatal androgenisation were assessed in the female fetus shortly after 
treatment and also in young adult sheep. Fetal ovarian and adrenal steroidogenic gene 
 
v 
expression was monitored and found to be altered in response to elevated levels of sex 
steroids. At d90 the morphology of the developing ovary was not changed by prenatal 
androgens. In the adult a detailed ovarian and endocrine assessment was undertaken, by 
examination of ovarian morphology, hormone levels, ovulatory cycles, hypothalamic 
pituitary ovarian function and follicle steroidogenesis, during the first breeding season. In 
addition, the metabolic effects of prenatal androgens were monitored by measuring body fat, 
insulin and glucose homeostasis and liver function. Neither maternal nor fetal prenatal 
androgenisation during mid-gestation resulted in a perturbed hormonal milieu or polycystic 
ovaries in young adults. These treatments did however programme a clear ovarian phenotype 
demonstrated by the increased capacity of follicles to ecrete androgens, independently of an 
abnormal endocrine environment and disordered folliculogenesis. Furthermore, animals that 
were exposed maternally to TP developed fatty liver and had increased insulin secretion in 
response to glucose load. A major outcome of this study was the finding that the fetally 
injected control animals were phenotypically different than the maternal control animals. In 
fact, some of the reproductive and metabolic features of maternal TP exposure were found in 
the fetal control group. This unexpected finding has r ised the possibility that it is the fetal 
exposure to stress, that is secondary to elevated maternal androgens, rather than androgens 
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The endocrine system encompasses a precise balance of circulating hormones that are crucial 
for homeostatic maintenance and the control of normal physiological functions, including 
reproduction and metabolism. A series of tightly contr lled feedback loops link these 
systems together to form highly efficient processes that maintain homeostatic equilibrium. 
The hypothalamic pituitary ovarian (HPO) axis is an example of such a process. It is the bi-
directional passage of hormonal signals along this ax that regulates the timing of puberty 
and the whole sequence of events that are required fo  initiation of regular menstrual cycles, 
implantation of the conceptus and the maintenance of pregnancy. A separate set of hormonal 
signals are released by the brain to stimulate another endocrine gland, the adrenal, forming 
the hypothalamic pituitary adrenal (HPA) axis. The adrenal gland is a major source of 
steroids, in addition to the gonads, secreting androgens, mineralocorticoids and 
glucocorticoids. It is particularly important in the regulation of physiological stress, initiating 
the ‘fight or flight’ response and maintaining kidney function. The metabolic system also 
plays a central role in the regulation of the HPO and HPA axes, which in turn, can finely 
tune the processes that are involved in lipid accumulation and fat distribution and contribute 
to maintaining normoglycaemia. A major role for insulin in the control and maintenance of a 
range of metabolic and non-metabolic tissues is realised with peripheral targets including 
muscle, fat, liver, skin, adrenals, bone and the ovary.    
 
Dysregulation of this delicate balance of hormonal signals, which act in a complex manner to 
organise congruent tissue and body function, results in pathophysiologies associated with a 
multitude of endocrine, reproductive and metabolic disturbances. One such outcome is a 
common disorder in women termed polycystic ovary syndrome (PCOS) that can encompass 
all three of these disturbances. Dissecting out the origin(s) of PCOS, whether genetic or 
epigenetic, has thus far been challenging, particularly due to the heterogeneity of the 
disorder. This literature review will describe early mammalian reproductive development 
and adult reproductive function, detail the current k own aetiology for PCOS and treatment 
strategies, and discuss how the ovary, adrenal and metabolic systems are intertwined to 
produce the features of PCOS in women. In parallel, th  various animal models of PCOS, in 
which the female fetus is exposed to increased androgens in utero, and how these contribute 
to the current body of knowledge concerning PCOS, will be described. 
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1.1 Mammalian reproductive function 
 
During fetal development the gonadal ridge and meson phroi (primitive kidneys) form the 
urogenital ridge, from which the sexually indifferent gonads arise at around the fourth week 
of gestation in the human (1) and between 23-24 days in the sheep fetus (2). Primordial germ 
cells (PGCs) migrate to and enter the gonad around the time of gonad formation (3), 
proliferating so that a large reserve of germ cells populate the developing gonad. From a 
founder pool of approximately 100 PGCs (3), as many as 250,000 germ cells are predicted to 
be present in the human ovary by 10 weeks of development (4). Gonadal sexual 
differentiation occurs soon after the establishment of the germ cell population, at 7 weeks of 
gestation in humans (5) and between d32-35 in sheep (2). In the female, primordial germ 
cells, termed gonocytes, differentiate into oogonia and undergo further mitosis before 
entering meiosis which is subsequently arrested during prophase I (6). Oocytes are first 
detected in the human ovary at around 16 weeks of gestation (7) and while estimates of the 
total number at this stage vary (8), peak oocyte numbers occur in the mid-gestation ovary. 
However, a great number will degenerate through atresia before follicle formation. 
Primordial follicles consist of an oocyte surrounded by a layer of flattened or squamous 
granulosa cells and are assembled during fetal developm nt in humans and domestic animals 
(9, 10). The first primordial follicles form at around d75 in the fetal sheep ovary (11). It is at 
this time that the majority of oocytes undergo programmed cell death, known as atresia. 
During the third trimester of pregnancy follicles can grow as far as the antral stage (Section 
1.1.1) in the human and sheep fetal ovary (12). An illustration of the timeline for gonadal 
formation, sexual differentiation and the timing of primordial follicle assembly in the sheep 
is provided in Figure 1.1. At birth the mammalian ovary is thought to contain a finite number 
of primordial follicles (13, 14) reported to be in the region of 1 million follicles in the human 
(7, 15) and approximately 70-90,000 in the sheep (16), although some reports attempt to 
contradict this dogma (17). Primordial follicles are quiescent for much of an individual’s life 
and will either have one of two fates, being activated to progress through transitionary 
follicles stages until follicular dominance is reached and ovulation of a developmentally 
competent oocyte occurs, or more commonly, follicles will undergo atresia, which will occur 
in the majority of the follicle population (10, 18). From an estimated 0.5 million primordial 
follicles present at the beginning of menarche in women, only about 400 are ovulated during 
an average un-interrupted ovulatory lifespan (7). 
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Figure 1.1  Ovine gonadal development. The developmental timeline for gonad formation, 
PGC migration, proliferation and meiosis, and the first appearance of activated follicles in 
the fetal sheep. 
           Adapted from Juengel et al. 2002 (2) 
 
 
1.1.1 Follicle development 
 
In the ovary, primordial follicles are activated, and undergo transition into progressive stages 
of follicle development, which can take weeks to months to complete (7, 19). The oocyte 
enlarges over this time as ribonucleic acid (RNA) is accumulated and protein is synthesised 
and it gains the competence for fertilisation (20). The human oocyte will increase in size 
from ~20µm to 60-120µm but meiosis is not resumed (21). The oocyte becomes surrounded 
and is nursed by somatic ovarian cells, including granulosa cells and thecal cells, which 
undergo mitosis so that the whole follicle diameter b comes much larger over development 
while the overall increase in oocyte volume is initially much less (22). In the sheep, oocyte 
and follicle diameter get larger concomitantly during early follicular growth (23). From the 
resting primordial stage, follicles enter the primary (pre-antral) stage which is distinguished 
by the ‘plumping’ up of the surrounding granulosa cells into a single layer of cuboidal cells, 
which begin to proliferate (13) (Fig. 1.2). The oocyte secretes glycoproteins forming a 
surrounding layer called the zona pellucida that separates the oocyte from the granulosa cell 
layer (24). The chief function of the zona pellucida is related to the binding of sperm and 
induction of the acrosomal reaction, facilitating entry into the oocyte (25, 26). The zona 
pellucida contains numerous gap junctions to allow f r the bi-directional flow of paracrine 
factors secreted by the oocyte and granulosa cells (27). 
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In the secondary (antral) stage follicle, granulosa cells continue to proliferate forming 
multiple layers. The formation of a basement membrane round the outer edge of the 
granulosa layer separates these cells from the thecal layer (Fig. 1.2). Theca cells are recruited 
from the surrounding stroma and interstitium during the later secondary stage of follicular 
development in domestic species such as the cow and sheep (23, 28). The thecal layer is 
composed of the theca interna, containing many blood vessels, and the theca externa, the 
outer capsule (20). In early secondary stage follicles there is formation of fluid filled antral 
spaces within the granulosa layer and these follicles are termed small antral follicles (Fig. 
1.2). In large antral follicles a large antral cavity filled with follicular fluid coalesces, 
separating the cumulus granulosa cells directly adjacent to the oocyte from mural granulosa 
cells adjacent to the basement membrane (21). These follicles continue to grow until a 
dominant follicle is selected for ovulation. The pre-ovulatory (tertiary) follicle (Fig. 1.2) 
continues to grow at the expense of the subordinate an ral follicles which undergo atresia. 
Approximate follicle diameter sizes for each developmental stage in the human and sheep 




Figure 1.2  Ovarian follicle development. The growth trajectory of ovarian follicles from the 
resting primordial stage to the pre-ovulatory stage. The somatic cells, the granulosa and 
thecal cells, house the oocyte in a follicular unit and support oocyte maturation and 
acquisition of developmental competence. The complete process of follicle development 
(so that the oocyte is ready to ovulate) takes at least 85 days in the human (24) and ~5 
months in the sheep (29).                                        
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1.1.2 The ovulatory cycle  
 
In pre-pubertal girls, the HPO axis is suppressed, the ovary is quiescent and gonadotrophin 
and sex hormones are therefore present at low levels. Puberty is triggered by the activation 
of hypothalamic gonadotrophin releasing hormone (GnRH) secretion and is associated with a 
growth spurt, and in females, the beginning of breast development (21). Menarche follows 1-
2 years later and is directly correlated with body mass, particularly body fat composition. In 
general a threshold weight of 47 kg has been postulated to be necessary to initiate adult 
reproductive function (21). The human menstrual cyce spans an approximate 28 day period, 
and is split into two distinct phases, the follicular phase and the luteal phase, which are 
separated by ovulation on day 14 (Fig. 1.3).  
 
 
Figure 1.3  The hormonal profile over the human menstrual cycle.  
             
            Adapted from Shechter and Boivin 2009 (30) 
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The HPO axis is the physiological circuitry that is re ponsible for initiation and maintenance 
of ovulation and menstruation in females. Signalling is initiated in the hypothalamus, which 
is situated below the thalamus at the base of the brain, and contains numerous nuclei that 
control physiological homeostasis such as thirst and hunger as well as blood pressure and 
heart rate (31). A major endocrine role of the hypothalamus is the release of a variety of 
neurohormones which travel via the median eminence to the pituitary gland, located below 
the hypothalamus in the fossa of the sphenoid bone (21). The pituitary is split into two 
distinct glands: the anterior and posterior lobe. The posterior pituitary is the site of 
vasopressin and oxytocin synthesis. The anterior pituitary contains a number of highly 
specialised cell types including the gonadotrophs, thyrotrophs, lactotrophs, somatotrophs and 
corticotrophs that are each responsible for producing and secreting specific hormones that 
have vital roles in maintaining homeostasis. The thyrotrophs, lactotrophs, somatotrophs and 
corticotrophs synthesise thyroid stimulating hormone, prolactin, growth hormone (GH) and 
pro-opiomelanocortin (POMC) the precursor of adrenocorticotrophin hormone (ACTH), 
respectively, which have non-gonadal targets and each are stimulated by their own specific 
releasing hormone produced by the hypothalamus (32). The gonadotrophs are basophilic 
cells which synthesise, store and secrete the gonadotrophins, luteinising hormone (LH) and 
follicle stimulating hormone (FSH) (33), which are leased from gonadotrophs upon 
pulsatile stimulation by the hypothalamic decapeptide GnRH that binds to GnRH receptors 
(GnRHR) situated on the gonadotroph (32). The expression of GnRHR can be regulated by 
GnRH, and is up-regulated by pulsatile GnRH neuronal firing, and conversely de-sensitised 
by sustained GnRH stimulation (34, 35).  
 
LH and FSH are heterodimeric glycoproteins that are made up of a non-covalently linked 
common α subunit and a specific β subunit (36), of which all three types of subunit 
expression are stimulated by GnRH (34). While LH and FSH are synthesised and stored by 
the same cell type, and both stimulated through GnRH signalling, their biological properties 
are quite different (37). LH has a very short half-life of just 20 min and protein turn over is 
high and short-lived so that the pulsatile pattern of this hormone is maintained. Every time 
there is a burst of GnRH activity, there is a subsequent release of LH, followed by a decline 
before the next round of neuronal GnRH firing is initiated. On the other hand, FSH has a 
longer half life than LH, and secretion does not follow a pulsatile pattern (38). LH receptors 
(LHR) and FSH receptors (FSHR) are expressed by thecal cells and granulosa cells, 
respectively, by the pre-antral stage of follicle dvelopment (39, 40). LHR are also up-
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regulated in the granulosa cells of large pre-ovulatory follicles, as they mature as part of 
follicular dominance and preparation for ovulation (39, 40). The gonadotrophins act in an 
endocrine manner on the ovary, to promote folliculogenesis, ovulation and subsequent luteal 
function. 
 
Primordial follicle initiation and early follicle growth are not completely dependant on 
gonadotrophins, since a hypopituitary state does not prevent these processes occurring (41). 
Instead gonadotrophins may act in combination with other factors to regulate growth (42-
44). However, the presence of circulating FSH is esential for the growth of large antral 
follicles. FSH stimulates the expression of the steroidogenic enzyme, aromatase, and 
promotes the induction of LHR, in granulosa cells of antral follicles (45). During the latter 
part of the luteal phase and early follicular phase FSH levels increase (Fig. 1.3) to promote 
the growth of healthy antral follicles (46), which are approximately 2-5mm in diameter in 
women (47). At the same time LH is secreted from the pituitary in a pulsatile manner as a 
direct consequence of pulsatile firing of hypothalamic GnRH neurons. The frequency of 
pulsatile LH secretion increases to approximately one per hour during the follicular phase, 
and is required for maintenance of antral follicle development (45, 48).  
 
The presence of LH, in combination with FSH, is responsible for ovarian steroid production 
by growing follicles through the two-cell, two-gonadotrophin mechanism (14, 40, 49) (Fig. 
1.4). Thecal cells produce androgens through a series of steroidogenic steps upon binding of 
LH to the LHR. Androstenedione is synthesised and diffuses to the granulosa cell 
compartment where it is converted to estrone and estradiol, by aromatase, under the 
influence of FSH binding to the FSHR (14). In addition to acting as a substrate for estradiol 
synthesis, thecal androgens, including testosterone and androstenedione, may also augment 
granulosa cell aromatase activity through binding to androgen receptors (AR) present on 
granulosa cells (50, 51).  
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Figure 1.4  The two cell, two gonadotrophin mechanism. The cartoon illustrates the 
synthesis of androstenedione (A4) from cholesterol, by the thecal cell, upon LH stimulation. 
A4 diffuses across the basement membrane to the granulosa cell where it is converted to 
estradiol (E2) upon stimulation with FSH. E2 is synthesised in the granulosa cell and not the 
thecal cell, due to the presence of the aromatase. The specific enzymatic steps which 
catalyse each reaction in the steroidogenic pathway (depicted by individual purple arrows) 
are described in detail in Section 1.1.5.  
 
At the beginning of the follicular phase the pool of antral follicles have differing degrees of 
FSH sensitivity. The follicle with the lowest threshold for FSH stimulation will most quickly 
up-regulate granulosa cell LHR and aromatase (45). This action culminates in increased 
sensitivity to gonadotrophins (52), and an exponential increase in estradiol production over 
the follicular phase (Fig. 1.3). Estradiol has a number of effects. It acts locally at the level of 
the reproductive tract to promote proliferation of the endometrium in preparation for 
implantation (53, 54). It also acts peripherally, by negative feedback indirectly to the 
hypothalamus (55) and directly to the pituitary (56), to dampen FSH secretion. In addition, 
the granulosa cells of antral follicles also produce large amounts of inhibin which add to the 
negative feedback effect on FSH secretion from the pituitary (21) (discussed further in 
Section 1.1.4). Follicles that are less sensitive to FSH will not survive the decline in FSH 
secretion and undergo atresia. In women, one dominant follicle will remain and continue 
growing from ~5mm up to ~20mm (45, 47) despite the reduction in circulating FSH. This 
follicle also has marked aromatase activity (57-59) and further augments estradiol 
production. Estradiol additionally exerts an intra-ovarian positive feedback loop, inducing 
the up-regulation of estrogen receptor (ER) in granulosa cells, the effect of which stimulates 
further estradiol production (21). In conjunction with FSH, estradiol stimulates the 
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expression of LHR in late antral follicles (21). Gonadotrophin dependency and timing of 
expression of the gonadotrophin receptors are summarised in Table 1.1. 
 
The growth promoting affects of insulin-like growth factor (IGF) signalling also have a role 
within the dominant follicle. IGF1 is predominantly produced by the liver in response to 
stimulation by GH which is secreted by the pituitary (31). In addition, IGFII and some IGF1 
is produced by the steroidogenic cells of the ovary (60). IGF1 stimulates granulosa cell 
proliferation as well as enhancing FSH-induced estradiol secretion (61, 62). A reduction in 
the levels of IGF binding proteins (IGFBPs) in large preovulatory follicles would lead to 
enhanced IGF bioavailability and therefore support the continuation of growth and steroid 
production (63, 64). Furthermore, the blood supply to large follicles is increased, to support 
enhanced delivery of gonadotrophins to granulosa cells (65). The pro-angiogenic factor, 
vascular endothelial growth factor (VEGF) stimulates he growth and branching of blood 
vessels in large follicles and is increased by gonad trophin-stimulation of granulosa cells of 
pre-ovulatory follicles of Macaque monkeys (66). In fact, the treatment of Marmoset 
monkeys with a VEGF antagonist, VEGF-Trap, to block angiogenesis, resulted in the loss of 
large antral follicles without affecting earlier follicle stages (67).  
 
At around day 12 of the human menstrual cycle, estradiol secretion from the preovulatory 
follicle reaches a certain threshold and, instead of negative feedback, this triggers a positive 
feedback mechanism to the hypothalamus and pituitary gland (21). The effect of this is a 
sustained burst of GnRH neuronal firing and de-granulation of gonadotrophs, resulting in a 
large surge of LH release from the pituitary (Fig. 1.3). It is this high amplitude peak of LH 
that triggers, approximately 36 hours later, ovulation and the release of the oocyte, through 
inflammatory-mediated rupture of the ovarian wall (68, 69). As well as follicular rupture, 
ovulation is associated with oocyte maturation and luteinisation of granulosa cells. In the 
oocyte, meiosis I is resumed and completed, there is xpulsion of the 1st polar body and 
meiosis II is entered before being arrested again, leading to cytoplasmic maturation (21). As 
soon as the LH surge occurs follicular estradiol secretion declines and large amounts of LH-
induced progesterone are synthesised, by thecal and granulosa cells (14). This is secondary 
to an induction of steroidogenic enzymes in the granulosa cells.  
 
Following ovulation, the follicular cells become terminally differentiated and luteinise to 
form the corpus luteum. The corpus luteum is a highly vascularised glandular structure, in 
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which the extensive blood supply allows for the delivery of low density lipoprotein to the 
granulosa lutein cells, promoting progestogenic steroidogenesis (14). The high levels of 
progesterone secreted during the luteal phase have two roles: to prime the endometrium for 
possible implantation (53, 54) and, with luteal inhibin and estradiol secretion, to negatively 
feedback to the hypothalamus to dampen pituitary gonad trophin secretion and block 
follicular activity in the ovary (21). FSH concentrations remain low and LH pulsatility is 
reduced to approximately one every six hours (21). The continuous, albeit slowed, secretion 
of LH ensures maximal progesterone secretion from the corpus luteum over the luteal phase 
(Fig. 1.3). If conception and embryo implantation do not occur, the corpus luteum undergoes 
luteolysis and progesterone levels decline. In the human and higher primates luteal 
regression is thought to be inherent to the corpus luteum so that the low levels of LH do not 
promote long-term survival (21). In women, progesteron  withdrawal initiates menstruation 
and the endometrium is sloughed off. This represents day 1 of the next menstrual cycle. The 
progesterone block on gonadotrophin secretion is remov d and tonic LH and FSH secretion 
is initiated once more to promote antral follicle growth. 
 
1.1.3 The sheep estrous cycle 
 
The sheep, like most other mammalian species including omestic animals and rodents, 
undergoes reproductive cyclicity termed estrous cycling. Menstruation does not occur in 
these species as is the case in humans and some priates. The estrous cycle is divided into 
distinct stages known as estrus, metaestrus, di-estrus and pro-estrus.  In sheep the estrous 
cycle occurs over a 17 day period, in which the follicular phase takes place over the first 2-3 
days and there is a pro-longed luteal phase lasting approximately 15 days. During estrus, a 
period of 24-36 h, the ewe is receptive to the male and will allow mating, and ovulation 
occurs. The luteal phase is split into metaestrus in which there is formation of the corpus 
luteum (often corpora lutea) and progesterone levels increase, di-estrus during which 
progesterone levels are maximal and pro-estrus when t  corpus luteum regresses and 
progesterone levels decline. Most antral follicle growth and development occurs during the 
luteal phase, since, unlike women, the corpus luteum does not produce inhibin and estradiol 
as an additional break to gonadotrophin secretion. The final pre-ovulatory stages are 
completed during the short follicular period (21). With the exception of primordial follicles, 
the follicle diameters at each developmental stage are much smaller in the sheep than in the 
human (Table 1.1). Furthermore, in sheep, regression of the corpus luteum is induced by a 
Chapter 1                                                                                        Literature Review 
     
 12 
luteolytic factor rather than being spontaneous as in humans. The endometrium secretes the 
prostaglandin, PGF2α, as a result of stimulation by oxytocin released by the corpus luteum. 
The endometrium is sensitised to oxytocin by the up-regulation of oxytocin receptors 
towards the end of the luteal phase (21). PGF2α travels to the ovary via the uterine vein and 
ovarian artery where it acts directly on the corpus luteum to promote luteal regression (21).  
 
Much of what is known about the regulation of follicle growth and development by 
gonadotrophins stems from studies in the sheep. As in humans, antral follicle growth is 
dependent on the presence of both LH and FSH and while follicles at earlier stages are 
responsive to gonadotrophins, survival is not dependant on them (70). Hypophysectomy 
(71), immunosuppression of GnRH (72) or desensitisation of the pituitary by chronic GnRH 
stimulation (73), ablates the FSH signal and prevents follicle growth in ewes beyond that of 
2.5 mm in diameter. In hypogonadotrophic ewes, establi hed through chronic administration 
of a GnRH analogue, the addition of exogenous gonadtrophins has shown that FSH alone 
can drive the growth of a pre-ovulatory follicle, however LH alone cannot (73, 74). There is 
however evidence for the role of LH in the selection of the dominant follicle. Campbell et
al., using a GnRH-antagonist treated ovine model witha controlled infusion of FSH and LH, 
showed that withdrawing FSH and LH led to atresia in pre-ovulatory follicles, however, 
removal of FSH but continued treatment with LH permitted some survival of pre-ovulatory 
follicles, albeit with an overall reduction in the ovulation rate (75). Furthermore, LH can 
indirectly influence FSH secretion by increasing estrogen secretion and inhibin production, 
further promoting survival of the dominant pre-ovulatory follicle (76). 
 
The most striking deviation from the regular cyclicity seen in women is the control of 
reproductive function by external environmental factors that ensure birth at optimal times of 
the year. In sheep, HPO activation or suppression i regulated by day-length and thus sheep 
are seasonal breeders. The switching on of the HPO axis, by initiation of hypothalamic 
GnRH pulses occurs as a direct response to changing photoperiod, such that shortening day 
length and lengthening nights in autumn trigger thecommencement of estrous cycling. 
During the hours of darkness the pineal gland, attached to the epithalamus in the brain, 
secretes a hormone called melatonin, and it is the prolonged period of melatonin secretion 
that is responsible for hypothalamic activation (21). In springtime, as the nights shorten, so 
does the duration of melatonin secretion and consequentially estrous cycling terminates. 
Ewes enter anestrus and are reproductively inactive until the following autumn. Male sheep 
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are also affected by seasonality, with reduced sperm p oduction and quality as the 
photoperiod lengthens. 
 
Follicle Stage Primordial 








_ _ + + 
LHR _ _ TC + 
TC + 
GC + 
FSHR _ _ GC + GC + 
Size (human)
1 
30 µm 200-400 µm 
Small: 2-7 mm 




 <60 µm >60 µm 
Small: 1-3 mm 
Large:3-4 mm 
4-8 mm 
Table 1.1  Follicular characteristics in the human and sheep. Gonadotrophin dependency, 





the follicle sizes listed for sheep are approximate and are known to vary between breeds 
(77). TC: thecal cells, GC: granulosa cells. 
 
1.1.4 The role of activin, inhibin and follistatin in reproductive function 
 
Activin and inhibin are members of the transforming growth factor (TGF) β family of 
signalling molecules. They possess similar structures and are made up of a set of subunits 
including inhibin α, inhibin βA and inhibin βB (78), which are respectively encoded by the 
INHA, INHBA and INHBB genes (Fig. 1.5) (79). Dimerisation of these subunits i to specific 
conformations leads to the formation of activin or inhibin proteins with opposing biological 
effects. Figure 1.5 illustrates the possible subunit conformations required to form each of 
these signalling proteins. Activin binds to activin type I and type II serine threonine receptor 
kinases to initiate downstream TGFβ signalling (80). Binding to a type II receptor (ACVR2A 
and ACVR2B) leads to dimerisation and phosphorylation of a type I receptor (ACVR1, 
ACVR1B and ACVR1C) (81) and subsequent SMAD protein s gnalling (82). Inhibin 
suppresses activin action by binding to and occupying the activin receptor (83, 84). Inhibin 
can also signal through the TGFβR3 (also known as β-Glycan), which increases the binding 
affinity of inhibin to activin type II receptors (85). The negative effects of inhibin action can 
also be augmented by sequestration to secreted binding proteins (86). Follistatin, encoded by 
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the FST gene, is a glycoprotein that binds to both activin and inhibin (87, 88), negating 
activin signalling although having a negligible effect on inhibin action (88-90). 
 
 
Figure 1.5  The activin and inhibin subunits. The possible conformations of inhibin subunit 
(α, βA and βB) dimerisation to produce activin A, activin AB, activin B, inhibin A or inhibin B. 
The gene names for each inhibin subunit are in brackets. Dimers are covalently linked by a 
disulphide bond (red line). 
 
Activin and inhibin are known to have both endocrine and paracrine roles and are expressed 
in a range of reproductive and non-reproductive tissue  (91). The most commonly studied 
role for these proteins is their gonadal and extra-gonadal role in reproductive function (92). 
Both the ovary and the pituitary express activin and i hibin, and these molecules have 
essential reproductive roles in pituitary function a d folliculogenesis (92, 93). One of the 
major contributions to this system is the respectiv stimulatory and suppressive effect that 
activin and inhibin exert on FSH secretion (94, 95). There is differential expression of 
activins and inhibins. Across the menstrual cycle in women, systemic activin A is found to 
be raised around the late follicular stage, then falls again until the late luteal/early follicular 
phase when there is a peak before falling again (96). During the follicular phase circulating 
inhibin B is elevated, however it is inhibin A that is increased in the luteal phase (97, 98). 
Free follistatin is not found to vary over the menstrual cycle and is present at low levels in 
serum, suggesting local action (99, 100). Furthermore, l w levels of activin A and activin B 
are present in serum indicating autocrine or paracrine action, while inhibin may have actions 
both locally and peripherally (98, 101). 
Chapter 1                                                                                        Literature Review 
     
 15 
1.1.4.1 The role of activin, inhibin and follistatin in the pituitary 
 
In the pituitary, the local action of activin and follistatin have respective stimulatory and 
inhibitory effects on the secretion of FSH from thegonadotroph (102), while the endocrine 
action of gonadal inhibin is also responsible for the suppression of FSH release (103). This 
inhibin-mediated control of activin signalling appears to be limited to the gonadotroph since 
inhibin does not reverse the activin-mediated suppression of GH nor ACTH from 
somatotrophs and corticotrophs, respectively (85, 102). The in vitro affects of activin and 
inhibin on FSH function are well documented. Exposing a rat pituitary cell line to an activin 
B neutralising antibody suppresses the secretion of FSH (104), as does treatment with 
follistatin (105). The local pituitary bio-availability of activin has also been demonstrated to 
be regulated by hypothalamic GnRH secretion. Low amplitude GnRH pulse stimulation of 
female rats led to an increase in pituitary activin βB (INHBB) and FSHβ (FSHB) subunit 
messenger (m) ribonucleic acid (RNA) expression (106), in agreement with human studies 
showing an increase in FSH synthesis as a result of low frequency luteal phase GnRH pulses, 
although this in vivo mechanism is overcome by strong inhibition by luteal progesterone, 
estradiol and inhibin (107). Not only does GnRH signalling lead to an up-regulation of 
activin subunits, activin is required for GnRH-mediated FSH synthesis and has a role in 
increasing gonadotroph sensitivity to this hormone. I  vitro studies have shown that activin 
can target the FSH (108, 109) and GnRH gene promoters (110). While activin can act 
directly to increase FSH transcription, high levels of activin A can indirectly induce GnRH 
gene expression thus augmenting downstream FSH release. 
 
1.1.4.2 The role of activin, inhibin and follistatin in the ovary 
 
In the ovary, activin and inhibin act locally to regulate folliculogenesis (92) and ACVR1 and 
ACVR2 are expressed in granulosa cells, thecal cells and the oocyte (111). Studies have 
demonstrated the role of activin in follicle growth, differentiation and the selection of large 
pre-ovulatory follicles in vitro. Culture of rat granulosa-oocyte complexes with activin A and 
insulin led to an increase in granulosa cell number, which could be inhibited by the addition 
of follistatin (112). Similarly, the inhibitory effects of follistatin were confirmed by the over-
expression of follistatin (FST) in mice, leading to follicle growth arrest and infertility in adult 
females (113). Activin A, in the presence of FSH, also led to the formation of large pre-
ovulatory-like follicles in vitro (112). In vivo, the growth affects of activin were 
Chapter 1                                                                                        Literature Review 
     
 16 
demonstrated in an INHA mouse knockout model, in which the lack of inhibin-mediated 
activin inhibition resulted in extensive granulosa cell proliferation that led to the 
development of ovarian tumours (114). Furthermore, ACVR2 knockout resulted in mice with 
antral stage follicle arrest (115), illustrating the importance of activin for regulated follicle 
growth and differentiation. 
 
The selection of the pre-ovulatory follicle is enhaced by the numerous roles of activin. Xiao 
et al. reported that activin treatment of rat granulosa cells induced the up-regulation of 
FSHR, which was reversed by the addition of follistatin (116). Activin also enhanced follicle 
sensitivity to FSH and LH in these cultures, which resulted in increased aromatase activity 
(estradiol secretion), as well as progesterone and inhibin production (116). FSH-induced 
LHR induction has also been shown to be stimulated by activin in combination with FSH, in 
rat granulosa cells (117). Miró et al. demonstrated that the precise role of activin in 
regulating granulosa cell steroidogenesis was stage dependent. The authors cultured rat 
undifferentiated (-FSH), differentiated (+FSH) and pre-ovulatory (+FSH and LH) granulosa 
cells with activin A. They found no change in steroid synthesis in undifferentiated cells, 
however in the presence of FSH, estradiol and progesterone secretion was increased (118). 
Increased aromatase activity (estradiol secretion) was present in pre-ovulatory cells in 
response to activin, as well as in differentiated cells, however in the presence of LH 
progesterone secretion was in fact suppressed (118). In accordance with this, treatment of 
bovine pre-ovulatory granulosa cells with activin A suppressed progesterone production 
from these cells (119). These data imply that while activin has a role in stimulating 
differentiation in the mature follicle, it also prevents premature luteinisation from occurring 
thus exerting a dual role in inducing and maintaining the folliculogenic phenotype (92). 
 
A major local ovarian role for inhibin is the stimulation of LH-mediated androgen synthesis 
by thecal cells. In vitro inhibin treatment of human thecal cells led to an increase in 
androstenedione and dehydroepiandrosterone (DHEA) production, an effect which could 
also be suppressed by treatment with activin A (120). Accordingly rat thecal interstitial cells 
and thecal implants treated with LH, increased androgen biosynthesis upon the addition of 
inhibin (121). Inhibin also increased LH-stimulated androstenedione secretion by bovine 
thecal cells, which was again reversed by activin A treatment (122). The increase in 
androgens is required as a substrate for aromatase conversion to estradiol within the 
granulosa cell (123) (Fig. 1.4). As the follicle matures, inhibin secretion from granulosa cells 
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increases in parallel with an increase in local steroid production. Hillier et al. showed that the 
treatment of human immature follicles with FSH results in an increase in inhibin that is 
augmented further by the addition of androgens. Furthermore, treating pre-ovulatory thecal 
cells with LH led to an increase in inhibin synthesis, corresponding to the time when 
steroidogenesis is high (124).  
 
Therefore, as the follicle matures local activin levels are thought to decrease while levels of 
inhibin and follistatin rise. Activin maintains the growing, estradiol secreting unluteinised 
preovulatory granulosa cells, and at the time of the LH surge, activin is withdrawn and 
inhibin increases, thereby exerting key roles in follicle interactions and maturation. This 
complex system may be dysregulated in ovarian disorers such as PCOS. In PCOS, a 
syndrome characterised by the follicular arrest of immature follicles, it has been shown that 
serum activin A is elevated and follistatin levels are low, which could contribute to this 
phenotype observed in these patients (125, 126). A decrease in follicular fluid inhibin A and 
inhibin B subunits have been described in women with PCOS (127), as well as a reduction in 
the expression of INHA and INHBA subunit mRNA from PCOS granulosa cells (128). 
However, peripheral inhibin concentrations have been found to be increased in women with 
PCOS (129, 130). It is clear that activin and inhibin signalling in the ovary is complex and 
involves tightly controlled processes that are dependent on the stage of folliculogenesis and 
the presence of various intra- and extra-ovarian factors, which include IGFs, IGFBPs (131) 
and also other members of the TGFβ signalling family including growth differentiation 
factor (GDF) 9 and bone morphogenetic protein (BMP15) ( 32). 
 
1.1.5 Ovarian steroidogenesis 
 
The ovary is a major source of steroid synthesis in the adult, predominantly secreting 
estrogens and androgens during the follicular phase of the ovulatory cycle, and progestagens 
during the luteal phase. The steroidogenic machinery r quired for the synthesis of the sex 
steroids is also present during fetal development, with the fetal ovary proposed as a source of 
steroid production. The steroidogenic pathway takes place within the mitochondria and 
cytosol of cells and involves a complex series of enzymatic steps converting steroid 
precursors into various hormones from a primary precursor. Free cytoplasmic cholesterol is 
transported from the outer to the inner mitochondrial membrane by steroidogenic acute 
regulatory protein (StAR), a protein present in the mitochondria of steroidogenically active 
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tissues (133). Various classes of enzymes are then responsible for the sequential conversion 
of cholesterol and include the cytochrome (CYP) P450 enzymes and the hydroxysteroid 
dehydrogenases (HSD). CYP enzymes are monooxygenases, hydrolysing and cleaving their 
steroid substrate (134). Examples of the CYP enzymes include CYP17 (17α-hydroxylase), 
CYP19 (aromatase) and CYP21 (21-hydroxylase that is expressed in the adrenal), which are 
microsomal proteins, and CYP11A (P450 side chain cleavage) and CYP11B (11β-
hydroxylase that is expressed in the adrenal), which are membrane bound (134). The HSDs 
are alcohol dehydrogenase reductases which catalytical  reduce and oxidise their steroid 
substrates (134). The CYP enzymes are products of a single gene, however, in contrast, the 
HSD proteins consist of various gene isoforms that are often species and tissue specific 
(134). Figure 1.6 illustrates the steroidogenic pathw y in the ovary that culminates in the 
production of progesterone, androgens and estrogens. Below a short description of each of 
the main enzymes involved in ovarian steroid biosynthesis are provided. 
 
• CYP11A (P450 side chain cleavage) 
The conversion of cholesterol into pregnenolone by CYP11A is the rate-limiting step of the 
steroidogenic pathway, acting first in the chain of enzymatic reactions inside the 
mitochondrial matrix (133). Access to CYP11A is contr lled by StAR, which is tightly 
transcriptionally regulated. CYP11A is well conserved between species and expressed in 
numerous tissues other than the ovary, including adrenal, placenta and testis (134). 
Pregnenolone is transported from the mitochondrial m trix and travels to the endoplasmic 
reticulum whereupon it is converted into a series of teroid products in the presence of the 
appropriate enzymes.                                                                                                 
                                                   
• CYP17 (17α-hydroxylase) 
CYP17 is responsible for two successive catalytic reactions leading to the formation of 
androgenic precursors. Firstly, CYP17 adds a hydroxyl group (hydroxylase) to pregnenolone 
or progesterone, converting these substrates to the intermediaries 17α-OH pregnenolone and 
17α-OH progesterone, respectively. These products are then cleaved by CYP17 (lyase 
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• 3β-HSD 
Encoded by the gene HSD3B1 and 2, 3β-HSD1 and 2, respectively (135), are involved in the 
substrate conversion of intermediate steroids pregnenolone to progesterone, 17α-OH 
pregnenolone to 17α-OH progesterone and DHEA to androstenedione. In the human, the two 
isoforms of 3β-HSDs are thought to be differentially expressed, with 3β-HSD1 expression 
exclusive to the non-classically regulated steroidogenic tissues including mammary tissue, 
placenta and skin, and 3β-HSD2 expression localised to the gonads and adrenal gland (136, 
137).  
 
• CYP19 (aromatase) 
Aromatase is required for the catalytic conversion of androgenic substrates into estrogenic 
products. CYP19 reduces androstenedione and testostrone into estrone and estradiol, 
respectively. As well as being expressed in the ovary (138), CYP19 is expressed abundantly 
in the human (138), cow, pig and horse placenta (139), however it is not expressed in the 
placenta of rats and mice (140). There is widespread expression of CYP19 across tissues 
with notable expression in adipose tissue and bone, a d therefore these tissues are alternative 
sources of estrogen (138). 
 
• 17β-HSD 
There are numerous isozymes of the 17β-HSD protein, which are encoded by HSD17B 
genes, however they share little homology, possessing differing roles and substrate 
specificity depending on the tissue type in which they are expressed (134). Type 1 17β-HSD 
is expressed in the gonad and is thought to have species dependant roles such that the 
enzyme converts androstenedione into testosterone, or strone into estradiol, in rodents, 
however, in humans this activity is restricted to the estrogenic pathway (134). Other isoforms 
exist including 17β-HSD3 which converts androstenedione into testosterne in the testis 
(141), and 17β-HSD7 may be responsible for ovarian estradiol synthesis during the luteal 
phase of the cycle in mice (142, 143) and primates (144). 
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Figure 1.6  The steroidogenic pathway in the ovary. Precursors and products of the 
steroidogenic pathway are represented in black and the enzymes required for each bio-
synthesis step are indicated in blue. 
 
 
1.1.5.1 The cellular expression of steroidogenic enzymes in the adult 
ovary across species 
 
In the human ovary, StAR is localised to the thecal cells of pre-ovulatory follicles as well as 
being present in the corpus luteum in steroidogenic cells of thecal and granulosal origin 
(145). The expression of StAR in the oocyte throughout follicle development, as well as the 
expression in thecal cells of late pre-antral follicles, have also been described in the sheep 
ovary (146). The expression of CYP11A is reported in the granulosa cells and thecal cells of 
antral or pre-ovulatory follicles in the pig (147) and rat (148), and exclusively in the thecal 
cells of the human ovarian follicle (149). In the sheep, CYP11A is expressed in thecal cells 
from the late pre-antral stage onwards, however it is not expressed in granulosa cells until 
the late antral stage (146). CYP17 is predominantly expressed by the ovarian thecal cell as a 
means of androgen production and is not thought to be present in granulosa cells of women, 
sheep, cattle and pigs (149-151). In thecal cells, CYP17 is up-regulated by the early antral 
stage in the sheep ovary (146). The expression of 3β-HSD may be species specific: 
immunolocalisation has been observed in the thecal cells of sheep and pigs, but in the 
granulosa cells of cattle (151). Conversely 3β-HSD has been observed in ovine granulosa 
cells up to the small pre-antral follicle stage, whereas expression in thecal cells was first 
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noted in large pre-antral follicles and beyond (146).  In the rat, 3β-HSD is expressed in both 
thecal and granulosa cells of antral and pre-ovulatory follicles (152). The granulosa cells are 
the site of aromatase expression in the human ovary (138, 150) and aromatase is expressed in 
granulosa cells of large antral follicles in the sheep (146). In the pig however, CYP19 has 
been localised to both thecal and granulosa cells of pre-ovulatory follicles (147). There is 
abundant expression of 17β-HSD1 in granulosa cells of human (153, 154) and rat ov ries 
(155), which is required for the final conversion step of androstenedione into estradiol via 
CYP19-mediated estrone conversion (Fig. 1.4 and 5). 
 
1.1.5.2 Steroidogenesis in the fetal ovary across species 
 
In the mouse it is suggested that the fetal ovary is not steroidogenically active. While 3β-
HSD can be detected in the mouse fetal ovary, the expression of CYP11A, CYP17 and 
CYP19 during the time of sexual differentiation is infrequent (156). Similarly, in the rat 
E18.5 fetal gonad, CYP11A was not detected by immunolocalisation or by an activity assay 
involving the conversion of tritiated cholesterol into pregnenolone (157). Conversely, the 
bovine fetal ovary has been demonstrated to be steroidogenically active throughout 
gestation, with the secretion of androstenedione, estrone and estradiol from cultured fetal 
ovaries. Estradiol production was found to peak in these ovaries from early to mid-gestation 
(158). Additionally, active steroidogenesis in the sheep fetal ovary is described. Quirke et al. 
found the presence of estradiol in d35 fetal ovary homogenates and androstenedione and 
testosterone in d75 fetal ovaries. Furthermore, StAR, CYP11A, CYP17 and CYP19 mRNA 
were detected in all fetal ovaries by d35 of gestation (159). Interestingly, HSD3B transcript 
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1.2 Polycystic Ovary Syndrome – an ovarian, endocrine and 
metabolic disorder 
 
PCOS is a common disorder affecting between 6-10% of women in their reproductive years 
(160). It has been recognised for many years but never fully characterised and many 
aetiological mechanisms are not understood. PCOS occurs in humans, but as this review will 
discuss, animal models have been developed over the last two decades that have contributed 
to our basic understanding and have also revealed the complexity of the syndrome. 
 
1.2.1 Clinical features and diagnostic criteria 
 
Amenorrhea, a polycystic ovarian morphology and their association with clinical endocrine 
abnormalities, such as elevated androgens, have been documented for many years. As far 
back as 1935, Stein and Leventhal described these features in a subset of women and also 
commented on the heterogeneity present between individuals (161). Many women first 
present to their doctor when they are adolescents or young women that are experiencing 
irregular (oligomenorrhoea) or absent (amenorrhoea) menses, or difficulty in conceiving 
(162). These symptoms reflect the reproductive elemnt of PCOS for which the syndrome is 
named. On ultrasound scan, these women are likely to have polycystic ovaries (PCO) which 
are defined as having more than 12 antral follicles that are between 2-9mm in diameter (Fig. 
1.7). The ovarian volume is also likely to be enlarged (163). Rather than being ‘cystic’ these 
ovaries are polyfollicular, with an increased number of antral stage follicles present in the 
periphery of the ovary and a thickened stromal compartment. However, there are many other 
features of PCOS that are often clinically and biochemically apparent. A major biochemical 
marker of PCOS is raised androgens which symptomatically result in hirsutism and acne 
(162). Other hormones are also frequently affected; including elevated levels of LH and an 
increased LH to FSH ratio (164, 165). Women are oftn, but not always, clinically obese 
which combined with the other features of PCOS makes them particularly prone to the 
development of the metabolic syndrome (162, 166). The accumulation of central fat, a 
feature that is facilitated by hyperandrogenism is a risk factor for cardiovascular disease, 
insulin resistance and type II diabetes. Women with PCOS tend to have elevated serum 
insulin concentrations before and after stimulation with glucose (167, 168). Insulin 
insensitivity in these women is also independent of body mass index (BMI) and therefore an 
intrinsic feature of PCOS that is exacerbated by obesity. A further clinical feature is the 
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presence of acanthosis nigricans, a dark pigmentatio  that occurs on the folds of skin and is a 
marker of insulin resistance. It is common in obesity and endocrine disorders including 
PCOS (169, 170).  
 
 
Figure 1.7  An ultrasound scan of a normal and polycystic human ovary.  
        From Norman et al. 2007 (163) 
 
While there are a range of clinical, biochemical and ultrasonographic features of PCOS, they 
are by no means all inclusive, and this has led to ifficulty in the acceptance of standardised 
criteria used to diagnose this widely occurring andheterogeneous syndrome (171, 172). No 
one criterion is sufficient to diagnose PCOS and over the last two decades slightly differing 
guidelines have been published in what should constitute a positive diagnosis. The 1990 
National Institute of Health (NIH) guidelines stated that chronic anovulation combined with 
the clinical or biochemical presence of hyperandrogenism was sufficient to identify PCOS 
(173). In 2003, the Rotterdam consensus was published that expanded on the NIH guidelines 
and included the presence of PCO as a diagnostic criterion for PCOS (174). This resulted in 
the possible definition of four separate but closely r ated phenotypes of PCOS and reflected 
more on the complexity and heterogeneity of the syndrome (Table 1.2). It has been estimated 
that, of the women that are diagnosed based on the Rott rdam criteria, approximately two 
thirds have ‘severe PCOS’ combining all of the features of PCOS, whereas less than 10% 
will possess these features without PCO (175). The remaining women are split between 
‘mild PCOS’ or ‘ovulatory PCOS’ phenotypes (175). These criteria therefore allow for a 
more broad definition of the different types or severity of PCOS. Both sets of guidelines are 
careful to rule out underlying illnesses such as congenital adrenal hyperplasia, androgen 
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secreting tumours and Cushing’s syndrome as potential sources of androgen excess that are 
unrelated to PCOS, but may initially share common features (163).  
 
 
PCOS Traits Mild PCOS Ovulatory PCOS Severe PCOS 
Anovulation/ 
hyperandrogenism* 
PCO Yes Yes Yes No 
Androgens ↑ ↑↑ ↑↑ ↑↑ 
Ovulation Irregular Normal Irregular Irregular 
Insulin Normal ↑ ↑↑ ↑↑ 
Table 1.2  The criteria for the diagnosis of PCOS based on the 2003 Rotterdam consensus.  
This set of criteria results in a broad spectrum of severity of PCOS and highlights the 
heterogeneity of the disorder. * Women falling into this category would be classified as 
PCOS under the guidelines published in1990 by the NIH.  
       Adapted from Norman et al. 2007 (163) 
 
Unsurprisingly, the introduction of the broader Rotterdam criteria in the diagnosis of PCOS 
has resulted in a higher overall prevalence of women with PCOS (176). Additionally, the 
increasing level of obesity and diabetes in Western countries, if not an underlying cause, 
certainly augments the severity of PCOS. Obesity and anovulation have long been known to 
be associated with one another (177). This is especially proven by the spontaneous re-
instigation of normal ovarian cyclicity when women reduce their dietary intake and assume 
regular exercise (178-180). Further complexity is added when ethnicity is taken into account: 
the prevalence of PCOS is altered between different ethnic populations, and is increased in 
populations in which insulin resistance and the metabolic syndrome are common (181). 
Studies have shown that there is an increased prevalence of PCOS in Hispanic Americans 
opposed to white or black Americans (182). The prevalence of PCOS in Asian women from 
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1.2.2 Current management and treatment strategy 
 
It is widely agreed that the initial treatment to improve reproductive function in overweight 
patients should be weight-loss (163, 179, 184, 185). Studies have shown that a 2-5% 
decrease in body weight, particularly in central fat, can improve the metabolic and 
reproductive characteristics of PCOS (186). Furthermore, an 11% reduction in body fat was 
associated with vastly improved insulin sensitivity and lowered basal levels of insulin, and 
reduced LH concentrations (187). In women who do not wish to become pregnant, treatment 
with an oral contraceptive pill is a strategy to regulate menstrual bleeding and also to 
suppress androgens, thereby improving some of the clinical manifestations of this hormone, 
including hirsutism and acne (163). There are a range of options for treatment to induce 
ovulatory cycles and increase the chances of conception. These include treatment with anti-
estrogens such as clomiphene citrate, which has the effect of dampening of estrogen negative 
feedback and increasing the secretion of gonadotrophins, particularly FSH (188). This 
treatment has been shown to improve ovulation rate and increase the chances of conception 
in young women (188, 189), however it has also been linked to multiple pregnancy and 
miscarriage (184, 190). Not all women are however responsive to these drugs (191) and 
therefore other ways of reducing estrogen concentrations, including treatment with 
aromatase inhibitors such as letrozole (192), or antagonising steroid biosynthesis by 
inhibiting 17α-hydroxylase (CYP17) (193), can be used in conjunctio  with drugs such as 
clomiphene. Another strategy is to treat with exogenous FSH, which can successfully restore 
ovarian cyclicity (194).  
 
Other ways to reduce the androgen burden include the use of the synthetic glucocorticoid, 
dexamethasone, which suppresses adrenal androgen production can also improve ovulation 
and pregnancy rate when combined with clomiphene (195). Anti-androgens combined with 
the oral contraceptive pill can also be used to treat acne and hirsutism. Both cyproterone 
acetate (an androgen receptor blocker and progestagen) and finasteride (a 5α-reductase 
inhibitor, which blocks the synthesis of dehydrotestosterone [DHT]) can be used (196). 
Flutamide is anti-androgen that has been shown to be beneficial in that it can lower 
androgens, decrease visceral fat and cholesterol and improve hirsutism (197-201). 
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To combat the metabolic characteristics of PCOS, aside from the obvious and essential 
changes to lifestyle, drugs are commonly prescribed to improve insulin sensitivity. One of 
the most widely used drugs is the biguanide, metformin, which reduces the hyperglycaemic 
state by suppressing hepatic gluconeogenesis thereby lowering glucose production by the 
liver, and stimulating glucose uptake by peripheral tissues, thus improving insulin resistance 
(202). Treatment with metformin reduces fasting insuli  levels, lowers concentrations of LH 
and androgens and can induce ovulation in PCOS (203-206). Combining metformin with 
clomiphene treatment has proven to be successful in some but not all patients (207-210), 
although it is suggested that clomiphene treatment is overall more effective the metformin 
(211). The thiazolidinediones including troglitazone, pioglitazone and rosiglitazone, are 
insulin sensitising drugs that have also been used to treat PCOS. Treatment with these drugs 
have been shown to reduce androgen levels, induce ovulation and improve insulin resistance 
(212-216). While the use of the thiazolidinediones have had clear benefits to the PCOS 
phenotype in clinical trials there has since been concern over their safety and these drugs are 
no longer used to treat PCOS (217).  
 
Each patient must be individually assessed to tailor the most appropriate treatment to their 
specific needs. Not all patients will respond particularly well to drugs and treatment is 
largely symptomatic. In many cases using anti-estrogens or anti-androgens in conjunction 
with insulin sensitisers and a strict weight loss programme can be the most beneficial (179, 
184, 185, 197, 207, 208). In some patients these treatments are extremely successful leading 
to the induction of ovulatory cycles and improved metabolic function, however in others, 
current treatment is not adequate. This emphasises the complexity and variation in this 
disorder that can make PCOS particularly difficult to reat. 
 
1.2.3 Heritability of PCOS 
 
PCOS is a heritable trait that can be passed down the generations from mother to daughter 
and features of PCOS including hirsutism and metabolic traits are often present in relatives 
of women with PCOS (218). In fact, sisters of women with PCOS, who have PCO 
themselves, have fewer but comparable biochemical traits compared to their sisters (219). 
One of the major indications that PCOS is genetically inherited is the finding, in a large 
study of Dutch twins, that monozygotic twins shared twice as much resembling features  of 
PCOS features than dizygotic twins (220). Other twin studies have highlighted the 
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heterogeneity between individuals proposing that a number of genes may be involved in the 
inheritance of PCOS (221). In addition it is known that male siblings or sons of women with 
PCOS also have higher risks of the metabolic implications associated with PCOS (222-224) 
pointing towards genetic involvement. While a lot of research has gone into the search for a 
gene or set of genes that are responsible for the heritable features of this syndrome this has 
not been very successful, although a number of candid te genes are proposed to be involved 
(225). It is now emerging that the more likely mode of inheritance of PCOS is through post-
transcriptional epigenetic alterations to the genome that alter the expression of certain genes 
in offspring. These changes could be programmed by the maternal and/or fetal environment, 
and it is possible that this, in combination with the inheritance of PCOS susceptibility genes, 
could result in the highly variable and heterogeneous nature of the syndrome (221). 
Furthermore, in the event of obesity the susceptibility to PCOS traits are more pronounced, 
which may be additive or a result of altered gene expression, or even a combination of both 
(225). The potential modes of transfer of these traits are discussed below. 
 
1.2.3.1 Candidate genes associated with PCOS 
 
A range of genes have been implicated in PCOS that affect steroidogenesis and metabolism 
(225, 226), although the poor reproducibility and small sample size of many of these studies 
has been limiting (225, 227, 228). A promising study, published by Barber et al., found that 
variants of the fat mass and obesity-associated (FTO) gene, which is associated with insulin 
resistance, obesity and type II diabetes (229-231), were linked to PCOS even after correcting 
for BMI, however, there was no association with increasing androgenaemia (232). Other 
genes that may be associated with PCOS and have a rol in insulin insensitivity include the 
peroxisome proliferator-activated receptors (233) and the insulin receptor (234). While one 
study found a mild association between the variable number of tandem repeats region of the 
insulin gene that is responsible for regulating insuli  secretion, with PCOS susceptibility 
(235), others did not (236, 237).  
 
Potential gene candidates for PCOS include genes involved in steroid biosynthesis. There are 
varying and inconsistent reports for the association of PCOS with the presence of specific 
alleles of the CYP11A gene (238, 239). A link between PCOS and polymorphisms of the 5α-
reductase gene have also been identified (240). Studies haveshown that 5α-reductase, which 
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is involved in conversion of testosterone into its more potent metabolite DHT and promoter 
of adrenal androgen output, may have implications for the androgenecity observed in PCOS 
(241-243). Another mechanism to alter circulating adrogen levels in PCOS would be via 
the aromatase enzyme, encoded by CYP19. However studies in this regard are once again 
inconsistent (239, 244). Although the CYP17 gene is a good candidate for linkage with 
PCOS, the presence of specific alleles has not been associated with PCOS (245-247), 
however, some have been linked to BMI and insulin resistance (247).  
 
Other correlations with PCOS have been found in patients that carry a specific allele of the 
extracellular matrix glycoprotein, fibrillin 3 (FBN3) gene, which has also been associated 
with increased fasting insulin and insulin resistance (248-250). Since the fibrillins can also 
regulate members of the TGFβ family (251, 252), which have roles in normal and 
pathophysiological ovarian function (253-256), the FBN3 gene became a gene widely 
researched for its link with PCOS. In addition, a recent study found that in ovaries from 
women with PCOS, the FBN3 protein was reduced or absent in primordial to primary 
follicles when compared to normal ovaries (257). This implies a role for this protein in 
folliculogenesis and links it to circumstances when these processes are disordered. 
 
1.2.3.2 Epigenetic transfer of PCOS traits 
 
The epigenetic modulation of gene expression during development and post-natally confers 
the plasticity that is crucial to allow adaptation to the external environment (258). 
Perturbations in this system however can lead to the pre-disposition and onset of adult 
chronic diseases (259, 260). The Barker hypothesis, co ned in 1990, postulated that exposure 
of a fetus to environmental insults at critical periods of development could programme long 
term changes in gene expression that manifest in adulthood (261, 262). This mode of 
epigenetic inheritance may therefore be transferred from mother to fetus through nutrition, 
stress, hormonal imbalances, exposure to environmental toxins and so forth that could have 
adverse effects on fetal development (263). There are numerous studies that highlight this 
programming phenomenon: one of the most cited being the long-term metabolic effects and 
cardiovascular disease, prevalent in offspring of wmen that were pregnant during the Dutch 
hunger winter in 1944-45 (264, 265). The low caloric intake and undernutrition during 
pregnancy resulted in a cohort of people that were born with low birth weights and were 
susceptible to diabetes, pulmonary disease and cancers in adult life, which was particularly 
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prevalent if starvation occurred during the third trimester of pregnancy (265, 266). 
Interestingly, obesity was more common in those indiv duals whose mothers were starved 
during early pregnancy (267) and early exposure to undernutrition has also been associated 
with schizophrenia and personality disorders (268, 269). Other studies have indicated that 
fetal adaptation to an unfavourable environment in utero can result in poor sensitivity to a 
plentiful post-natal environment (270, 271). This is commonly reflected by rapid post-natal 
catch-up growth which itself has been associated with the onset of obesity, diabetes and 
cardiovascular disease (270, 272, 273). In addition to utritional stress, maternal emotional 
stress, anxiety or depression can have adverse effects on fetal neurodevelopment (274). For 
example, assessment of infants of pregnant women in New York at the time of the 9/11 
attacks, found that they displayed cognitive and behavioural impairments at 9 months of age 
(275). Fetal exposure to the stress hormone cortisol has been directly shown to lead to poor 
cognitive development in the infant which is confounded by insecure maternal attachment 
revealing both the prenatal and post-natal impact of anxiety on long-term development (276).  
 
Animal studies have been particularly revealing in research of the cognitive, behavioural and 
metabolic aspects of fetal programming. The administrat on of a synthetic cortisol, 
dexamethasone, to pregnant rats leads to low birth weight in offspring, hypertension, obesity 
and type II diabetes (277-280). Undernutrition in sheep during early to mid-gestation results 
in increased adiposity in offspring (281), abnormal growth of the liver in adults (282) and 
has even been shown to programme an increased response t  emotional stressors and 
differential cognitive responses (283). Late gestation l undernutrition in the sheep leads to 
perturbed insulin-glucose homeostasis in adult offspring (284, 285). Studies of rodent 
programming models have shown that these traits can also be transferred to subsequent 
generations (286-288), demonstrating the inter-generational heritability that can occur as a 
result of adaptation to the in utero environment. 
 
There is evidence that humans are susceptible to epigenetic programming throughout life 
(258), however particularly sensitive periods during fetal or early life are vulnerable to 
adverse alterations to the environment (263). Widespread epigenetic changes are known to 
occur in the fetus during early embryogenesis and gametogenesis as this is crucial for the 
maintenance of cell lineage (260). There are various f rms of epigenetic modifications that 
can control gene expression (Fig. 1.8). One of the most studied is deoxyribonucleic acid 
(DNA) methylation in which biochemical changes are pplied to DNA to negatively regulate 
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transcription. This is a stable change in transcriptional control that is passed on during cell 
division (289).  
 
The majority of the genome is thought to be methylated to prevent aberrant gene expression 
(290). This genetic ‘mark’ occurs on cytosine (C) and guanine (G) dinucleotide repeats that 
are termed CpG sites (the ‘p’ referring to the linking phosphate bond). DNA 
methyltransferases are responsible for the catalytic transfer of methyl groups to the 5’ 
position of cytosine (289) and thereby maintain gene xpression patterns. Areas abundant in 
CpGs are called CpG islands and these are predominantly located in gene promoters but can 
be situated in downstream transcriptional regions (289). The binding of the methyl group 
confers transcriptional silence that is mediated by changes in chromatin structure through the 
recruitment of histone deacetylases (291). The removal f histone groups from lysine 
residues on the nucleosome by histone deacetylases renders the gene less transcriptionally 
active (Fig. 1.8) due to decreased binding of transcription factors and a more closed 
chromatin structure (259, 291). Hypomethylated CpG islands are generally found on 
promoters of genes in which transcription is constitutively active (289). An additional source 
of epigenetic control that is rapidly emerging is the role of small non-coding micro 
(mi)RNAs (Fig. 1 8). These are highly conserved across species and are approximately 22 
nucleotides in length (292). These short sequences bind to 3’ complementary sequences of 
target genes, dampening protein expression by preventing translation or tagging the mRNA 
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Figure 1.8  Methods of epigenetic regulation of gene transcription. The cartoon illustrates 
the normal chromatin structure and binding of transcription factors (TF) to DNA promoting 
gene expression. The action of histone deacetylases and DNA methyltransferases results in 
modification to the chromatin structure and prevention of TF binding to the promoter (P) 
region of the gene, thus suppressing transcription. An additional source of epigenetic 
control is the binding of specific microRNAs to the 3’ end of the mRNA sequences, inhibiting 
protein expression. 
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1.2.4 The development of animal PCOS models 
 
Given the lack of success in identifying candidate gene(s) to explain the heritability of 
PCOS, it is now believed that the epigenetic processes described, may be involved in the 
early programming of these reproductive and metabolic traits. Without being able to target 
specific genes, the development of animal models of PCOS would be challenging, however, 
there are numerous rodent (294, 295), non-human primate (296-298) and ovine (299-301) 
models available. The development of a model with PCOS-like traits occurred inadvertently 
through studies that were concerned with the masculinisation effects of prenatal androgens in 
non-human primates. Following behavioural studies in young offspring, animals were 
retained and allowed to mature into adulthood. It was in these individuals that the first 
observations of features reminiscent of PCOS were not d, including hyperandrogenism, 
PCO and anovulation (296, 298). 
 
If increased androgens are the basis for epigenetic programming of PCOS-like traits in 
humans, then the question arises as to the source of this steroid during pregnancy. It is 
possible that the hyperandrogenic state of a mother with PCOS could transfer sex steroids to 
the fetus (302). However, long-term studies have indicated that the level of circulating 
maternal androgens during mid- or late-pregnancy have no influence on the development of 
PCOS in adolescent daughters (303). Furthermore, in instances where maternal androgens 
are particularly high, due to an androgen secreting tumour, virilisation does not occur in 
female fetuses suggesting that the placenta is an adequ te barrier to androgens (304). 
Nevertheless, increased androgens could result in placental modifications that then go onto 
mediate programming effects (305). 
 
It is mostly argued that the fetus or the fetal environment is the source of increased 
androgens. In the fetus, androgens may be elevated through overactive ovarian or adrenal 
steroidogenesis. PCOS is also more common in women that have congenital adrenal 
hyperplasia (306), in which, due to a mutation in the CYP21 gene, steroid precursors are 
shunted into the androgen biosynthesis pathway. The fetal exposure of these women to 
increased adrenal androgens results in PCOS characteristi s, however, these phenotypes are 
severe in that these women are virilised (307), which is not a feature of PCOS. There is some 
suggestion that female fetuses that share the womb with a male twin could be exposed to 
increased androgens (308). In litter bearing species such as rodents and pigs there is evidence 
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that female offspring that have intrauterine positins between two males are born with 
masculinised morphological and behavioural traits (309). In female human fetuses, the effect 
of elevated prenatal androgens due to the presence of a male co-twin is not really known; 
however, there is some associative evidence for programming effects. Studies have observed 
the masculinisation of auditory development (310), dental crown size (311) and brain 
volume (312) in females from female-male twin sets. Reproductive fitness was reported to 
be affected in females that were opposite sex twins, measured by reduced fecundity (313), 
however, other studies have not identified this association (314, 315). 
 
The relationship between PCOS in adulthood and elevated in utero sex steroids may be 
causative or associative, and whether the altered fetal environment stems from maternal or 
fetal sources, is not known. The development of anim l models of PCOS have however 
provided insight into the fetal origins of this disorder, and in parallel with human studies, 
have contributed to our current understanding of the pathways that might lead to the ovarian, 
endocrine, adrenal and metabolic perturbations present in PCOS. The remainder of this 
review will discuss the findings from human and animal studies, which although can be 
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1.3 The ovary and PCOS 
 
1.3.1 Ovarian morphology and follicular growth in PCOS 
 
The polyfollicular phenotype, a striking characteristic of PCOS, is associated with 
anovulation and acyclicity and a disrupted hormonal profile in women (316). Studies of 
ovary biopsies from women with PCOS have highlighted aberrant follicle growth trajectories 
that might account for the increased numbers of small follicles present in these ovaries. In 
fact Webber et al. reported that in women with anovulatory PCOS there was an increased 
density of pre-antral follicles, particularly in the primary follicle pool. In both ovulatory and 
anovulatory PCOS the proportion of primary follicles increased and there was a 
corresponding decrease in the proportion of primordial follicles present (317). The enhanced 
number of growing primary follicles was speculated o be due to either an increase in the 
pool of primordial follicles or a decline in the rate of follicle regression (317). Maciel t al. 
also reported an increase in the number of growing primary follicles present in the ovaries of 
women with PCOS, however, they did not find an alter tion in the number of primordial 
follicles present, suggesting that the primordial reserve is not greater nor is there increased 
activation to transitional follicles. These authors found a greater number of follicles in PCOS 
compared to control ovaries at each follicle stage, without an increase in atresia, suggesting 
that the follicular growth trajectory is slowed (318).  
. 
Unlike the study by Maciel et al. other studies have found that parallel to the increase in total 
number of small growing follicles, there was an altera ion in the proportions of follicles at 
each developmental stage (317). Webber et al. also showed that there was a reduced loss of 
preantral follicles in cultured ovarian slices suggesting that atresia may in fact be reduced in 
PCOS (319). However, prior to culture, the proportion of healthy to atretic follicles between 
PCOS and control patients was not actually different (319). Discrepancies between studies 
may be related to the high level of heterogeneity present in individuals with PCOS, as well 
as slightly differing criteria for the diagnosis ofthe syndrome. Furthermore, separating 
women with PCOS into ovulatory and anovulatory cohorts for these types of studies is 
essential.  
 
Alterations in the level of follicular GDF9 have been proposed to have a role in the 
perturbation of follicle growth in PCOS ovaries. GDF9 and BMP15 are TGFβ oocyte-
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derived factors (320, 321) that are essential for follicular growth. In mouse knockout studies, 
GDF9 -/- blocks the growth of follicles at the primary stage affecting thecal, granulosa and 
oocyte function (322). The importance of BMP15 has been demonstrated in the Inverdale 
breed of sheep that carry a natural mutation in the BMP15 gene (323, 324). Sheep with a 
double mutation in BMP15 (FecXI/FecXI) have no follicular growth past the primary stage, 
with normal growth and development up until that point (253). Interestingly this effect is 
dose-dependent: a heterozygous mutant carrying one n rmal BMP15 allele has an increased 
ovulation and fecundity rate (324). Teixeira Filho et al. found that there was decreased 
oocyte GDF9, but not BMP15 expression, assessed by in situ hybridisation, in ovaries from 
women with PCOS and PCO when compared to control subjects. This decline in GDF9 
occurred in follicles of all developmental stages and implicates the loss of this oocyte-
derived growth factor in the aetiology of arrested or slowed follicular growth (325). 
 
Anti-müllerian hormone (AMH), also a member of the TGFβ superfamily, is another factor 
proposed as potential candidate for follicle growth irregularities in PCOS. AMH is derived 
from granulosa cells (326) and regulates the entry of follicles into the growing phase. In 
mice, AMH -/- results in an ovarian phenotype similar to that described in ovaries of women 
with PCOS (317), in which there is a decline in primordial follicle number and a reciprocal 
increase in growing primary follicles (327). Convers ly, culturing mouse ovaries with AMH 
leads to a reduced proportion of primary follicles, suggesting that AMH inhibits primordial 
follicle activation (328). Stubbs et al. investigated the link between AMH and follicle type 
and growth in PCOS and non-PCOS ovaries. They found that fewer primordial and 
transitional follicles were positive for AMH immunostaining in anovulatory PCOS compared 
to control and ovulatory PCOS ovaries, and that the AMH negative follicles had fewer 
granulosa cells (329). This study provides evidence that the loss of the AMH signal may 
have a role in the activation of primordial follicles but AMH may also have a role in 
granulosa cell proliferation throughout development. Another study by Stubbs et al. found 
that granulosa cell proliferation in preantral follicles was in fact increased in anovulatory 
PCOS compared to control and ovulatory PCOS ovaries (330). Due to the increased number 
of preantral follicles present in PCOS, the levels of AMH are increased (331), therefore this 
could be exerting a stimulatory effect on granulosa cell mitogenesis. Raised levels of ovarian 
AMH are not thought to effect peripheral primordial follicle development since these 
follicles do not possess a blood supply (19) and the cortical area is generally avascular (316). 
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1.3.1.1 The effect of the prenatal hormonal environment on ovarian 
morphology and follicular growth 
 
Prenatal androgenisation studies in sheep have shown that ovarian morphology and follicular 
dynamics are disrupted during fetal life. Exposure to testosterone from day (d)30-90 of a 147 
day gestation, led to an overall decrease in the number of follicles in the d140 ovary 
suggesting an effect on ovarian reserve (332). Steckler et al. showed that the proportion of 
follicles grouped by stage was also altered so that t ere was a decrease in the primordial 
follicle number and a reciprocal increase in follicles beyond the primordial stage, indicating 
increased and premature follicular recruitment (332). Similarly, Forsdike et al. found 
increased primary follicle number at the expense of primordial follicle number in 8 month 
old d30-90 prenatally androgenised lambs (333) in line with studies the human PCOS 
ovaries (317, 318), although by 20 months this effect was not observed as more follicles 
were growing in the control cohort (333). In adult d30-90 prenatally androgenised offspring, 
the tracking of ovarian follicles with the use of ultrasound revealed that prenatal testosterone 
programmed the failure of large follicles to regress (334). This is in agreement with human 
studies that show a reduction of follicular atresia in PCOS ovaries (319). This follicular 
persistence is speculated to be programmed by estrog n since prenatal treatment with DHT 
from d30-90 did not result in failure of regression (335). Interestingly, DHT, and not 
testosterone exposure, resulted in an increased number of small follicles in adult ovaries on 
ultrasound scan (335). 
 
1.3.1.2 The effect of the adult hormonal environment on ovarian 
morphology and follicular growth 
 
In addition to a programmed or epigenetic origin of the ovarian phenotype in PCOS, the 
consequential altered hormonal environment that the ovary is subjected to is also thought to 
contribute to the progression of the syndrome. The hyperandrogenaemia present in women 
with PCOS, partly caused by increased ovarian synthesis (Section 1.3.2), may also directly 
affect follicle growth. Vendola et al. treated adult normal-cycling Rhesus monkeys with 
testosterone or DHT for a short period and found that is acute treatment led to an increase 
in the number of preantral and small antral follicles compared to control ovaries. Thecal cell 
number and width was increased and granulosa and thecal cell immunostaining for the 
proliferative marker Ki67, showed an increase in proliferation following both testosterone 
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and DHT treatments. There was no effect on follicular atresia (336). These treatments also 
resulted in a significant increase in IGF1 mRNA in granulosa and thecal cells of preantral 
and small antral follicles as well as an up-regulation of IGFR1 mRNA, particularly in thecal 
cells (337). This is significant given the role of the IGF signalling system in follicle growth. 
In mice, IGF1 -/- results in arrested follicle growth due to thesuppression of granulosa cell 
FSHR expression, an effect which could be rescued by the addition of exogenous IGF1 
treatment (338). Unsurprisingly, IGF1 is found to be selectively expressed in follicles that 
are proliferating, and is switched off in luteinised follicles (339). The fact that the changes in 
gene expression in the studies by Vendola et l. were observed after both testosterone and 
DHT treatment indicate an androgenic signalling effect (336, 337).  
 
In addition, a study from the same laboratory investigated the expression of AR in the adult 
Rhesus monkey ovary following short-term testosteron  treatment. Weil et al. found that this 
treatment resulted in an up-regulation of AR mRNA in granulosa cells and a down-regulation 
in theca cells and stroma from ovaries of testostern  treated animals. Moreover there was 
increased granulosa cell proliferation and decreased poptosis in those follicles with more 
abundant AR (340), providing further evidence that increased follicle number and 
proliferation are androgenically regulated (336, 340). The same group also went on to show 
that AR and FSHR mRNAs are co-localised in healthy, growing follicles and short-term 
testosterone treatment also up-regulated granulosa cell FSHR (341) indicating that androgens 
indirectly promote follicle growth through enhancement of follicle sensitivity to FSH, 
possibly involving the up-regulation of follicular IGF1 (337). Although these animals were 
not subject to a chronic or prolonged period of adult androgen exposure, these studies 
highlight the effects of the local steroid environment in perturbing ovarian function, which 
are separate to the intrinsic effects programmed by androgens during fetal life. The evidence 
from the studies in the prenatally androgenised sheep (332-335) and that of Vendola et al. 
and Weir et al., suggest that the follicular dysregulation in women with PCOS (317-319, 
329, 330) may be both epigenetic as well as a product of the additive effects of androgens in 
adult life. 
 
Women with PCOS also tend to be hyperinsulinaemic: a product in part of increased central 
adiposity and the associated development of insulin resistance. The effects of increased 
insulin, which can directly target the ovary, may also contribute to the growth arrested 
phenotype of the PCOS follicle. It is known that insulin targets the granulosa cell via the 
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insulin receptor rather than the insulin-like growth factor 1 receptor (IGFR1) (342), and 
insulin treatment of cultured granulosa cells from PCOS patients leads to increased LH 
stimulated estradiol and progesterone production (343). These data imply that elevated 
insulin, common in PCOS, would drive early differentiation of granulosa cells and arrest 
follicle growth and are discussed further in Section 1.6. 
 
1.3.2 Ovarian steroidogenic output in PCOS 
 
Gilling-Smith et al. demonstrated the increased ability of thecal cells to produce androgens 
in PCOS. Androstenedione secretion was significantly i creased in cultured PCOS thecal 
cells compared to controls, both basally and following LH stimulation (344). Progesterone 
production was also enhanced in the PCOS thecal cells, which was speculated to contribute 
to increased androstenedione levels through conversion by steroidogenic enzymes (344). 
This finding has additionally been demonstrated in thecal cells over multiple culture 
passages implying that this is a stable and intrinsic phenotype (345). Evidence for the global 
up-regulation of thecal steroid synthesis in PCOS is also provided by the finding that genes 
involved in the steroidogenic pathway, including CYP11A and CYP17 are up-regulated in 
PCOS theca, as well enhanced enzyme activity of CYP17, HSD3B and HSD17B (345). 
 
Furthermore, steroid output from granulosa cells are lso disrupted in PCOS which is 
dependent on the ovulatory status of the individual (316). Willis et al. showed that normal 
and ovulatory PCOS granulosa cells respond to FSH and LH in much the same way, by 
increasing estradiol and progesterone production, with only large follicles responding to LH. 
However, the authors found that in anovulatory PCOS, not only was the response to LH 
augmented in terms of estradiol and progesterone secretion, but some small follicles also 
responded to LH (346). This latter observation could imply premature differentiation of 
granulosa cells that could contribute to the follicle growth arrest associated with suppressed 
FSH secretion (316).  
 
In the ovary insulin signalling also has a role in the control of steroid synthesis. Rice et al. 
showed that while insulin signalling in terms of glucose uptake and metabolism is impaired 
in anovulatory PCOS granulosa-lutein cells, steroidogenesis in the form of progesterone 
secretion is unaffected (347). This is thought to be due to alternate cellular downstream 
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insulin signalling pathways relaying the metabolic and steroidogenic responses to insulin. In 
this regard it is possible that a hyperinsulinaemic state, common in PCOS, would enhance 
granulosa cell steroid production in these individuals. Indeed, it has been shown that 
treatment of granulosa cells with insulin resulted in a significant increase in estradiol and 
progesterone secretion in subjects with PCOS (343).  
 
 
1.4 Endocrine disruption in PCOS models 
 
Since the early studies investigating the behavioural impact of prenatal testosterone on the 
offspring of non-human primates (348, 349), many studies have utilised this model as an 
approach to study reproductive dysfunction and PCOS in a range of animal models. The 
hormonal and ovarian features of this model, reminiscent of the common characteristics of 
PCOS have been well described in such studies. Endocri e disruption including LH 
hypersecretion and increased LH pulse frequency, have been observed in prenatally 
androgenised non-human primates (350, 351), sheep (299, 352) and perinatally androgenised 
mice (295) and rats (294). Numerous studies across a range of altricial and precocial animal 
species find that prenatal androgens have mixed effects on the timing of puberty, adult 
ovarian cyclicity, LH hypersecretion and increased LH pulse frequency and the ability to 
produce an LH surge (350). While timing of treatment, dose, type of androgen administered 
and species difference may account for some disparity, it is clear that in utero androgen 
exposure of a female fetus has a universal impact on reproductive fitness (350). In the sheep, 
as reviewed in detail below, administration of prenatal testosterone from d30-90 leads to a 
polyfollicular phenotype (301), perturbations in the timing of puberty (353, 354) and 
acyclicity (355), as well as LH hypersecretion and increased LH pulse frequency (299, 352). 
This phenotype has also been observed in other specie . In non-human primates early and 
late prenatally testosterone treated offspring exhibited polyfollicular ovaries (356), 
anovulation (350, 356) and delayed puberty (357). LH hyper-secretion was however 
restricted to those animals treated during the early gestational period (358).  
 
In altricial species including mice and rats, testosterone treatment around the perinatal period 
corresponds to the developmental stage during mid-gestation in many precocial species, such 
as non-human primates and sheep. Early neonatal androgen treatment of mice from postnatal 
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day (PND) 1-3 leads to acyclicity in adults (359). Prenatal treatment of dams with DHT 
resulted in LH hypersecretion and an increased GnRH pulse frequency in adult offspring 
(295). In rats, testosterone treatment at PND 1 delays puberty in addition to rendering 
animals acyclic (360, 361). Interestingly, postponing treatment until PND 5 results in the 
advancement of puberty and acyclicity in the rat (361). Additionally, late prenatal DHT 
treatment of dams resulted in a lack of inducible LH surge and an increased LH pulse 
frequency (294). Similar to studies in non-human primates and sheep, the ovaries of 
prenatally androgenised mice and rats display the characteristic polyfollicular phenotype. In 
rats, PCO and acyclicity has been induced by the treatment of adult animals with the 
estrogenic compound, estradiol valerate (362, 363), demonstrating a role for other steroids in 
the programming of these features. The pre-pubertal tre tment of rats with testosterone or 
DHT also results in an adult PCO phenotype (364, 365). Due to wealth of literature 
concerning the effects of prenatal androgens on gonad trophin dynamics, only touched upon 
here, a detailed overview will be restricted to the studies concerning the sheep PCOS model 
as this is the species studied in this thesis. 
 
1.4.1 Gonadotrophin dynamics in the prenatally androgenised sheep 
 
During development there is a critical period for masculinisation of the brain. In males, 
testosterone, produced by the developing testes, drives this programming so that the central 
nervous system is organised in a male-specific way (366-368). This directs the sequence of 
events controlling neuroendocrine and reproductive function in pre-pubertal and adult 
animals. In sheep, sexual differentiation is thought to occur between d30-100 (369). The 
specific periods for the programming of different types of reproductive function are however 
thought to be distinct. More than 30 years ago, Clarke et al. demonstrated that early 
testosterone treatment (d30-80) led to a severe masculini ed external genital phenotype in 
female offspring, whereas administering testosteron at a later stage of gestation (d50-100) 
led to a less severe or normal genital phenotype (370). Male behavioural traits were however 
programmed in testosterone treated animals regardless of the gestational period of exposure, 
with aggressive male-like behaviour observed in femal  animals (370). These ewes 
displayed mounting behaviour and also adopted the standing male urination posture (370).  
 
In the male sheep puberty begins at approximately 10 weeks of age, however, in females this 
does not occur to around 30 weeks of age, coinciding with the commencement of ovarian 
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cyclicity (371). Puberty is timed in part by growth, and in females, external cues such as 
photoperiod (369, 372). The onset of puberty is defined by the hypothalamic decrease in 
sensitivity to the negative effects of gonadal estradiol, stimulating an increased GnRH pulse 
frequency and subsequently increased tonic LH secretion from the pituitary (371). It is the 
release of the pre-pubertal gonadotrophin suppression that initiates sexual maturation and 
reproductive competence (369). Studies of prenatal androgenisation in females have also 
identified the role that testosterone plays in programming the timing of puberty onset. These 
confirm that exposure of a female ovine fetus to androgens earlier, from d30-90 of gestation, 
led to a masculinised external phenotype (373, 374), whereas exposure later, from d89-135, 
did not (374). However, in addition to studies investigating the effects of prenatal androgens 
on external and behavioural masculinisation, studies by Wood et al. and Herbosa and Foster, 
showed that the timing of puberty (increase in tonic LH) and defeminisation of the LH surge 
is also programmed before birth. In utero androgen exposure led to the advancement of 
puberty in females, illustrated by an early increase in LH secretion (between 16-20 weeks of 
age) independent of photoperiod, with the critical gestational period for this programming 
determined to be earlier (d30-90), rather than later (372-374).  
 
Herbosa and Foster also demonstrated that in early (d30-76) treated female sheep, the 
estradiol positive feedback pathway was diminished. These animals did not display an LH 
surge following stimulation with a large dose of estradiol indicating that this ovarian-
pituitary feedback system was lacking. In the later tr ated (d89-135) group, the LH response 
to estradiol did occur, however, the timing of the surge was delayed (374). Interestingly, a 
study by Wood et al. showed that d30-51 and d65-86 prenatal testosterone t eatment regimes 
both led to the differential effects in external masculinisation as described above and also to 
mutual advancement of puberty (375). Treatment from d30-86 resulted in defeminisation of 
the LH surge, however, this effect was absent in anm ls exposed to androgens during the 
two shorter periods (d30-51 and d65-86), who responded to estradiol, albeit significantly 
later than controls (375). These findings suggest that the length of prenatal androgenisation, 
as well as the timing, may be of importance in programming adult neuroendocrine function. 
Additionally, the dose of testosterone administered can affect the overall phenotype. Kosut et 
al. identified a dose-response effect for the consequential external masculinisation and 
timing of puberty effects of prenatal androgens, however, the estradiol positive feedback 
system was impaired at all doses (376), suggesting that this pathway is particularly 
vulnerable to an altered prenatal steroid environment. 
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The differential effects of androgens and estrogens have since been implicated in the 
programming of these reproductive traits. Since testosterone is readily converted into 
estrogen by aromatase, of which there are large amounts present in the placenta, the 
programming effects of androgens may have androgenic and/or estrogenic origins. Increased 
fetal serum estradiol was in fact recently demonstrated following prenatal testosterone 
administration in sheep from d30-90 of pregnancy (377). Non-aromatisable DHT has been 
commonly used in parallel with an aromatisable androgen, such as testosterone propionate 
(TP) or testosterone cypionate, to delineate between th  effects of androgens and estrogens. 
The prenatal effects of androgens in controlling positive and negative feedback have been 
investigated in this way. Masek et al. treated pregnant ewes with either DHT or testosterne 
from d30-90 of gestation. They found that both DHT and testosterone treatment resulted in 
the advancement of puberty in female offspring, however only TP treatment diminished the 
LH surge response to estradiol (353). These results imply androgenic programming of the 
hypothalamus but an estrogenic programming effect regulating estradiol positive feedback to 
the pituitary. 
 
These early studies describe ovine prenatal androgenisation experiments where the 
established method for monitoring hypothalamic-pituitary function is the ovariectomised 
model with addition of exogenous estradiol back into the animal to mimic ovarian 
production of this steroid (OVX + E2). This method avoids the effects of other ovarian 
factors on this system that might distort the findings related to estrogen signalling as well as 
standardising the amount of estradiol that each anim l s exposed to. While this provides a 
more controlled steroid environment, the endogenous hormonal profile from ovary-intact 
animals is important to study to identify the true physiological impact of prenatal androgens. 
For instance, Birch et al. found that while exposing fetuses to testosterone from d30-90 or 
d60-90 resulted in advancement of the initiation of tonic LH increase in gonadectomised 
animals, in ovary-intact animals ovarian cycling, as indicated by raised progesterone 
secretion, begun at the same time as control animals at around 30 weeks of age (355). 
Sharma et al. similarly did not find any advancement in the timing of puberty in prenatally 
d30-90 or d60-90 androgenised ovary-intact female sheep assessed by progestogenic cycling, 
although the timing of increased LH secretion was advanced. However, these animals did 
display a diminished estradiol positive feedback response (378) as described in the OVX + 
E2 model (378). Another study carried out by Sarma et l., found neither advancement nor 
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normal timing of puberty, but rather a 4 week delay in the commencement of cyclicity in 
ovary-intact d30-90 prenatally androgenised ewes (352). 
 
The differential effects of androgens and estrogens on the reproductive outcome in ovary-
intact sheep have been studied. Veiga Lopez et al. determined the differential effects of DHT 
and testosterone on positive and negative estradiol feedback (354). During the pre-pubertal 
stage (5 months of age) a GnRH antagonist was initially given to dampen endogenous 
ovarian estradiol. A small dose of exogenous estradiol was then administered to animals to 
reflect luteal phase estradiol levels. In this study, unlike other ovary-intact investigations 
(355, 378), an increase in tonic LH secretion was found to occur at a younger age in both 
DHT and testosterone prenatally treated female offspring (354). Administering a large dose 
of estradiol, equivalent to that found in the follicular phase, resulted in a normal LH surge in 
both control and DHT but not testosterone treated pr -pubertal animals (354). These results 
agree with the findings of earlier studies in the OVX + E2 model (353) that estradiol positive 
and negative feedback are differentially regulated by androgens and estrogens. 
 
Veiga-Lopez and colleagues have also demonstrated th  differential effects of prenatal 
androgenisation on hormonal and ovulatory dynamics during estrus. They have shown that 
during the first breeding season it is testosterone a d not DHT treatment, from d30-90 of 
gestation, that leads to increased peri-ovulatory estradiol concentrations, as well as a delayed 
LH surge in response to estradiol, which is additionally dampened in comparison with 
controls (354). The increased level of estradiol secretion during the follicular phase is a 
likely consequence of an increased number of antral follicles pertaining to the polyfollicular 
phenotype, that are observed in testosterone but not DHT-exposed animals (301). These 
effects appear to have an estrogenic mode of programming that is distinct from other 
reproductive traits of prenatal androgenisation. For example, hypergonadotrophism is 
observed in female offspring from sheep prenatally exposed to both testosterone and DHT 
(379), suggesting an androgenic programming effect.  
 
The timing of in utero androgenisation can also affect the hormonal dynamics in the adult. 
Studies have shown that prenatal androgen treatment from gestational d30-90 but not d60-90 
resulted in the dampening of the LH surge in respone to increased estradiol (378, 379). The 
reduced LH surge observed in these animals does not appear to be linked to the absolute 
amount of estradiol secreted by the ovary since peri-ovulatory estradiol secretion is increased 
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(354, 380) and administering high levels of exogenous estradiol to these animals pre-
pubertally also results in a diminished LH surge (353, 378). This suggests that there may be 
impairment at the level of the hypothalamus and/or pituitary gland. It is possible that the 
pituitary receptivity to estrogens may be altered or desensitised (379) or that the 
pathophysiological increase in LH pulse frequency and mplitude during the follicular phase 
(352) may account for more depleted pituitary gonadtroph stores. Prenatal testosterone 
treatment from d60-90 does not affect cycle regularity or luteal function, evidenced by 
normal preovulatory estradiol, and unaltered luteal progesterone secretion or length, in the 
first or second breeding seasons (299, 355). Conversely, in d30-90 treated offspring, while 
regular cycles present in the first breeding season, animals become anovulatory by the 
following season (355). Prenatal androgens from d60-90 does however lead to an increase in 
the LH pulse frequency during the follicular phase and still affects the timing of the LH 
surge, which is delayed following a peak in estradiol, although the amplitude of the LH surge 
is unaffected (299). 
 
The LH hypersecretion and increased pulse frequency a d amplitude that is observed in the 
prenatally androgenised ewe (299, 352) also suggests a defect in estradiol negative feedback. 
In the pre-pubertal d30-90 androgenised sheep, there is an increase in LH pulse frequency 
and amplitude and a greater LH to FSH ratio (352). This latter effect is thought to reflect the 
increase in LH secretion rather than a decrease in FSH secretion, since administration of a 
GnRH antagonist ablated LH secretion but only had a sm ll dampening effect on FSH (352). 
Furthermore, GnRH bolus stimulation leads to an increased response in LH but not FSH in 
both d30-90 testosterone and DHT exposed animals (379). This indicates that the reduction 
in estradiol negative feedback is mediated by an increase in sensitivity to GnRH, that this is 
an androgenic programming effect, and also provides evidence for the differential control of 
LH and FSH secretion in these animals (379). Given that these hormones are secreted from 
the same gonadotroph and that estradiol negative feedback is known to regulate both LH and 
FSH secretion (381) this is unexpected. It is possible that other modulators of FSH secretion 
may play a role, of which activin, inhibin and follistatin have been proposed (382). One 
piece of evidence for this is the differential effect of estradiol stimulated LH and FSH release 
from the ovine pituitary (383). Baratta et al. demonstrated that stimulating ovine pituitary 
cells with estradiol in vitro resulted in diminished FSH but augmented LH secretion. FSHB 
and INHBB subunit mRNA was also reduced, suggesting a role for activin B in activating 
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FSH secretion. Indeed, incubating pituitary cells with an activin B neutralising antibody 
reduced FSH secretion but did not affect LH secretion (383). 
 
Mannikam et al. published extensive adult pituitary gene analyses in d30-90 testosterone 
treated female offspring which did not, however, reveal alterations in the expression of 
INHBB, INHA, FST or β-Glycan subunits, although there was a treatment related up-
regulation of an ACVR1 (379). Interestingly, GnRHR, ERα and ERβ gene expression were 
unaffected as were LHβ and FSHβ subunits, however, the common α gonadotrophin subunit 
was up-regulated by prenatal testosterone exposure (379). Since ACVR1 was up-regulated 
but there was no affect on LHβ expression, these authors suggest that the increased LH 
secretion observed in these animals may occur via post-translational modifications of the 
LHβ subunit, alterations to GnRHR or ER degradation (379). 
 
In the ovary, the expression of activin and inhibin subunit and follistatin mRNA have also 
been examined in prenatally androgenised offspring (301). West et al. measured follicular 
mRNA expression by in situ hybridisation in ovaries from 5 week old animals that were 
exposed to testosterone or DHT in utero from d30-90. The study found a significant increase 
in the number of follicles expressing FST and a trend for decreased INHBB in testosterone 
and DHT exposed animals, suggesting that intra-ovarian activin levels could be diminished 
through an androgenic programming effect (301). The authors hypothesise that a reduction in 
activin availability could contribute to the selection defects (112) and follicle growth arrest 
(113) that are present in polycystic ovaries in women (125-128). Indeed, West e al. 
demonstrate increased antral follicle number in prenatally androgenised lamb ovaries. 
However, the fact that this phenotype is observed in the testosterone and not DHT exposed 
animals, suggests an estrogenic course of action, and therefore does question the role of 
activins at this stage given that the authors found that altered FST and INHBB expression 
followed androgenic programming (testosterone and DHT) (301). Furthermore, the serum 
levels of gonadotrophins were not altered by 5 weeks in these animals implying that 
potential altered ovarian activin levels were not having an endocrine effect on FSH secretion, 
thereby not affecting growth of follicles in the FSH-dependant stage (301). This suggests 
that the polyfollicular phenotype and altered activin/follistatin mRNA observed in these 
lambs may not be causally associated. 
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1.5 The adrenal gland and PCOS 
 
Like the HPO axis which regulates ovarian function, the HPA axis modulates adrenal 
function and controls the body’s response to stress, primarily mediated through the 
production of cortisol. This circuitry is regulated and controlled through feedback loops so 
that increasing levels of cortisol negatively feedback to the pituitary to dampen ACTH 
secretion (384). The HPA axis maintains physiological homeostasis and functions in a 
circadian pulsatile manner so that cortisol production during the day is timed (385). In the 
event of physiological stress the HPA axis is activated to produce a surge in cortisol. Such 
stressors that are known to activate the HPA axis include physical stress such as 
hypoglycaemia (386), undernutrition (387), intense ex rcise (388), and surgery (389), as well 
as emotional stress (390). The main driver of adrenal steroidogenesis is ACTH which is 
released from the anterior pituitary (384). Corticotrophs within the pituitary secrete ACTH 
upon stimulation by corticotrophin releasing hormone, secreted by the hypothalamus (384). 
ACTH regulates adrenal steroidogenesis through a number of pathways, including the uptake 
of lipids from plasma into adrenocorticotroph cells and the formation of cholesterol esters 
(32, 391). Furthermore, ACTH stimulates StAR expression, thus driving the transport of 
cholesterol across the mitochondrial membrane (392). 
 
The adrenal glands are anatomically situated above the kidneys in the retroperitoneum, and 
are also responsible for the biosynthesis of mineralocorticoids, which are important for 
kidney function, and adrenal androgens (31). The adr nal glands are composed of distinct 
tissue regions that each has a specific role. The inn r medullary region is responsible for the 
secretion of catecholamines, adrenaline and noradren lin , which are required for the body’s 
‘fight or flight’ response. The outer cortical region or ‘cortex’ produces the corticosteroids. 
The cortex itself is split into three zones that contain specific cell types responsible for the 
secretion of hormones. These zones, from the inner to outer cortex, include the zona 
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1.5.1 Steroidogenesis in the adrenal gland 
 
The adrenal is a major source of hormones and each cortical zone contains the specific 
enzymes required for conversion of cholesterol precursors into distinct groups of hormones 
(Fig. 1.9). Within the zona reticularis androgens are synthesised including DHEA, DHEA 
sulphate (DHEAS), androstenedione and testosterone (384, 393). The glucocorticoids, 
cortisol and corticosterone, are produced in the zona fasciculata (31, 384). The zona 
glomerulosa produces the mineralocorticoid, aldoster n  (384). For the synthesis of 
glucocorticoids additional enzymes are involved including the P450 enzymes CYP21 and 
CYP11B1. The conversion of the androgen DHEA into DHEAS is catalysed by DHEA 
sulfotransferase 2A1 (SULT2A1). The role of CYP11A, 3β-HSD, CYP17 and 17β-HSD are 
described in Section 1.1.5. Below is a description of the enzymes involved in adrenal-
specific steroidogenesis with focus on the glucocorti id and androgen pathways. 
 
• CYP21 (21-hydroxylase) 
In the zona fasciculata, the catalytic conversion of 17α-OH progesterone into deoxycortisol 
is carried out by CYP21, which is exclusively express d in the adrenal gland (134). The 
human fetal adrenal gland also expresses CYP21 which is present from 14 weeks of 
gestation and beyond (394, 395). In the ovine fetus the presence of CYP21 is well 
characterised in late gestation due to the role of cortisol in regulating parturition in the sheep 
(396-398). 
 
• CYP11B1 (11β-hydroxylase) 
In the final step in the cortisol biosynthesis pathway deoxycortisol is hydroxylated into 
cortisol by the enzymatic action of CYP11B1, specific to the adrenal cortex (134). Like 
CYP21, CYP11B1 is present in the developing adrenal gl nd in humans (395), rodents 
(399), primates (395) and sheep (400). 
 
• SULT2A1 
DHEA is sulphated by SULT2A1 to produce DHEAS, which s the most highly produced 
adrenal hormone (401). SULT2A1 is exclusively present in the adrenocortical cells of the 
zona reticularis  (401) 
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Figure 1.9  The steroidogenic pathway in the adrenal gland. Precursors and products of the 
steroidogenic pathway are represented in black and the enzymes required for each bio-
synthesis step are indicated in blue. Pathways in grey are alternative steroidogenic 
pathways. 
 
1.5.2 Adrenal androgen production and PCOS 
 
The adrenal gland is a significant contributor to circulating androgens in women. While 
DHEAS is exclusively produced by the adrenal, the adrenal contribution to DHEA, 
androstenedione and testosterone is thought to be approximately 50%, 50% and 25%, 
respectively, with the remainder produced by the ovary or by peripheral conversion (393). 
Both DHEA and DHEAS are produced by the fetal adrenal gland (402), but their secretion 
declines after birth until adrenarche at about 6-8 years in the human (403). Adrenarche is a 
phenomenon that occurs in humans and higher primates (404, 405). At adrenarche the zona 
reticularis matures and the adrenal produces DHEA and DHEAS, before the onset of puberty 
and the associated rise in sex steroids (403), without an associated increase in cortisol 
production (401). During this time there is a reciprocal increase in CYP17 and decrease in 
3β-HSD in the zona reticularis to favour androgen production (406, 407). The role of 
adrenarche in human physiology is however poorly understood (407). 
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In addition to ovarian hyperandrogenism in women, androgen excess in the form of DHEA 
and DHEAS secretion is known to occur in some women with PCOS (408-411). Moreover, 
daughters of women with PCOS have been shown to have an exaggerated adrenarche and 
produce higher levels of DHEAS than controls (412). The same individuals also had 
increased serum 17α-OH progesterone after stimulation with ACTH, suggesting increased 
activity of CYP17 (412). In addition to DHEA, androstenedione levels are also greater in 
women with PCOS following ACTH stimulation (413, 414). This is suggestive of a heritable 
programming effect of PCOS that may be induced by maternal hyperandrogenism. Indeed, in 
the rhesus monkey model of PCOS, basal levels of DHEA were elevated in prenatally 
androgenised animals compared to controls (297, 415). Zhou et al. demonstrated that after 
stimulation with ACTH, both DHEA and androstenedione were found to be significantly 
increased in these animals. In control animals DHEA reached peak values 15 min after 
ACTH stimulation and then declined, however in prenatally androgenised monkeys DHEA 
levels were still increasing 60 min following stimulation (415). Basally, androstenedione 
levels were not altered between control and prenatally androgenised group, however 15, 30 
and 60 min post-ACTH stimulation, androstenedione was significantly elevated in the 
treated groups (415). In the control cohort, androstenedione peaked at 15 min, however in 
the prenatally androgenised monkeys this did not happen until 30 min post-ACTH (415). 
Interestingly, there were no alterations in the serum levels of 17α-OH progesterone in the 
rhesus monkey model following adrenal stimulation (415), unlike studies in humans (412-
414). 
 
1.5.3 Glucocorticoid production and PCOS 
 
There are numerous downstream roles for the glucocorticoids which are crucial for 
maintaining homeostasis in a variety of tissues. Cortisol has permissive roles in fat 
metabolism and hepatic glycogen production from protein. Cortisol also has roles in the 
central nervous system, cardiovascular control, immune response and inflammation and also 
acts on muscle, bone and the kidneys (31). Cortisol exerts its effect through binding of the 
glucocorticoid receptor (GR), which depending on the tissue requirement for cortisol action, 
will vary in expression. Cortisol is secreted in a diurnal rhythm increasing during the night 
and low throughout the day (416). This is important for the regulation of metabolic processes 
that occur during sleep, including gluconeogenesis and lipolysis (417-419). Cortisol 
negatively regulates insulin action so that it prevents glucose uptake and storage by 
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peripheral tissues and releases insulin-mediated inhibition of liver glucose production (31). 
This latter effect on gluconeogenesis occurs through the stimulation of the gluconeogenic 
enzyme phosphoenolpyruvate carboxykinase (PEPCK) gene, which is inhibited by insulin 
(420). The catalytic action of PEPCK is the rate-limiting step of the synthesis of glucose 
from non-carbohydrate sources such as lactate and its regulation is important in maintaining 
glucose homeostasis (421, 422). The effect of cortisol on PEPCK expression has also been 
shown to be long-term in that exposure to high levels of glucocorticoids during late 
pregnancy in the rat can lead to the permanent up-regulation of hepatic PEPCK and GR gene 
expression, culminating in hyperglycaemia (423). Cortis l also increases appetite and 
therefore caloric intake, and can have a direct effect on fat, stimulating lipolysis and 
inducing differentiation of adipocytes. Cortisol exc ss can therefore lead to obesity which is 
characterised by central fat distribution, and is a distinct symptom of disorders of cortisol 
production such as Cushing’s syndrome (31). 
 
Given the wide ranging and complex roles of cortisol, glucocorticoid action in peripheral 
tissues must be carefully regulated. Tissues can control the amount of cortisol that can act 
locally by increasing or decreasing the levels of the inactive metabolite of cortisol, cortisone. 
This process is regulated by the action of the hydroxysteroid dehydrogenase enzymes, type 1 
and type 2 11β-HSD, which interconvert active inactive forms of crtisol (31). Type 1 11β-
HSD catalytically converts cortisone into cortisol in cortisol target tissues such as muscle, 
liver, fat and bone and can act bi-directionally (424). Type 2 11β-HSD is responsible for the 
inactivation of cortisol by conversion into cortisone. This reaction is important in tissues that 
are targets of the mineralocorticoids such as the kidney. Glucocorticoids can bind to the 
mineralocorticoid receptor with a higher affinity than the mineralocorticoid aldosterone, and 
thus these hormones compete for binding sites. The inactivation of cortisol by type 2 11β-
HSD is therefore a crucial requirement for mineralocorticoid signalling in this tissue (31, 
424). Cortisol can also negatively regulate its own expression by directly down-regulating 
GR, which also leads to a reduction in type 1 11β-HSD expression, and therefore cortisol 
levels decline (31). The placenta characteristically lso expresses type 2 11β-HSD, to protect 
the fetus from elevated maternal glucocorticoids, which might adversely effect the fetus 
(425). 
 
Like increased adrenal androgen output, studies have revealed that the secretion of 
glucocorticoids can also be dysregulated in PCOS. Women with PCOS appear to have an 
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enhanced HPA activation to stress, demonstrated by increased levels of ACTH and cortisol 
output compared to controls in response to a stress stimulus (426). Similar effects have been 
found in the Rhesus monkey model of PCOS, in which prenatal androgenisation 
programmed the increased secretion of corticosterone upon adrenal stimulation with ACTH, 
although cortisol was unchanged (415). In control anim ls corticosterone peaked 15 min 
post-ACTH; however, levels were still increasing in the androgenised animals after 60 min. 
Also, treatment with the synthetic glucocorticoid dexamethasone, to suppress adrenal 
steroidogenesis, resulted in a decrease in corticosterone levels in control, but not in the 
PCOS-model monkeys (415). While not published it was noted in a review by Dumesic et al. 
that basal and ACTH-stimulated levels of cortisol were not altered in the prenatally 
androgenised sheep PCOS model (427). 
 
 
1.6 The role of obesity and metabolic dysregulation in PCOS 
 
Obesity and the associated metabolic disorders including type II diabetes have been steadily 
increasing in Western populations for the last few decades and are now present in epidemic 
proportions (428, 429). The relatively recent advances in technology and changes in 
lifestyles have resulted in a sudden shift in daily calorie consumption and a parallel increase 
in sedentary behaviour (428, 430), which are now becoming more prevalent in adolescents 
and young adults (431). The negative effects of these abrupt alterations in the external 
environment are clear, with central fat accumulation linked to various illnesses including 
cardiovascular disease, hypertension, metabolic syndrome and reproductive dysfunction 
(430, 432). It is unsurprising therefore that central adiposity is associated with PCOS (166). 
Increased central obesity leads to insulin resistance, and as food is consumed more and more 
insulin is required to store glucose as glycogen in the peripheral tissues. A hyperinsulinaemic 
state evolves to compensate for the increased resistance to insulin in tissues such as muscle 
and fat in which the uptake of glucose occurs, and to the liver in which glucose release is 
suppressed (433). Over time this physiological intervention is no longer adequate and 
glucose homeostasis is inappropriately regulated resulting in hyperglycaemia and the 
development of type II diabetes mellitus (434). 
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Insulin acts on peripheral tissues by binding to the to the insulin receptor, a heterotetramer 
that is composed of two extracellular α-subunits and two membrane spanning β-subunits 
linked by disulphide bonds (200). Binding of the ligand to the α-subunits results in 
phosphorylation of the tyrosine kinase of the intracellular β-subunits. This leads to the 
phosphorylation and activation of downstream signalling cascades, resulting in the 
recruitment of the insulin receptor substrates which a tivate either the phosphoinositide 3′ 
kinase intracellular pathway, involved in driving glucose transport, or the mitogen activated 
protein kinase pathway, that promotes the mitogenic ffects of insulin (433). Perturbation in 
the expression of some of these pathway constituents in both adipocytes and muscle has been 
linked with insulin resistance and type II diabetes (435-437). Furthermore, intrinsic 
abnormalities have been documented in insulin signall ng in PCOS. Post-receptor defects 
have been identified in fat and muscle of women with PCOS (438-440). In cultures of skin 
fibroblasts from women with PCOS, a defect in insulin receptor signalling was identified 
where basal activation of the insulin receptor was increased, and hence insulin-stimulation 
had little effect on receptor auto-phosphorylation compared to controls (441). It has also 
been shown that the defects affecting insulin signalling in skin fibroblasts are selective so 
that it is the metabolic pathway and not the mitogenic pathway that is affected (442). In 
skeletal muscle from women with PCOS, however, there are indications that the mitogenic 
downstream effects of insulin are altered (443, 444). 
 
There is a positive correlation between increasing central adiposity and insulin, glucose, 
triglyceride and cholesterol measurements and the insulin resistance index (445). Increased 
central fat in women is also associated with elevatd free total testosterone indexes which are 
directly regulated by the presence of sex hormone bi ging globulin (SHBG) which binds 
androgens, sequestering their activity. SHBG is decreased in these individuals and the 
subsequent rise in unbound testosterone is associated wi h male-like fat distribution (430). 
Approximately 40% of obese PCOS women are insulin resistant (167, 168, 446) which is 
significantly more prevalent than the levels found i  ethnicity, age and weight matched 
control populations (447, 448). Moreover, women with PCOS are more likely to develop 
type II diabetes than weight matched controls (449, 450). While central fat mass, insulin 
resistance and hyperandrogenism are correlated with PCOS (451), not all women with PCOS 
are obese and a significant number have normal BMIs. It appears that while central obesity 
and elevated androgens in PCOS are associated with insulin resistance, obesity may exert an 
additive secondary role to the overall phenotype of insulin hypersecretion, rather than a 
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causative one (430). Dunaif et al. demonstrated that insulin-stimulated glucose utilisation 
was perturbed in both lean and obese PCOS women, with both subsets experiencing reduced 
insulin sensitivity compared to controls, however these effects were significantly worse in 
the presence of obesity (167, 168, 446). These studies indicate that some degree of 
hyperinsulinaemia may be common to all women with PCOS and it is not entirely due to 
decreased insulin clearance. This may reflect pancre ti  β-cell dysfunction, and that only 
obese women with PCOS are likely to become glucose intolerant (434, 452).  
 
The hyperandrogenic state present in PCOS combined with hyperinsulinaemia and central 
obesity, form a vicious circle of positive feedback in which one feature augments the next. 
There is evidence that androgens can directly increase adipocyte number in cultured female 
rat adipose tissue (453) and decrease hepatic insulin receptor numbers (454), which could 
modulate insulin-mediated hepatic glucose suppression. There is also some evidence for the 
development of mild insulin resistance through exposure to androgens (455, 456), however, 
treatment of women with androgen antagonists had variable outcomes (200, 457-459). What 
is known is that hyperinsulinaemia in PCOS can augment androgen production by 
stimulating ovarian thecal cell androgen production (434, 460, 461). One of the mechanisms 
that has been proposed to mediate this is the insulin induced increase in thecal 17α-
hydroxylase activity (205). Women with PCOS who had been treated with metformin 
demonstrated a reduction in the levels of 17α-OH progesterone after LH stimulation, and a 
concomitant decrease in serum androgen levels, compared to women with PCOS who had 
not undergone the insulin sensitising treatment (205). Furthermore, in vitro treatment of 
cultured porcine thecal cells with insulin in the presence of LH has been demonstrated to 
lead to the up-regulation of StAR and CYP17 transcripts (462). 
 
Insulin and the insulin receptor are highly homologus to IGF1 and the IGF1R, respectively 
(463), and insulin and IGF1 can bind to both receptors albeit with less affinity than the native 
ligand (464). IGF1, IGF1R and insulin receptor genes are expressed in the human ovary (60), 
and while there is some insulin present in follicular fluid (465) this is thought to be through 
perfusion from the systemic circulation. In PCOS, the increased concentration of peripheral 
insulin is proposed to lead to increased stimulation of the ovarian IGF1R and lead to 
increased steroidogenesis (434). However, it has also been shown that in cultured granulosa 
cells the inhibition of the insulin receptor but not the IGF1R had a detrimental effect on 
estrogen and progesterone synthesis (342) suggestin that the insulin receptor is required in 
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these cells. Likewise in human thecal cell cultures, while both insulin and IGF1 stimulated 
androgen production (461, 466-469), only inhibition of insulin receptor signalling prevented 
the increase in androgen biosynthesis (461, 469). 
 
The selective perturbations of insulin signalling pathways leading to metabolic dysregulation 
in peripheral tissues and insulin resistance may not affect ovarian insulin signalling required 
for steroidogenesis. Therefore insulin is capable of stimulating androgen production in the 
ovaries of women that are insulin resistant (468). Indeed studies have shown that in cultures 
of human PCOS granulosa cells the metabolic but not he mitogenic/steroidogenic actions of 
insulin are defective (347, 470). Outside the ovary, insulin has other actions to enhance 
androgen production. Insulin can act directly on the liver to suppress the hepatic production 
of IGFBPs (471, 472), thereby further augmenting free IGF1 levels in PCOS. In addition, 
insulin can negatively regulate the production of SHBG by the liver in women with PCOS 
(472, 473), hence further increasing the bioavailability of androgens. Additional evidence for 
the role of insulin in enhancing circulating androgen levels are the findings that treating 
women with PCOS with insulin sensitising drugs such as metformin or troglitazone (204, 
213), or with drugs that inhibit insulin secretion including diazoxide or somatostatin (474, 
475), considerably lowers free androgen and increases SHBG levels. 
 
1.6.1 Metabolic dysregulation in the prenatally androgenised animal 
model of PCOS 
 
The metabolic features of early androgen exposure as well as the reproductive characteristics 
are clear in models of PCOS in rodents (365, 476), non-human primates (298, 477) and 
sheep (478, 479). Pre-pubertal administration of DHT to female rats leads to increased body 
weight and fat, and enlarged adipocytes, as well as raised circulating leptin and insulin 
resistance (365). Other studies have shown a re-distribution of fat in female mice exposed to 
androgens peri-natally so that there is an increase in mesenteric (visceral fat) and also an 
increase in lean muscle mass (480). Assessment of prenatally androgenised female mice 
revealed hyperglycaemia and a reduced glucose toleranc  that was caused by impaired 
pancreatic islet function (476). In vitro treatment of pancreatic islet cells with androgens also 
resulted in diminished response to glucose stimulation implying that both programming by 
androgens and elevated endogenous androgens in the adult can contribute to the metabolic 
phenotype (476). 
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In the prenatally androgenised Rhesus monkey model, differential metabolic defects were 
detected in adult animals as a result of early and l te gestational androgen exposure. In early 
treated offspring pancreatic β-cell function was impaired with a decrease in acute pancreatic 
responsiveness to glucose, however, in late treated offspring insulin sensitivity was 
decreased and this was correlated with increasing BMI (298). Assessment of the fat 
distribution in adult animals that were exposed to androgens early in gestation revealed that 
total abdominal fat and visceral fat were significantly increased compared to controls at the 
expense of other fat depots, indicating a re-distribu ion of fat reserves (477). In late TP 
treated Rhesus monkeys however, there was an overall increase in the percentage of total 
body fat and central adiposity compared to early treated and control animals (481). In the 
ovine model of PCOS, in which the pregnant ewe was administered androgens from d30-90 
of gestation, increased insulin concentrations and  reduced sensitivity to insulin were 
reported in 5 week old offspring (478). The same metabolic defects were observed in 11 
week old lambs that were prenatally treated with TP or DHT from d30-90, indicating that 
these traits are programmed by androgenic actions (479). Furthermore, the time window in 
which this programming occurs was narrowed down to mid-gestation, since androgenisation 
from d60-90 resulted in a similar phenotype to the d30-90 offspring (479). Glucose clearance 
was not however altered in the ovine PCOS model following glucose tolerance testing, 
implying that instead of a pancreatic defect in these animals, hyper-insulinaemia occurred as 
a compensatory mechanism to insulin resistance in pripheral tissue (479). 
 
In addition to the early programming of metabolic dysfunction in the PCOS model, the direct 
effect of obesity was examined in the prenatally androgenised sheep (479, 482). Offspring 
that had been prenatally exposed to TP from d30-90 were over-fed from 14 weeks of age 
until they were 25% heavier than controls. Ovarian cycling defects and perturbations in 
hormonal dynamics were most profound in obese TP-treated offspring compared to non-
obese TP-exposed animals. Obesity in control animals also led to mild reproductive 
anomalies compared to the TP-treated animals (482). At 20 weeks of age insulin sensitivity 
was severely impaired in the obese TP-exposed animals, compared to the non-obese TP 
treated ewes, and obese controls also had a mild phenotype that was not as pronounced as the 
non-obese TP-exposed animals (479). Therefore while prenatal androgens can programme a 
pre-disposition to be insulin insensitive, the external environment can significantly augment 
this phenotype. This draws parallels with the impact of obesity in women with PCOS. 
Furthermore, the clinical studies that show improvement of the metabolic and reproductive 
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aspects of PCOS through treatment with insulin sensitisers (204, 213) have been replicated 
in the sheep model. A sub-group of adult sheep that were exposed to TP from d30-90 of 
gestation were treated with the insulin sensitiser rosiglitazone for 8 months commencing 
after the first breeding season (483). This resulted in reduced insulin concentrations and 
improved insulin sensitivity, compared to TP-treated animals without insulin sensitising 
treatment. This treatment also resulted in a much hig er proportion of ewes that were cycling 
in the second breeding season in comparison to no intervention (483). Similar results were 
described in the prenatally androgenised Rhesus monkey model in which treatment with 
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1.7 The objectives of this thesis 
 
As discussed, PCOS is a complex disorder encompassing a variety of features that present 
with differing permutations and severity from patien  to patient. The advent of the prenatally 
androgenised animal model has allowed for research into the origins of this disorder, which 
appear to be centred on the fetal programming effect of steroid hormones including 
androgens and estrogens. Studies that have administered alternative androgens to the mother, 
such as DHT that cannot be aromatised into estrogens, have aided the current understanding 
of the differential effects that the steroid hormones can exert. In this thesis, a novel model of 
prenatal androgenisation is introduced, with the objective of improving or adding to the 
present knowledge of the origins of PCOS. This intervention involves the delivery of 
androgens directly to the ovine fetus during mid-gestation and by-passes the maternal 
circulation and thus potential placental steroid modification effects (Chapter 3). Over 
development and in adult life, the reproductive, endocrine and metabolic aspects that are 
common to PCOS, and present in other animal models, are assessed and compared to an 
established mid-gestational maternal model of prenatal androgenisation. 
 
In addition to assessing the adult hormonal (Chapter 6) and ovarian (Chapter 7) dynamics 
that are central to PCOS, a number of additional, and novel, pathways or features are also 
investigated throughout this thesis. These include the examination of the role of genes and 
proteins that have developmental roles such as cell differentiation, proliferation and 
apoptosis, including the inhibitors of differentiation (Ids) and the Roundabout (ROBO) and 
SLIT family, in the fetal ovary (Chapter 4). This characterisation of the Ids for the first time 
in the mammalian ovary prompted a thorough investigation of Id protein localisation and 
gene regulation in the normal adult ovary (Chapter 5) and the ovary after prenatal 
androgenisation (Chapter 7). In addition, this ovine model of PCOS is used to investigate 
novel alterations in adult metabolic tissues, including adrenal function (Chapter 8), the 
development of fatty liver, and the expression of the gluconeogenic enzyme PEPCK and the 
growth factor, IGF1, in adult livers (Chapter 9). 
 
The work presented in this thesis reveals the effects of prenatal androgenisation during 
development, which perturbs ovarian, adrenal and liver gene expression. In the young adult 
animal, a thorough endocrine and ovarian assessment d monstrates that mid-gestation 
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androgenisation of the ovine fetus does not result in the hormonal or ovarian morphological 
features typical of adult PCOS. This provided a uniq e model in which to investigate 
intrinsic programming alterations in the ovary in the absence of high levels of LH and 
androgens. Major findings that are discussed in this esis include an enhanced drive for 
ovarian and adrenal androgen production, and early indications of metabolic and hepatic 
dysfunction, in adult prenatally androgenised offspring. In addition, a substantial part of this 
work involved the characterisation of the direct fetally androgenised cohort which revealed a 
separate but common phenotype, occurring in both control and androgenised animals. This 
surprising finding highlighted two important points that suggest that: A) a combination of 
pathways may programme the adult features of PCOS that could occur independently or be 
additive, and B) a relatively uninvasive fetal and/or maternal procedure is sufficient to 
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This chapter details the general materials and methods that were employed in this thesis. Any 
work that was carried out in conjunction with others is duly acknowledged in the chapters in 
which the specific work was presented. All reagents and chemicals listed in this thesis were 
purchased from Sigma-Aldrich (Gillingham, Dorset, UK), unless otherwise stated.  
 
2.2 Animal husbandry 
 
A flock of Scottish Greyface ewes were purchased for these studies and housed and cared for 
at the Marshall Building, Roslin, Midlothian under the regulations authorised by UK Home 
Office Project Licence Number 60/3744. The animals included in these studies were bred 
over two consecutive years from 2007-2009. 
 
2.2.1 Mating and pregnant ewe husbandry   
 
Ewes with good body conditioning scores (2-3) were mated with Texel rams under natural 
seasonal breeding conditions from November to January. Prior to mating, estrous cycles 
were aligned in two separate groups that were staggered over two weeks to achieve 
pregnancy at the same time for the majority of animls within each group. Chronogest CR 
sponges impregnated with 20mg flugstone acetate (Inrvet UK Ltd., Buckinghamshire, UK) 
were inserted into the vagina for 10-12 days. At sponge withdrawal animals were given 
0.5ml prostaglandin estrumate (i.m.; Schering Plough Animal Health, Welwyn Garden City, 
UK) to terminate the luteal phase. Ewes not carrying a reference paint marker on their hind 
to indicate ram-ewe contact, were considered not mated, and were returned for mating a 
second time. Pregnancy was confirmed by ultrasound scan and ewes placed into treatment 
groups according to the number of fetuses (singleton, twin or triplet pregnancies). Pregnant 
ewes were housed in groups in spacious enclosures and fed hay ad libitum, supplemented 
with Excel Ewe Nuts (0.5-1.0 kg daily; Carrs Billington, Lancashire, UK) and Crystalyx 
Extra High Energy Lick (Caltech Solway Mills, Cumbria, UK). To avoid dominant females 
from over-feeding at the expense of smaller ewes, these animals were housed in separate 
pens. All ewes were boosted against Clostridial diseases and Pasteurellosis 4-6 weeks before 
lambing by treatment with Heptavac P Plus (Intervet UK Ltd.). 
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2.2.2 Pregnant ewe treatment regimes 
 
Treatment regimes began at gestational d60-62 of an average 147 day gestation and are 
illustrated in Table 2.1. TP (AMS Biotechnology (Europe) Ltd., Abingdon, UK) was 
dissolved in vegetable oil (Sainsbury’s SO organic range) and 5% ethanol to a concentration 
of 100mg/ml and stored in an incubator at 37°C, to prevent crystal formation, until ready to 
use. Vehicle controls (C) consisted of vegetable oi and 5% ethanol and was stored in the 
same way. Maternal injections were delivered (i.m.; 1ml) into the hind region and included 
ewes carrying singleton, twin and triplet pregnancies of which there was an equal 
distribution for control or TP groups. Fetal injections were carried out only in singleton or 
twin pregnancies following anaesthesia of the mother. Ewes were sedated using 10mg 
Xylazine (i.m.; Rompun; Bayor Plc Animal Health Division. Berkshire, UK), left to settle 
for 10 min, then given 2.0mg/kg ketamine (i.v.; Keteset; Fort Dodge Animal Health, 
Southampton, UK). Ewes were additionally administered a post-operative dose of antibiotics 
(1ml/25kg; i.m.; Streptacare; Animalcare Ltd., York, UK). Under surgically sterile 
conditions, injections were performed with the guidance of ultrasound using a vaginal probe 
fitted with a needle guide. A 20G Quincke spinal needl  (BD Biosciences, Oxford, UK) was 
inserted through the uterine wall and into the flank of the fetus. Delivery of fluid into the 
peritoneal cavity (200µl) was monitored by ultrasound and any anomaly such as leakage into 
amniotic fluid or uptake into the fetal circulation was recorded. Ultrasound was performed 
by Dr Colin Duncan and fetal injection carried out by Professor Alan McNeilly or Kirsten 
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Table 2.1  The pregnant ewe treatment regimes and resulting offspring. Timings of 
treatment regimes for pregnant ewes and a breakdown of treatment cohorts, listing 
concentration of TP delivered, age of sacrifice and collection, and number of offspring 
present in each group. F: female, M: male.   
 
2.2.3 Husbandry and assessment of lamb and young adult offspring 
 
Lambs were suckled or supplemented with a powdered lamb milk substitute (Shepherdess, 
SCA Mill, North Yorkshire, UK), then weaned gradually onto hay and grass, away from 
dams, at 12 weeks. Lambs were also vaccinated at 3 and 7 weeks with Heptavac P Plus 
(Intervet UK Ltd.). Various parameters were assessed in offspring from birth until 11 months 
of age, to assess the effects of prenatal androgenisation on growth, metabolic homeostasis 
and adrenal sensitivity. These included glucose tolrance testing (GTT), synacthen testing 
and serial blood sampling and are described in detail in the specific chapter in which these 
methods are included. 
Gestational Day 
(d) 
Treatment Conc. Collection Stage 
Offspring 
Sample Size (n) 
Maternal Treatment Regime 
Fetal (d70) F:3 , M:8 
Fetal (d90) F:6 , M:12 





Adults (11 months) F:5 
Fetal (d70) F:6 , M:5 
Fetal (d90) F:8 , M:13 








Adults (11 months) F:9 
Fetal Treatment Regime 
C - Fetal (d70) F:4 , M:5 
d60 
TP 20mg Fetal (d70) F:8 , M:3 
Lambs (12 weeks) F:6 , M:11 
C - 
Adults (11 months) F:4 
Lambs (12 weeks) F:6 , M:10 
d62 and d72 
TP 20mg 
Adults (11 months) F:8 
Lambs (12 weeks) M:6 
C - 
Adults (11 months) F:4 
Lambs (12 weeks) M:4 
TP 1mg 
Adults (11 months) F:5 
Lambs (12 weeks) M: 10 
TP 4mg 
Adults (11 months) F:5 
Lambs (12 weeks) M:2 
d62 and d82 
TP 20mg 
Adults (11 months) F:7 
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2.3 Animal sacrifice and collection of specimens 
 
2.3.1 Fetal, lamb and adult animal sacrifice 
 
Pregnant ewes were euthanised at d70 or d90 of pregnancy and their fetus(es) immediately 
collected, or lambs were born and sacrificed at 3 months or 11 months of age. For 11 month 
old animals, estrous cycles were synchronised so that animals were sacrificed during estrus. 
Ewes received two injections of 125mg prostaglandin estrumate (i.m.; Schering Plough 
Animal Health) 11 days apart to ensure that all cyces were aligned.  Euthanasia was carried 
out in accordance with the regulatory outline of Schedule 1: Appropriate Methods of 
Humane Killing of the Animals (Scientific Procedures) Act 1986. A single lethal injection of 
pentobarbitone sodium (150mg/kg; i.v.; Euthetal; Merial Animal Health Ltd., Essex, UK) 
was administered to the animal. 
 
2.3.2 Tissue and plasma collection 
 
A range of tissues were collected from animals for studies outlined in this thesis, as well as 
ongoing studies in the Duncan laboratory (Table 2.2). Fetal blood was also collected in 
heparinised tubes at the time of sacrifice, spun at 3000 rpm at 4°C for 15 min and the plasma 
stored at -20°C. Weights of various postnatal tissue  were recorded immediately following 
dissection and before excising a small portion for fixing or freezing. These included lamb or 
adult ovaries, testes, adrenal glands, pituitaries and in the adult only, omental fat.  Tissues 
were either fixed in Bouins solution, to prevent tissue degradation and maintain tissue 
integrity, or snap frozen in dry ice followed by storage at -80°C, to prevent RNA 
degradation. In adult cohorts, an additional liver sample was collected and embedded in 
cassettes containing OCT compound (VWR International, Leicestershire, UK) and snap 
frozen in dry ice. These samples were stored at -80°C. 
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Table 2.2  Bank of ovine tissues collected at the time of sacrifice. * Tissue collected from the 
mothers during fetal collection. 
1
Tissue fixed only. 
2
Tissue snap frozen only. N.B. Not all of 
















Adrenal Gland     
Fat 
subcutaneous 
    
Fat visceral     
Heart     
Kidney     
Muscle    
2 
Liver     
Lung     
Pancreas     
Placenta     
Thymus     
Thyroid Gland     
Spleen     
Testes/Ovaries     
Epididymis     
Uterus     
Mammary Gland  
1
   
Scrotum 
1
    
Skin 
1
    
Pituitary Gland 
1
    
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Tissues including the ovary and liver were processed for histological assessment in the 
studies described in this thesis. 
 
2.4.1 Tissue fixation, processing and sectioning 
 
Tissues were fixed in Bouins solution at the time of collection for 24 h and then transferred 
to 70% ethanol. Samples were processed in an automated Leica TP1050 tissue processor 
(Leica Microsystems, Milton Keynes, UK) followed byembedding in heated liquid paraffin 
wax and cooled into blocks for long term storage at room temperature. Tissues were 
sectioned at a thickness of 5µm using a Leica RM 2135 microtome and wax ribbons were 
transferred to a pre-heated water bath (55°C), to float the sections to remove creases in the 
tissues. Sections were mounted onto charged slides (Superfrost Plus, ThermoScientific, 
Gerhard Menzel Gmbh, Braunschwein, Germany) and placed in an incubator at 50°C 
overnight to dry. 
 
2.4.2 Haematoxylin and eosin staining 
 
In order to visualise tissue morphology microscopically, haematoxylin and eosin (H&E) 
staining was performed. Haematoxylin stains cell nuclei blue/purple and is counterstained 
with eosin which leaves a pink residue in the cytoplasmic region of cells. This technique 
allows for the determination of differential tissue patterns, or, the identification of particular 
cell types such as the granulosa cells of an ovarian follicle. Sections were de-waxed in 
xylene (VWR International; 2x5 min), re-hydrated through a series of alcohols (100%, 
100%, 95%, 70% ethanol and distilled H2O (dH20) for 20 sec each) and tissue was stained in 
haematoxylin for 1 min before rinsing in dH2O. Tissue was very briefly rinsed in acid 
alcohol (1% HCl in 70% ethanol) to remove excess traces of purple stain from the glass slide 
and washed in dH20. Sections were placed in Scott’s tap water (blueing reagent) for 30 sec 
and rinsed dH20, before immersion in eosin for 30 sec and a further washing step. The tissue 
was subsequently dehydrated through a series of alchols (70%, 80%, 95%, 100%, 100% 
ethanol for 20 sec each) and cleared in xylene for 5 min, before mounting with a cover slip 
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(VWR International) using pertex mounting media (Cell Path, Hemel Hempstead, UK). 
Slides were allowed to dry for a sufficient time in a fume hood before visualisation of tissue 
using a light microscope. 
 
2.4.3 Immunohistochemistry and immunofluorescence 
 
The immunolocalisation of proteins in tissues can be achieved using immunohistochemistry 
and immunofluorescence techniques. The former involves visualisation of antigen binding 
via a colourimetric enzymatic reaction, while the latter consists of detection of a bound 
fluorescent signal at the protein of interest. The advantage of immunofluorescence is that 
dual localisation may be carried out so that two different proteins assigned to fluorophores 
emitting different spectrums of colour can be visualised. In this thesis both types of protein 




This technique utilises the antibody to antigen binding principle that is employed by the 
immune systems of mammalian species to combat foreign invasion of bacteria or viruses. 
Primary antibodies recognise a specific antigen epitope and bind strongly to it when they 
come into contact. In the direct method of immunohistochemistry this is a one step process 
where the primary antibody is bound directly to a reporter molecule, however, this method 
can be insensitive due to the low abundance of binding. More common is the indirect method 
that uses two or even three layers of complexes to considerably increase binding and amplify 
the signal. Secondary antibodies bind to the bound primary antibody thus adding a second 
layer that will involve multiple binding to an antigen. They are often chemically linked to 
biotin or peroxidase, which recruit binding proteins that consist of the tertiary antibody or 
complex. This complex contains an enzyme such as alkaline phosphatase or horseradish 
peroxidase (HRP) and binds with a high affinity to the secondary antibody. In the case where 
a biotinylated secondary antibody is used the ABC tertiary complex is applied which is 
consists of an avidin-biotin-peroxidase complex. When HRP-conjugated secondary 
antibodies are employed a tertiary step is applied consisting of addition of a peroxidase anti-
peroxidase immunoglobulin (IgG) complex. The final step in the process involves the 
addition of a compound (substrate) which reacts with the enzyme linked to the tertiary 
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complex to form a strong colour or stain. A commonly used organic compound for this 
purpose is 3,3'-diaminobenzidine (DAB), which is oxidised in the presence of peroxidase 
producing a brown colour. 
 
2.4.3.1.1 Antigen retrieval 
 
It is often necessary to include an antigen retrieval step to the immunohistochemistry 
protocol. This process, usually by heating but can be chemical, breaks the cross linking of 
proteins that can be induced by the fixative and thus exposes the antigen epitopes for 
antibody binding that might otherwise be inaccessible. In these studies cross-links were 
removed by heating in a citrate based buffer. Following de-waxing and dehydration 
(described in Section 2.4.2), slides were completely submerged in a pressure cooker 
containing citrate buffer (0.05M, pH 6.0) and pressure cooked for 5 min before cooling for 
20 min. The sections were rinsed in dH2O and then washed in phosphate buffered saline 
(PBS; 2x5 min). 
 
2.4.3.1.2 Blocking steps 
 
A caveat of utilising a technique based on a biological binding principle is the occurrence of 
naturally occurring molecules in tissues and cells that can interfere with exogenously 
introduced molecules and thereby increase the risk of non-specific binding and false-
positives, otherwise known as ‘background staining’. There are a number of steps in an 
immunohistochemistry protocol to reduce the extent of non-specific binding of endogenous 
molecules present in the tissue. The first step is blocking of endogenous peroxidase activity 
that must be carried out when implementing peroxidase-based detection systems. Quenching 
of peroxidase activity was performed by the addition of 3% hydrogen peroxide (diluted in 
dH2O) for 10 min and further PBS washing (2x5 min). In addition to the presence of 
endogenous peroxidase, endogenous biotin will also be present in some tissues, which may 
result in non-specific staining when the biotinylated secondary antibody system is employed. 
To mask these sites an avidin/biotin kit (Vector Laboratories, Peterborough, Cambs, UK) 
was used when necessary. Avidin was added to the section to bind endogenous biotin for 15 
min, slides were then washed in PBS and incubated with biotin for 15 min to saturate any 
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remaining biotin-binding sites introduced by the exogenous avidin. Slides were subsequently 
washed in PBS. The final blocking step involves the incubation of tissue with normal serum 
belonging to the host animal that the secondary antibody was raised in. IgGs present in the 
serum can therefore bind to non-specific sites present in the tissue so that they will be 
inaccessible to the secondary antibody. Slides were ca fully wiped with tissue to remove 
excess liquid and placed in a humidity chamber containing damp paper towels. If necessary 
an area around the tissue was isolated with use of a wax pen (Daido Sangyo Co., Ltd., 
Tokyo, Japan) to introduce a hydrophobic barrier and retain the solution over the tissue. This 
was especially useful if the tissue size was small (e.g. fetal ovary) so that it could be easily 
identified, or, if a high concentration of antibody was required then a smaller volume could 
be added. The appropriate normal serum was incubated wi h the tissue, in a closed humidity 
chamber, for 1 h at room temperature. 
 
2.4.3.1.3 Primary antibodies 
 
Both monoclonal and polyclonal primary antibodies are commonly used in 
immunohistochemistry. Excess normal serum was removd from the slide and the primary 
antibody, diluted to the appropriate optimised concentration in normal serum, was added to 
the tissue overnight at 4°C. Negative controls are detailed fully in each experimental chapter. 
They consisted of primary antibody omission, the us of non-specific IgGs or, where 
commercially available, binding proteins for that an ibody were purchased and pre-incubated 
in excess with antibody before applying to tissue.  
 
• Monoclonal antibodies 
Monoclonal primary antibodies are the most specific type as they exclusively bind to one 
antigen epitope and are produced from clones of immune cells. In the antigen-immunised 
mouse, spleen cells are collected and fused with myeloma cells, which introduce 
immortalisation. These hybrid cells are cultured in a selective medium and the supernatant 
containing secreted monoclonal IgGs is collected. Specific clones are tested for their binding 
ability and are then propagated in vitro or in vivo. 
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• Polyclonal antibodies 
Polyclonal primary antibodies are a mixture of IgGs that bind to a selection of epitopes 
present on a specific antigen. Common host animals inc ude mice, rabbits, goats, chickens 
and sheep that are immunised against a certain antigen. Serum containing the polyclonal IgG 
is collected and purified. 
 
2.4.3.1.4 Colourimetric detection, counterstaining and mounting 
 
Following incubation with the primary antibody, sections were washed with PBS containing 
1% tween (PBST; 2x5 min) and subsequently incubated with the appropriate species 
secondary biotinylated antibody diluted 1:500 in normal serum for 1 h at room temperature. 
Slides were washed in PBST (2x5 min) and the tertiary ABC complex (Vector Laboratories) 
added for 1 h at room temperature as per the manufacturer’s protocol. Colourimetric 
detection was achieved by the addition of liquid DAB substrate (Dako, Glostrup, Denmark) 
diluted as directed and incubated with the tissue for approximately 30 sec to 1 min. The 
enzymatic reaction was stopped when slides were placed in dH2O. Tissue was counterstained 
with haematoxylin for 1 min and rinsed in dH2O. Acid alcohol and Scott’s tap water were 
applied as described in Section 2.4.2 (omitting the eosin step) as were dehydration of tissue 
and subsequent mounting with cover slips and pertex. 
 
2.4.3.1.5 Light microscopy and imaging 
 
Protein immunolocalisation was visualised using a Standard 20 Zeiss light microscope (Carl 
Zeiss Ltd., Welwyn Garden City, UK) and images captured using an Olympus Provis BX2 
microscope (Olympus America Inc., Center Valley, PA, USA), attached to a Canon E0S 30D 
Microcam camera (Canon Inc. Headquarters, Tokyo, Japan) using Axiovert v4.8 software 
(Carl Zeiss Ltd.). Images were exported as Jpg files and scale bars and appropriate text 
embedded in figures using Photoshop CS (Adobe Systems Inc., Mountain View, CA, USA). 
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Similarly to immunohistochemistry, there are various methods for immunofluorescent 
antigen detection. The direct method involves the sole addition of a primary antibody 
conjugated to a fluorophore (a fluorescent dye that emi s light at a certain wavelength). The 
indirect method includes the addition of a secondary antibody which is chemically linked to 
the fluorescent chromagen rather than the primary antibody. Finally, a more sensitive 
method of indirect detection can be achieved by the addition of a fluorophore-conjugated 
tertiary antibody that binds the regular secondary antibody and amplifies the signal to a 
greater extent. The immunofluorescence protocols in these studies implemented this latter 
method of antigen detection. Tissue sections are initially treated in the same way as for 
immunohistochemistry (Section 2.4.3.1) up to and including addition of the secondary 
antibody, however, the dilution of the primary antibody and the type of secondary antibody 
used is dependant on the type of tertiary detection system employed. 
 
2.4.3.2.1 Streptavidin detection system 
 
For a fluorescent detection system using a streptavidin tertiary complex conjugated to a 
fluorophore, the primary antibody concentration remains the same as for 
immunohistochemistry and the secondary antibody is biotinylated. This is a more 
economical method and is optimal for good quality, reliable antibodies that do not require 
use at very high concentrations. Following PBST washing (2x5 min) the tertiary complex, 
Streptavidin Alexafluor -488 (Invitrogen, Paisley, UK) which emits green light when excited 
at this wavelength and is visible at a reduced wavelength, was added to the tissue section at 
1:200 (diluted in PBS) for 1 h at room temperature. From this point onwards slides were 
incubated, and all washing steps were performed, in the dark to reduce photo bleaching 
through natural light exposure. Sections were washed in PBST (2x5 min) and re-blocked 
with the appropriate normal serum for 30 min before application of the second primary 
antibody overnight at 4°C. On the third experimental d y as on day 2, the second 
biotinylated antibody was added, followed by addition of the tertiary complex, Streptavidin 
Alexafluor -546 (Invitrogen), which emits a red colour upon excitation. Following PBST 
washes (2x5 min) sections were counterstained by incubation with 4',6-diamidino-2-
phenylindole (DAPI), a nuclear stain that emits blue light, diluted 1:1000 in PBS for 10 min. 
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Tissue was rinsed in PBS and mounted with cover slips using PermaFluor aqueous mounting 
media (Fisher Scientific Ltd., Leicestershire, UK). 
 
2.4.3.2.2 Tyramide enhanced detection system 
 
The tyramide enhanced system of detection is optimal for primary antibodies that bind less 
well to the intended target as it is possible to dilute them 10-fold of that optimised for 
immunohistochemistry; however, the reagents are more expensive. Secondary antibodies 
used in this system are peroxidase-conjugated and applied to slides at 1:200 (diluted in 
normal serum) for 1 h at room temperature. Slides wre washed in PBST (2x5 min) and, in 
the dark, were incubated with Tyr-Fluorescein (green; PerkinElmer, Cambridge, UK) diluted 
1:50, in buffer supplied by the manufacturer, for 10 min at room temperature. Following 
PBST washes (2x5 min) tissue underwent antigen retrieval by placing slides in pre-heated 
citrate buffer pH 6.0 (0.05M) and micro-waving on full power for 2.5 min. The slides were 
cooled for 30 min then re-blocked in normal serum for 30 min and the secondary primary 
added overnight at 4°C. On the third day the secondary peroxidase-linked antibody was 
applied, followed by the tertiary complex, a Tyr-Cy3 (red; PerkinElmer), as above. Sections 
were washed, counterstained and mounted as described in Section 2.4.3.2.1. 
 
The advantage of these systems is that they can also be combined so that primary antibodies 
raised in the same species may be used together in the same experiment, since the secondary 
antibodies employed are conjugated to different report r systems. For example, a goat 
primary antibody could be detected using an anti-goat biotinylated secondary antibody and 
the streptavidin tertiary system followed by a second goat primary antibody which could be 
detected using an anti-goat peroxidase linked secondary antibody and the tyramide tertiary 
system. 
 
2.4.3.2.3 Fluorescent microscopy and imaging 
 
Images were captured using an LSM 510 Meta confocal microscope and Zen 2008 software 
(Carl Zeiss Ltd.). Images were exported as Jpg files and assembled using Photoshop CS 
(Adobe Systems Inc.). 
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Radioimmunoassays (RIAs) were employed as a highly sensitive method for detection of a 
range of hormones in sheep plasma. The technique utilises antigen-antibody binding as an 
inverse measure of the quantity of an antigen (hormone) in the sample. An antigen of interest 
is radioactively labelled, often with the gamma radioisotope Iodine-125 (125I) as iodine atoms 
readily incorporate into the tyrosine residues of a protein. A known concentration of this 
radiolabelled antigen (tracer) and an unknown concentration of antigen in serum are 
combined with a primary antibody specific to the antigen. The antigen competes with the 
tracer for antibody binding, displacing it, so that as the concentration of the antigen in the 
serum sample increases, the quantity of bound radioactive tracer decreases. The primary 
antibody is then precipitated by binding to a secondary antibody and the unbound and bound 
fractions are separated by washing in a detergent based buffer. A solid pellet is formed by 
centrifugation, the unbound fraction is discarded an the radioactivity of the bound fraction 
is measured using a gamma counter. There is an inverse r lationship between the number of 
gamma counts in a sample and the concentration of ulabelled antigen which is determined 
by the use of a standard binding curve. 
 
2.5.1 Serum extraction 
 
In some assays it is necessary to first extract the serum from the sample to prevent non-
specific binding of the antibody to serum binding proteins. When optimising the assay an 
experiment with and without extraction should be performed initially to determine whether 
differences in binding occur. Assays in this study that were identified as requiring serum 
extraction included testosterone, androstenedione and estradiol. Extraction volumes were 
100µl serum for testosterone, 150µl serum for androstenedione and 200µl serum for estradiol 
assays. In large glass Pyrex test tubes, serum was mixed with 2ml diethyl ether (VWR 
International) in a fume hood and vortexed for 3 min. Tubes were placed in a bath containing 
dry ice and industrial methylated spirit (VWR International), to freeze the serum into a solid 
state. The solvent containing the extracted sample was poured off into 12x75mm glass test-
tubes (Fisher Scientific Ltd.) and the solvent allowed evaporate overnight. Tubes containing 
the extract were covered and refrigerated at 4°C for st rage of up to two weeks. Prior to 
assay the extract was re-constituted in phosphate gelatine buffer saline (PGBS) assay buffer 
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(Table 2.3) 30 min before use. The volume of assay buffer added was 300µl for testosterone 
and androstenedione assays (if assaying testosterone in male serum samples 500µl should be 
added) and 200µl for estradiol assays. Since only small amounts of estradiol were detectable 
in the samples, the extraction was performed in duplicate and the assay carried out directly in 
the extraction tubes. 
 
 






Up to 1l with  dH2O: pH with HCl 
Phosphate Buffer 0.05M pH 7.5 Quantity (g) 
Na2HPO42H2O 66.75 
NaH2PO42H2O 19.5 
Bovine Serum Albumin (BSA) 1.0 
Thiomersal 0.1 
Up to 1l with  dH2O: pH with HCl 





Up to 1l with  dH2O: pH with NaOH 
Table 2.3  RIA assay buffers. Reagents and quantities required to prepare buffers specific to 
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2.5.2 Assay protocol 
 
The steroid assays (testosterone, progesterone, androstenedione, estradiol and cortisol) were 
performed over two days with the addition of antibodies and tracer on day 1 and separation 
on day 2. Assays were set up in duplicate including total count (T0), non-specific binding 
(NSB), zero binding (B0) and high and low quality control (QC) tubes. Standards were set 
up in order of increasing concentration followed by unknown samples, also in duplicate. 
Firstly, the required volumes of unknown/standard an  ssay buffer (Appendix A) were 
added to the 10x75mm polypropylene test-tubes (Sarstedt Ltd., Leicester, UK). The primary 
antibody (100µl) and tracer (100µl) diluted in assay buffer to working concentration and 
required amount of radioactivity (Appendix A) in counts per minute (cpm) respectively, 
were then added to the tubes. Assay buffer (200µl), primary antibody (100µl) and tracer 
(100µl) were added to B0 tubes. Assay buffer (300µl) and tracer (100µl) were added to NSB 
tubes. In progesterone and cortisol assays where th serum sample was not extracted, the 
same volume of charcoal-stripped sheep plasma was included in the tubes containing 
standards, NSBs and B0s. Tracer alone (100µl) was added to T0 tubes. Tubes were vortexed, 
covered and incubated at room temperature for a minimum of 4 hours.  
 
The secondary antibody (100µl), consisting of a combination of donkey anti-rabbit IgG 
(Diagnostics Scotland; T022; 1:60) and normal rabbit serum (NRS; MP Biomedicals, 
Illkirch, France; 1:600) diluted in assay buffer, was added to all tubes except T0 tubes. Tubes 
were vortexed, covered and incubated overnight at 4°C. On day 2, 1ml wash buffer 
(polyethylene glycol 4%, saline 0.9%, triton 0.2%) was added to each tube apart from T0 
tubes, and tubes were centrifuged at 3000 rpm at 4ºC for 30 min. The supernatant was 
discarded and the tubes were carefully blotted to remove excess liquid before processing the 
assay on a Wizard 1470 Automatic Gamma Counter (Perkin-Elmer Inc., MA, USA) to give 
raw γ counts.  
 
For non-steroid assays, including LH and FSH, a four day protocol was implemented where 
the tracer, secondary antibody and wash solution were added on days 2, 3, and 4, 
respectively, with overnight incubations at 4°C following each step. For the Multispecies 
Leptin Assay Kit (Millipore), tracer was added on day 2 and the primary antibody 
precipitated directly in supplied wash buffer contai ing goat anti-guinea pig IgG on day 3. 
In-house buffers, standards, and secondary antibodies were employed for the MAIA 
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Oestradiol Assay Kit (Inverness Medical UK) and it was possible to dilute the supplied 
tracer to around 12,000 cpm to extend the use of the kit. Detailed descriptions of the 
antibody concentration, tracer count, standard concentrations, required buffer and volume of 
each component, for each assay carried out, are listed in Appendix A. 
 
2.5.3 Assay Analysis 
 
Computational software AssayZap (Biosoft, Cambridge, UK) was used to analyse the raw 
data (γ counts per min) generated from each bound fraction (pellet). This programme 
automatically constructs a standard curve from a pre-determined method file and calculates 
results by interpolating unknown values with those f the standard binding curve. Data were 
exported to an Excel file for further analysis. Quality controls, included in every assay were 
used to determine inter- and intra-assay co-efficients of variation (CVs). These were usually 
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2.6 Enzyme-linked immunosorbent assay 
 
Similarly to immunohistochemistry and radioimmunoassay, enzyme-linked immunosorbent 
assays (ELISAs) also work on the antigen-antibody binding principle as a method for the 
detection and quantification of an unknown quantity of protein in a sample. This thesis 
utilised a commercially available ELISA kit for the determination of plasma insulin (80-
INSOV-E01, Alpco Diagnostics, Salem, NH, USA). This a say incorporated the two-site or 
‘sandwich’ enzyme immunoassay format in which 96-well polystyrene microtiter plates 
were pre-coated with a specific anti-antigen (insulin) IgG. The sample containing an 
unknown quantity of insulin was added and bound to the coated well. The anti-insulin 
conjugate, which is bound directly to the reporter molecule HRP, was subsequently added 
creating a sandwich of antigen bound between two layers of antibody. The amount of bound 
antigen was then determined by the addition of 3,3’,5,5’-tetramethylbenzidine (TMB) 
substrate initiating an enzymatic colourimetric reaction. The reaction was terminated by 
adding an acidic stop solution, resulting in a colour change from blue to yellow, with the 
intensity of colour directly proportional to the amount of antigen present in the sample. The 
optical density was immediately read on a spectrophotometer (ThermoMax Microplate 
Reader; Molecular Devices, CA, USA) at 450nm with a reference wavelength of 650nm to 
control for background. Concentrations were determined by extrapolation from a standard 
curve, subtracting any background measured by the addition of a set of blanks, and the 
results calculated using SoftMax Pro software (Molecu ar Devices). Low and high 
concentrated calibrators were also included to determine assay precision within and between 
assays. The insulin ELISA inter- and intra-assay CVs were <6% and 5%, respectively, and 
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2.7 Western blotting 
 
Western blotting is a method for the qualitative and semi-quantitative detection of a target 
protein in tissues or cells. This method utilises antigen-antibody interactions to bind to and 
detect a specific protein in a sample. A known quantity of total protein is separated by 
molecular weight (Mw) using sodium dodecyl sulphate (SDS) polyacrylamide gel 
electrophoresis (PAGE). The proteins are subsequently transferred to a membrane, which is 
probed with a specific primary antibody and an HRP-conjugated secondary antibody. 
Chemiluminescent detection is employed to visualise protein bands: contact with the HRP 
conjugate and the chemiluminescent reagents results in cleavage and production of a 
luminescent signal in proportion to the amount of bund antibody. The light emitted from 
this reaction is visualised by exposure of the immunoblot to photographic film allowing for 
the detection of individual protein bands on the blot. The use of an internal control 
concomitantly ensures consistent loading and can be used as a reference for semi-
quantification of results. 
 
2.7.1 Protein digestion 
 
To extract protein from tissue, a small representative piece was excised over dry ice to 
ensure that the material did not thaw and the sample was immediately transferred to a 1.5ml 
eppendorf containing 300µl lysis buffer consisting of 1% NP-40, 150mM NaCl, 5mM EDTA 
pH 8.0, 50mM Tris-HCl and proteinase inhibitor (1 tablet per 20ml; Roche Diagnostics 
GmbH, Mannheim, Germany). Samples were kept on ice for subsequent steps. Tissue was 
homogenated by sonicating twice for approximately 5 sec each with a cooling period on ice 
in between to ensure the samples did not get hot and allow for maximal digestion with lysis 
buffer. Samples were centrifuged at 3000 rpm at 4°C for 5 min to pellet unwanted cellular 
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2.7.2 Protein concentration measurement 
 
Protein concentrations were determined using the Bradfo d assay (485), which is a routine 
spectrophotomic method that involves quantification through a colorimetric assay. The 
technique involves the binding of Coomassie Brilliant Blue dye to proteins which shifts the 
absorbance from 465nm to 595nm. This change can be monitored so that increased 
absorbance at 595nm is proportional to the quantity of protein present in the sample. To 
prepare the Bradford reagent, 100mg of Coomassie Brilliant Blue G-250 was dissolved in 
50ml 95% ethanol. To this, 100ml 85% (w/v) phosphoric acid was added and the solution 
was placed on a stirrer for 30 min. A final volume of 1l was prepared with dH2O and the 
solution filtered through Whatman grade 1 filter paper. This solution was stored at room 
temperature and used for Bradford assays. The Bradford assay was performed with the use of 
an automated Cobas Fara centrifugal analyser (Roche Diagnostics, Welwyn Garden City, 
UK) and individual steps were programmed as follows. To cuvettes 256µl of filtered 
Coomassie Brilliant Blue stock solution was added an incubated at 37°C for 100 sec. After 
95 sec an initial absorbance reading at 595nm was taken and 25µl sample, diluted in 50µl 
dH2O, was added to each cuvette. This mixture was incubated at 37°C for a further 180 sec 
and a final absorbance at 595nm read. The concentratio  of samples was extrapolated from a 
standard curve constructed from the dilution of BSA diluted in dH2O, ranging from 0-
100mg/l. If samples were too concentrated (>100mg/l) they were diluted with dH2O to fall 
within the middle of the standard curve. A QC was included in every assay to ensure assay 
precision. Inter- and intra assay CVs were <5% and <2%, respectively. 
 
2.7.3 Preparation of gels 
 
Polyacrylamide gels were prepared in advance and could be stored at 4°C for up to 2 days 
before use. Glass plates (BioRad Laboratories Ltd., Hertfordshire, UK) were thoroughly 
cleaned and assembled, ensuring no gaps were present arou d the edges of gel casters. The 
resolving (separating) and stacking gels were prepared s described in Table 2.4, however, 
tetramethylethylenediamine (TEMED) and 10% ammonium persulphate (APS) were added 
only immediately prior to pouring of the individual gel. Resolving gels were poured with 
approximately 1.5cm remaining at the top of the plates. To speed up polymerisation, a layer 
of dH2O was carefully pipetted in this space and the gel set for 30 min. The layer of water 
was tipped off and remaining liquid removed by blotting with tissue. The stacking gel was 
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subsequently overlaid onto the resolving gel and a 14-well toothed comb inserted. The gel 
was set for 30 min, before proceeding to Western blotting or storing at 4°C. 
 
 
Reagent Resolving (10%) Stacking (5%) 
Acrylamide 3.33ml 1.3ml 
TRIS-HCl 2.5ml (1.5M; pH 8.8) 2.5ml (0.5M; pH 6.8) 
dH2O 4.2ml 6.1ml 
SDS (10% w/v) 100µl 100µl 
APS (10% w/v) 40µL 40µl 
TEMED 20µl 20µl 
Table 2.4  Preparation of Western blot gels. Reagents and volumes required to prepare 10% 
and 5% resolving and stacking gels, respectively, for use in SDS-PAGE.  
 
 
2.7.4 Western blot protocol 
 
Protein was diluted to 4µg/µl in lysis buffer and 20µg combined with 2X Laemmli buffer 
consisting of 0.1M Tris-HCl pH 6.8, 20% glycerol, 2% (w/v) SDS, 0.16% (w/v) 
bromophenol blue and 3% β-mercaptoethanol to give a 10µl final volume (5µl protein and 
5µl Laemmli buffer). Protein was denatured at 95°C for 5 min and the sample loaded onto 
10% SDS-polyacrylamide gels. A full-range rainbow molecular weight marker (5µl; GE 
Healthcare, Buckinghamshire, UK) was additionally applied to one well per gel. Gels were 
submerged in a running buffer consisting of 0.025M Tris, 0.192M glycine and 0.1% SDS 
and electrophoresis performed in tanks (BioRad Labor tories Ltd.) at 100V at room 
temperature for approximately 1.5 h, or, until the bromophenol blue dye reached the bottom 
of the resolving gel. For the transfer, sponges and filter paper cut to size were soaked in cold 
transfer buffer consisting of 0.025M Tris, 0.192M glycine and 20% methanol and layers of 
sponge and filter paper (x2) were assembled. The gel was carefully placed on the filter paper 
and the hydrophobic polyvinylidene difluoride membrane (Amersham Hybond-P, GE 
Healthcare) placed on top. A further layer of filter paper (x2) and sponge was added and 
compression from top to bottom applied to ensure ai bubbles were removed. The whole 
assembly was kept wet at all times in transfer buffer to prevent the protein drying out. 
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Transfer of protein to the membrane was carried out in tanks (BioRad Laboratories Ltd.) 
filled with transfer buffer at 100V at 4°C for 1.5 h. Membranes were blocked in 5% milk 
powder and tris buffered saline (TBS; pH 8.0) containing 10mM Tris and 0.15mM NaCl 
with the addition of 1% tween (TBST), for a minimum of 1 h at room temperature and then 
overnight at 4°C. Membranes were incubated with prima y antibodies against the antigen of 
interest or an internal control such as α-tubulin or β-actin, diluted in 5% milk/TBST, for 1 h 
at room temperature. Immunoblots were washed repeatdly with TBST for 30 min and 
incubated with an anti-rabbit- or anti-mouse HRP-conjugated IgG, respectively (1:2000; 
Dako), diluted in 5% milk/TBST, for 1 h at room temperature. Following further TBST 
washing for 30 min, protein bands containing bound antibody were visualised with the 
addition of enhanced chemiluminescent detection reagents (Amersham ECL Plus Western 
Blotting Detection System, GE Healthcare) as per the manufacturer’s instructions. 
Immunoblots were immediately exposed onto photographic X-ray film (Fujifilm Super RX, 
Bedford, UK) and processed using a photographic developer (SRX-101A, Konica Minolta 
Medical Imaging Inc., NJ, USA). The size of the visualised protein band was confirmed with 
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2.8 Gene expression analysis 
 
2.8.1 RNA extraction 
 
To study the expression level of a specific transcript in a tissue sample the coding region, or 
messenger (m)RNA was first extracted and purified from the sample. The tissue type 
governed the method of RNA extraction depending on the composition of lipid, blood or 
fibrous material. 
 
2.8.1.1 RNA extraction using the Qiagen RNeasy Mini Kit 
 
The Qiagen RNeasy Mini Kit (Qiagen Ltd., West Sussex, UK) was applied to a range of 
tissues including; fetal ovary and liver, placenta, fetal and adult adrenal and adult pituitary. 
Under sterile conditions, over dry ice, a small (~30mg) piece of representative tissue was 
excised and placed in a 2ml eppendorf containing a metal ball bearing (Qiagen Ltd). To each 
tube 600µl RNeasy lysis buffer (RLT Buffer)/1% β-mercaptoethanol was added and the 
tissue lysed using a TissueLyser (Qiagen Ltd.) for 4 min at 25Hz. RLT Buffer contains 
guanidine-thiocyanate, which denatures proteins, inact vating RNases that could degrade 
RNA present in the sample. Following homogenisation, the samples were centrifuged for 3 
min at 13,000 rpm and the supernatant transferred to a fresh 1.5ml eppendorf. The 
homogenate was thoroughly mixed with 600µl 70% ethanol nd transferred to an RNeasy 
spin column. Subsequent centrifugation and wash steps were performed as per the 
manufacturer’s instructions. On column DNase digeston was included during the protocol as 
advised to avoid DNA contamination of the purified RNA. RNase free DNase I (Qiagen 
Ltd.) was incubated on the column for 15 min at room temperature. At the final step, RNA 
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2.8.1.2 RNA extraction using the Qiagen RNeasy Micro Kit 
 
The Qiagen RNeasy Micro Kit was required for the extraction of RNA from cells where a 
low yield would be anticipated compared to tissues, and involves the use of a similar 
protocol as the Qiagen RNeasy Mini Kit. In this thesis this kit was applied to the extraction 
of RNA from cultured granulosa cells, and thecal cel s from individual follicles, and is 
specifically described in Chapters 5 and 7, respectively. 
 
2.8.1.3 Measurement of RNA concentration 
 
RNA concentration and purity were determined using a NanoDrop 1000 spectrophotometer 
(Fisher Scientific Ltd.). A 1.5µl volume was pipetted onto the fibre optic cable and the 
concentration of RNA measured based on the absorbance reading at 260nm. The absorbance 
ratio at 260nm and 280nm (260/280) was also given and is a measure of RNA purity. This 
value should be ~2.0, indicating a pure RNA sample without the presence of contaminants 
such as protein, DNA or extraction reagents. 
 
2.8.2 Complementary DNA synthesis 
 
Complementary (c)DNA must be synthesised from mRNA to provide a template for the 
DNA replication, exerted by Taq polymerase during the polymerase chain reaction (PCR), 
and DNA amplification. Complementary DNA is synthesis d from mRNA by reverse 
transcriptase (RT), transcribing single stranded DNA from an RNA template. RNA was 
diluted to a concentration of 100ng/µl in nuclease fre  (NF) H2O and cDNA synthesised 
from 200ng RNA using the High Capacity cDNA Reverse Transcription Kit (Applied 
BioSystems, CA, USA). Volumes and concentrations of each component are described in 
Table 2.5 and prepared in 0.2ml thin-walled PCR tubes (Axygen Inc., distributed by Thistle 
Scientific Ltd., Glasgow, UK). A sample omitting RT was included as a negative control. 
Using a thermocycler (G-Storm GS1, GRI Ltd., Essex, UK) samples were incubated at 42°C 
for 1 h followed by 95°C for 10 min to inactivate the enzyme. The resulting cDNA was 
stored at -20°C and the quality was determined by PCR (Section 2.8.4) for the house-keeping 
gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and visualised on a gel (Section 
2.8.4.1) before further use in experiments. 
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Reagent Volume (µl) Final Conc. 
RT Buffer 2.0 1X 
dNTPs 2.0 1mM 
MgCl2 2.4 3mM 
Random Hexamers 1.0 0.25µM 
RNase Inhibitor 1.0 20U 
MultiScribe RT 1.0 2.5U 
NF H2O 8.6 - 
RNA (100ng/µl) 2 200ng 
Final Volume 20µl  
Table 2.5  The cDNA reagents, volumes and final concentrations required for cDNA 
synthesis. The High Capacity cDNA Reverse Transcription Kit was purchased from Applied 
BioSystems. dNTP: deoxyribonucleotide. 
 
 
2.8.3 Primer design and validation 
 
Primers for PCR and quantitative real-time (qRT)-PCR were designed using Primer3 Input 
v0.4 software (486). Primers were often designed from the bovine (Bos taurus) genome and 
sometimes from the pig (Sus scrofus) genome published on the Ensembl Genome Browser 
database. Primer regions were selected so that the forward and reverse sequence was intron-
exon spanning and the resulting product size would be in the region of 150-250 base pairs 
(bp) long. Primer sequences were ‘BLASTed’ using the Basic Local Alignment Search Tool 
(BLAST) provided by the National Center for Biotechnology Information (NCBI) to assess 
the likelihood of obtaining other similarly sized products using those primers. Where 
possible the sequences were BLASTed against the Bos taurus, Sus scrofa and Ovies aries 
(sheep) genomes, available on NCBI, to gauge the lev l of species conservation. A high 
degree of homology was often identified, particularly between the cow and sheep genome. 
Primers were validated by conventional PCR (Section 2.8.4) to ensure binding to one 
product at the expected molecular weight. To confirm specificity of the gene product DNA 
sequencing was additionally performed (Section 2.8.5).  
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2.8.4 Polymerase chain reaction 
 
PCR is a routine method used in laboratories to qualitatively and quantitatively assess gene 
expression within tissues or cells. The technique is based on the amplification of a small 
region of double stranded (ds) DNA to assess whether or not a certain gene is expressed in a 
tissue and how abundant it is. Forward and reverse p imer sequences for a specific gene 
anneal to the 3’ complementary sequence of denatured single-strand cDNA template and 
cycles of DNA replication ensue. DNA (Taq) polymerase I adds dNTPs to the 3’-hydroxyl 
group of the extending strand, forming a phoshodiester bond with the 5’-phosphate group of 
the dNTP, and synthesises DNA in the 5’-3’ direction. Since the original DNA template 
double strand is separated into two single strands  elongation occurs on both strands each 
cycle exponentially increases the amount of DNA in the reaction. The reagents and volume 
required for a single PCR reaction are listed in Table 2.6. A reaction omitting cDNA was 
always included as a negative control. PCR reactions were performed using a thermocycler 
(G-Storm GS1, GRI Ltd.) with a cycling programme set out in Table 2.7 
 
Reagent Volume (µl) Final Conc. 
Green GoTaq Flexi Buffer 2.0 1X 
dNTPs 0.2 0.2mM 
MgCl2 0.6 1.5mM 
Forward Primer 1.0 0.5µM 
Reverse Primer 1.0 0.5µM 
NF H2O 3.7 - 
GoTaq Hot Start Polymerase 0.5 0.25U 
cDNA 1.0 - 
Final Volume 10µl  
Table 2.6  The PCR reagents, volumes and final concentrations used per PCR reaction. The 
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Step Temp. (°C) Time (min:sec) 
Enzyme activation 95 05:00 
dsDNA denaturing 72 00:30 




Final extension 72 10:00 
Table 2.7  The PCR thermo-cycling conditions. * The annealing temperature was pre-
determined during validation to the optimal temperature for binding. 
 
 
2.8.4.1 Gel electrophoresis 
 
The PCR product was run on a 2% agarose gel to visualise a single band. For a 120ml gel, 
2.4g agarose (VWR International) was dissolved in dH2O by microwave heating and 6µl 
ethidium bromide was mixed into the gel liquid, which was set in a mould containing a 
toothed comb. The 10µl PCR product was pipetted into wells alongside a well containing 5µl 
100Kb ladder combined with 1µl 6X loading dye (Promega UK Ltd.). Electrophoresis was 
performed at 100V for 45 min. Ethidium bromide bound DNA was visualised using an ultra 
violet (UV) light box and product size determined by reference to the Mw ladder. 
  
2.8.5 DNA sequencing 
 
To ensure genetic specificity of the PCR product, DNA sequencing was utilised to confirm 
that the primers were annealing to the gene of interes . A 25µl PCR reaction volume was 
prepared (all the reagents in Table 2.6 multiplied by 2.5) and run on a 2% agarose gel 
(Section 2.8.4.1). Under UV, the PCR band was cut out using a scalpel blade and placed into 
an Ultrafree MC-Centrifugal Filter column (Millipore, Durham, UK) which was centrifuged 
at 7,000 rpm for 5 min. NF H2O was added to the flow through to bring the volume to 200µl 
and the DNA product transferred to a clean 1.5ml eppendorf. To each tube, 460µl ethanol, 
30µl 3M NaAc (pH 5.2) and 1.5µl glycogen (Roche Diagnostics Gmbh) were added and 
mixed thoroughly. Samples were placed on dry ice for 30 min, thawed and centrifuged at 
13,000 rpm for 15 min. The supernatant was discarded and the pellet washed in 200µl 70% 
ethanol and spun at 13,000 rpm for a further 15 min. The supernatant was discarded and the 
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pellet air-dried for 5-10 min before re-suspension in 12µl NF H2O. The concentration of 
DNA was measured using a NanoDrop 1000 spectrophotometer (Fisher Scientific Ltd.), 
where a 260/280nm ratio of ~1.8 was an indication of pure good-quality DNA. DNA was 
sent to Technical Services at the MRC-Human Genetics Unit, based at the Western General 
Hospital, Crewe Road, Edinburgh. DNA was sequenced using the BigDye Terminator v3.1 
Cycle Sequencing Kit and processed on an ABI 3130 Sequence Analyser (Applied 
Biosystems), as per the manufacturer’s instructions.  
 
2.8.6 Quantitative real time - PCR 
 
QRT-PCR was used to determine the absolute amount of a gene present in a sample, relative 
to an internal control. This method was applied to range of genes in a variety of tissues, all of 






The SYBR Green method for qRT-PCR was implemented in this the is. SYBR Green is a 
reporter cyanine dye that intercalates with dsDNA emitting green fluorescence. During the 
denaturing step of the PCR reaction, dsDNA becomes single stranded DNA and the 
fluorescence is lost.  When the primers anneal to their target and extension occurs, SYBR 
Green binds the newly synthesised dsDNA strand and the amount of fluorescence emitted is 
proportional to the quantity of product present in that cycle. The amount of gene is 
determined by the cycle threshold (Ct) value. The Ct is the cycle at which the fluorescence 
reaches a certain threshold, above that of background fl orescence, during the exponential 
phase of the reaction. The PCR cycle is repeated 35 times so that genes with an extremely 
low abundance can still be detected. To further validate primers for use with SYBR Green 
chemistries, a standard curve constructed by double dilution (1:2) of an appropriate cDNA 
template was prepared. A linear curve generating a straight line with an R2 value near to 1.0 
and a slope of -3.33 was desired as this gave an indication of primer efficiency (~100%).  An 
example of one such standard curve is illustrated in Figure 2.1. To ensure primer binding 
specificity, a dissociation (melting) curve was included, post PCR-cycling, during each run. 
The plot is the fluorescent signal emitted at the primer melting temperature. A single high 
peak would indicate binding to one product (gene of interest) therefore discriminating 
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between non-specific and specific binding. More than one peak would suggest that the 
primers were binding unintended targets thus invalidating results. An example of a 




Figure 2.1  A SYBR
 
Green qRT-PCR standard curve. The curve was generated by a series of 
1:2 dilutions using adult sheep liver cDNA to test primer efficiency. Primers were designed 
to bind to the IGF1 gene.  
 
Chapter 2                                                                                         General Materials and Methods 
                                                                                
 88 
 
Figure 2.2  A SYBR
 
Green qRT-PCR dissociation (melting) curve. The curve was generated 
from the same standard curve run for the IGF1 primers illustrated in Figure 2.1. 
 
 
2.8.6.2 SYBR Green qRT-PCR protocol 
 
QRT-PCR was performed on either a 96 or 384 well plate format (Applied Biosystems). A 
10µl final volume was prepared containing 5µl PowerSYBR Green Master Mix (1X; Applied 
Biosystems), 0.5µl primer pairs (0.5µM), 3.5µl NF H2O and 1µl cDNA. The plates were 
briefly spun to remove liquid from the side of the w ll, and the plate loaded into an ABI 
7900HT Fast Real Time PCR machine (Applied Biosystem ). The qRT-PCR cycling 
programme is detailed in Table 2.8. All samples were run in duplicate and negative controls 
included a reaction containing cDNA prepared withou reverse transcriptase and a reaction 
replacing cDNA with NF H20. Each set of samples were run for the gene of interes  in 
parallel with GAPDH as an internal control. 
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Step Temp. (°C) Time (min:sec) 
Enzyme activation 95 05:00 






60 00:15 Dissociation step 
95 00:15 
Table 2.8  The qRT-PCR cycling conditions. PCR was performed on the ABI 7900HT Fast Real 
Time PCR machine (Applied Biosystems) using the default software settings. 
  
 
2.8.6.3 SYBR  Green qRT-PCR data analysis 
Data were compiled using ABI 7900HT v2.3 software and exported to an Excel file. Sample 
duplicates were checked to ensure precision and the issociation curve inspected to confirm 
specificity of PCR product. To analyse raw Ct values the delta (∆)Ct method was employed 
to give an absolute expression values relative to GAPDH as follows: 
 
ΔCt = Ct of mean Gene of Interest – Ct of mean GAPDH 
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2.9 Statistical analyses 
 
The majority of data dealt with in this thesis was the comparison of the mean value of raw 
data between two treatment groups. For example the maternal TP treated animals were 
compared with the maternal control treated animals. Likewise each fetally treated TP dose 
was compared back to the fetal control treated cohort. Often there is also reference to the 
comparison between the maternal and fetal injected ohorts in which the controls groups in 
each model are compared. Any deviation from this is clearly stated. Statistical analysis was 
performed using the computational software GraphPad Prism v4.0 (GraphPad Software Inc., 
San Diego, CA). The data were initially assumed to be normally distributed over the 
Gaussian bell-shaped curve and an unpaired or paired two-tail Student’s t-test was applied as 
appropriate. In the cases where the data were not normally distributed (calculated by 
GraphPad Prism) a non-parametric Mann Whitney test wa  alternatively applied. Intra-group 
variances were often unequal, which could reflect sample size and also the heterogeneity 
present in large mammals. Numerical data were present d graphically as the mean ± sem and 
asterisks used to indicate significant variation betwe n groups. Some analyses in this thesis 
included the proportional classification of defined categorical groups. These data were 
subjected to a chi (χ2) -squared goodness of fit analysis in which the expected distribution of 
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This thesis describes two models of prenatal androgenisation in the sheep: a novel model of 
direct fetal androgenisation and a well-established model of indirect maternal 
androgenisation. These treatment paradigms are based on the method of delivery of 
androgens to the fetus, one avoiding and one allowing the maternal transfer of exogenous 
steroids across the placenta. In the direct fetal tre ted cohorts, fetuses were injected directly 
with TP on two occasions, either at d62 and d72 or d62 and d82 of a 147-day gestation, and 
these female offspring were studied as lambs and adults (Fig. 3.1). In a parallel group, 
pregnant ewes were injected with TP intramuscularly, twice weekly from d62-102 in line 
with previous studies in the sheep, and are referred to as the maternally treated group. The 
programming effects in lamb and adult offspring from this cohort were also studied (Fig. 
3.1). The effect of prenatal androgenisation was additionally examined in the fetus to 
investigate the effects of high levels of exogenous androgens during development. Cohorts 
included female fetuses that were maternally exposed to androgens twice weekly from d60 
and assessed at d70 and d90, and fetuses that were dir ctly injected with androgens at d60 
and assessed at d70 (Fig. 3.1).  
 
 
Figure 3.1  The timings of prenatal treatment and prenatal and postnatal assessment of 
animals. The illustration represents the ovine gestational time-line in days (d) and 
treatment paradigms during mid-gestation. Offspring were assessed fetally and also at 10 
weeks (wks) and 11 months (mo) of age. FI: Fetal injection, MI: Maternal injection. 
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The rationale for directly injecting fetuses with TP was to avoid the placental aromatisation 
of this androgen into estrogens, including estrone a d estradiol, by the enzyme aromatase. 
Indeed it has been recently shown that treatment of a pregnant ewe from d30-90 does lead to 
the elevation of estradiol and estrone levels in the fetus (377), which may have important 
consequences for the programming of reproductive function in adults (301, 335, 354, 487, 
488). Another purpose of developing the direct fetal injection model was to allow 
manipulation of the dose of androgen to which the fetus is exposed. While many studies 
have used the non-aromatisable testosterone, DHT, to delineate between the effects of 
androgens and estrogens in fetal programming (301, 35 365, 488), the treatment of the 
mother with either TP or DHT does not allow for dosage control and the amount of steroid 
reaching the fetus could be variable. A further consideration is the effects that androgens 
could have on the mother that could indirectly impact on fetal growth and development, such 
as the induction of insulin resistance in response to elevated androgens (489). The direct fetal 
injection model therefore avoids any additional maternal influences that are not a direct 
consequence of elevated androgens. 
 
The fetal injections were timed to coincide with the period of androgen exposure in the 
maternally treated group. Initial pilot experiments were conducted and found that directly 
injecting the fetus before d55 of gestation resulted in an unacceptable risk of spontaneous 
abortion. In addition, injecting directly into the amniotic fluid as a method of delivering the 
steroid to the fetus was also associated with an unacceptable incidence of abortion. This 
thesis discusses the effects of direct fetal TP at d62/72 and at d62/82. The d62/72 cohort was 
developed during preliminary studies that showed that after ten days androgen 
concentrations were, in fact, still significantly elevated, therefore subsequent studies were 
conducted with the second TP depot delayed until d82 to prolong exposure. These treatments 
resulted in an abortion risk of ~1-2% per injection. 
 
In order to measure the degree of mid-gestation testosterone exposure in the developing 
female fetus, various parameters were examined that are known to be programmed by 
exposure to the male sex hormone. These included assessment of masculinisation of the 
genital region and also of the effect of treatment o  the placenta and its capacity to 
metabolise steroids. There is also evidence for the adv rse effects of in utero steroids on fetal 
growth, and therefore the effect of androgenisation on birth weight and adult weight was also 
assessed.  
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The timing of prenatal androgen exposure is crucial to the development of the urogenital 
tract (490). The ano-genital distance (AGD) is a sexually dimorphic trait that is a measure of 
the masculinity of the external genitalia in a newborn, and is about twice as long in males 
than females (491, 492). The AGD is determined during development by the level of 
testosterone present in the fetal environment and is therefore a bioassay for this. 
Manipulation of testosterone concentration during a specific programming window will alter 
the AGD (490, 493, 494). Accordingly, the AGD was increased in female lambs that were 
born from mothers that were administered testosterone from d30-90 of pregnancy (377, 495). 
Androgenisation during this period of sexual differentiation results in the external and 
internal masculinisation and defeminisation of the female fetus resulting in the development 
of penis and empty scrotum and the suppression of the lower vagina and opening, although 
the intra-abdominal development of the ovaries is normal (350, 370, 373, 374, 495). The 
specific timing of androgen exposure to the masculinisation of the genitals was narrowed 
down by Clarke et al. who showed that treating pregnant ewes with androgens from d30-80 
and d50-100 both led to clitoral enlargement in ewes but only the earlier treated group 
developed a penis and scrotum. Conversely testosterone treatment from d70-120 had no 
effect on external genital development (370). Aggressive male behaviour was observed in 
the d30-80 and d50-100 groups but not in groups treated after d70. On the other hand all 
ewes exposed to increased androgens before d90 exhibit d male urinating postures, however, 
animals treated later from d90-140 did not (370). The concentrations of steroid hormones in 
the fetal circulation during maternal and fetal trea ments were therefore measured to gauge 
the level of exposure to testosterone, and also to estrogen, and these findings were related to 
the masculinisation effects of offspring. 
 
The placenta is the site of transfer of steroid hormones from mother to fetus. Androgens can 
also act directly on the placenta, as previous unpublished work in the lab has demonstrated 
the expression of AR protein in the placenta. Placental AR gene expression was therefore 
measured to assess whether androgen reception, and therefore action, could be altered by 
high levels of testosterone in the maternal or fetal nvironment. Furthermore, the placental 
expression of genes encoding enzymes that have a role in the metabolism of steroid 
hormones was studied. Aromatase, which is encoded by CYP19, is responsible for the 
conversion of testosterone into estrogen metabolites (134). The relationship between the 
expression of placental CYP19 and fetal estradiol levels and whether this correlated to 
treatment group, was investigated. In addition, the genes involved in the metabolism of 
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cortisol were also examined.  The type 1 and type 2 11β-HSDs, encoded by HSD11B1 and 
HSD11B2 genes, respectively, are essential for regulating he bioavailability of the 
glucocorticoid cortisol. Type 1 11β-HSD converts cortisone into cortisol, whereas type 2 
11β-HSD acts in the opposite direction, inactivating cortisol (424). Pregnancy, the process of 
treating the mother or the fetus, and/or the physiolog cally elevated circulating levels of 
steroid hormone, could stimulate a stress response. Th refore the placental expression of 
HSD11B1 and HSD11B2 was assessed to determine how the placenta might re ulate the fetal 
exposure to maternal cortisol. 
 
As well as looking directly at the hormonal milieu of the fetus and accompanying placental 
gene expression, the effect of prenatal androgens on the growth of the fetus was monitored 
by assessment of birth weight. In girls that are born small for gestational age (SGA) or have 
intra-uterine growth restriction (IUGR) it has been shown that these individuals have an 
increased propensity to develop the reproductive anomalies associated with PCOS, including 
hyperandrogenism, reduced ovulation rate, hyperinsulinaemia, insulin resistance and obesity 
(496-499). In another study PCOS was correlated with IUGR however while these women 
were hyperandrogenic they were normoinsulinaemic (500). Conversely other studies have 
not found any association between SGA and the development of PCOS in adulthood (501, 
502). It may be that being SGA or IUGR is associated with these pathophysiological states in 
the adult rather than being caused by them. SGA or IUGR is more common in babies of 
women with PCOS (503) and it is possible that the alt red maternal steroid environment is 
responsible for both short-term and long-term effects in offspring. Indeed, it is known that 
the exposure to glucocorticoids during the perinatal period results in lowered birth weight 
and metabolic perturbation in adult offspring (277, 2 8, 286). There may also be species 
differences related to the effect of elevated in utero androgens on fetal growth. In the early 
prenatally androgenised sheep model in which TP is administered from d30-90 there is 
increased incidence of IUGR (332, 377, 495). However in the rhesus monkey model, 
prenatal androgenisation during early or late gestation, did not alter birth weight (504). 
 
The objective of this chapter is to primarily validte the maternal and fetal prenatal 
androgenisation models. The aims were to study: A) androgen exposure by assessing 1) 
circulating testosterone and 2) biomarkers of testoster ne exposure, B) the role of the 
placenta including 1) androgen reception, 2) androgen metabolism to estrogen, circulating 
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estradiol and effect on the fetal pituitary and 3) cortisol metabolism and circulating cortisol, 
and C) birth weight. By assessing these outcomes in the offspring that were maternally 
exposed to TP from d62-102, it will confirm that androgenisation has occurred as expected, 
and that it is in line with other ovine models of prenatal androgenisation. Furthermore, the 
characterisation of the direct fetal model will allow for comparison between indirect and 
direct exposure to TP during the same gestational period and may differentiate between 
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3.2 Materials and Methods 
 
3.2.1 Experimental animals 
 
The female animals assessed in this chapter are detaile  in Table 3.1. 
 
Study Treatment Sample number (n) 
Fetus 
Fetal Treatment Injection at d60, assessed at d70 C = 4, TP 20mg = 8 
Treatment from d60-70, assessed at d70 C = 3, TP = 6 
Maternal Treatment 
Treatment from d60-90. assessed at d90 C = 6, TP = 8 
Lamb 
Fetal Treatment Injection at d62 and 72 C = 6, TP 20mg = 6 
Maternal Treatment Treatment from d62-102 C = 9, TP = 7 
Adult  
Injection at d62 and 72 C = 4, TP 20mg = 8 
Fetal Treatment 
Injection at d62 and 82 
C = 4, TP 1mg = 5, 4mg = 5, 
20mg = 7 
Maternal Treatment Treatment from d62-102 C = 5, TP = 9 
Table 3.1  The experimental cohorts discussed in this chapter, the treatment regime and 
corresponding sample numbers. 
 
 
3.2.2 Hormonal analysis 
 
Fetal blood collected at the time of death was assayed for testosterone, estradiol, cortisol, LH 
and FSH by RIA. Serum was extracted from the samples as described in Section 2.5.1 and 
the RIA carried out as detailed in Section 2.5.2 with the specific protocol for each assay 
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Hormone Primary antibody 











Rabbit anti- Testosterone 
(R3S07-259; AMS 
Biotechnology, Oxfordshire, UK) 













Rabbit anti-Cortisol (20-CR5; 
Fitzgerald, MA, USA) 
















C5288113; CA, USA) 






Table 3.2  The hormones measured in fetal blood by RIA. The primary antibodies, tracers 
and standards employed for each RIA are listed. Radiolabelled tracer was supplied by MP 
Biochemicals, Illkirch, France and the standards by Sigma-Aldrich. NIDDK: National Institute 
of Diabetes and Digestive Diseases, NIAMDD: National institute of Arthritis, Metabolism and 
Digestive Diseases. *This in-house assay has been described previously by McNeilly et al. 
(505).  
 
3.2.3 Gene expression analysis in the placenta 
 
Genes analysed in the placenta and the forward and reverse primer sequences are listed in 
Table 3.3. Placental tissue from the fetal side wascollected, and RNA extraction, cDNA 
synthesis and qRT-PCR protocols were followed as detailed in Section 2.8. 
Table 3.3  The primers for genes analysed in the placenta by SYBR Green qRT-PCR. Gene 
names and accession numbers, forward and reverse primer sequences (5’-3’) and PCR 
product sizes are listed.  
 
Gene (Accession No.) Forward Sequence Reverse Sequence 
Product 
Size (bp) 
AR    
(XM_001253942) 
GCCCATCTTTCTGAATGTCC CAAACACCATAAGCCCCATC 233 
CYP19                    
(NM_001123000) 
AATCCAGCACTCTGGAAAGC ACGTCCACATAGCCCAAGTC 152 
HSD11B1  
(NM_001123032) 
ATTCTTGGCCTCATCGACAC TCCATGATCTTCCTTCCTGG 191 
HSD11B2  
(NM_174642) 
TGTGCCAAGAGCACTACAGG CTCTACATGTGCCCTGCTCA   120 
GAPDH 
(NM_001034034) 
GGCGTGAACCACGAGAAGTATAA AAGCAGGGATGATGTTCTGG 229 
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3.2.4 Postnatal measurements 
 
The weight (kg) was recorded for each animal at birth, at approximately 10 weeks and 10.5 
months of age. The AGD, the distance between the anus d the bottom of the vagina, was 
measured at 10 weeks and 11 months of age. At 11 months, at the time of sacrifice, a 
photograph was taken of the genital area and later analysed for the presence of abnormal 
genital development. The genital area was classed a normal or abnormal with mild, 
moderate or severe changes of the labial folds and clitoral region. In the most severe cases 
there was vaginal stenosis and superior fusion of the labial folds. Three investigators 
independently and blindly classed each photograph into a group based on previously agreed 
classifications. The vaginal phenotype was also assessed by examining the degree of stenosis 
in these animals by the vaginal insertion of sponges that are required for cycle 
synchronisation. Furthermore, masculinisation of the brain was assessed by observation of 
urinating postures. 
 
3.2.5 Statistical analyses 
 
For the hormonal and gene expression analyses as well as the comparison of body weight 
and AGD, the difference between two means was assessed, and these data were therefore 
statistically analysed using a student’s unpaired t-test assuming equal variances. In the 
instances where data were not normally distributed (unequal variances) a non-parametric 
Mann Whitney test was alternatively used. The values ar  presented as the mean ± sem. Data 
collected from the classification of animals by theextent of abnormal genital development 
were proportions and therefore a chi (χ2) squared test was performed. These values were 
presented as a percentage. For statistical tests, P values of P<0.05 were considered 
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3.3.1 The effect of androgen exposure on circulating testosterone and 
biomarkers of testosterone exposure 
 
To assess the fetal phenotype in this model, maternlly TP-exposed fetuses were collected at 
gestational d70 and d90, approximately 10 days or 30 days after commencement of twice 
weekly maternal treatment with 100mg TP. Control animals received an oil (vehicle) 
injection. At d70 (P<0.05) and d90 (P<0.001) female fetuses had significantly elevated 
levels of serum testosterone compared to female controls (Fig. 3.2.A). In fact testosterone 
levels were raised to a comparable level to that of the age-matched male fetus (Fig. 3.2.A). 
The direct injection of the fetus with 20mg TP resulted in vastly higher circulating 
testosterone than in the maternal cohort. Serum testost rone levels in females fetally injected 
with TP were in the order of eighty times greater than female controls (P<0.01) and twenty 




Figure 3.2  The fetal hormonal environment post-TP treatment. Testosterone was 
measured by RIA in mid-gestation fetuses that were maternally (A) or fetally (B) exposed to 
TP. Male controls (A; d70 n=8, d90 n=12, B; d70 n=5) are included in A and B as a 
comparative measure. Different letters represent a statistically significant difference. The 
data at d70 and d90 in A) were analysed separately.  
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To confirm that the mid-gestation prenatal androgenisation model did not result in 
masculinisation of the urogenital tract, the AGD was measured at 10 weeks (Fig. 3.3.A-C) 
and in the adult ewe at approximately 10.5 months (Fig. 3.3.D-F), and was not found to be 
altered by mid-gestation exposure of the fetus to androgens in any of the treatment cohorts. 
 
 
Figure 3.3  The effect of mid-gestation prenatal androgenisation on the AGD of offspring. 
AGD was recorded at 10 weeks (A-C) and at ~10.5 months (D-E) in maternally and fetally 
d62/72 and d62/82 treated animals, respectively.  
 
While there were no indications of external masculinisation in the new-born, in terms of 
AGD, and the external genitalia appeared normal, there was evidence of changes to the labial 
region of the vagina that were associated with matern l androgenisation in the adult ewe. 
When TP was administered to the pregnant ewe from d62-102, changes in the development 
of the genital region were observed in adult offspring including clitoral hypertrophy, some 
fusion of the labia and stenosis of the lower vagin in the most severe cases. The extent of 
the abnormality was characterised as mild, moderate or severe in appearance and this is 
illustrated in the panels in Fig. 3.4.A. At 11 months of age photographs of the genital area 
were taken and blindly classified as one of the four groups in Figure 3.4.A. Nearly all the 
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animals (~90%) in the maternally androgenised group were found to have a severe labial and 
vaginal phenotype using this classification (P<0.01; Fig. 3.4.B). In these animals, it was not 
possible to insert a progesterone sponge for cycle synchronisation, and it would not be 
possible to mate these ewes naturally. 
 
In the fetally TP-exposed cohorts some animals were also found to possess the severe 
vaginal phenotype (~25% in the d62/72 TP 20mg group; Fig. 3.4.C and ~20% and ~15% in 
the d62/82 TP 4mg and 20mg group, respectively; Fig. 3.4.D). The severity of the phenotype 
was however more variable in these groups with some including animals with mild or 
moderate abnormalities and some having the appearance of normal genitalia (Fig. 3.4.C and 
D). It was possible to insert a vaginal sponge in 62.5% of the d62/72 TP 20mg group and 
100%, 80% and 71% of the d62/82 TP 1mg, 4mg and 20mg groups respectively. The ewes 
collectively exhibited some masculinisation of the brain however, as all androgenised 
animals stood to urinate. The fact that the most severe genital defects occurred in the 
maternally treated cohort, in which circulating testosterone was significantly lower compared 
to the fetally injected cohort in which the severe phenotype occurred less frequently, 
suggests that other metabolites of testosterone may be responsible for the programming of 
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Figure 3.4  The effect of mid-gestation prenatal androgenisation on genital development. In 
the 11 month ewe anatomical abnormalities in the development of the vagina and external 
genitalia were characterised as normal, mild, moderate and severe and representative 
images are shown in A). The degree of vaginal abnormality was semi-quantified by 
allocation of each animal to a phenotype in maternal (B) and fetal d62/72 (C) and d62/82 
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3.3.2 The role of other steroid metabolites and associated changes in 
placental function 
 
Fetal estradiol concentrations were measured to assess whether this hormone was altered as a 
result of increased exogenous TP, arising through the conversion of testosterone into 
estrogenic metabolites. Estradiol was significantly elevated in the maternally TP-exposed 
d90 female fetus compared to controls (P<0.01; Fig. 3.5.A). This effect was found at d90 
only. There was no alteration in the fetal serum estradiol concentration in the fetally TP-




Figure 3.5  The fetal hormonal environment post-TP treatment. Estradiol was measured by 




These findings suggest that the development of the urogenital tract can be affected during 
mid-gestation through estrogenic programming. This ra es the question as to the site of 
steroid conversion with the most obvious candidate being the placental conversion of 
testosterone to estradiol, particularly in the maternally treated group in which steroids must 
cross through this tissue. The receptivity of the placenta to increased testosterone was 
assessed by measuring AR gene expression to identify whether androgen reception, and 
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hence signalling, in the placenta might be altered as a result of treatment. In addition, the 
placental expression of CYP19 was assessed to determine whether the potential for p acental 




Figure 3.6  Placental AR and CYP19 expression post-TP. AR and CYP19 mRNA expression was 
measured in d70 and d90 maternally (A and C, respectively) and d70 fetally (B and D, 
respectively) androgenised fetuses. In A and C the lines represent statistical comparison 
between control cohorts at two gestational ages. * P<0.05. 
 
 
The placental expression of AR was shown to decrease over gestation from d70 to d90 
(P<0.05; white bars; Fig. 3.6.A). However, neither maternal nor fetal administration of TP 
altered AR mRNA expression in the placenta (Fig. 3.6.A and B), suggesting that androgen 
reception is not affected by these treatments. In the maternal control cohorts, there was a 
significant increase in CYP19 gene expression between d70 and d90 (P<0.05), implying that 
the placenta could have increased aromatase activity at this later gestational age (white bars; 
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Fig. 3.6.C). In parallel to the pattern of estradiol secretion observed in the d70 and d90 
maternally TP treated cohort, CYP19 expression was not changed at d70 but was increased at 
d90, however this did not quite reach statistical significance (P=0.053; Fig. 3.6.C). Similarly, 
the expression of CYP19 remained normal in the placentas of fetally TP-exposed d70 fetuses 
(Fig. 3.6.D).  
 
The associated increase in fetal estradiol concentrations with urogenital changes in the adult, 
suggest that estradiol may exert some effect on the developing fetal brain. Therefore an 
assessment of hypothalamic pituitary function was crried out by measuring gonadotrophin 
levels. Maternal androgenisation led to a decrease in circulating LH in the d70 and d90 fetus 
(P<0.05; Fig. 3.7.A) however fetal androgenisation did not significantly lower LH levels. 
Similarly, FSH concentrations were reduced by maternal TP exposure at d70 (P<0.05) and 
d90 (P<0.001), but not by fetal TP treatment (Fig. 3.7.B). 
 
 
Figure 3.7  Gonadotrophin measurements in the peripheral serum of the prenatally 




In addition to exogenously altering testosterone lev ls and subsequent effects on endogenous 
estradiol concentrations in some fetuses, it is also possible that the process of treating the 
mothers and/or fetuses could inadvertently cause a stress response that would result in 
changes to fetal cortisol exposure, either directly, or through placental changes. Cortisol was 
therefore measured directly in the fetus in maternally and fetally treated cohorts, however, 
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cortisol concentrations were not different as a consequence of androgenisation (Fig. 3.8.A). 
Interestingly, there was twice as much cortisol hormone present in those fetuses that were 





Figure 3.8  Cortisol measurement in the peripheral serum of the prenatally androgenised 
fetus.  Cortisol was measured by RIA at d70 and d90. The effect of maternal and fetal TP 
exposure was assessed (A) and the amount of cortisol present in the fetal circulation 
following the fetal control injection was compared with maternal controls (B). 
 
 
Given that cortisol was measured 10 days after fetal tre tment however, this could indicate 
that cortisol levels were more raised, closer to the time of injection and that injecting the 
fetus results in elevations of the stress hormone. While this may be due to the responsiveness 
of the fetal adrenal (Chapter 8) it is also possible that changes in the placental expression of 
the genes that regulate cortisol bioavailability could be altered. Therefore the expression of 
HSD11B1 and HSD11B2 were assessed. In line with cortisol concentrations, prenatal 
androgenisation did not alter the placental expression of HSD11B1 or HSD11B2 mRNA 
(Fig. 3.9.A-D) however there was a trend related to the method of TP delivery. The 
expression of both HSD11B1 (Fig. 3.9.E) and HSD11B2 (Fig. 3.9.F) at d70 was higher in 
fetally injected animals compared to maternal controls espectively. The type 1 isoform was 
the most abundantly expressed HSD11B relative to GAPDH, suggesting promotion of 
cortisol synthesis. 
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Figure 3.9  Placental HSD11B expression post-TP. HSD11B1 and HSD11B2 mRNA expression 
was measured in d70 and d90 maternally (A and C, respectively) and d70 fetally (B and D, 
respectively) androgenised fetuses. The expression of HSD11B1 and HSD11B2 isoforms 
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3.3.3 The effect of mid-gestation androgenisation on birth weight and 
post-natal growth 
 
Since increased in utero steroids have been associated with IUGR and lowered birth weight, 
the birth weights of animals were recorded along with body weights in lambs (10 weeks) and 
in adults (11 months). Exposure of an ovine fetus to TP maternally from d62-102 or fetally at 
d62 and d72 or d62 and d82 had no effect on birth weight (Fig. 3.10.A-C, respectively), or 
total body weight at 10 weeks (Fig. 3.10.D-F, respectiv ly) or 11 months (Fig. 3.10.G-I, 
respectively) of age. There was also no effect of treatment paradigm on the weights at any 
developmental stage. 
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Figure 3.10  The effect of mid-gestation prenatal androgenisation on the weight of 
offspring.  Birth weight (A-C) and body weight at 10 weeks (D-F) and 11 months (G-I) of age 
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Androgenisation of the pregnant ewe with 100mg of TP twice weekly from d62-102 raises 
the testosterone levels in the female fetus to comparable levels of a control male fetus at the 
same gestational age (d70 and d90 in this study). This is in line with previously reported fetal 
circulating testosterone levels in sheep that were exposed for a longer period, from d30-90 of 
gestation (377). The direct fetal injection model raises female testosterone levels beyond that 
of a normal male fetus to supraphysiological levels. These animals were assessed at d70, 
exactly 10 days after the direct injection of 20mg TP. Animals reported elsewhere in this 
thesis including lambs and adults that received two fetal injections and/or different doses of 
TP (1mg, 4mg) were not available as fetuses to measur  the circulating steroid hormones. 
We would predict from the considerable levels of TP present in the d70 fetus after ten days 
that the exogenous exposure is long-lasting and sufficient to span the same period of 
exposure as in the maternally injected cohort. 
 
The increased conversion of testosterone to estrogen was also confirmed in the maternally 
TP-exposed cohort (377). This effect was not observed until d90, when the increase in 
substrate and placental expression of CYP19, which encodes the enzyme aromatase, 
coincided. It is also possible that local conversion of testosterone to estrogen could take 
place in the fetal tissues including the ovary or liver (506, 507). Nevertheless the huge 
elevations in testosterone concentrations in the fetally injected cohort did not yield a parallel 
increase in plasma estradiol concentration implying that the majority of estradiol at this time 
originates from the transfer of placental metabolites. It was also found that the expression of 
CYP19 mRNA was increased over gestational age, which was also associated with a decline 
in placental AR gene expression, suggesting that androgen signalling may have a role in 
regulating placental aromatase. 
 
A direct bioassay of the extent or timing of fetal androgenisation is the measurement of 
AGD. Androgenisation from d62-102 occurred after the critical programming window for 
masculinisation and as expected the AGD in both treatm nt models were normal. This is in 
contrast to the increased AGD reported in lambs born t  mothers that were androgenised 
from d30-90 of pregnancy and therefore resulting in a severe masculinised phenotype in their 
offspring (377, 478, 495). These animals were also born with masculinised genitalia that 
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included a penis and empty scrotal sac (370, 373, 34, 495). It should be noted however that 
this severe form of masculinisation is not a feature present in women with PCOS.  
 
A defeminised phenotype was however present in our maternally exposed cohort, in line 
with previous studies that find clitoral enlargement a d abnormal vagina development in 
sheep exposed during the mid-gestation period (d50-100) without the external 
masculinisation effect of early androgenisation (370). Very few animals in the fetally 
exposed cohorts had genitalia that resembled the sev re or moderate phenotype pointing 
towards a mainly estrogenic role of programming. This is supported by the clear evidence of 
estrogenic programming of reproductive function in women that were prenatally exposed to 
high levels of the synthetic estrogen diethylstilbestrol (DES). DES was administered to 
pregnant women to prevent miscarriage, however, in female offspring, it led to reproductive 
tract abnormalities (508) and a high risk of developing vaginal and cervical cancers (509). In 
our animals, there may however be some role for testosterone given that the phenotype was 
not completely absent in the fetally treated cohort. On the contrary, although estradiol was 
not altered at d70 in the fetally injected cohort, it is possible that variations in estradiol in 
some animals, due to local conversion of steroids, might programme similar abnormalities as 
that observed in the maternally treated cohort. 
 
In addition to the physical markers of increased in utero androgen exposure, neurological 
changes were also observed. In sheep, the programming of masculinised behaviour in the 
brain, also occurs during early to mid-gestation (370). The androgenised ewes in our study 
adopted male urinating postures, so that instead of squatting, urine was released in a standing 
position. These animals were easily identified due to their soiled hind region. Although the 
programming of this masculine behaviour in adult ewes as not quantified they appeared to 
be common to all prenatally androgenised animals, including the maternally and fetally 
treated cohorts, implying an androgenic mode of programming. 
 
It is clear that exposing the female ovine fetus to increased androgens mid-way through 
gestation has subtle effects on urogenital development that does not lead to a fully virilised 
phenotype, but does result in a partial defeminisation of the genital tract and behavioural 
traits. These programming effects are likely mediated by the brain and therefore a method to 
investigate this was to examine the secretion of the pituitary gonadotrophins, LH and FSH. A 
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defect in this higher centre, that could include thhypothalamus and/or the pituitary, was 
confirmed by reduced circulating concentrations of LH and FSH following maternal 
androgenisation. The increased estradiol present in this cohort and not in the fetally 
androgenised cohort point to estrogenic actions. While estrogen may programme changes in 
the brain it is also possible that reduced gonadotrophin secretion is a direct effect of negative 
feedback signalling, on either the hypothalamus and/or the pituitary, by raised levels of 
estradiol. It has been shown that administration of exogenous estradiol to a sheep fetus at 
d105 can dampen LH and FSH secretion, however this effect was not found at d90, 
suggesting that the development of estradiol negative feedback may in fact occur later in 
development (510). Hypothalamic portal vasculature and gonadotrophin immunopositive 
gonadotrophs are both present in the ovine fetus by d60-70 of gestation (511, 512) and 
gonadotrophin secretion is controlled by GnRH signalling (513). The gonadotrophins are 
known to peak during mid-gestation in the sheep fetus (514) and have been hypothesised to 
have a direct role in gonadal formation. Inhibition of gonadotrophin secretion by 
administration of an GnRH agonist does in fact effect t stis development but not ovary 
formation (515). Therefore the effect of lowered gonadotrophins on the mid-gestation female 
fetus is not known and may not be associated with genital tract formation, but rather 
highlights the plasticity the developing brain that is a direct target for steroid signalling 
during this time. 
 
The trend to increased cortisol concentrations ten days after injection in the fetally treated 
control cohort suggests the induction of a stress rponse in either the mother or the fetus. 
Corresponding to this change was the possible dysregulation of the placental HSD11B genes 
which could regulate the transfer of glucocorticoids across the placenta.  The type 1 11β-
HSD isoform was most abundantly expressed in the ovine placenta at d70 and d90 and 
although not affected by prenatal androgenisation, expression tended to be up-regulated as a 
consequence of the fetal injection paradigm when assessed at d70. This implies that a short 
and uninvasive procedure during pregnancy, that may be associated with maternal 
anaesthesia or the fetal injection itself, could be accountable for placental changes that alter 
the mediation of glucocorticoid transport to the fetus. This is an important point that is 
emphasised throughout this thesis and further illustrates the general plasticity of the fetus to 
external programming events. 
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Post-natal parameters were also monitored as an assay of the extent of pre-natal 
androgenisation of lambs and adult ewes of the two treatment models. Prenatal androgens 
and cortisol have been linked to reduced birth weight. In humans, there is a higher incidence 
of SGA or IUGR in babies from women with PCOS (503) and while some reports associate 
low birth weight with the development of PCOS in daughters (496-500) others do not (501, 
516). In non-human primates, prenatal androgenisation during early or mid-gestation does 
not however lead to reduced birth weight (504). Conversely, in the sheep model, exposure to 
TP from d30-90 does lead to IUGR and accompanying post-natal catch-up growth (332, 377, 
495). In our models, mid-gestation TP treatment from d62-102 did not result in reduced birth 
weight and growth trajectories into lamb and adulthood were normal. This difference may be 
a feature of the later exposure of our animals to androgens than in other sheep models. 
 
In the context of previous literature, the maternal androgenisation sheep model is in line with 
the degree of masculinisation that would be expected to result from the gestational timing of 
TP exposure, in terms of AGD, external genital development and behavioural traits. It is also 
found that the treatment of ewes with TP during mid-gestation leads to elevated estradiol 
levels in the fetus, in addition to testosterone concentration. The fetally exposed cohort, 
while having pharmacological levels of testosterone in the circulation during mid-gestation, 
did not possess the same frequency of genital ambiguity as the maternally exposed group. 
They did however display the same masculinised behavioural traits. All animal birth weights 
were normal and not affected by prenatal androgenisation and all individuals had healthy 
growth trajectories. It is therefore concluded that the external programming effects of 
treatment are minimal and generally reflect that of the subtle masculinised phenotype present 
in PCOS. The reproductive programming events mediat by increased prenatal exposure to 
androgens were studied in both fetus and adult offspring. The following chapter assesses the 
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The developing fetus is vulnerable to changes in the hormonal and nutritional environment 
that can manipulate highly plastic processes and pre ispose many adult pathophysiologies 
(517). Dysregulation of fetal programming can lead to an increased stress response as well as 
a propensity to develop cardiovascular, metabolic and reproductive disorders including 
PCOS (518-520). While PCOS is present in adult women of reproductive age (162), the 
early origins of this syndrome may occur in the fetus (350). Evidence from studies in non-
human primates, supplemented by experiments in rodents and sheep, reveals that increased 
in utero exposure to androgens leads to perturbed menstrual and estrous cycles, 
polyfollicular ovaries, hyperandrogenism, increased LH secretion, hyperinsulinaemia and 
increased adiposity in the adult (297, 365, 477-479). As these traits are reminiscent of PCOS, 
the androgen-exposed female fetus can inform us about the developmental programming of 
various features of PCOS.  
 
The effects of maternal androgen administration on the reproductive phenotype of female 
adult offspring have been well documented; however, these are likely to be secondary to an 
early direct effect on one or more fetal tissues. The adult consequences of increased prenatal 
androgens include LH-dependent ovarian hyperandrogenism and hyperinsulinaemia, both of 
which can cause PCO (521, 522). Therefore it was hypot esised that the adult PCO 
phenotype is secondary to fetally programmed hormonal a d/or metabolic changes, rather 
than a direct effect on the developing ovary. Thus the aim of this chapter is to assess the 
effect of in utero androgenisation on the fetal ovary at the time of follicle formation. 
 
In fetal life, germ cells migrate into the developing ovary and multiply within oogonial 
clusters (523). These clusters break down and the germ cells associate with somatic cells to 
form primordial follicles (524). Concomitantly, there is a marked reduction in germ cell 
number through apoptosis (525). In the sheep, these k y stages of ovarian development peak 
between days 55-90 of gestation (524). Both fetal and maternal androgenisation investigative 
approaches, to study the effects of androgens on the developing ovary, were assessed. This 
study examined the d90 fetal ovary after maternal adrogenisation followed by assessment 
of the d70 ovary. In addition, this was compared to the novel direct fetal androgenisation 
model at d70, where the fetus was injected with TP at d60 gestation to avoid placental 
metabolism, as described in Chapter 3. 
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The effect of androgenisation on cell proliferation a d germ cell volume was examined by 
immunolocalisation of Ki67 and OCT3/4. However, it was also hypothesised that if 
androgens had a direct effect on the ovary, they would alter the expression of genes involved 
in pathways associated with ovarian function or development. Key candidate pathways were 
consequentially assessed: A) the expression of genomic receptors for testosterone and 
estradiol within the fetal ovary (526), B) the steroidogenic potential of the fetal ovary, by 
quantifying the expression of key genes involved in ovarian steroid synthesis (159), and C) 
the ROBO/SLIT pathway that has important roles during mammalian development (527). 
SLIT1-3 ligands are secreted glycoproteins that bind the ROBO1-4 receptors (527). They 
can regulate cell migration by acting as a repulsive cue (528) and promote apoptosis and 
tissue remodelling (529). In the ovine fetal ovary the expression of SLIT2, SLIT3, ROBO1, 
ROBO2 and ROBO4 peak at around d70 coinciding with the onset of follicle formation 
(530). Importantly, these genes have been shown to be regulated by gonadotrophins and 
steroids in the female reproductive tissues (527, 531, 532). A final pathway was also 
examined; D) the expression and localisation of the Ids. The Id1-4 proteins are basic helix 
loop helix (bHLH) transcription factors that negatively regulate transcription. They are 
crucial to the timing of tissue-specific gene expression during embryogenesis, by interaction 
with DNA-binding domains (533) to control growth and differentiation (534). The study of 
the Ids in this model presented a novel opportunity to investigate their expression for the first 
time in the mammalian fetal ovary. 
 
Herein the effects of maternal exposure to androgens on the developing ovine fetal ovary at 
d90 of gestation are described. The effects of matern l androgenisation and direct fetal 
exposure to increased testosterone on the fetal ovary at d70 of gestation are also quantified. 
Differential functional alterations that could be early determinants of an adult ovarian 
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4.2 Materials and Methods 
 
4.2.1 Experimental animals 
 
The female animals assessed in this chapter are detaile  in Table 4.1. 
 
Study Treatment Sample number (n) 
Fetus 
Fetal Treatment Injection at d60, assessed at d70 C = 4, TP 20mg = 8 
Treatment from d60-70, assessed at d70 C = 3, TP = 6 
Maternal Treatment 
Treatment from d60-90. assessed at d90 C = 6, TP = 8 
Table 4.1  The experimental cohorts discussed in this chapter, the treatment regime and 
corresponding sample numbers. 
 
4.2.2 Tissue collection 
 
Both fetal ovaries (either at d70 or d90) were dissected and one was stored in Bouins fixative 
for 24 h prior to transfer to 70% ethanol and embedded in paraffin wax while the other was 
snap frozen and stored at -80°C.  
 
4.2.3 Ovarian histology 
 
The fixed ovaries were processed for histology as described in Section 2.4. Ovary sections 
(5µm) were stained with H&E to determine their morphology. Immunohistochemistry was 
performed on fetal ovaries for OCT3/4, Ki67, Id1, Id2, Id3, Id4, AR, ERα and ERβ proteins. 
Immunohistochemistry was carried out as detailed in Section 2.4.3.1. For negative controls, 
blocking peptides were available for Id1-4 and AR. For OCT3/4, Ki67 and the ER 
antibodies, negative controls consisted of omission of the primary antibody and substitution 
with non-specific IgGs. The product details and dilutions for each of the antibodies used in 
this chapter are listed in Table 4.2. Immunohistochemistry for the ER antibodies in the fetal 
ovary required further optimisation due to technical difficulties resulting in poor staining. 
For these antibodies, a further amplification step was utilised following incubation with the 
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tertiary compound, using a tyramide signal amplification kit (PerkinElmer, Cambridge, UK). 
The DNP amplification reagent from the kit was diluted 1:50 with 1X Amplifying Buffer 
and incubated with the tissue for 10 min at room tep rature. The slides were washed in 
PBS (3 x 5 min). Anti-DNP conjugated to HRP, diluted 1:100 with normal goat serum 
(NGS), was subsequently added to the tissue for 30 min at room temperature. The tissue was 
washed in PBS (3 x 5 min) before the routine staining with DAB and the remainder of the 
protocol performed as previously described. While this antibody amplification method 
produced immuno-staining, it was very widespread and it was not certain as to the specificity 
due to the presence of some staining in the controls using this method (Appendix B). 
 




Polyclonal Rabbit (N20; sc-816) Santa Cruz 
Biotechnology Inc., Santa Cruz, USA 
1:150 GARB 
ERα 
Monoclonal Mouse (VP-E614; clone 6F11) Vector 





Monoclonal Mouse (MCA1974S; clone PPG5/10) 
Serotec, Oxford, UK 
1:30 GAMB 
Id1 
Polyclonal Rabbit (C20; sc-488, BP sc-488 P) Santa 





Polyclonal Rabbit (C20; sc489, BP sc-489 P) Santa 
Cruz Biotechnology Inc. 
1:800 GARB 
Id3 
Polyclonal Rabbit (C20; sc490, BP sc-490 P) Santa 
Cruz Biotechnology Inc. 
1:200 GARB 
Id4 
Polyclonal Rabbit (L20; sc491) BP (sc-491 P) Santa 





Monoclonal Mouse (NCL-Ki67-MMI),  Novocastra 





Polyclonal Goat (C20; sc-8629), Santa Cruz 
Biotechnology Inc. 
1:200 RAGB 
Table 4.2  The proteins analysed by immunohistochemistry in the fetal ovary. The primary 
antibodies and respective concentrations used for immunohistochemistry are listed. 
Secondary antibodies applied were goat-anti rabbit biotinylated (GARB), goat anti-mouse 
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4.2.4 Stereological analysis of fetal ovaries 
 
Maternally exposed d90 fetal ovaries were stained for Ki67 and OCT3/4 as described above 
and subjected to a stereological assessment to quantify proliferation index or germ cell 
volume, respectively, in control versus TP-treated animals. Stereology was undertaken using 
Image-Pro Plus 6.2 software combined with a Stereology 5.0 plug-in (MagWorldwide, 
Wokingham, UK). Each fixed ovary was sectioned through its entirety (5µm sections) and 
ten evenly spaced tissue sections were studied for each animal. Each tissue section was 
analysed using the Leitz DMRB microscope (x60 objectiv ) with a Prior Pro-Scan automatic 
stage attached (Prior Scientific Instruments Ltd., Cambridge, UK) for tiling purposes. Due to 
relatively few Ki67 positive cells present in the d90 ovary, all positive cells were counted per 
section. The proliferation index was calculated relative to the average area of each counted 
section for that individual. Germ cell volume was measured by selecting crosses that 
overlapped positive OCT3/4 cells in at least five randomly placed grids/fields per ovarian 
section. Germ cell volume was calculated by dividing the number of crosses selected by the 
number of crosses per field (432) and multiplied by 100 to give percentage values. 
 
4.2.5 Semi-quantitative analysis of fetal ovaries 
 
Fetal ovaries underwent immunohistochemistry for Id1, I 2, Id3, Id4, and AR as described 
above and were microscopically assessed to determin changes in protein expression 
between control and TP-treated animals in both the maternally and fetally treated groups. 
Staining intensity was classified as weak, moderate or intense to give a measure of 
expression and fetal ovarian sections were subsequently categorised in a randomised blinded 
assessment by two investigators with reference to staining exemplars. Variation in staining 
assessment between observers was <5%. 
 
4.2.6 Quantitative real time -PCR 
 
RNA was extracted from whole fetal ovaries using the Qiagen RNeasy Micro Kit (Qiagen 
Ltd.) and cDNA synthesised as detailed in Section 2.8.1.1 and 2.8.2, respectively. A number 
of genes were assessed by qRT-PCR in control and TP-treated cohorts which are listed in 
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GCCCATCTTTCTGAATGTCC CAAACACCATAAGCCCCATC 233 
ERα                          
(NM_001001443) 
GAATCTGCCAAGGAGACTCG CCTGACAGCTCTTCCTCCTG 187 
ERβ 
(NM_001009737.1) 
GAGGCCTCCATGATGATGTC GGTCTGGAGCAAAGATGAGC 208 
CYP19                    
(NM_001123000) 
AATCCAGCACTCTGGAAAGC ACGTCCACATAGCCCAAGTC 152 
CYP11A 
(NM_001093789.1) 
CAACGTCCCTCCAGAACTGT CAGGAGGCAGTAGAGGATGC 172 
HSD3B1 
(NM_001135932) 
GGAGACATTCTGGATGAGCAG TCTATGGTGCTGGTGTGGA 200 
StAR 
(NM_001009243) 
GCATCCTCAAAGACCAGGAG CTTGACACTGGGGTTCCACT 194 
CYP17  
(NM_001009483) 
AGACATATTCCCTGCGCTGA GCAGCTTTGAATCCTGCTCT 215 
FSHR 
(NM_001009289) 
TAAGCACTTGCCAGCTGTTC CTCATCGAGTTGGGTTCCAT 196 
LHR 
(NM_214449.1) 
TCCGAAAGCTTCCAGATGTT GAAATCAGCGTTGTCCCATT 199 
Id1 
(NM_001097568) 
TCTGGGATCTGGAGTTGGAG ATACGATCGTCCGCTGGAA 151 
Id2 
(NM_001034231) 
CATCTTGGACTTGCAGATCG AGAGAGCTTTGCTGTCATTTG 185 
Id3 
(NM_001014950) 
ACTCAGCTTAGCCAGGTGGA TTTGGTCGTTGGAGATCACA 160 
Id4     
(NM_001546) 
TCACTGCGCTCAACACCGACC TTCCCCCTCCCTCTCTAGTGCTCCTG 132 
ROBO1 
(NM_133631) 
TTGAATTCAGGAGCAACTCC ATTAGCTGCCCTCACAAGGC 161 
ROBO2 
(NM_001128929) 
CTGAGAATCGGGTTGGAAAA AGGTTCTGGCTGCCTTCTTT 181 
ROBO4 
(NM_019055) 
TGTGAGGCCAGCAACCGGCT GTGGGCTCTGGGTGGCCCCA 164 
SLIT2 
(NM_004787) 
TGGAGGTGTCCTCTGTGATG TTATCCTTTCCCCTCGACAA 173 
SLIT3 
(NM_003062) 
GGAGCCTTCACCCAGTACAA ACACCAGCCCATCAAACAGT 166 
GAPDH 
(NM_001034034) 
GGCGTGAACCACGAGAAGTATAA AAGCAGGGATGATGTTCTGG 229 
Table 4.3  Genes analysed by SYBR Green qRT-PCR in the fetal ovary. Gene names and 
accession numbers, forward and reverse primer sequences (5’-3’) and respective product 
sizes are listed. 
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4.2.7 Statistical analyses 
 
An unpaired Student’s t-test was utilised to compare the means of two groups when 
analysing the gene expression data. In instances whre data were not equally distributed a 
Mann Whitney test was applied. A chi-squared test was applied to the categorical data 
gathered from the immunohistochemical analysis of the ovaries. P-values of P<0.05 were 






















Chapter 4                                                                      Prenatal androgens a d the developing ovary 




4.3.1 Maternal prenatal androgenisation does not alter d90 ovine 
ovary morphology or structure 
 
To investigate the effect of mid-gestation androgen exposure (d60-90) on the ovine fetal 
ovary a morphological and immunohistochemical assessm nt was undertaken. The gross 
morphological structure of the d90 ovary was not altered as a consequence of maternal 
androgen treatment when assessed microscopically. Ce l proliferation was quantified across 
the ovary by immunohistochemistry for Ki67 (Fig. 4.1.A). Stereological measurements 
indicated no change in the number of proliferative cells (Fig. 4.1.B). Furthermore, germ cell 
specific OCT3/4 immunohistochemistry (Fig. 4.1.C) revealed no variation in germ cell 
volume for control versus maternal TP-exposed ovaries, following quantitative stereological 
evaluation (Fig. 4.1.D).  
 
 
4.3.2 Maternal prenatal androgenisation affects d90 ovarian 
steroidogenic gene expression 
 
The d90 fetal ovary expresses receptors to androgens a d estrogens. Maternal 
androgenisation had no effect on the expression of mRNA for genomic AR (Fig. 4.2.A), ERα 
(Fig. 4.2.B) or ERβ (Fig. 4.2.C). Functional changes in response to increased in utero 
androgens were however observed in the d90 fetal ovary resulting in gene expression that 
could significantly impact ovarian steroidogenic potential. QRT-PCR detected reductions in 
the expression of steroidogenic genes including StAR (P<0.01; Fig. 4.2.D), CYP11A 
(P<0.05; Fig. 4.2.E), and CYP17 (P<0.01; Fig. 4.2.G), but not HSD3B1 (Fig. 4.2.F) nor 
CYP19 (Fig. 4.2.H). Interestingly, LHR (Fig. 4.2.I) and FSHR (Appendix B), crucial 
components in stimulating the steroidogenic pathway in ovarian steroidogenic cells in the 
adult ovary, were also expressed in the d90 ovine fetal ovary, and in the case of LHR, was 
significantly down-regulated following maternal androgen exposure (P<0.05). 
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Figure 4.1  The analysis of cell proliferation and germ cell number in the d90 maternally 
exposed fetal ovary. Immunohistochemistry for Ki67 (A) and OCT3/4 (C) with respective 
stereological quantification of ovarian cell proliferation (B) and germ cell volume (D) in the 
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Figure 4.2  Gene expression analysis in the d90 maternally exposed fetal ovary. The effect 
of maternal TP exposure on AR, ERα, ERβ, StAR, CYP11A, HSD3B1, CYP17, CYP19 and LHR 
(A-I) gene expression in the d90 fetal ovary. * P<0.05 and ** P<0.01.  
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4.3.3 Maternal prenatal androgen exposure and other developmental 
regulatory molecules in the d90 ovary  
 
The effect of maternal androgenisation on the expression of candidate molecules involved in 
the control of cell proliferation, death and differentiation in the d90 fetal ovary, was 
assessed. The expression of the SLITs and ROBOs that are expressed during follicle 
formation in the developing ovine ovary was examined, however; there were no differences 
in the expression of SLIT2 or SLIT3 ligands or ROBO1, ROBO2 or ROBO4 receptors after 
maternal androgenisation (Appendix B). All four Id proteins (Id1-4) were expressed in the 
d90 ovine fetal ovary (Fig. 4.3.A-D). Immunohistochemistry for Id1 revealed protein 
localisation confined mostly to the germ cells (Fig. 4.3.D). In contrast, Id2 and Id3 protein 
(Fig. 4.3.A and B, respectively) were strongly expressed in the germ cells and somatic cell 
streams and Id3 staining was present in pre-granulosa cells adjacent to germ cells (Fig. 
4.3.B). Id4 protein expression was present in some but not all somatic cells and pre-
granulosa cells and localised to the germ cells (Fig. 4.3.C). While no changes were observed 
for Id2, Id3 and Id4 mRNA or protein expression following maternal exposure to androgens 
(Appendix B), staining intensity for Id1 was increas d in control versus TP-exposed d90 
ovaries in both germ and somatic cell types (P<0.01; Fig. 4.3.E), although no variation 
existed at the transcript level (Fig. 4.3.F). Id1 protein was present in the ovarian stromal cell 
streams and more strongly expressed in the germ cell cytoplasmic compartment in TP-
exposed d90 ovaries compared to controls (Fig. 4.3.D).  
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Figure 4.3 Id expression analysis in the d90 maternally exposed fetal ovary. 
Immunohistochemistry for Id2, Id3, Id4 and Id1 (A-D) in the d90 ovine fetal ovary. Id1 
protein expression is altered by maternal TP-exposure (D and E); however, mRNA is not 
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4.3.4 The effects of maternal and fetal androgenisation on d70 ovarian 
steroidogenic gene expression 
 
The d70 fetal ovary also expresses receptors for and ogen and estrogens. While there were 
no differences in the expression of AR mRNA (Appendix B), immunohistochemistry for the 
AR protein revealed variations in the level of receptor present (Fig. 4.4.A). Staining intensity 
for AR was increased in direct fetal TP-exposed d70ovaries (P<0.05; Fig. 4.4.B) but not 
significantly altered in the maternally exposed d70 ovaries (Fig. 4.4.C). In contrast, direct 
fetal exposure to TP resulted in a down-regulation of the expression of both ERα (P<0.001; 
Fig. 4.4.D) and ERβ (P<0.05; Fig. 4.4.F) while maternal androgenisation did not alter their 
expression (Fig. 4.4.E and 4.4.G, respectively).  
 
Maternal androgenisation did not lead to changes in the expression of CYP11A (Fig 4.5.A), 
CYP17 (Fig. 4.5.B), CYP19 (Fig. 4.5.C), StAR, HSD3B1, LHR or FSHR (Appendix B) in the 
d70 fetal ovary. Conversely, direct fetal androgenisation did result in alterations to the 
potential ovarian steroidogenic capacity at d70. The expression of CYP11A was decreased 
(P<0.05; Fig. 4.5.D), whereas CYP17 mRNA was not altered (Fig. 4.5.E) and CYP19 
expression was up-regulated (P<0.05; Fig. 4.5.F). There were no changes in StAR, HSD3B1, 
LHR and FSHR (Appendix B) gene expression in this cohort. 
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Figure 4.4  Ovarian steroid receptor expression in the prenatally androgenised d70 fetus.  
Immunohistochemical expression of ovarian AR in a directly treated d70 fetus (A; insert 
represents negative control), and quantification of the effect of fetal and maternal 
treatments (B and C). Analysis of fetal and maternal treatment effects on ERα (D and E) and 
ERβ (F and G) gene expression. *P<0.05, ***P<0.001. 
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Figure 4.5  Steroidogenic gene expression analysis in the d70 androgen exposed fetal ovary. 
Effect of TP-exposure on ovarian CYP11A, CYP17, CYP19 gene expression in the maternally 
(A-C) and fetally treated (D-F) d70 fetus. *P<0.05. 
 
 
4.3.5 The effect of maternal and fetal androgenisation on other 
developmental regulatory molecules in the d70 ovary 
 
The ROBO and SLIT genes are known to peak in the ovine fetal ovary du ing mid-gestation. 
No significant changes were identified for SLIT2 (Fig. 4.6.A) or SLIT3 (Fig. 4.6.B) mRNA 
expression due to maternal androgenisation, nor following direct fetal androgenisation (Fig. 
4.6.D and E, respectively). Direct fetal androgenisation reduced the expression of ROBO1 
(P<0.05; Fig. 4.6.F) while maternal androgenisation had no effect on its expression (Fig. 
4.6.C). There were no trends or differences in the expression of ROBO2 or ROBO4 after 
either maternal or fetal androgenisation (Appendix B).  
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Figure 4.6  ROBO and SLIT expression analysis in the d70 androgen exposed fetal ovary. 
Effect of TP-exposure on ovarian SLIT2, SLIT3 and ROBO1 gene expression in the maternally 
(A-C) and fetally treated (D-F) d70 fetus. *P<0.05. 
 
The Id genes were also examined in d70 prenatal androgenisation models. Both mRNA and 
protein expression for Id3 changed following in utero androgen exposure (Fig. 4.7) while no 
changes were observed for Id1, Id2 or Id4 (Appendix B). Id3 transcript was increased 
following direct fetal TP-exposure (P<0.05; Fig. 4.7.A), although this trend was not 
significant following maternal TP-exposure (Fig. 4.7.B). Id3 protein, however, was up-
regulated in maternal TP-exposed d70 ovaries, with s ronger expression observed 
particularly in the stromal compartment (Fig. 4.7.C), after both fetal treatments (P<0.05; Fig. 
4.7.D) and maternal treatments (P<0.01; Fig. 4.7.E). 
 
 
Chapter 4                                                                      Prenatal androgens a d the developing ovary 
                                                                                                   
 132 
 
Figure 4.7  Id expression analysis in the d70 androgenised ovary. Expression of Id3 mRNA in 
the d70 ovary of fetally (A) and maternally (B) TP-treated animals and a representative 
image of Id3 protein expression in the d70 maternal control and TP-treated ovary (C; 
arrows indicate intense somatic cell staining, insert represents negative control). Scale bars 
= 50μm. Quantification of Id3 protein is illustrated in d70 fetally (D) and maternally (E) 
treated ovaries. *P<0.05 and **P<0.01. 
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One key feature of PCOS is the development of PCO chara terised by an increased number 
of small peripheral preantral follicles, an enlarged ovarian volume and thickened stroma 
(162). It is not clear if the PCO phenotype represents fundamentally different ovaries or if it 
is an ovarian response to an altered hormonal or metabolic environment. Exogenous or 
endogenous androgens can make a normal ovary polycystic in appearance (522), as can 
hyperinsulinaemia (521) and increased LH concentrations (535). These hormonal and 
metabolic changes are present in women with PCOS (162, 304, 536), and are seen in the 
ovine model of PCOS (299, 378), so it is possible that PCO occurs in response to the 
postnatal environment. As prenatal androgenisation in an ovine model leads to both an adult 
and prepubertal PCO phenotype (301), whether this was reflected in changes at the time of 
follicle formation in fetal life was investigated. 
 
In women, it has been suggested that since polycystic ovaries contain more growing follicles, 
without a reduction in primordial follicles, they may contain a larger pool of follicles (316, 
330). Given that the follicle pool is set in fetal life, follicle number was investigated in the 
d90 fetus after maternal androgenisation. At d90 of gestation, around the time of follicle 
formation, maternal androgenisation had no effects on cell proliferation or germ cell volume. 
Smith et al. utilised a similar ovine model of prenatal androgenisation from gestational d30-
90 and also found no alteration in oocyte number at d90, however, by d140 of gestation, 
there was a significant increase in the number of gr wing follicles (488). As germ cell 
proliferation is complete by d90 it is unlikely tha there is more germ cell proliferation or 
follicles formed. It is possible that reduced germ cell loss occurs at later stages of gestation 
leading to an increased number of follicles at birth. However as the PCO phenotype develops 
when maternal administration of androgens stops at d90 (299, 355) any effect at later 
gestational stages may be secondary to effects on other fetal reproductive or metabolic 
tissues programmed by androgenisation prior to d90.
 
The mid-gestation sheep fetal ovary has the capacity to be steroidogenically active, 
expressing a number of enzymatic components of the steroid biosynthesis pathway including 
StAR, CYP11A, HSD3B1, CYP17 and CYP19 (159). Products of these pathways including 
progesterone, androstenedione, testosterone and estra iol are readily detectable in ovine fetal 
ovarian tissue homogenates by d75 (159). The role of f tal ovarian steroid production is not 
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clear but there are ARs and ERs in multiple tissues including the ovary (526). The results 
showed a significant reduction of StAR, CYP11A and CYP17 transcripts in the d90 maternal 
TP-exposed ovary. As StAR and CYP11A are rate-limiting steps in the steroidogenic 
pathway (537) the intrinsic alterations following increased exposure to androgens could have 
a significant impact on the steroidogenic capability of the fetal ovary. In addition, maternal 
prenatal androgenisation also led to a decrease in d90 ovarian CYP17 that encodes the 
enzyme 17α-hydroxylase, responsible for androgen production. Furthermore, the ability of 
the d90 fetal ovary to respond to circulating endocrine factors was impaired as LHR 
expression was significantly reduced, and this is as ociated with a reduction in the 
circulating levels of the gonadotrophins (Chapter 3). Although the consequence of these 
alterations is not clear, these changes are an indication that the steroidogenic function of the 
fetal ovary at d90 is altered by maternal androgenisation. 
 
As the mid-gestation fetal ovary matures, cells differentiate, and this is associated with a 
reduction in germ cell number. The expression of the Id genes in the fetal ovary was 
therefore investigated with the hypothesis that fetal androgenisation could augment their 
expression to delay some differentiation pathways to potentially alter ovarian cell growth 
and development. For the first time it is revealed that all four Ids are differentially expressed 
in germ cells and somatic cells of the fetal ovary t the time of follicle formation. Although 
maternal androgen treatment had no effect on Id expression at the mRNA level there was a 
striking difference in the immunostaining for Id1 in the d90 fetal ovary. In the fetal ovaries 
of control animals moderate Id1 staining could be detected in the germ cells, however after 
maternal androgenisation there was intense staining of the germ and somatic cells. Whether 
this is a direct or indirect effect of androgen is not known and it is also not clear what 
functional effect this change would have. Considering its role in other tissues, Id1 may 
facilitate suppression of subsets of genes required for cell-specific development and 
apoptosis. The Ids are generally most highly expressed at times when proliferation is high 
and are decreased in terminally differentiated cells (538, 539). With this in mind it is 
possible that the up-regulation of Id1 protein reflects further functional changes in the fetal 
ovary and may delay gene expression necessary for ovarian developmental and maturational 
processes.  
 
It remains possible that an increase in Id1 at d90 could be a precursor to the increased 
number of growing follicles present in the d140 ovary, reported previously (488). However 
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that study, like most previous studies, of the ovine adult phenotype after prenatal 
androgenisation, commenced maternal androgen treatment at d30 (335, 354, 355, 378, 478). 
It is clear however that starting treatment on d60 still results in a reproductive phenotype 
with reduced estrous behaviour (540) as well as hormonal abnormalities, including increased 
LH pulse frequencies (299). The non-human primate model however is much more 
characterised and shows a similar effect on menstrual cycles, serum gonadotrophins and 
androgens, and importantly PCO morphology, when the androgens are started at the early or 
later stage (298, 358, 477, 541).  
 
The effects of androgenisation on the d70 fetal ovary using both indirect maternal treatment 
and the novel direct TP model were assessed, avoiding any effects of estrogenic 
programming that might occur as a result of placental aromatisation. Indeed, although 
elements of the PCOS phenotype were observed in sheep exposed to the non-aromatisable 
androgen DHT, there were no clear alterations in ovarian morphology observed in offspring 
from TP exposed mothers (354), although adult gonadtrophin profiles may still be 
perturbed (301, 353). The fetuses were injected with TP at d60 and the ovaries were studied 
at d70 when the circulating testosterone concentrations were still markedly elevated (Chapter 
3). The fetal ovary expresses aromatase and it is not k own if the intra-ovarian estradiol 
concentrations are increased after fetal injection of TP. However, there was no difference in 
the circulating estradiol concentration at this stage in either direct or indirect treatments 
(Chapter 3). It was therefore possible to compare the fetal ovarian effects of very high 
concentrations of testosterone (fetal treatment) wih a moderate elevation of testosterone 
(maternal treatment) associated with an adult ovarian phenotype. 
 
The changes in the expression of the steroidogenic zymes reported at d90 of gestation 
were not observed at d70 of gestation after maternal a drogenisation. While no change in 
CYP11A mRNA expression occurred at d70 with maternal androgenisation, direct fetal 
exposure to TP did inhibit the expression of CYP11A. This may suggest that androgens 
directly regulate CYP11A expression and that it occurs earlier after exposure to higher 
concentrations of TP. Aromatase was significantly increased in the direct treatment d70 
ovaries whereas no change occurred in the maternal xposure cohort. The significance of this 
in the fetus is not known, nor is it clear if this is a dose effect of the testosterone or whether 
raised estradiol can inhibit a testosterone-dependent increase in expression.  
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Direct fetal TP treatment also reduced the mRNA expr ssion of both ERα and ERβ, a feature 
not present in the maternally TP-exposed d70 or d90fetal ovary. This suggests that 
androgens can affect the ability of the ovary to respond to estradiol. It was not possible to 
confirm this at a protein level due to non-specific staining in the immunohistochemistry 
controls (Appendix B) but a previous study has described expression of ERα and ERβ in 
multiple fetal ovarian cell types including germ cells, surface epithelium, and stromal cells 
(526). It is therefore possible that TP can directly affect fetal ovary somatic cell function. 
Although the role of estrogen receptors in the fetal ovary is not clear, while ER knockout 
mice are infertile (542, 543) early reproductive trac  development is unaffected (544). 
However exposure to the synthetic estrogen DES during gestation can result in 
developmental abnormalities in the gonad and reproductive tract (508, 545, 546). 
 
Unlike ER expression, AR mRNA was not altered following either maternal or direct fetal 
prenatal androgen treatment, however, immunolocalisation of the protein revealed an up-
regulation of AR in direct TP-exposed d70 ovaries, with a comparable non-significant trend 
present in maternal TP-exposed d70 ovaries. Administration of DHT to pregnant rats has 
also been shown to lead to an increase in AR protein in the urogenital tract of female 
offspring (547). Although the increase in AR protein may be a result of ongoing exposure to 
high concentrations of testosterone, the fetal ovary appears to be able to adapt to increased 
androgen concentrations as no changes were found in AR in d90 fetal ovaries. This is in 
contrast to findings by Ortega et al. in a prenatally androgenised ovine model, where treating 
pregnant ewes with DHT or TP from d30-d90, led to small increases in AR protein in d90 
and d140 fetal ovaries (548). It may be that these diff rences represent a concentration effect 
or are a result of longer exposure. However, the increase in ovarian AR after direct TP 
injection in this study, and after maternal DHT (548), suggests an androgenic mode of up-
regulation. The lack of agreement between the mRNA and protein expression levels 
observed in this study may be due to an early mRNA response to increased androgens or 
changes in mRNA stability or translation or protein turnover. Since the entire frozen ovary 
was extracted for mRNA additional validation such as Western blotting was not possible. 
 
These observations have revealed that functional changes occur in the fetal ovary as early as 
d70 and that these are more marked after direct treatment with TP in which there are supra-
physiological concentrations of circulating androgen. Similarly, when examining the Ids, Id3 
was up-regulated after direct exposure to TP at both the mRNA and protein level. After 
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maternal androgenisation the trend to increase fetal ovarian Id3 mRNA was not significant 
however there was an increase in Id3 immunostaining. Id3 up-regulation occurred in the 
oocytes and was particularly clear in the somatic cells. This is also consistent with a role for 
the Ids in fetal ovarian development and indicates that up-regulation of their expression by 
androgens could have the potential to alter future ovarian development.  
 
In each of the previous examples, with the possible exception of CYP19 expression, the 
effects of direct and indirect androgenisation on the d70 fetal ovary have been similar. There 
was however also a significant change in the expression of ROBO1 mRNA in the fetal ovary 
following direct TP-exposure. The SLIT/ROBO pathway can regulate cell migration and 
promote cell death (527) therefore it was hypothesised that they had an important role in 
follicle formation in the fetal ovary. Given that there are steroid response elements in the 
promoter region of these genes (532), and steroids can inhibit SLIT/ROBO expression in the 
adult female reproductive tract (527, 532), it was suspected that they may be target 
molecules for androgens in the fetal ovary. The fetal TP-injection did in fact lead to 
inhibition of the expression of d70 ovarian expression of ROBO1. ROBO1 is the most 
abundantly expressed ROBO and its localisation to the pre-granulosa cells of forming 
follicles suggests an involvement in primordial follicle assembly (530). Although the 
functional effects have not been assessed these findings would be consistent with a direct 
effect of androgen in inhibiting the ovarian SLIT/ROBO pathway. The nature of the change 
in ROBO1 expression in the fetal ovary and the response to different steroid exposure in vivo 
is not clear. However, an alteration in expression of SLIT/ROBO components during the 
time corresponding to primordial follicle formation, when a finite population of resting 
oocytes are produced, could have an important impact on adult reproductive success. 
 
While this chapter examines only the fetal ovarian phenotype, prenatal androgen exposure at 
different time points is associated with changes in adult ovarian function (350, 540). It is also 
postulated that these are secondary to the hormonal environment, such as increased LH 
concentrations, and the metabolic environment, with increased insulin concentrations that 
such fetal androgenisation causes (304, 549). Even in the fetus, in which there are exogenous 
and subsequent endogenous changes in the steroid environment, other circulating hormones 
such as the gonadotrophins are affected (Chapter 3) and it is possible that this has indirect 
roles in reproductive programming. The mid-gestation fetal ovary undergoes marked growth, 
development and remodelling to form the pool of follicles that will remain throughout the 
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reproductive lifespan and it expresses both AR and ER (524, 526). Although the morphology 
of the fetal ovary at d90 gestation is unchanged by exposure to androgens, prenatal 
androgenisation leads to early subtle, but neverthel ss notable functional alterations. The 
consequences of these changes may alter ovarian development and contribute to an ovarian 
phenotype in later life. Although estradiol may have a role in manipulating ovarian 
development it is clear that androgens can have direct effects. However, even in the presence 
of large concentrations of TP in the pharmacological range, the effects remain subtle.  
 
In conclusion, the PCO phenotype in the adult may not e tirely be due to the hormonal and 
metabolic environment and there may be direct androgen effects on the developing ovary 
before d90 that programme future ovarian morphology. The following chapters therefore 
investigate the adult hormonal and ovarian outcomes to determine the primary and possible 
secondary effects of prenatal androgens. Firstly, a detailed assessment of the Ids in the 
normal adult ovary and characterisation of the signalling pathways involved is presented, and 
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The ovary, unlike other adult mammalian tissues, undergoes persistent cyclical remodelling 
with regulated proliferation, differentiation and cell death. Introduced in Chapter 4, the Id 
proteins are a subfamily of regulatory dimeric bHLH transcription factors. These factors 
regulate many genes, including those required for gr wth and differentiation, through 
binding to E-box (CANNTG) sequences on the promoter region of target genes (550, 551). 
Id proteins lack a basic DNA-binding domain and can heterodimerise with other bHLH 
proteins to block chromatin binding and thus subsequent transcriptional activity (552). Four 
known mammalian Id isoforms (Id1-4) have been identifi d and can regulate growth and 
differentiation across embryonic tissues (553-555), where both overlapping and non-
redundant functions are reported (556, 557). Predictably, these properties have led to Id 
proteins being implicated in tumourigenesis in various adult tissues (534, 558). 
 
Upstream mediators of Id expression include members of the TGFβ superfamily (559), that 
include the BMPs and activin (80).  Dimeric TGFβ ligands interact with a range of BMP 
type-1 and type-2 serine/threonine kinase receptor complexes to activate the smad signalling 
pathway (80). BMPs signal through the smad 1/5/8 pathw y whereas activin activates the 
smad 2/3 cascade which are phosphorylated upon activation by receptor complexes (560), 
and both are antagonised by smad 6 and smad 7 (561). Signalling by TGFβs has been linked 
to Id gene regulation during development, controlling the timing of differentiation and 
lineage commitment (557, 562-565). This has particular significance for the adult ovary in 
which BMPs and activin are involved in many processes governing follicle development and 
oocyte maturation and competency (255, 566, 567). Furthermore, although not yet 
characterised in the adult mammalian ovary, Id mRNA is reported to be expressed in the hen 
(Gallus domesticus) and the Ids are speculated to be involved in the control and timing of 
follicle selection and granulosa cell differentiation in this avian species (568, 569). 
 
Although the molecular regulation of proliferation a d differentiation in the adult ovary is 
not fully understood, members of the TGFβ family appear to have key mechanistic roles. 
The expression of the Id proteins has been studied in the ovine fetal ovary and may be 
differentially expressed in response to in utero programming (Chapter 4). Therefore it was 
hypothesised that the Ids have roles in the regulation of growth and differentiation of the 
steroidogenic cells of the adult mammalian ovary. The localisation of Id protein expression 
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(Id1, Id2, Id3 and Id4) in the pre- and post-pubertal sheep ovary was therefore studied. It was 
also hypothesised that the Id proteins are differentially regulated by the TGFβ family 
members through intracellular smad signalling pathwys. Accordingly smad proteins were 
localised in the ovine ovary in vivo and the effects of ovarian BMPs (BMP6, BMP15 and/or 
GDF9) and activin A on the expression of Id genes in primary cultures of non-luteinised 
granulosa cells in vitro were investigated. This chapter describes the consiste t localisation 
of the Id proteins in the normal ovine ovary in vivo and demonstrates differential gene 
regulation by BMPs and activin A in vitro.  
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5.2 Materials and Methods 
 
5.2.1 Experimental animals 
 
To characterise the expression of the Ids in the lamb nd adult ovary, ovaries from Scottish 
Greyface lambs (n=12), pregnant ewes (n=15) and non-pregnant ewes (n=5), were collected 
for immunohistochemical studies. Granulosa cells were collected from a further cohort of 
Scottish Greyface ewes (n=10) for culture studies. The animals in this study included the 
offspring of control maternal injections from d62-102 of gestation as well as other animals 




Tissue was processed for histology as described in Section 2.4.1 and underwent 
immunohistochemical staining (Section 2.4.3.1) for caspase-3, Id1, Id2, Id3, Id4, phospho- 
(p) smad 2/3, p-smad 1/5/8, smad 6 and smad7 (Table 5.1). Primary antibodies were 
incubated with blocking peptide, prior to application, or in the absence of a specific blocking 
peptide (smad 6 and smad 7) negative controls consisted of incubation with non-specific 
rabbit IgGs and omission of the primary antibody. To ensure the binding specificity of smad 
6 and smad 7, Western blotting was additionally carried out as previously described (Section 
2.7), using protein extracted from ovine granulosa cells. Specific bands were visualised for 
smad 6 and smad 7 at approximately 52 and 42 kDa, respectively, as anticipated (Fig. 5.1).  
 
5.2.3 Immunofluorescence  
 
Id1, p-smad 1/5/8 and smad 6 were visually localised in the ovine ovary by 
immunofluorescence. Ovary sections were treated in the same way as for 
immunohistochemistry but for the following alterations to the protocol. Following incubation 
with the secondary antibody on day 2 and washing, the appropriate tertiary antibody was 
applied (Table 5.1) for 1 h if using streptavidin or 10 min if using tyramide detection systems 
(described in Section 2.4.3.2). Sections were subsequently retrieved by microwaving for 2.5 
min in 0.01M sodium citrate buffer pH 6.0 (tyramide tection system only) and then 
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blocked in NGS for 1 h before overnight incubation with the second primary antibody at 
4°C. On day 3 the appropriate secondary and tertiary complexes were applied and 
counterstaining and imaging was carried out as detailed in Section 2.4.3.2.1 and 2.4.3.2.31.  
 
 
Table 5.1  List of primary, secondary and tertiary antibodies used immunohistochemistry 
(IH) and immunofluorescence (IF) experiments. Secondary antibody; 1) GARB (Dako, 
Glostrup, Denmark) 1:500, 2) Goat anti-Rabbit Peroxidase (Dako) 1:200. Tertiary antibody; 
A) Streptavidin Alexafluor 546 (s-11225 Invitrogen, Paisley, UK) 1:200, B) Tyramide 
Fluorescein (Perkin Elmer LAS, Inc. MA, USA) 1:50. 
 
 
                                                
1 Immunohistochemistry and immunofluorescence undertak n for this chapter was carried out, in part, 
by Sophie Etherington under supervision by KH. 






Polyclonal Rabbit (Asp175, #9661) Cell Signalling 
Technology Inc., USA 
IH 1:100 1  --------- 
Id1 
Polyclonal Rabbit (C20; sc-488, BP sc-488 P) 






Polyclonal Rabbit (C20; sc489, BP sc-489 P) Santa 
Cruz Biotechnology Inc. 
IH 1:500 1 --------- 
Id3 
Polyclonal Rabbit (C20; sc490, BP sc-490 P) Santa 
Cruz Biotechnology Inc. 
IH 1:400 1 --------- 
Id4 
Polyclonal Rabbit (L20; sc491) BP (sc-491 P) 
Santa Cruz Biotechnology Inc. 
IH 1:200 1 --------- 
p-Smad 
2/3 
Polyclonal Rabbit (Ser465/46; # 3101) Cell 
Signalling Technology Inc., 










Polyclonal Rabbit (IMG-555), Imgenex Corp, 




Smad 7 Polyclonal Rabbit (IMG-531), Imgenex Corp. IH 1:100 1 --------- 
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Figure 5.1  Validation of smad 6 and smad 7 immunohistochemical staining specificity by 
Western blot. In each lane 20µg of protein was loaded. Primary antibodies applied were α-
tubulin as an internal control (1:4000; Monoclonal mouse anti- α-tubulin, T9026; Sigma), 
smad 6 (1:300, Polyclonal rabbit anti- smad 6, IMG-555; Imgenex Corp.) and smad 7 (1:800; 
Polyclonal rabbit anti smad 7, IMG-531; Imgenex Corp.). 
 
 
5.2.4 Quantification of thecal Id expression in healthy and atretic 
follicles 
 
To obtain a quantitative measurement of thecal Id expression in follicles, staining intensity 
for Id1, Id2, Id3 and Id4 proteins were classified n three groups: absent, partial or intense 
stain. Follicles were classified as atretic or non-atretic based on immunostaining for activated 
caspase-3 in a serial section. Forty non-atretic and forty atretic follicles (50:50 pre-antral and 
antral) were examined across 6-8 different ovaries and a count performed categorising 
follicles into the appropriate staining class based on clear visual reference pictures agreed by 
three observers. Proportional data were presented as a percentage of the total number of 
follicles examined in each group.  
 
5.2.5 Cell culture and quantitative real time PCR 
 
Granulosa cells were collected and cultured as previously described (570). Follicles 
(<3.5mm) were collected from ovaries of ten Scottish Greyface ewes during the estrous 
cycle.  Follicles were hemisected and the granulosa cells collected by flushing thecal shells 
using a 1ml syringe. The supernatant containing granulosa cells was removed and cells 
collected by centrifugation, washed, and re-suspended in culture medium (McCoys 5a 
medium with sodium bicarbonate, supplemented with 0.1% BSA, 0.5x PenStrep, 3mM L-
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glutamine, 5µM transferrin, 0.3mM testosterone, 4nM selenium, 0.01µM insulin, 0.01µM 
ovine IGF-1 LR3 (Novozymes Biopharna AU Ltd, Australia), and 1nM FSH (NIDDK). 
Three separate experiments consisted of pooling granulosa cells from 3-4 animals to obtain 
sufficient numbers. Approximately 75,000 granulosa cells per well were cultured in 200µl 
medium with the addition of 100ng/ml activin A and/or BMP6, BMP15 and/or GDF9 (R&D 
Systems, Abingdon, UK) in treatment wells, or carrier-only in control wells, at 37°C/5% 
CO2 for 24 h
2. These concentrations were chosen based on the existing literature regarding 
BMP and activin effects on ovine steroidogenic cells (571, 572). 
 
Cells were lysed in 50µl RLT Buffer containing 1% β-mercaptoethanol and one volume of 
70% ethanol was added and the contents mixed and trsferred to an RNeasy MiniElute spin 
column (Qiagen Ltd.). RNA was extracted using the Qiagen RNeasy Micro Kit as per the 
manufacturer’s guidelines (Qiagen Ltd.). Lysed cells from 2-3 wells were pooled in order to 
obtain adequate RNA concentration and purity (A260/ 280 ratio) which were measured using 
a NanoDrop 1000 spectrophotometer (Fisher Scientific Ltd.) as described in section 2.8.1.3. 
RNA was stored at -80°C until cDNA was synthesised from 200ng total RNA per reaction as 
described in Section 2.8.2 using the High Capacity DNA Reverse Transcription Kit 
(Applied BioSystems). Primer sets were designed for amplification of partial regions of 
target genes by qRT-PCR (Table 5.2) and qRT-PCR was performed. The full protocol was 










                                                
2 Granulosa cell collection and culture was performed by Dr Julia Young 
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TCTGGGATCTGGAGTTGGAG ATACGATCGTCCGCTGGAA 151 
Id2 
(NM_001034231) 
CATCTTGGACTTGCAGATCG AGAGAGCTTTGCTGTCATTTG 185 
Id3 
(NM_001014950) 
ACTCAGCTTAGCCAGGTGGA TTTGGTCGTTGGAGATCACA 160 
Id4 
(NM_001546) 
TCACTGCGCTCAACACCGACC TTCCCCCTCCCTCTCTAGTGCTCCTG 132 
GAPDH 
(NM_001034034) 
GGCGTGAACCACGAGAAGTATAA AAGCAGGGATGATGTTCTGG 229 
Table 5.2  Cultured granulosa cell gene analysis using SYBR
 
Green qRT-PCR. Gene names 




5.2.6 Statistical analyses 
 
For the quantification of Id protein expression in the ovary, a chi squared test was applied to 
analyse whether Id expression was associated with healthy follicles. For the gene expression 
analysis data, the relative expression level of each t rget gene to GAPDH was quantified 
using the ∆∆Ct method (fold difference) so that control data were standardised between 
qRT-PCR runs to 1.0. Data are presented as the mean ± sem and statistical analysis was 
performed using a one way analysis of variance (ANOVA) with Bonferroni pair-wise 
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5.3.1 Id proteins are expressed in ovine follicles 
 
Id proteins were localised in sheep ovaries from different functional stages including pre-
pubertal, pregnant and non-pregnant states. Specific immunostaining was observed for Id1, 
Id2, Id3 and Id4 in the follicles of all ovaries examined (Fig. 5.2). These were consistently 
localised to granulosa cells in follicles throughout development from primary to pre-
ovulatory stages. In addition, consistent weaker staining was observed in the theca cells of 
these follicles (Fig. 5.2). Id2 immunostaining was lso apparent in the oocytes at all 
follicular stages and there was strong antibody binding observed across the ovarian stroma 
(Fig. 5.2.D-F). Weak Id3 expression was visible in the oocytes of primordial follicles (Fig. 
5.2.G; black arrows) whereas the zona pellucida exhibited a high level of Id3 expression 
across follicle development (Fig 5.2.H and I). Specific immunostaining was also observed in 
endothelial cells for each Id protein examined (Fig. 5.2), particularly Id3 where there was 
strong blood vessel localisation of this protein (Fig. 5.2.G; grey arrows).  
 
5.3.2 There is differential localisation of Ids in granulosa cells 
 
The Id1 antibody revealed intense staining of peri-oocytic cumulus cells (Fig. 5.2.A-C), a 
striking observation that was reproduced across follicular development and in all specimens, 
including pre-pubertal lamb and pregnant sheep ovaries s well as cycling ovaries. Although 
Id4 was more intensely immunostained than Id3 their localisation was similar across the 
granulosa cells and was maintained throughout follicle development (Fig. 5.2.G-L). 
However, unlike Id1, Id3 and Id4, immunoreactivity for Id2 was consistently most intense in 
those mural granulosa immediately adjacent the antral cavity of tertiary follicles (Fig. 5.2.F). 
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Figure 5.2  Id protein expression in the adult ovine ovary. Immunohistochemistry for Id1 (A-
C), Id2 (D-F), Id3 (G-I) and Id4 (J-L) protein in the ovary, illustrates from left to right, staining 
in primordial or primary, secondary or early antral, and tertiary or late antral follicles. 
Arrow in B) indicates intense peri-oocytic Id1 expression. Insets in C), F), I) and L), are 
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5.3.3 Id immunostaining is reduced in the theca cells of atretic follicles 
 
There was differential staining of Id proteins in the theca cells of some follicles (Fig. 5.3.A 
and B). Id1, Id2, Id3 and Id4 protein expression was reduced in the thecal layer of atretic 
follicles, by reference to activated caspase-3 immunostaining in serial sections (Fig. 5.3.C), 
while granulosa cell expression was maintained (Fig. 5.3.A and B). This phenomenon was 
encountered consistently in atretic follicles and could be quantified so that intense antibody 
staining in the thecal layer of healthy follicles was lost resulting in partial or absent 
expression of Id1, Id2, Id3 and Id4 proteins in follicles undergoing atresia (P<0.0001; Fig. 
5.3.D-G). No significant differences for Id protein expression, or alteration in thecal cells in 
atresia, were observed between pre-antral and antral follicles (Fig. 5.3). 
 
5.3.4 There is no specific peri-oocyte p-smad immunostaining in ovine 
follicles 
 
The most striking feature of Id localisation in the ovine ovary was the intense staining for 
Id1 in the cumulus granulosa cells closest to the oocyte. We therefore hypothesised that an 
oocyte-derived paracrine factor may regulate the expression of Ids in the neighbouring cells. 
As members of the TGFβ superfamily are excellent candidates for an oocyte-secreted factor 
we investigated the localisation of the main TGFβ signalling pathways in the follicles. P-
smad 1/5/8 proteins could be localised to the nucleus of both theca and granulosa cells (Fig. 
5.4.A and B). Indeed, the punctate pattern of more int nse staining (Fig. 5.4.B) suggests a 
specific regulated role for this pathway in such cells. However the staining was not increased 
or decreased in the granulosa cells next to the oocyte in any follicle examined. The 
alternative p-smad 2/3 pathway could also be detectd in nuclei of both theca and granulosa 
cells of the follicle (Fig. 5.4.D and E). Although t is staining was more uniform it also did 
not demonstrate a differential staining pattern in the granulosa cells surrounding the oocyte. 
Although it is clear that the cells surrounding theoocyte operate both smad 1/5/8 and 2/3 
pathways the consistent immunostaining pattern did not reveal a direct relationship with the 
peri-oocyte Id1 expression in cumulus granulosa cells. 
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Figure 5.3  The expression of Ids in healthy and non-healthy ovine follicles. Id2 expression in 
an adjacent healthy follicle (HF) and an atretic follicle (AF), at low (A) and high (B) 
magnification, and activated caspase-3 protein expression (C) in the corresponding follicles. 
Arrows in A) show thecal layer and in C) depict positive caspase-3 immunoreactivity 
indicating apoptosis in those cells. Scale bars = 50μm. Absent, partial or intense Id1 (D), Id2 
(E), Id3 (F) and Id4 (G) expression was classified in thecal cells of healthy and atretic, pre-
antral and antral follicles and is illustrated for each Id. Chi-squared statistical analysis 
showed a significant difference between the healthy and atretic categories for Id1, Id2, Id3 
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Figure 5.4  Smad protein expression in the adult ovine ovary. Immunohistochemistry for p-
smad 1/5/8 (A and B), p-smad 2/3 (D and E), smad 6 (G and H) and smad 7 (J and K) in the 
ovary. Arrow in G) identifies smad 6 positive immunostaining in granulosa cells and in H) 
indicates staining in a blood vessel. Respective negative controls in C), F), I) and L) represent 




Chapter 5                                                 Id expression in the adult ovary 
                                                                                        
 152 
5.3.5 The peri-oocyte localisation of smad 6 in granulosa cells 
 
Both of the inhibitory smads, smad 6 and smad 7, were found to have widespread ovarian 
expression (Fig. 5.4). Smad 6 revealed a similar localisation to smad 1/5/8 where staining 
was limited to some granulosa and thecal cells only (Fig. 5.4.G and H). However more 
intense nuclear staining was observed in some cumulus cells, notably around the oocyte, and 
also in cortical blood vessels (arrows in Fig. 5.4.G and H, respectively). Smad 7 staining was 
more uniform in the granulosa and thecal cells of all of the follicles examined (Fig. 5.4.J and 
K). To ensure the specificity of smad 6 and 7 antibody binding in the sheep, Western blotting 
for these proteins was also performed in ovine granulosa cell protein extracts. Specific bands 
were visualised for both smad 6 and 7 at the expected Mw (Fig. 5.1) confirming the 
expression of these proteins in this cell population and supporting the specificity of the 
immunohistochemistry.  
 
The relationship of the smads to Id1 was subsequently investigated using co-
immunofluorescence (Fig. 5.5). P-smad 1/5/8 did not co-localise in the cumulus layer with 
Id1 (Fig. 5.5.A). There was however some co-localisation between smad 6 and Id1 staining 
in the peri-oocyte granulosa cells (Fig. 5.5.B). This suggests that manipulation of the smad 
signalling system may yet have a role in the specific staining pattern of Id1 in the peri-oocyte 
granulosa cells. 
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Figure 5.5  The co-localisation of Id1 protein p-smad 1/5/8 and smad 6 in the ovine ovary. 
Co-immunofluorescence of Id1 (red) with p-smad 1/5/8 (green) (A) and smad 6 (green) (B) 
in follicles of the ovary. Merged pictures include DAPI nuclear counterstain (blue). Scale 
bars = 100μm. 
 
5.3.6 Activin and BMP signalling regulates Id gene expression in ovine 
granulosa cells in vitro 
 
In order to investigate the effect of stimulating the smad 2/3 and smad 1/5/8 pathways on Id 
expression, ovine granulosa cells were cultured with activin A and/or BMP6 and the levels 
of Id gene mRNA were analysed by qRT-PCR. Overall ANOVA analysis revealed that Id1 
(P<0.0001), Id2 (P<0.0001), Id3 (P<0.0001) and Id4 (P<0.05) were all changed by the 
treatments in the same pattern (Fig. 5.6). Stimulation with activin A led to the down-
regulation of Id1 and Id3 mRNA expression whereas conversely, BMP6 treatment up-
regulated these genes (Fig. 5.6.A and C, respectively; Bonferroni pair-wise analysis 
P<0.001). It was particularly notable for Id1 expression where activin A and BMP6 
treatment led to a 5-fold decrease and 7-fold increase in mRNA, respectively (Fig. 5.6A). 
Furthermore, treatment with activin A significantly negated the BMP6-induced up-regulation 
of Id1 (Bonferroni pair-wise analysis P<0.05; Fig. 5.6.A). 
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To further explore the potential roles of TGFβ mediated regulation of Id1 expression in the 
cumulus cells, culture experiments were conducted where the granulosa cell population 
received doses of the oocyte-secreted factors BMP15 and/or GDF9 and Id1 gene expression 
was measured (ANOVA P<0.001; Fig. 5.6.B). Similarly to the effects produced with the 
BMP6 cultures, BMP15 treatment also led to an increase in Id1 transcript (Bonferroni pair-
wise analysis P<0.01; Fig. 5.6.B). GDF9 alone did not significantly alter Id1 gene expression 
however in combination with BMP15 this increased 8-fold (Bonferroni pair-wise analysis 
P<0.001; Fig. 5.6.B).  
 
Figure 5.6  The effect of BMP signalling on Id gene expression in cultured ovine granulosa 
cells. Effect of activin A and/or BMP6 (A), and GDF-9 and/or BMP15 (B) on Id1 gene 
expression, and activin A and/or BMP6 on Id2 (C), Id3 (D) and Id4 (E) gene expression, in 
ovine granulosa cells cultured for 24 h, n=3; three experiments using cells from a total of 
ten sheep. An ANOVA analysis revealed overall significant differences for each gene; Id1 (A; 
P<0.0001 and B; P<0.001), Id2 (P<0.0001), Id3 (P<0.0001) and Id4 (P<0.05) and a pair-wise 
comparison to the control column using the Bonferroni post test are illustrated. *P<0.05, 
**P<0.01, ***P<0.001.  
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This study describes Id protein expression across the developing mammalian ovary and 
provides evidence for functional roles in normal adult tissue.  For the first time it has been 
shown that Id1, Id2, Id3 and Id4 are expressed in the granulosa and theca cells of healthy 
mammalian adult ovarian follicles across development. The Ids have two main functions; 1) 
to maintain proliferation and 2) to inhibit differentiation (553, 555). Such regulation during 
development ensures that the appropriate level of gr wth leading to patterning can occur 
prior to lineage commitment and the terminal differentiation of cells. The adult ovary 
similarly undergoes persistent tissue remodelling, resulting in the growth and differentiation 
of somatic follicular cells which house the oocyte. Bi-directional paracrine communication 
between theca cells, granulosa cells and the oocyte result in the accumulation of genetic and 
developmental competence for ovulation, fertilisation and subsequent embryogenesis. Id 
proteins are differentially expressed throughout development in many species including the 
mouse and Xenopus laevis and can have non-redundant actions as well as cell- p cific roles 
(557, 573). We propose a role for the Id proteins in the sheep ovary that might involve 
transcriptional regulation critical for normal folliculogenesis that may be analogous to those 
observed during development.  
 
Cumulus cell specific Id1 expression as well as the somatic cell wide Id protein expression 
was hypothesised to be regulated by activin and/or BMPs, present in the mammalian ovary, 
which are known to promote growth and differentiation in granulosa and thecal cells of 
various species (574-576). The steroidogenic cells of the adult ovary are fairly transient and 
possess similar characteristics to embryonic tissues or progenitor cells of which there are 
widespread reports of TGFβ-mediated Id mRNA and protein regulation (562, 563, 565). In 
this study it is shown that activin and BMPs can alter Id gene expression in ovine granulosa 
cells in vitro, and moreover, follicles have the cellular machinery for TGFβ signalling in 
vivo. This was demonstrated in ovine granulosa and thecal cells by the expression of p-smad 
1/5/8 and p-smad 2/3 and the presence of smad 6 andsma  7 inhibitors indicating regulation 
of TGFβ signalling.  
 
Id proteins may be regulated in ovine granulosa cells by various BMPs and activin that act in 
an opposing way to balance growth and differentiation appropriately.  Id1 and Id3 expression 
was significantly increased following BMP6 stimulation of granulosa cells in vitro whereas 
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activin A down-regulated these genes. Therefore Id protein regulation in the sheep ovary 
may be a target not only of BMPs but also activin. The effect of activin on Id function is not 
well described however our findings are consistent with a previous study reporting a 
negative association with activin treatment and Id gene expression (564). Reports of the 
specific expression of BMPs in the ruminant follicle vary (574, 577, 578), however it is 
probable that BMP4, 6 and 7 have actions in these clls and may all regulate Id expression 
although this is yet to be established. We also found that treating cells with both activin A 
and BMP6 reduced the BMP-mediated up-regulation of Id genes, suggesting a competing 
regulatory role for these paracrine molecules.  
 
The universally increased Id1 protein expression observed in peri-oocytic cumulus cells in 
follicles throughout development suggests a specific regulatory mechanism exerted by Id1 
that is likely mediated by paracrine signalling from the oocyte. Although this study revealed 
TGFβ-mediated signalling via smad 1/5/8 and/or smad 2/3 across the whole follicle, neither 
pathway could be directly linked to the cumulus-specific Id1 up-regulation. P-smad 2/3 was 
strongly but not differentially localised in granulosa cells and while p-smad 1/5/8 expression 
was more limited to certain cells this was not specific to the cumulus layer. In fact, co-
immunofluorescence established that in the cumulus cell  Id1 and p-smad 1/5/8 were not 
present in the same cell and thus led to a hypothesis that smad 1/5/8 and/or smad 2/3 may 
indirectly regulate Id1 in these cells. Intermediary factors might include the inhibitory smads 
and it was observed that smad 6 displayed a more differential expression pattern with some 
up-regulation in the cumulus cells as well as some co-localisation with the Id1 protein. Smad 
6 may repress smad signalling in some of these cells although the factor(s) regulating such 
an interaction are unknown. Specific oocyte-secreted factors in the sheep include TGFβ 
signalling molecules such as BMP6 (574) and BMP15 (GDF9b) (253) that activate smad 
1/5/8 signalling in granulosa cells (579). BMP15 stimulates granulosa cell proliferation 
while inhibiting differentiation (580, 581) and is essential for folliculogenesis in the sheep 
(253). 
 
Alternatively the lack of co-localisation observed between Id1 and p-smad 1/5/8 raises the 
possibility that the smad 2/3 pathway could in fact be responsible for the up-regulation of Id1 
in peri-oocytic cumulus cells. Activin, an activator f smad 2/3, led to a decrease in Id1
message in granulosa cell culture experiments. However, this effect could be cell specific 
since the majority of granulosa cells in these cultures are mural and the response may well be 
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different in cumulus granulosa cells, modulated by factor(s) secreted by the oocyte. GDF-9, 
an oocyte-secreted TGFβ member closely related to BMP15 (320), is an excellent candidate 
for triggering such a response. Its signalling pathw y is less clear as it can influence both 
smad 1/5/8 and smad 2/3 responses (582). GDF-9 signalling has been shown to be essential 
for cumulus cell function where activation of smad 2/3 brings about the up-regulation of 
cumulus-specific genes (583). This paracrine signalling through smad 2/3 is crucial for 
normal cumulus cell expansion, resulting in a local milieu enabling the acquisition of oocyte 
developmental competence (584-586). In vitro GDF-9 (non-significant) and BMP15 can in 
fact increase Id1 gene expression in cultured ovine granulosa cells and both ligands together 
enhance this response further although it is reiterated that these findings are limited to a 
largely mural granulosa cell population which may differ from cumulus cells. In context this 
latter finding is interesting since the synergy between these growth factors is known to be 
important for granulosa cell proliferation in the sheep (587). It is hypothesised that while the 
surrounding granulosa cells produce activin that might negate Id1 expression via smad 2/3, 
TGFβ signal from the oocyte such as BMP6, BMP15 and/or GDF-9 may lead to Id1 up-
regulation in these cumulus cells.  
 
The Id proteins were down-regulated in the thecal cells of atretic ovine follicles and not 
altered in granulosa cells. Follicular atresia occurs when FSH levels decrease during the 
follicular phase of the estrous cycle leading to apptosis in subordinate follicles (588). The 
present study identifies a differential change in Id protein distribution in these follicles that 
may be triggered by autocrine or intracrine thecal signalling, which is potentially inhibitory 
and does not effect granulosa cell expression. As mo t changes associated with atresia are 
detected in the granulosa cell population these theca-specific changes are of interest. 
However theca-specific Id protein down-regulation in atretic follicles is merely associative 
with no evidence at this stage of a causal relationship.  
 
This study is the first to carry out a comprehensive immunohistochemical examination of the 
Id proteins in the adult mammalian ovary. In conclusion, Id1, Id2, Id3 and Id4 are present in 
the ovine ovarian follicle and may be regulated by BMPs and/or activin via smad signalling. 
Further studies are required to establish how important the Ids are for the regulation of 
proliferation and differentiation of steroidogenic cells occurring during folliculogenesis and 
the physiological significance for fertility and reproductive diseases. Control and non-treated 
animals linked to the PCOS studies were used as a re ou ce to discover new insights into 
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normal ovarian physiology. In Chapter 7, the ovarian phenotype of the prenatally 
androgenised ewe is assessed. The expression profile of the Id genes is therefore examined to 
determine if their expression may be changed in a PCOS-like animal model. Before this a 
detailed assessment of the hormonal profile and ovarian cyclicity of prenatally androgenised 
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In women with PCOS it is the disruption of the hormnal milieu that causes the 
characteristic features associated with PCOS that are often first noted clinically. The 
diagnosis of PCOS is partially based on biochemical criteria including hyperandrogenaemia 
that is in part secondary to enhanced pituitary secretion of the gonadotrophin LH (162). The 
other major clinically important feature of PCOS is irregular menstruation 
(oligomenorrhoea) or the complete absence of menses (amenorrhoea) due to the cessation of 
normal ovarian cyclicity (162). 
 
In PCOS, perturbations to the HPO axis often involve LH hypersecretion and an increased 
LH pulse frequency, due in part to increased sensitivity of the pituitary to GnRH (589). 
Studies in the prenatally androgenised ovine fetus have identified a parallel set of features in 
adult ewe offspring (355, 374, 378). These endocrine a omalies occur through testosterone 
treatment of the mother and it is therefore possible that some of these effects are mediated by 
estrogen that is formed by aromatisation during placental transport and will pass into the 
fetus (377). Studies that use a subtractive approach by treating pregnant animals with the 
non-aromatisable androgen DHT have gone some way in deli eating differences between the 
programming effects of androgens and estrogens (353, 354). 
 
Veiga Lopez et al. have unequivocally identified the programming effects of alternate sex 
steroids using this approach (354). Through comparison of female offspring prenatally 
treated with TP or DHT from gestational d30-90, they r vealed that in ovary-intact animals 
androgens affect programming of the estradiol negative feedback to the hypothalamus and 
pituitary that is involved in follicular selection, whereas, the positive feedback to the 
hypothalamus and pituitary required for the generation of the LH surge is altered by early 
exposure to estrogens (354). Likewise the increased LH pulse frequency and amplitude 
observed in prenatally androgenised sheep (299, 352) is thought to occur through increased 
sensitivity to GnRH mediated through androgenic programming (379).  
 
The timing of prenatal exposure to androgens is also important. Two common models of 
prenatal androgenisation that exist in the sheep typically involve TP exposure from 
gestational d30-90 or from d60-90. These models have demonstrated differential effects on 
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LH surge dynamics, estradiol negative feedback and cyclicity depending on the window of 
in utero androgenisation. Generally treatment of pregnant ewes from d60-90, which is 
outside the window of fetal sexual differentiation, results in a more subtle reproductive 
phenotype (355, 369, 378) compared to those treated from d30-90 (352-354). In these 
studies, d60 rather than d30 was selected as a starting gestation for treatment as this avoids a 
severe reproductive phenotype, with marked masculinisation of the external genitalia, which 
is not seen in women with PCOS. In addition, this gestational period facilitates the 
assessment of the effects of direct administration of TP to the fetus in a parallel cohort 
(Chapter 3). 
  
In women with PCOS, as well as in prenatal androgenisation models of PCOS in the sheep, 
non-human primate and rodent, LH secretion tends to be enhanced (295, 296, 379, 589). In 
addition to potential dysregulation by HPO feedback systems to either the hypothalamus or 
the pituitary to target LH release from the gonadotroph, there may be intrinsic changes at the 
level of the pituitary that exert these effects. LHmay be stimulated locally in a number of 
ways; through reduced sensitivity to estradiol negative feedback, mediated by a reduction in 
pituitary ERα, by increased sensitivity to GnRH due to the up-regulation of the GnRHR, or 
by increased expression of the LHβ subunit itself. In fact, Mannikam et al. examined the 
expression of various pituitary genes in this regard in sheep prenatally androgenised from 
d30-90 a model in which increased LH secretion and pulse amplitude was present. The 
authors did not find significant alterations in the mRNA expression for ERα, LHβ, FSHβ or 
GnRHR, however the common gonadotrophin subunit α-GSU was up-regulated in adult 
sheep (379). In addition it is possible that alterations in the expression of local paracrine 
regulators of gonadotrophin secretion might be affected by prenatal androgenisation. These 
include the activins and inhibins that are positive and negative regulators of FSH secretion, 
respectively (93, 103, 104). In the d30-90 prenatally ndrogenised sheep there were trends 
for increases in INHA, INHBB and follistatin, and the activin receptor (ACVR1) was up-
regulated in the adult pituitary, however there was no change in inhibin receptor β-Glycan 
gene expression (379). Although animal models of PCOS can inform us of the pathways 
involved in alterations of the hormonal milieu the molecular mechanisms of these changes 
have still not been fully elucidated. 
 
The aim of this chapter is to elucidate the effect of prenatal androgens on HPO axis function 
in young adult sheep and to determine how the route f androgen administration or the 
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timing of exposure may affect the outcome. The objectiv s included an assessment of: A) 
systemic hormone concentrations, including; 1) measurement of plasma levels of 
androstenedione, testosterone, estradiol and progesterone (to monitor ovulation regularity) 
and 2) a measure of hypothalamic and pituitary functio  by assessment of LH pulsatility and 
basal LH and FSH secretion and B) pituitary gene expression for GnRH, androgen and 
estrogen receptivity, gonadotrophin subunit expression and local expression of the activins 
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6.2 Materials and Methods 
 
6.2.1 Experimental animals 
 
The adult female ewes assessed in this chapter are detailed in Table 6.1. 
 
Study Treatment Sample number (n) 
Adult 
Injection at d62 and 72 C = 4, TP 20mg = 8 
Fetal Treatment 
Injection at d62 and 82 
C = 4, TP 1mg = 5, 4mg = 5, 
20mg = 7 
Maternal Treatment Treatment from d62-102 C = 5, TP = 9 
Table 6.1  The experimental cohorts for the study of hormonal regulation and ovarian 
cyclicity, treatment regime and corresponding sample numbers. 
 
6.2.2 Hormonal analysis 
 
Progesterone concentration was measured in plasma obtained from weekly blood samples 
taken over 4 weeks from ~8.5-9.5 months of age (during late January and early February) by 
RIA as described in section 2.5.2 and specific assay re gents and CVs are detailed in Table 
6.2. The protocol specific to the progesterone RIA and reagent concentrations are detailed in 
Appendix A. Progesterone values greater than 1ng/ml were considered large enough to imply 
probable ovulation with reference to previous studies investigating hormone secretion during 
the ovine estrous cycle (72, 380, 590, 591). 
 
LH was measured in peripheral venous plasma from serial samples taken during the course 
of a 6 h period in adults at ~ 10-10.5 months old, in early March. Estrous cycles were 
synchronised prior to this assessment with an initial injection of 125mg prostaglandin 
estrumate (i.m.; Schering Plough Animal Health, Welwyn Garden City, UK) to terminate the 
luteal phase and align cycles, before a second prostaglandin injection 24 hours before the day 
of sampling to ensure that all animals were in the follicular phase. Animals were cannulised 
in the jugular vein following administration of local anaesthetic, and housed in crates with a 
supply of fresh water and hay during the experimental period. Sampling commenced at 
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10.00h and blood (1ml) was drawn every 10 min until 16.00h. Heparinised blood samples 
were spun at 3000 rpm for 15 min at 4°C and the plasma collected and stored at -20°C until 
further use. RIA was employed to measure LH at each of the time points (37 in total) as 
described in section 2.5.2 and reagent details and CVs listed in Table 6.2. Specific LH RIA 
protocol details are detailed in Appendix A. Pulses w re defined if the LH concentration was 
>1ng/ml and were approximately one third greater or m e than that of the two preceding LH 
values in line with previously published studies in the sheep (592). 
 
FSH was measured on the day of serial sampling, by RIA using the same protocol for LH 
measurements (Section 2.5.2 and Appendix A). Table 6.2 lists specific reagent details for the 
FSH RIA. Two samples were measured for FSH, one from the start of sampling and one at 
the end (6 h apart), and the average of these values calculated. Estradiol was also measured 
on the same day as the serial sampling for LH took place, although this steroid was measured 
in one sample only from each animal (the same time point was used for all the animals). 
Estradiol was measured in plasma using a commercially available RIA kit of which the 
details and CVs are listed in Table 6.2. These samples were serum extracted prior to RIA 
(Section 2.5.1). Specific details for RIA measurement of estradiol are detailed in Appendix 
A. Testosterone and androstenedione concentrations were measured in peripheral blood 
samples at approximately 10 months of age. These hormones were measured by RIA 
following extraction of serum from the sample as decribed in section 2.5.1. Reagent details 
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Hormone Primary antibody 













Rabbit  anti-Androstenedione 
(07-109216; MP Biomedicals,  
Illkirch, France) 
Andro-








Rabbit anti- Testosterone (R3S07-









































Table 6.2  The hormones measured in sheep peripheral plasma by RIA.  A list of primary 
antibodies, tracer and standards employed for each RIA. Unless otherwise stated 
radiolabelled tracer was supplied by MP Biochemicals, Illkirch, France and the standards 
were from Sigma. *This in-house assay is described in McNeilly et al. (505). 
 
 
6.2.3 Pituitary gene expression analysis 
 
The expression of a range of genes was investigated in the adult sheep pituitary. The 
methodology used for these experiments are as describ d in Section 2.8 of the Materials and 
Methods chapter, which details RNA extraction, cDNA synthesis, primer validation and 
SYBR Green qRT-PCR protocols that were utilised for assessment of this tissue. The primer 
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Table 6.3  Adult pituitary gene analysis using SYBR
 
Green qRT-PCR. Gene names and 




6.2.3.1 Statistical analyses 
 
In this chapter, where the differences between two means were assessed, including the qRT-
PCR pituitary gene expression experiments and hormonal analysis, data were statistically 
analysed using a student’s unpaired t-test assuming equal variances. In the instances where 
data were not normally distributed (unequal variances) a non-parametric Mann Whitney test 
was alternatively employed. For the d62/82 experimental cohort in which there were 
numerous treatment groups, statisitcal analyses were conducted so that each TP-treated 
group (shaded bar) was compared to the control group (white bar). The values are presented 
as the mean ± sem. Data collected from proportional assessment were subjected to a chi (χ2)
squared test. These values were presented as a percentage. P values of P<0.05 were 
considered statistically significant.  
Gene (Accession 
No.) 






GAAGAGACCCGATGTCACCCAGC TGTCGTCCTCTATCTCCACGTACCCG 113 
INHBB 
(NM_176852) 
ATGGCCTGGCCTCCTCCCG CTTCAGGTAGAGCCACAGGCTGGC 101 
INHA 
(NM_174094) 
GAGCCCGAGGACCAAGATGTCTCC CCTCAGCCTCTCCAGCATCTGGC 91 
Β-Glycan 
(NM_214272) 
AATGGCACGCACTTCATTTT GTCCCCTGGAAATCCGTTAT 186 
AR 
(XM_001253942) 
GCCCATCTTTCTGAATGTCC CAAACACCATAAGCCCCATC 233 
ERα                          
(NM_001001443) 
GAATCTGCCAAGGAGACTCG CCTGACAGCTCTTCCTCCTG 187 
LHβ 
(NM_001009380)  
TCACTTTCACCACCAGCATC AAGGAGACCATTGGGTCCAC 166 
FSHβ 
(NM_001009798) 
TGTTGCTGGAGAGCAATCTG AGTCTGCATGGTGAGCACAG  238 
GnRHR 
(NM_001009397) 
GCAGTGAAAAGCAACAGCAA  GGCAGCTGAAGGTGAAAAAG 214 
GAPDH 
(NM_001034034) 
GGCGTGAACCACGAGAAGTATAA AAGCAGGGATGATGTTCTGG 229 
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6.3.1 Peripheral levels of estradiol, androstenedione and testosterone 
are not altered by prenatal androgenisation in young adults  
 
Peripheral estradiol concentration was measured in blood collected on the same day as the 
pulse bleed for LH measurement. Accordingly animals were in the follicular phase of the 
estrous cycle as described. Estradiol, predominantly secreted by the ovary, was not changed 
as a result of prenatal androgenisation in maternal (Fig. 6.1.A) or fetal (Fig. 6.1.B and C) 
treatment groups. Androstenedione and testosterone which can be produced by both the 
ovary and also the adrenal gland were also not altered by prenatal androgens. There was no 
difference in secretion of androstenedione or testoster ne in maternally (Fig. 6.1.D and G, 
respectively) or fetally (d62/72; Fig. 6.1.E and H, respectively) treated offspring. There 
appeared to be an increase in both androstenedione and testosterone in animals fetally 
exposed to 4mg TP (Fig. 6.1.F and I, respectively), although this did not reach statistical 
significance for either hormone. 
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Figure 6.1  The plasma hormonal profile of young adult prenatally androgenised offspring. 
The effect of prenatal androgenisation in determining circulating estradiol (A-C), 
androstenedione (D-F) and testosterone (G-I) in young adults in maternally and fetally 
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6.3.2 Estrous cycles in the first breeding season are not universally 
present and HPO activation is variable regardless of treatment regime 
 
To determine whether animals were ovulating, progesterone, which would be elevated 
during the luteal phase, was measured. Luteal phases,  a measure of estrous cyclicity, were 
classified as absent, intermittent or regular based on progesterone secretion measured over a 
4 week period at ~8.5-9.5 months of age. The majority f young adult animals during this 
first breeding season displayed at least one high progesterone measurement (>1ng/ml) to 
indicate that ovulation had occurred. Two large progesterone values measured over 2-3 
weeks suggested that estrous cycling was regular in those individuals; however, this was 
observed in fewer animals. In some animals ovulation had not occurred during the sampling 
period. However, prenatal androgenisation was not found to affect the number of luteal 
progesterone peaks in young adult animals in the first breeding season. There was no 
significant difference in the number of animals falling into each category following maternal 
(Fig. 6.2.A) or fetal (Fig. 6.2.B and C) TP exposure. There was also no overall effect of 
treatment strategy when control groups were compared (Fig. 6.2.D).  
 
In addition to investigating the estrous cycle regularity in young adults, the degree of 
hypothalamic pituitary axis activation during the follicular phase was also assessed. Serial 
blood sampling over a 6 h period was performed in an m ls that were ~10.5 months old and 
LH subsequently measured to assess the frequency and amplitude of LH peaks 
corresponding to the follicular phase of the cycle. Like the ovulation rate amongst animals, 
LH pulsatile secretion was variable during this firt breeding season, being present in some 
animals (Fig. 6.3) and absent in others (Fig. 6.4). In those animals that LH peaks were 
present, pulsatile secretion occurred every 2-3 hours with peak amplitudes ranging from 2-
4ng/ml (Fig. 6.3). Prenatal control or TP treatment did not bear any relationship to the 
presence or absence of LH pulses in young adult sheep (Fig. 6.3 and 6.4, respectively, and 
Table 6.4). Furthermore, the number of animals with LH pulses did not necessarily equate to 
prostagenic cycling and often animals that displayed LH pulsatility were not previously 
cycling. However, these measurements were taken at different times with the measurement 
of LH pulsatility occurring towards the end of the breeding season. 
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Figure 6.2  Estrous cyclicity in prenatally androgenised ewes in the first breeding season. 
Estrous cyclicity was determined by a peak in progesterone secretion, denoting the 
presence of a luteal phase, from weekly samples collected over a 4 week period during 
January and February in maternal (A), fetal d62/82 (B) and fetal d62/72 (C) prenatally 
treated cohorts. D) Compares control groups from each cohort. No estrous cycles = no 
discernable luteal phases. Intermittent estrous cycles = at least one luteal phase detected. 
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Figure 6.3  The presence of LH pulses during the first breeding season. Pulsatile LH 
secretion was measured over a 6 h period in early March. Illustrated are representative LH 
profiles from individual animals in the maternal C (A) and TP (B) cohort, the fetal d62/72 C 
(C) and TP 20mg (D) cohort and the fetal d62/82 C (E), TP 1mg (F), TP 4mg (G) and TP 20mg 
(H) cohort. 
Chapter 6                                                                      Prenatal androgens a d the endocrine system




Figure 6.4  The absence of LH pulses during the first breeding season. In some animals 
pulsatile LH secretion did not occur when measured over a 6 h period in early March. 
Illustrated are representative LH profiles from individual animals in the maternal C (A) and 
TP (B) cohort, the fetal d62/72 C (C) and TP 20mg (D) cohort and the fetal d62/82 C (E), TP 
1mg (F), TP 4mg (G) and TP 20mg (H) cohort. 
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 Prostagenic Cycles LH Pulses 
Treatment None Intermittent Regular Absent Present 
MI C 2 2 1 2 3 
MI TP  4 4 1 5 4 
FI d62/72 C 2 2 0 3 1 
FI d62/72 TP 20mg 2 4 2 3 5 
FI d62/82 C 1 2 1 1 3 
FI d62/82 TP 1mg 2 3 0 3 2 
FI d62/82 TP 4mg 0 4 1 2 3 
FI d62/82 TP 20mg 1 4 2 6 1 
Table 6.4  The number of animals displaying estrous cycles and LH pulsatility during the first 
breeding season. Prostagenic cycling was measured from January to February whereas LH 
pulsatility was measured in March. 
 
6.3.3 Prenatal androgenisation may have subtle effects on 
gonadotrophin secretion and pituitary function 
 
Basal LH and FSH levels were also compared in the prenatally androgenised ewe. There was 
a lot of individual variation present between animals making it difficult to interpret 
nevertheless while there was no change in basal LH between the maternal (Fig. 6.5.A) and 
fetal d62/72 (Fig. 6.5B) treated cohorts, there was a trend for lower LH levels in the fetal 
d62/82 TP 1mg and 4mg groups and significantly lesscirculating LH was present in the TP 
20 mg group (P<0.05; Fig. 6.5.C). Likewise, basal FSH levels were not altered after 
maternal treatment (Fig. 6.5.D) but fetal treatment at d62/72 (Fig. 6.5.E) and at d62/82 (Fig. 
6.5.F) did result in lower FSH levels compared to controls, although these were non-
significant trends. The LH to FSH ratio was therefo not altered after maternal 
androgenisation (Fig. 6.5.G) however it was non-sigificantly increased in the fetal d62/72 
TP-treated group (Fig. 6.5.H) but not changed following fetal d62/82 treatment (Fig. 6.5.I). 
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Figure 6.5  Basal LH and FSH concentrations and the LH to FSH ratio in the prenatally 
androgenised ewe. Basal LH (A-C), basal FSH (D-F) and LH:FSH (G-I) in maternally, fetal 
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Since ewes presented varying degrees of cyclicity the levels of basal LH and FSH were 
compared with the presence of prostagenic cycles and LH pulsatility. Unsurprisingly the 
presence of intermittent and regular estrous cycles and LH pulsatility was associated with 
higher levels of basal LH (Fig. 6.6.A). However this relationship was not identified for FSH, 
with no correlation existing between FSH concentration and the presence or absence of 




Figure 6.6  The association of LH and FSH levels with the presence of estrous cycles and LH 
pulsatility. All animals from each treatment cohort were grouped together as treatment 
regime was not shown to affect cyclicity or LH pulsatility. *** P<0.01. Comparison of LH 
concentrations in ewes that were regularly ovulating (dark shade; A) with no ovulations 
(white bar; A) did not reach statistical significance. 
 
Gene expression analysis was performed in the adult pit itary to determine the effect of 
prenatal androgens on the receptivity to the steroid h rmones androgen and estrogen and also 
the hypothalamic hormone GnRH. The mRNA expression of AR was not changed by 
prenatal androgenisation (Fig. 6.7.A-C) nor was the expression of ERα (Fig. 6.7.D-F), 
however there was a downward trend in ERα expression following fetal d62/82 exposure but 
this was not significant due to the variation present in the controls (Fig. 6.7.F). The 
expression of GnRHR was not altered following either maternal androgenisation (Fig. 6.7.G) 
or fetal d62/72 TP (Fig. 6.7.H), however pituitary GnRHR was down-regulated in animals 
that were fetally treated at d62 and d82 with 1mg TP (P<0.05) and 4mg and 20mg TP (non-
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significant; Fig. 6.8.I). This loss of GnRHR mirrors the decline in LH and FSH hormone 
measured in the same cohorts (Fig. 6.5.C and F, respectively). 
 
 
Figure 6.7  The hormonal receptor gene expression in the adult pituitary. The effect of 
prenatal androgenisation on gene expression in the pituitary was determined by qRT-PCR. 
In maternally and fetally d62/72 and d62/82 treated animals, respectively, AR (A-C) and ERα 
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To establish whether intrinsic changes could take place in the pituitary to govern the 
availability of LH or FSH, the specific subunit gene expression for these subunits was 
assessed. Indirect maternal TP expression resulted in an up-regulation of LHβ subunit 
expression in the adult pituitary (P<0.05; Fig. 6.8.A), although FSHβ subunit expression was 
unaffected (Fig. 6.8.D). Direct fetal TP treatment had no effect on LHβ (Fig. 6.8.B and C) or 
FSHβ (Fig. 6.8.E and F) subunit gene expression.  
 
 
Figure 6.8  Gonadotrophin subunit gene expression in the adult pituitary. The effect of 
prenatal androgenisation on gene expression in the pituitary was determined by qRT-PCR. 
In maternally and fetally d62/72 and d62/82 treated animals, respectively, LHβ (A-C) and 
FSHβ (D-F) gene expression was assessed. * P<0.05. 
 
The pituitary expression of the inhibin subunits, INHA, INHBA and INHBB were not altered 
by maternal or fetal prenatal androgenisation (Fig. 6.9 A-I). The expression of the inhibin 
receptor, β-Glycan, in the pituitary was also not affected by these treatments. 
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Figure 6.9  The inhibin subunit and receptor gene expression in the adult pituitary. The 
effect of prenatal androgenisation on gene expression in the pituitary was determined by 
qRT-PCR. In maternally and fetally d62/72 and d62/82 treated animals, respectively, INHA 
(A-C), INHBA (D-F), INHBB (G-I) and β-Glycan (J-L) gene expression was assessed. 
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In this study, not all animals in either control or treated cohorts were cycling, as determined 
by prostagenic increases over a 4 week period during the first breeding season (January – 
February). In addition, only some animals exhibited pulsatile LH secretion which was 
measured at the end of the breeding season (March). The presence of pulsatility did not 
necessarily correlate with the presence of intermittent or regular cycles. In fact in the fetally 
injected d62/82 TP 20mg group only one animal had discernable LH pulses and it was the 
same individual that did not appear to be cycling at all in reference to progesterone 
concentrations. Conversely the other animals in this group were cycling but lacked LH 
pulsatility. When all of the animals from all treatment cohorts were grouped together ~75% 
of them were intermittently or regularly ovulating, however, only ~50% had signs of LH 
pulsatility. The lag time of one month between these xperiments has likely caused this 
discrepancy and measurement of LH at this time was towards the end of the breeding season 
at which point some animals may already have entered hypothalamic suppression of 
gonadotrophin secretion and therefore estrous cycling. Also the fact that not all animals were 
fully cycling throughout the first breeding season suggests that some young adults were still 
immature and had not fully switched on their reproductive axis at this time.  
 
Despite clear prenatal androgenisation of an ovine fetus from gestational d62-102, there were 
no obvious endocrine anomalies by the first breeding season in adult offspring. In line with 
previous reports investigating the programming effect of prenatal androgens during this mid-
gestational period, this study reveals an overall more subtle effect on adult endocrine 
function than other studies in which prenatal exposure to androgens has occurred over a 
longer and crucially, earlier, time in fetal development, coinciding with sexual differentiation 
(369). Androgen exposure of a female ovine fetus from d30-90 effects the timing of tonic 
LH initiation (353-355) and results in acyclicity in the second breeding season (355), LH 
hypersecretion and an increased GnRH (LH) pulse frequency (352). These animals exhibit a 
masculinised phenotype and are born with male external genitalia, including a penis and 
scrotum (370). In female ovine fetuses exposed to androgens after this period of 
neuroendocrine sexual differentiation, between d60 and d90, the effects on adult hormonal 
and ovarian function are less severe (369).  
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Birch et al. revealed that the timing of puberty is still advanced in d60-90 animals but rather 
than complete anovulation, sheep have intermittent cycles in their second breeding season 
(355). Studies assessing estradiol feedback and cyclicit  over successive breeding seasons 
found that in the first breeding season there was no effect of TP from d30-90 or d60-90 on 
the timing, number and duration of ovulatory cycles, however, estradiol positive feedback 
was affected in both cohorts illustrated by a delay in the LH surge that was even longer in 
the d30-90 group (378). In the same study, the magnitude of the LH surge in the d60-90 
group was not affected however it was dampened in the d30-90 cohort (378). In the second 
breeding season d60-90 treated animals displayed regular estrous cycles (299) however in 
d30-90 treated adult offspring more than half of the animals were acyclic (379). By the third 
breeding season d60-90 TP exposed animals had normal cycle regularity and luteal function, 
however, LH pulse frequency was increased and the timing of the LH surge was still affected 
(299). The concentrations of testosterone in the fetal treatment cohort are supraphysiological 
(Chapter 3) and the effects are similarly negative wh n compared to the maternal treatment 
cohort. This confirms that programming of the hypothalamic pituitary axis is based of time 
and duration of exposure rather than degree of exposure. 
 
Not all of the ewes in this study were cycling at the time of assessment, implying that the 
HPO axis had not fully matured in some animals. Accordingly basal LH levels were 
correlated with the presence of prostagenic cycles and LH pulsatility, however, basal FSH 
was not. Basal FSH levels were nevertheless reduced in both fetal treated cohorts as a result 
of prenatal androgenisation although this was a non-sig ificant trend. Interestingly basal LH 
was also reduced in the fetal d62/82 TP exposure group, significant at the 20mg dose. Since 
there were no changes in the gene expression of either LHβ or FSHβ subunits in these 
cohorts, it is possible to speculate that the lowered gonadotrophin levels in this cohort could 
be directly related to the down-regulation of pituitary GnRHR in the same animals. Since 
GnRH is known to regulate the expression of GnRHR in the pituitary it may be that in these 
animals GnRH signalling is dampened or chronic low frequency GnRH may drive down-
regulation of its receptor (593), although this was not assessed. Alternatively, given that 
there are no peripheral changes in estradiol or testosterone levels, nor pituitary AR or ERα 
mRNA, that may affect GnRHR expression through feedback pathways (593), the change in 
GnRHR gene expression could be an intrinsic effect of direct prenatal androgenisation in 
which the sensitive developmental period occurs around d80 of gestation or after. 
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Mannikam et al. also postulated that the LH hypersecretion that is  consequence of prenatal 
androgens from d30-90 of gestation, may be due to changes in pituitary gene expression. 
Similarly to our ovine model, they did not identify any alterations in the expression of ERα, 
FSHβ or GnRHR in the adult pituitary of maternally treated offspring (379). However, unlike 
these authors, we found that maternal androgenisation over mid-gestation did result in an up-
regulation for the LHβ subunit. The increase in LHβ subunit expression may indicate an 
increased gonadotroph drive for synthesis and storage of this hormone that has not yet 
become, or is stimulated to be, hyper-secretory. Our animals, unlike the cohort in the 
Mannikam et al. study were not LH hypersecretory, however our animls were 11 months of 
age opposed to 22 months. It is possible that this p enotype had not developed in our cohort 
or, due to the later period of androgenisation, wasnot a programmed effect (378). Robust 
conclusions are however difficult to come to when not all of the animals appear to have a 
fully functional HPO axis. Nevertheless, we did notidentify alterations in the inhibin subunit 
expression profile or the regulation of the inhibin receptor, β-Glycan, in agreement with the 
findings of Mannikam et al. (379).  
 
In this chapter, the hormonal dynamics in response to prenatal androgenisation via the 
mother or directly to the fetus during mid-gestation were assessed. Overall, there were no 
changes in ovarian cyclicity, peripheral steroid horm ne secretion and GnRH pulsatility as 
measured by repeated LH measurement, as a consequenc  of these treatments. It is apparent 
however that an assessment in the more mature animal during the second breeding season 
may have revealed more changes in these regards, had this been feasible. Nevertheless, there 
were some effects of prenatal androgenisation that were present in the pituitary, despite the 
fact that the HPO axis may not have been fully active at this time, and this suggests that 
these are intrinsic effects that occur independently of feedback signalling from the ovary. 
Importantly, however, in an animal model, where the fetus is exposed to androgens during 
mid-gestation, the endocrine system in the young adult is essentially normal. This can 
therefore provide a platform to assess the effects of fetal androgen programming in the 
ovary, and other tissues, in the absence of other variables, such as high LH concentrations, 
hyperandrogenism and differences in ovarian cyclicity that could influence the overall 
phenotype. In the following chapter, this was utilised to determine if there were intrinsic 
differences in the ovary in the absence of a PCOS-like hormonal milieu. 
 
Chapter 7                                                                    Prenatal androgens and the ovary 








Chapter 7                                                   
The effect of prenatal androgen 














Chapter 7                                                                    Prenatal androgens and the ovary 




One of the defining features of PCOS is the presence of polycystic ovaries (162, 163). 
Morphologically, PCO are multifollicular, containing an increased number of antral (2-8mm) 
follicles that are located in the periphery of the ovary of which the larger follicles (5-8mm) 
are growth arrested (594). There is often failure to select a dominant follicle for ovulation 
leading to oligomenorrhoea or amenorrhoea (163). While PCO ovaries are present in most 
women with PCOS, this ovarian phenotype is present in ~20% of ‘normal’ women of 
reproductive age although PCO morphology is correlated with increased androgens and 
increased menstrual irregularity in these women (162, 595). 
 
In animal models, like the programming effects on the HPO axis, ovarian morphology and 
follicle dynamics are disrupted in prenatally androgenised offspring in a manner reminiscent 
of PCOS (316, 350, 427). In lambs, a polyfollicular phenotype occurs through prenatal 
androgenisation from d30-90 with TP, but not DHT, indicating an estrogenic mode of 
programming (301). Similarly PCO have been observed through early exposure to androgens 
in non-human primates (356) and rodents (364, 365). Disrupted folliculogenesis may occur 
through a number of pathways. Evidence from women with PCOS (317, 318) and prenatally 
androgenised sheep (332, 333) supports a role for increased primordial follicular recruitment 
into transitionary and primary follicle stages, with a reciprocal reduction in the primordial 
reserve. Moreover it appears that the level of follicular regression through atresia is 
diminished in both women (319) and sheep (334).  
 
The hyperandrogenic hormonal environment in PCOS may also be of importance in 
producing disordered folliculogenesis: the effects of which may be additive to fetal 
androgenic programming. In normal-cycling adult rhesus monkeys treated with testosterone 
for a short period (3-10 days) the number of growing follicles was increased, there was a 
greater thecal cell number and enhanced granulosa cell proliferation (336). An increased 
androgenic environment also led to up-regulation of AR (340), IGF1 (337) and FSHR (341) 
in the granulosa cells of small growing follicles of rhesus monkeys. These findings imply 
that signalling through the AR may play a role in enhancement of the IGF1 signalling and 
sensitivity to FSH, both crucial factors involved in folliculogenesis (338, 339). 
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A role for disordered activin, inhibin and follistatin in PCO has also been proposed. Activin 
and inhibin are members of the TGFβ superfamily that have opposing actions (80). They are 
made up of inhibin subunits encoded by the INHA, INHBA and INHBB genes (79) (Fig. 1.5) 
and activin signalling is essential for folliculogenesis (112, 113, 115, 116). Activin is 
proposed to act to promote granulosa cell function and proliferation, yet prevent premature 
luteinisation (118, 119). In the prenatally androgenis d lamb, intrafollicular activin 
availability may be targeted through a follicular increase in follistatin (301), a glycoprotein 
which sequesters activin (87). Furthermore, the INHBB subunit also tended to be lower in 
these follicles suggesting a loss of local activin production (301). 
 
As the follicle progresses through development, activin levels fall, while inhibin levels rise 
(124). Inhibin, in the presence of LH, enhances androgen production from human (120), rat 
(121) and bovine (122) thecal cells, while activin suppresses this action (120, 122). Increased 
ovarian androgen production is thought to contribute to the hyperandrogenism in PCOS 
(344, 345, 596), in conjunction with enhanced adrenal a drogen secretion (415, 597). Thecal 
cell androstenedione is increased in women with PCOS (344) which is augmented not only 
by the hypersecretory LH state and increased expression of thecal LHR (598), but also 
intrinsic alterations in thecal steroidogenic gene xpression (345, 598). Global enhancement 
of the steroidogenic pathway is found in thecal cels from women with PCOS with up-
regulation of StAR (598), CYP11A and CYP17 (345, 598) gene expression and increased 
enzyme activity of 17α-hydroxylase, 3β-HSD and 17β-HSD (345). 
 
A PCO ovary is therefore characterised by disrupted folliculogenesis, altered expression of 
growth factor systems and enhanced ovarian androgen production. These features are 
additionally associated with the hormonal environmet found in PCOS, including 
hyperandrogenism and LH hypersecretion. Whether the perturbed function in the ovary is 
caused by these peripheral hormonal changes, originates from early programming events, or 
is a combination of both, is not known. The studies outlined in Chapter 4, suggest that there 
are direct functional programming effects of androgens on the fetal ovary that may affect 
developmental signalling systems and steroidogenesis. The data presented in Chapter 6 show 
that mid-gestation prenatal androgen exposure does not affect peripheral hormonal 
concentrations, including androgens or LH, in the first breeding season. Therefore this 
allows for assessment of the primary effects of prenatal androgenisation on the adult ovarian 
phenotype without any impact from an abnormal hormonal environment. 
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The objectives of this chapter are to assess the impact of mid-gestation androgen exposure 
on the ovary by assessing: A) ovarian morphology and follicular dynamics, and B) follicle 
function, including 1) thecal cell androstenedione secretion and response to stimulation with 
LH, and 2) thecal cell gene expression related to steroidogenesis, hormone signalling and 
growth and differentiation, including the Id genes, identified as having a role in normal 
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7.2 Materials and Methods 
 
7.2.1 Experimental animals 
 
The adult female ewes assessed in this chapter are detailed in Table 7.1. 
 
Study Treatment Sample number (n) 
Lamb (ovarian morphology) 
Fetal Treatment Injection at d62 and 72 C = 6, TP 20mg = 6 
Maternal Treatment Treatment from d62-102 C = 9, TP = 7 
Adult  
Injection at d62 and 72 C = 4, TP 20mg = 8 
Fetal Treatment 
Injection at d62 and 82 
C = 4, TP 1mg = 5, 4mg = 5, 
20mg = 7 
Maternal Treatment Treatment from d62-102 C = 5, TP = 9 
Table 7.1 The experimental cohorts for the study of adult ovarian function and 




Lamb and adult ovaries were fixed in Bouins solution f r 24 h prior to processing and 
blocking in paraffin wax. Sections (5µm) were cut and mounted onto charged glass 
microscope slides. Ovarian sections were either stained for H&E or underwent 
immunohistochemical staining as described in Section 2.4.2 and 2.4.3.1, respectively. 
Antibodies and optimised working concentrations are detailed in Table 7.2. 
 
7.2.3 Assessment of follicle number, growth and cell death 
 
H&E stained or immunostained ovaries were assessed to calculate follicle number, including 
primordial, primary, pre-antral and antral follicle stages, or follicle proliferation and cell 
death suggesting atresia, respectively. Animals included in this assessment were maternally 
exposed (C = 5, TP = 9) or fetally exposed to androgens at d62 and d82 (C = 4, TP 4mg = 5). 
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Polyclonal Rabbit (N20; sc-816) Santa Cruz 




Polyclonal Rabbit (Asp175, #9661) Cell Signalling 
Technology Inc., USA 
1:100 GARB 
Ki67 
Monoclonal Mouse (NCL-Ki67-MMI),  Novocastra 




Table 7.2  List of antibodies used for immunohistochemistry in the adult ovary.  Antibody 
suppliers, working concentrations and appropriate secondary antibodies are listed.  
 
7.2.3.1 Assessment of follicle number  
 
Follicles were categorised into developmental stage ccording to human and ovine 
classification of follicle stage (23, 24). Primordial or resting follicles were classed as an 
oocyte surrounded by one layer of flattened granulosa cells (Fig. 7.1.A and B). Primary 
follicles contained an enlarged oocyte surrounded by one layer of cuboidal granulosa cells 
(Fig. 7.1.C). Follicles were classed as pre-antral if they contained two or more layers of 
granulosa cells, had formed a basement membrane and had begun to recruit thecal cells (Fig. 
7.1.D). Antral follicles contained many layers of granulosa cells, surrounded by a basement 
membrane and outer layers of thecal cells and had formed an antral cavity containing 
follicular fluid (Fig. 7.1.E and F). 
 
Follicle counting was carried out in at least 8 ovarian H&E stained sections from each 
individual, which were a distance of 100µm apart, to give a representative follicle count 
throughout the ovary. Counting was performed using a li ht microscope (Zeiss Standard 20, 
Carl Zeiss) and a manual clicker. The average number of follicles per section for each 
developmental stage classification was calculated for each animal and these values used for 
statistical analysis. The number of primordial follicles present in the ovary was not 
normalised to ovarian weight as primordial follicle number is finite and pre-determined. 
Since ovarian weight was not altered between treatmnt groups absolute follicle numbers per 
ovarian section are also described for those follicles beyond the primordial stage. 
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Figure 7.1  Follicle developmental classifications. H&E staining of primordial (A and B; 
indicated by arrows), primary (C), pre-antral (D), early antral (E) and late antral (F) ovine 
follicles. Scale bars represent 100µm (A, E and F) and 20µm (B-D). 
 
 
7.2.3.2 Assessment of antral follicle proliferation and atresia 
 
The same method for follicle counting was employed to quantify the number of antral 
follicles immuno-positive for Ki67 (a proliferative marker) and cleaved caspase-3 (a cell 
death marker). The average number of non-growing and growing or healthy and dying 
follicles per section was calculated for each animal and this proportional value used in the 
analysis3. 
 
                                                
3 Ovarian sectioning, H&E staining, follicle counting, immunohistochemistry and histological 
assessment undertaken for this Chapter was carried out, in part, by Elizabeth Oliver under supervision 
by KH. 
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7.2.4 Individual follicle analysis 
 
For these studies maternally treated (C = 5, TP = 9) and fetally treated at d62 and 82 animals 
(C = 4, TP 20mg = 7) were selected. Sample numbers va ied between experiments 
depending on the number and particular size of follicles that an individual ovary contained 
and will be referred to in each section. Ovaries were collected at 11 months of age 
immediately after the animal was euthanised. One ovary from each animal was placed in a 
petri dish containing PBS and cut in half. Individual follicles (>1mm) were carefully 
dissected using scissors and fine forceps under a dissecting microscope and cleaned as 
described previously (72). The diameter (mm) of each individual follicle was recorded. 
 
7.2.4.1 Collection of follicular fluid, thecal cell collection and culture  
 
The follicular fluid from each follicle was collected and stored separately. Each follicle was 
transferred to an individual well containing 1ml PBS in a 24 well plate, the follicle bisected 
and opened up releasing the follicular fluid, and the granulosa cells scraped out. The thecal 
shell was removed and the PBS containing follicular fluid and granulosa cells were separated 
by centrifugation at 400g for 10 min at room temperatu e. The fluid was collected and stored 
at -20°C and the granulosa cells were resuspended i 100µl RNAlater (Applied Biosystems) 
and stored at -20°C.  
 
For follicles up to 2.5mm, the thecal shell was cut into two halves. For follicles >2.5mm the 
thecal shell was peeled from the inside of the follicle shell, and also cut into two similar size 
pieces. For both sizes of follicles, one half was immediately placed in 250µl RNAlater 
(Applied Biosystems) and stored at -20°C. The other half was cultured in 24-well plates, 
initially in 1ml medium 199 for 1 hour and then transferred to media containing 100ng/ml 
LH (NIDDK ovine LH 23) and cultured a further hour at 37°C/5% CO2. After the culture 
period, the thecal shells were snap frozen and stored at -80°C and the media from both basal 
and LH cultures was stored at -20°C4. 
 
                                                
4 Follicle dissection, measurements and thecal cell cultures were performed by Drs. Carlos Souza, 
Julia Young and Prof. Alan McNeilly. 
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7.2.4.2 Androstenedione and estradiol measurements 
 
A RIA for androstenedione was performed in culture m dia collected from the thecal cell 
cultures (pre- and post-LH stimulation) and from follicular fluid, as described in Section 
2.5.2, and the reagents required and CVs are detailed in Table 6.2, in Chapter 6. Every 
culture media or follicular fluid sample corresponding to follicles that were ≥3mm in 
diameter was included in the assay and at least 3 follicles that were <3mm were included for 
each animal. Since androstenedione was not in this instance measured in plasma, the serum 
extraction step was not necessary. One deviation from the specific protocol for this assay, 
described in Appendix A, was the use of 20µl follicu ar fluid in 180µl buffer per assay tube 
(the volume of culture media used remained at 100µl). 
 
Estradiol was also assayed in same follicular fluid sample in which androstenedione was 
measured, using an in-house ELISA protocol. On day one, Nunc Immuno 96 MicroWell 
plates (Fischer Scientific Ltd.) were coated with 100µl of donkey anti-sheep IgG (1:200; 
713-005-147, Jackson ImmunoResearch, Suffolk, UK) diluted in coating buffer (1 tablet 
carbonate–bicarbonate buffer tablet [Sigma] in 100ml de-ionised water). Plates were sealed 
and stored overnight at 4°C in a humidity chamber to prevent evaporation. On day two, 
coating buffer was discarded and the plate washed tree times with 200µl wash buffer (de-
ionised water + 0.1% Tween-20). Estradiol antibody (In-house ASMR32; 1:300,000, diluted 
in 0.1M PGBS) in a volume of 100µl was added to each well. A NSB well was included as a 
control, with the addition of 100µl PGBS. The plate was sealed and incubated for 3 h at 
room temperature. The liquid was discarded and the plate washed three times with 200µl 
wash buffer per well. For the standards, 100µl of standard (0.78, 1.56, 3.2, 6.25, 12.5, 25, 50, 
100 pg/100µl β-estradiol; E8875, Sigma) was added to the wells in duplicate. The optimal 
sample dilution was determined and re-assayed if requi d. Sample volumes ranged from 1, 
10, 20 or 50µl follicular fluid, diluted with PGBS to a final volume of 100µl. Diluted 
samples were added to wells in duplicate. In NSB and B0 wells, 100µl PGBS was added. 
The tracer (estradiol conjugated to HRP; In-house) was diluted 1:500 in PGBS and 50µl 
added to each well including T0 wells. The plate was sealed and incubated for 2 h at room 
temperature. Following this, liquid was discarded an the plate washed five times with 200µl 
wash buffer. Substrate was prepared consisting of 33ml 0.1M citrate phosphate buffer pH 5.0 
(10.30g citric acid and 17.79g HNa2O4P, dissolved in 1l de-ionised water), 33µl 30% 
hydrogen peroxide and 30mg o-phenylenediame dihydrochloride (P8412, Sigma), and 200µl 
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was added to each well. The plate was wrapped in foil to protect from light and incubated for 
30 min at room temperature. After this time, 50µl stop solution (concentrated sulphuric acid 
[2NH2SO4] diluted 1:10 in de-ionised water) was added to the wells and the contents briefly 
combined using a plate shaker. Spectrophotometry was subsequently performed using a plate 
reader set to 495nm as described for the commercial ELISA kits detailed in Section 2.6. The 
intra- and inter- CVs for this ELISA were 6.7% and 10%, respectively5. 
 
To calculate the amount of androstenedione and estradiol present in the follicular fluid, the 
concentration from the RIA and ELISA, respectively, was standardised to the follicular size 
as follows: 
 
• Using the mathematical formula to calculate the volume of a sphere (4/3 x πr3) the 








• Follicle volume (mm3) was converted to volume (ml): 
 
Follicle vol. (ml) = vol. (mm
3
) x 0.001 
 
• To calculate total amount (ng) of hormone in PBS and follicle fluid solution, the 
concentration measured was divided by the volume of the follicle (ml) plus 1ml PBS 
that the fluid wad diluted in: 
 
Total amount (ng) = conc. (ng/ml; RIA/ELISA) x (1ml + follicle vol (ml)) 
 
• The total amount in the follicle (ng) was calculated by the total amount (ng) in solution 
divided by the follicle vol (ml): 
 
Total amount in the follicle (ng) = total amount (ng)/follicle vol. (ml) 
 
These calculations give the amount of either androstenedione or estradiol in each follicle 
expressed as ng/follicle.  
 
 
                                                
5 The estradiol ELISAs were performed by Sarah Henderson 
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For both culture media (androstenedione) and follicular fluid (androstenedione and estradiol) 
analyses, data were categorised into <3mm, 3-4mm and >4mm follicle diameter sizes. 
Values from individual follicles were used for comparison between control and treatment 
cohorts and for each treatment group the sample size was between n = 9 and 25 follicles for 
the <3mm group, n = 5 and 8 follicles for the 3-4mm group and n = 4 and 5 for the >4mm 
group.   
  
7.2.4.3 Thecal cell mRNA extraction, cDNA synthesis and qRT-PCR 
 
Thecal mRNA from ≥3mm follicles was extracted using the RNeasy Micro Kit (Qiagen 
Ltd.). Thecal cells stored in RNAlater (Applied Biosystems) were briefly spun, the RNAlater 
removed and 50µL RLT Buffer containing 1% β-mercaptoethanol was added to lyse the 
cells. One volume of 70% ethanol was added and the contents mixed and transferred to an 
RNeasy MiniElute spin column (Qiagen Ltd.). Subsequent purification steps were performed 
using the Qiagen RNeasy Micro kit. RNA was eluted with 14µL RNase free water (Qiagen 
Ltd.) and stored at -80°C6. RNA concentration was measured using a NanoDrop 1000 
spectrophotometer (Fisher Scientific Ltd.) as described in section 2.8.1.4. 
 
For the purpose of making cDNA from theca cells the SuperScript VILO cDNA synthesis kit 
(Invitrogen) was used instead of the standard kit described in other sections. This kit has 
been developed to give improved cDNA yield which is necessary when starting out with 
small amounts of RNA, and also to improve the efficien y of subsequent qRT-PCR so that 
low abundance target genes are amplified with greate  sensitivity. In a 20µL reaction 
volume, 100ng RNA was added to the mixture. Reaction components and volumes are listed 
in Table 7.3 and cDNA was synthesised in a thermocycler (G-Storm GS1, GRI Ltd.) 
programmed for incubation at 25°C for 10 min, then 42°C for 1 h and finally 85°C for 5 min 




                                                
6 RNA extraction from thecal cells was carried out by Dr. Julia Young. 
Chapter 7                                                                    Prenatal androgens and the ovary 
                                                                                                  
 193 
 
Reagent Volume (µL) Final Conc. 
VILO Reaction Mix 4 1X 
SuperScript Enzyme Mix 2 1X 
RNA variable 100ng 
NF H20 variable - 
Final Volume 20µL  
Table 7.3  SuperScript VILO cDNA synthesis. The reagents supplied in the SuperScript VILO 
cDNA synthesis kit (Invitrogen) and volumes required for cDNA synthesis of thecal cells are 
detailed. 
 
QRT-PCR was performed using SYBR Green reagents (Applied Biosystems) as described in 
Section 2.8.6.2 using 384-well reaction formats. A full list of genes examined in thecal cells 
and corresponding primer sequences are detailed in Table 7.4. Thecal cell gene expression 
was examined in all follicles collected >3mm and the subsequent analysis was carried out 
comparing expression in follicle sizes of 3-4mm and >4mm. Individual follicle gene 
expression values were utilised and for each treatmnt group the sample size ranged from n = 
5 to 7 in the 3-4mm group and n = 4 to 5 in the >4mm group. 
 
7.2.4.4 Statistical analyses 
 
The semi-quantitative analysis of follicle number and all the data gathered from qRT-PCR 
gene expression experiments, where the differences between two means were assessed, were 
statistically analysed using a student’s unpaired t-test assuming equal variances. In the 
instances where data were not normally distributed (unequal variances) a non-parametric 
Mann Whitney test was alternatively employed. For the hecal cell culture and follicular 
fluid hormonal assessment data were treated in the same way as above when comparing C 
and TP-treated groups or analysing the effect of changing follicle size. When analysing the 
effect of LH stimulation on thecal cell hormone outp t within a treatment group (before and 
after), a paired t-test was applied for repeated measures. These values are presented as mean 
± sem. Data collected from the qualitative assessment of follicular proliferation and atresia 
by immunohistochemical staining, or the proportional assessment of non-estrogenic and 
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estrogenic follicles were subjected to a chi (χ2) squared test. These values were presented as 










GCCCATCTTTCTGAATGTCC CAAACACCATAAGCCCCATC 233 
ERβ 
(NM_001009737.1) 
GAGGCCTCCATGATGATGTC GGTCTGGAGCAAAGATGAGC 208 
LHR 
(NM_214449.1) 
TCCGAAAGCTTCCAGATGTT GAAATCAGCGTTGTCCCATT 199 
IGF1R 
(XM_002696504.1) 
CCAAAACCGAAGCTGAGAAG TCCGGGTCTGTGATGTTGTA 199 
INSR 
(XM_002688832.1) 
CACCATCACTCAGGGGAAAC CAGGAGGTCTCGGAAGTCAG 247 
CYP11A 
(NM_001093789.1) 
CAACGTCCCTCCAGAACTGT CAGGAGGCAGTAGAGGATGC 172 
HSD3B1 
(NM_001135932) 
GGAGACATTCTGGATGAGCAG TCTATGGTGCTGGTGTGGA 200 
StAR 
(NM_001009243) 
GCATCCTCAAAGACCAGGAG CTTGACACTGGGGTTCCACT 194 
CYP17  
(NM_001009483) 
AGACATATTCCCTGCGCTGA GCAGCTTTGAATCCTGCTCT 215 
INHBA 
(NM_174363) 
GAAGAGACCCGATGTCACCCAGC TGTCGTCCTCTATCTCCACGTACCCG 113 
INHBB 
(NM_176852) 
ATGGCCTGGCCTCCTCCCG CTTCAGGTAGAGCCACAGGCTGGC 101 
INHA 
(NM_174094) 
GAGCCCGAGGACCAAGATGTCTCC CCTCAGCCTCTCCAGCATCTGGC 91 
Β-Glycan 
(NM_214272) 
AATGGCACGCACTTCATTTT GTCCCCTGGAAATCCGTTAT 186 
Id1 
(NM_001097568) 
TCTGGGATCTGGAGTTGGAG ATACGATCGTCCGCTGGAA 151 
Id2 
(NM_001034231) 
CATCTTGGACTTGCAGATCG AGAGAGCTTTGCTGTCATTTG 185 
Id3 
(NM_001014950) 
ACTCAGCTTAGCCAGGTGGA TTTGGTCGTTGGAGATCACA 160 
GAPDH 
(NM_001034034) 
GGCGTGAACCACGAGAAGTATAA AAGCAGGGATGATGTTCTGG 229 
Table 7.4  Thecal cell gene analysis using SYBR
 
Green qRT-PCR. Gene names and accession 
numbers, forward and reverse primer sequences (5’-3’) and PCR product sizes are listed. 
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7.3.1 The Lamb Ovary 
 
7.3.1.1 Lamb ovaries are multifollicular and morphology is not a 
consequence of prenatal androgenisation 
 
Lamb ovarian weight was not altered by prenatal androgenisation. Crude morphological 
examination of the 3-month lamb ovary, by assessment of H&E stained sections, revealed a 
multifollicular state with 10-30 large antral stage follicles routinely observed per section 
(Fig. 7.2). Control ovaries from both maternally and fetally exposed offspring exhibited this 
morphology and there was no clear relationship for antral follicle number between those 
ovaries of control and prenatally androgenised offspring. Representative whole ovary images 
from each treatment group are illustrated in Figure 7.2. 
 
 
Figure 7.2  Lamb ovarian morphology. H&E staining did not reveal differences in the 
number of antral follicles between control and prenatally androgenised cohorts in the ~3 
month lamb. Images represent maternal C (A) and TP (B) and fetal d62/72 C (C) and TP 
20mg (D) ovarian sections. Scale bars are 100µm. 
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7.3.2 The Adult Ovary 
 
7.3.2.1 Prenatal androgenisation has subtle effects on follicle number 
 
Unlike the multifollicular phenotype observed in lamb ovaries in which large follicles were 
often situated throughout the medullary and cortical stroma, the young adult ovaries 
exhibited a settled appearance with approximately 2-8 large antral follicles situated in the 
peripheral ovarian cortex (Fig. 7.3). Gross inspection of adult ovary sections stained with 
H&E did not reveal stark differences between control and TP-exposed ovaries, nor was 
PCO-like morphology observed in any of the treatment groups assessed (representative 
images are illustrated in Fig. 7.3).   
 
To investigate the follicular phenotype further, a detailed assessment was performed to 
assess follicle numbers over the stages of development by counting the number of 
primordial, primary, pre-antral and antral follicles (illustrated in Fig. 7.1) present in a 
representative portion of the ovary. A thorough stereological assessment of maternal control 
and TP exposed and fetal control and TP (4mg dose) treated animals was conducted. The 
number of primordial follicles present in the adult ovary was unaltered following both 
maternal and fetal TP exposure (Fig. 7.4 A and C, respectively). Similarly, maternal TP 
treatment did not influence primary, pre-antral or antral follicle number (Fig. 7.4.B). Direct 
fetal androgenisation did tend to increase in the number of antral follicles compared to 
control ovaries (Fig. 7.4.D), although this trend di not quite reach statistical significance 
(P=0.053). Primary and pre-antral follicle numbers were not affected by direct prenatal 
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Figure 7.3  Adult ovarian morphology. Representative H&E images of ovarian sections from 
each treatment cohort. Images represent ovaries from maternal C (A) and TP (B), fetal 
d62/72 C (C) and TP 20mg (D), and fetal d62/82 C (E), TP 1mg (F), TP 4mg (G) and TP 20mg 
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Figure 7.4  Follicle counts in the prenatally androgenised young adult sheep ovary. In 
maternal (A and B) and fetal d62/82 (C and D) treated cohorts the numbers of primordial, 
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7.3.2.2 Follicle regression may be dysregulated in the prenatally 
androgenised ewe 
 
Analysis of follicle proliferation and cell death was performed in the young adult ovary by 
immunohistochemical staining with markers for the activated cell cycle (Ki67) and apoptosis 
(cleaved caspase-3). A representative image of Ki67 immunostaining of an ovine antral 
follicle is shown in Figure 7.5.A and B. Figure 7.5.A depicts a non-growing follicle (grey 
arrow) adjacent to a growing follicle (black arrow). Positive nuclear staining is revealed 
throughout the granulosa and thecal cells of the growing follicle (Fig. 7.5.A and increased 
magnification in Fig. 7.5.B). In atretic follicles cleaved caspase-3 immunostaining was 
predominantly localised to the granulosa cell layer (Fig. 7.5.D and increased magnification 
in Fig. 7.5.E) with much less positive staining observed in the thecal layer. 
 
 
Figure 7.5  Immunohistochemical staining (brown) for Ki67 and cleaved caspase-3 in the 
adult ovary. Adult ovaries were stained for the proliferative marker, Ki67 (A and B), and the 
cell death marker, caspase-3 (D and E), to assess the proportion of follicle growth and 
regression, respectively. Negatives in C and F relate to Ki67 and caspase staining 
experiments, respectively. Scale bars are 100µm (A), 20µm (B and C) and 50µm (D-F). 
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In the same selection of follicles described in Section 7.3.2.1 (counted follicles) an in depth 
examination of follicle proliferation and atresia was carried out to assess the effect of 
maternal TP and fetal TP (4mg dose) exposure on follicle dynamics. In young adult ovaries, 
between 50-70% of antral follicles were growing and individual variation in this number was 
not related to indirect or direct prenatal androgenisation (Fig. 7.6.A and C, respectively). Of 
the total number of counted follicles the number of follicles with cell death suggesting 
atresia observed in control ovaries from maternal ad fetal treatment regimes was 16% and 
21%, respectively (Fig. 7.6 B and D). Prenatal androgenisation resulted in an increase in 
antral follicle atresia whereby the number of caspase positive antral follicles was increased 
following maternal (P<0.05; Fig. 7.6.B) and fetal (P<0.001; Fig. 7.6.D) TP exposure, 
doubling the respective figures to 32% and 38%. 
 
 
Figure 7.6  Antral follicle growth and atresia in the adult ovary of prenatally androgenised 
offspring. Growth (Ki67) and atresia (caspase-3) were determined by follicle 
immunostaining in maternal (A and B) and fetal d62/82 (TP 4mg; C and D) androgen 
exposed offspring, respectively. * P<0.05, *** P<0.001.  
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Analysis of the estrogenic status of the follicle was another approach utilised to assess the 
level of follicular degeneration occurring in the ovary. These experiments were carried out in 
the maternal TP and fetal TP 20mg treated cohorts, in which the follicular fluid from 
individual follicles was collected and the concentration of estradiol measured. A cut-off 
value of 30 ng/follicle estradiol was applied to distinguish between non-estrogenic (healthy) 
and estrogenic (not growing or dying) follicles. In both small (<3mm; P<0.05) and large 
(>3mm; P<0.05) follicles, there were significantly more estrogenic follicles in the maternal 
TP-exposed animals compared to controls (Fig. 7.7.A)  The presence of more healthy 
follicles suggests that even though there was increased atresia in these ovaries, overall, there 
was no negative impact on the healthy growing follicles. There was no significant treatment 





Figure 7.7  The proportion of non-estrogenic and estrogenic follicles in the prenatally 
androgenised ewe ovary.  Estradiol was measured in the follicular fluid of antral follicles by 
ELISA and estrogenic and non-estrogenic follicles were determined by a cut-off value of 30 
ng/follicle. Analysis was carried out in maternal TP (A) and fetal TP 20mg (B) treated 
offspring. * P<0.05. 
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7.3.2.3 Thecal androstenedione output is increased by prenatal 
androgenisation in vivo and in vitro and as a consequence of fetal 
injection 
 
The amount of androstenedione secreted by follicles wa  assessed by measurement of this 
hormone directly in the follicular fluid collected from each follicle. Over increasing follicle 
size the amount of androstenedione present in the follicle fluid was significantly reduced in 
control (maternally treated) animals (<3mm Vs 3-4mm, P<0.01 and 3-4mm Vs 4mm, 
P<0.05; Fig. 7.8.A). The negative relationship in the amount of androstenedione present in 
the follicular fluid and follicular size is thought to reflect conversion of this steroid into 
estradiol as the follicles mature. This inverse relationship was also found in the fetally 
treated control cohort (Fig. 7.8.B), however, androstenedione secretion compared to the 
maternally treated control cohort was in fact increased by approximately 3-fold in <3mm 
(P<0.05), 3-4mm (P<0.01) and >4mm (P<0.01) follicles (Fig. 7.8.B). 
 
Assessment of the effect of prenatal androgenisation in the young adult revealed that 
maternal TP-exposure led to an increase in androstenedione levels in the follicular fluid of 
the largest follicles (>4mm) although this did not quite reach statistical significance 
(P=0.055; Fig. 7.8.C). A similar non-significant trend was found in the fetally TP-exposed 
cohort in >4mm follicles (P=0.15; Fig. 7.8.D) in which there was a great deal of individual 
variation. Nevertheless the difference in the amount of androstenedione produced in fetally 
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Figure 7.8  Androstenedione measurement in the follicular fluid of prenatally androgenised 
ewes. Androstenedione was measured by RIA in antral follicles that were <3, 3-4 and >4 
mm in diameter. The concentration of androstenedione over increasing follicle size was 
compared in control animals (A), and between control treatment cohorts (B). The effect of 
prenatal androgenisation was assessed in maternally (C) and fetally d62/82 (TP 20mg; D) 
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In order to gain insight into the mechanism behind the effect of prenatal TP on thecal 
androstenedione secretion, the estrogenic status of the ollicle was additionally taken into 
account. In estrogenic follicles androstenedione secretion, in vivo, would be expected to fall 
due to conversion of this steroid into estradiol. In fact, while there was no difference between 
androstenedione concentration in >4mm follicles when non-estrogenic and estrogenic groups 
were compared in control cohorts, androstenedione concentration did show a trend to be 
reduced in estrogenic, compared to non-estrogenic folli les, of maternally and fetally TP-
exposed groups (Fig.7.9.A and C, respectively). As shown in Figure 7.8.C and in Figure 
7.9.A, the amount of androstenedione in follicular f uid of >4mm follicles was increased in 
maternal TP-exposed animals compared to controls. There was also a trend for increased 
androstenedione concentration in >4mm follicles from fetally TP treated offspring (Fig. 
7.8.D and Fig. 7.9.C). When follicle androstenedione concentrations from maternally and 
fetally treated ewes were split into groups for follicles that were and were not producing 
estradiol, androstenedione appeared to be most increased in the non-estrogenic follicles (Fig. 
7.9A and C, respectively).  
 
Therefore, it was hypothesised that in these follicles there is less conversion of 
androstenedione to estradiol. This did appear to be the case in the maternally TP-treated 
ewes (Fig. 7.9.B), in which there was a trend for reduced estradiol concentrations in the 
follicular fluid of >4mm follicles. Conversely, in the fetally TP treated cohort, the opposite 
trend was in place and there was increased estradiol concentrations in >4mm non-estrogenic 
follicles from the TP cohort (Fig. 7.9.D). The segration of follicles in to these groups 
resulted in a small sample size so these observations are trends and not entirely conclusive, 
however, this provides some evidence that in the matern l treated cohort there could be a 
defect in the conversion of androgens to estrogens in these follicles, which is not present in 
the fetally injected cohort. Unfortunately due to the lack of available good quality granulosa 
cell mRNA it was not possible to measure the gene expression of CYP19 to determine 
whether, even in the presence of increased substrate, hat it is the catalytic conversion of 
steroids that is defective in the maternally treated animals. 
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Figure 7.9  Androstenedione and estradiol concentrations in follicle fluid of non-estrogenic 
and estrogenic follicles. The concentration of androstenedione and estradiol was compared 
between non-estrogenic and estrogenic follicles in maternal (A and B, respectively) and 
fetal d62/82 (C and D, respectively) C and TP cohorts. 1 = 1 animal in group. 
 
 
The thecal cell capacity to produce androstenedione f llowing prenatal androgenisation was 
also determined in vitro. Androstenedione production and secretion was measur d after 
follicle culture pre- and post-LH stimulation. Under both culture conditions (-/+ LH) the 
concentration of androstenedione in culture media increased with follicle size in maternally 
treated cohorts, although the difference was more pronounced in TP treated animals (-LH, 
<3mm Vs 3-4mm; P<0.001 and 3-4mm Vs >4mm; P<0.05, +LH, <3mm Vs 3-4mm; 
P<0.001 and 3-4mm Vs >4mm; P<0.05) than control animals (non-significant; Fig. 7.10.A). 
In the maternal treated cohort the thecal cells responded to the addition of LH with either a 
trend or significant increase in androstenedione output in both control and TP-treated groups 
(indicated by asterisks in Fig. 7.10.A). Maternal prenatal androgenisation resulted in an 
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enhanced response to LH in >4mm follicles compared to control LH stimulated >4mm 
follicles (P<0.05). In fact, androstenedione secretion for LH stimulated control >4mm 
follicles was similar to the unstimulated TP >4mm follicles (Fig. 7.10.A). In the fetally 
treated cohort, androstenedione output was significa tly increased between <3mm and 
>4mm sized follicles in controls pre-LH stimulation (P<0.01), but this trend was less 
apparent in TP-treated animals, before stimulation, and in control and TP-treated animals 
post-LH stimulation (Fig. 7.9.B). LH stimulation only marginally increased androstenedione 
secretion across the treatment groups and the concentration was in fact reduced post LH in 
control 3-4mm and >4mm follicles (Fig. 7.9.B), although these alterations were not 
significant. 
 
Maternal prenatal androgenisation was found to have a bimodal effect on androstenedione 
secretion depending on the size of the follicle both before and after LH stimulation (Fig. 
7.10.C). In the smallest follicles (<3mm) prenatal TP-exposure led to a suppression in thecal 
androstenedione output basally (P<0.05) and after stimulation with LH (P<0.05). 
Conversely, androstenedione secretion was increased non-significantly in 3-4mm follicles 
and significantly in >4mm follicles from TP-exposed animals, during culture, before 
(P=0.095) and after (P<0.05) the addition of LH (Fig. 7.10.C). In the fetally androgenised 
cohort there was no association between prenatal androgens and androstenedione secretion in 
small or large follicles (Fig. 7.10.D). In fact, like the findings in the follicular fluid from 
these animals, the capacity to produce androstenedio  was increased in thecal cells from 
fetally treated compared to maternally treated animls (Fig. 7.10.E). Although this trend was 
present post-LH stimulation this effect was most pronounced pre-LH stimulation in <3mm 
(P<0.05), 3-4mm (P<0.01) and >4mm (P<0.01) follicles (Fig. 7.10.E). In the fetal treated 
cohort the lack of response to LH and no effect of prenatal androgenisation could therefore 
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Figure 7.10  Androstenedione measurement in culture media from thecal cells of prenatally 
androgenised ewes. Androstenedione concentration was measured in media pre- and post-
thecal cell stimulation with LH. The response to LH is depicted as line graphs for control and 
treated groups in maternally (A) and fetally (B) androgenised ewes. The effect of prenatal 
androgenisation was compared in maternally (C) and fetally d62/82 (TP 20mg; D) treated 
animals. The effect of treatment administration route was determined in control cohorts 
(E). Asterisks (*) above the joining line in (A) represent a significant difference between pre- 
and post-LH stimulation within the treatment group. * P<0.05 and ** P<0.01. 
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7.3.2.4 Prenatal androgenisation programmes increased thecal cell 
steroidogenic capacity and receptivity to LH  
 
Thecal cell gene expression analysis for a range of genes involved in the steroidogenic 
pathway was carried out in individual follicles, to determine whether intrinsic changes in 
thecal function could contribute to enhanced androstenedione synthesis. Follicles were 
grouped into size categories of 3-4mm and >4mm, to de ermine if expression changes were 
present earlier, or occurred later, in follicle development, or if they were present at all large 
follicle sizes (≥3mm). Analysis revealed that maternal prenatal androgenisation led to a 
global up-regulation of steroidogenic genes in ovine thecal cells from young adults. Maternal 
TP-exposure resulted in an up-regulation in thecal StAR mRNA from ≥3mm follicles 
(P<0.01), with the largest increase observed in >4mm follicles (P=0.051; Fig. 7.11.A). There 
was also a trend for increased thecal CYP11A across the follicle groups (Fig. 7.11.D). 
Similarly, HSD3B1 (P<0.01) and CYP17 (P<0.05) transcripts were also up-regulated in 
theca from ≥3mm follicles (Fig. 7.11.G and J, respectively).  
 
Direct fetal treatment led to changes in steroidogenic gene expression that were related to 
both prenatal androgens and also to the delivery method itself. Fetal TP-exposure resulted in 
an up-regulation of thecal StAR in 3-4mm follicles (P<0.05), however this was not altered in 
>4mm follicles (Fig. 7.11.B). In fact, StAR was significantly increased in fetally treated 
control compared to maternally treated control >4mm follicles (P<0.05; Fig. 7.11.C), 
indicating that both control and TP thecal cells are over-expressing StAR. In the fetally 
treated cohort, there was a trend for elevated thecal cell CYP11A expression in ≥3mm 
follicles of TP-exposed animals (Fig. 7.11.E). In this instance the fetal control injection did 
not differ to the maternal control animals (Fig. 7.11.F). Thecal HSD3B1 was non-
significantly altered by fetal androgenisation (Fig. 7.11.H), although the pattern of 
expression was similar to thecal StAR. There was an increase in 3-4mm follicle thecal 
HSD3B1 expression following fetal TP-exposure (Fig. 7.11.H) and an increase in HSD3B1 
mRNA in both control and TP-exposed cohorts in >4mm follicles compared to maternal 
controls (Fig. 7.11.H and I). This pattern was also repeated for CYP17 gene expression in 
which fetal TP-exposure significantly up-regulated CYP17 in 3-4mm follicles (P<0.05) and 
both control and TP treatments resulted in increased CYP17 in >4mm follicles (Fig. 7.11.K). 
The fetal injection itself resulted in a significant i crease in CYP17 expression in >4mm 
follicles when compared to maternal treated controls (P<0.05; Fig. 7.11.L).  
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Figure 7.11  The steroidogenic gene expression in thecal cells of prenatally androgenised 
ewes. The effect of prenatal androgenisation on thecal cell steroidogenic capacity was 
determined by qRT-PCR. In maternally and fetally d62/82 treated animals and in control 
cohorts respectively, the genes assessed were StAR (A-C), CYP11A (D-F), HSD3B1 (G-I) and 
CYP17 (J-L). * P<0.05 and ** P<0.01. 
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The ability of thecal cells to respond to hormonal signals was examined, by qRT-PCR 
analysis of a number of hormonal receptors, in follicles from prenatally androgenised sheep. 
In all follicle sizes assessed (≥3mm) neither maternal nor fetal prenatal TP-exposure led to 
alterations in the thecal mRNA expression of AR (Fig. 7.12.A and B, respectively), ERβ (Fig. 
7.12.C and D, respectively) or INSR (Fig. 7.12.E and F, respectively). Maternal prenatal 
androgenisation did however lead to a significant increase in the expression of thecal LHR in 
≥3mm follicles (P<0.05), that was present in both 3-4mm follicles (P<0.05) and in >4mm 
(non-significant) follicles (Fig. 7.12.G). A trend for increased LHR in 3-4mm follicles was 
also observed in fetally TP-exposed animals (Fig. 7.12.H), and in this instance there was no 
additional effect exerted by the fetal injection itself (Fig. 7.12.I). 
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Figure 7.12  The receptor gene expression in thecal cells of prenatally androgenised ewes. 
The effect of prenatal androgenisation on thecal cell hormonal receptivity was determined 
by qRT-PCR. In maternally and fetally d62/82 treated animals respectively, the genes 
assessed were AR (A and B), ERβ (C and D), INSR (E and F), and LHR (G and H). The effect of 
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7.3.2.5 Thecal cell expression of genes involved in growth and hormone 
secretion are affected by prenatal androgenisation 
 
Other genes that can affect follicle growth as well as the availability of steroid hormones 
were analysed including the activins and inhibins. The three subunits that make up these 
dimeric proteins, including INHA, INHBA and INHBB were analysed by qRT-PCR. There 
was a non-significant trend for increased thecal INHA and INHBA subunit mRNA 
expression, and INHBB was up-regulated (P<0.05), in 3-4mm follicles in maternally TP-
exposed animals (Fig. 7.13.A, D and G, respectively). Conversely, fetal TP-exposure had no 
effect on INHBB mRNA expression in thecal cells (Fig. 7.13.H), norwas there an effect of 
fetal injection treatment (Fig. 7.13.I). However, the fetal control injection did lead to a non-
significant downward trend in both thecal INHA and INHBA subunit expression in 3-4mm 
follicles when compared to maternal controls (Fig. 7.13.C and F, respectively). Fetal prenatal 
TP-exposure appeared to rescue this decrease in thecal INHA and INHBA in 3-4mm follicles 
(Fig. 7.13.B and E, respectively), although large individual variation existed.  
 
Thecal cell expression of the inhibin receptor β-Glycan (TGFβR3) was also examined. No 
changes were observed in the expression of thecal β-Glycan mRNA in either maternally 
(Fig. 7.14.A) or fetally (Fig. 7.14.A) TP-exposed animals at any follicle size analysed, nor 
was there an apparent effect of fetal treatment delivery (Fig. 7.14.C). IGF1 signalling was 
additionally assessed in the thecal cells of prenatally androgenised sheep. Thecal IGF1R 
mRNA expression was increased in ≥3mm follicles in maternally TP treated animals 
(P<0.05), this effect being particularly prominent i  3-4mm follicles (P<0.05; Fig. 7.14.D). 
Fetal prenatal androgenisation did not affect thecal IGF1R expression (Fig. 7.14.E), however 
in this case the fetal injection itself resulted in a significant up-regulation of IGF1R transcript 
(P<0.05, >4mm follicles; Fig. 7.14.F) indicating an increase in IGF1R in both fetally control 
and TP-treated animals (Fig. 7.14.E). 
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Figure 7.13  The activin and inhibin subunit gene expression in thecal cells of prenatally 
androgenised ewes. The effect of prenatal androgenisation on thecal cell inhibin subunit 
expression was determined by qRT-PCR. In maternally and fetally d62/82 treated animals 
and in control cohorts respectively, the genes assessed were INHA (A-C), INHBA (D-F) and 
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Figure 7.14  β -Glycan and IGF1R gene expression in thecal cells of prenatally androgenised 
ewes. The effect of prenatal androgenisation on thecal cell gene expression was 
determined by qRT-PCR. In maternally and fetally d62/82 treated animals and in control 
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7.3.2.6 The expression of the Id1 in thecal cells is differentially altered in 
the fetal treatment cohort  
 
The Id genes (Id1-3) were analysed in the thecal cells of prenatally androgenised offspring. 
Id1 was more abundantly expressed than Id2 (Fig. 7.15) and Id3 was not detected at the 
mRNA level in these cells. The expression of thecal Id1 was unaltered by maternal 
androgenisation (Fig. 7.15.A) and fetal androgenisation led to a down-regulation of this gene 
in >4mm follicles (P<0.05; Fig. 7.15.B). However, the fetal control cohort were found to 
have a significantly higher levels of Id1 than the maternal control group (Fig. 7.15.C), so that
the down-regulation by fetal TP exposure resulted in comparable Id1 expression to the 
maternal treated animals. There was no alteration in the expression of Id2 in any of the 
groups analysed (Fig. 7.15.D-E). 
 
 
Figure 7.15  Id gene expression in thecal cells of prenatally androgenised ewes. The effect 
of prenatal androgenisation on thecal cell gene expression was determined by qRT-PCR. In 
maternally and fetally d62/82 treated animals and in control cohorts respectively, Id1 (A-C) 
and Id2 (D-F) gene expression was assessed. * P<0.05. 
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In the sheep prenatal androgenisation model, West et al. reported that polyfollicular ovaries 
were present in 5 week old lambs that were exposed to testosterone, but not DHT, from d30-
90 of pregnancy (301). The present study found that while some ~3 month old lamb ovaries 
were highly polyfollicular, containing densely packed antral follicles, this was independent 
of treatment group and in fact there was a great del of individual variation concerning the 
number of follicles present. Indeed, there is a surge of follicular growth in the neonatal lamb 
at 2-4 weeks in which there is a peak of growing follicles followed by a wave of atresia (599, 
600), which would explain this multifollicular phenotype in these young lambs. In young 
adults this generalised polyfollicular morphology was lost and ovaries were found to contain 
fewer large antral follicles.  
 
While crude assessment did not appear to identify distinct differences in ovarian morphology 
as a result of prenatal androgenisation, other studies have suggested that folliculogenesis is 
disrupted in both women with PCOS (317, 318) and in the prenatally androgenised sheep 
model (332, 333) through alterations in follicular recruitment and regression. Therefore an in 
depth stereological examination of ovarian serial sections was performed to elucidate 
whether subtle differences occurred in response to prenatal androgens in terms of follicle 
number and also the level of follicle growth and atresia. Neither maternal nor fetal prenatal 
androgenisation resulted in changes in primordial cell number in ovaries from 11 month 
animals. Additionally no differences were found in the number of primary, pre-antral or 
antral follicles across the treatment groups althoug  there was a non-significant trend for an 
increased antral follicle number in those animals fetally exposed to 4mg TP. Furthermore, in 
line with the unaltered follicle number the proporti n of growing follicles, as assessed by 
follicles positive for the cell cycle marker, Ki67, was unaffected in both treatment cohorts. A 
study by Steckler et al. investigated the effect of prenatal androgenisation fr m d30-90 on 
ovarian reserve in the d140 fetal ovary, and reportd that there was decreased primordial 
follicle number (332), which was speculated to be a r sult of increased follicular recruitment 
of primordial follicles into transitional and primary follicles. The same affect is also shown 
in the d30-90 prenatally androgenised 8 month old anim l, however not in the 20 month old 
ewe (333). These studies are in agreement with human studies investigating follicular 
dynamics in the PCOS ovary, in which an increase in primary and antral follicle number has 
been reported, parallel to a decrease in primordial follicle number (317).  
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It is likely that these differences in follicular recruitment and growth between this study and 
previous studies are associated with the different treatment periods of in utero 
androgenisation. Indeed if these alterations were to occur through the androgenic actions of 
TP then the increased trend for antral follicle number present in the fetally d62-102 treated 
cohort, in which fetal testosterone levels are greatly increased compared to the maternal TP 
cohort, may reflect the longer period of treatment in previous studies (d30-90). In fact, DHT 
but not TP exposure from d30-90, was found to increase the number of small follicles in 
adult sheep ovaries (335). In terms of regulating follicle number, this might suggest that the 
duration of treatment or amount of androgen that the fetus is exposed to is more significant 
than the timing of treatment. Certainly germ cell number is not affected by maternal prenatal 
androgenisation in the d90 fetal ovary following exposure from d60-90 of gestation (Chapter 
4), whereas changes in primordial follicle number ar  reported by d140 as a result of a longer 
60 day exposure to androgens (332).  
 
Further to this, studies in sheep have found a reduction in follicular atresia that is associated 
with the estrogenic programming effects of prenatal androgenisation. Steckler et al. 
demonstrated that during culture of ovarian biopsies from d30-90 prenatally androgenised 
sheep, those animals exposed to TP, but not DHT, exhibited a reduction in follicle 
regression, although there was no difference between control and treatment cohorts prior to 
culture (335). The present study also found alterations in the amount of follicular atresia 
measured by the counting of cleaved caspase-3 positive follicles in ovarian serial sections. 
The fact that these changes were observed in maternal and fetal treated animals also suggests 
that there might be a direct androgenic programming element to the regulation of follicle 
degeneration. This is in contrast to observations of Steckler et al. and other studies using 
human PCOS ovaries where there was a reduction in follicular atresia (319). Given the 
observation that not all of these ewes were cycling during this time, implying that some of 
these animals were still immature, and the ovaries w re not yet polycystic in morphology, 
the changes in the rate of atresia may reflect intrinsic alterations in folliculogenesis that is 
occurring in the prenatally androgenised cohorts, that is not yet affected by extra-ovarian 
factors such as the gonadotrophins.  
 
In addition to measuring antral follicle atresia by caspase-3 immunostaining as an indicator 
of cell death in fetal TP 4mg exposed animals, the estrogenic status of follicles was also 
assessed in the fetal TP 20mg cohort. In contrast to the finding of increased atresia in 
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maternally treated animals, the estrogenic status of follicles from these animals suggested 
that there was an increased number of healthy follicles, particularly in those follicles that 
were >3mm. This would in fact indicate more follicuar activity and reduced follicular 
regression in the ovaries of these animals and this fits with previous literature that also 
proposes this mechanism in PCOS-models (319, 334, 335). Of course these fetal TP cohorts 
are slightly different in that a lower and higher dose of TP administration was assessed 
between experiments. This was due to limitations in the time available to assess all of the 
animals. Nevertheless, the data presented could sugge t that at least in the maternal treated 
cohort, while more follicles are estrogenic and appear healthy, more follicles are also 
programmed for cell death, resulting in a scenario whereby a possible phenotype for 
increased follicle number is cancelled out by increased follicle atresia in the young adult. 
Speculatively, intrinsic ovarian mechanisms may balance out the altered follicular dynamics 
to prevent a multifollicular phenotype from arising. As these animals were assessed at a 
young age it is possible that these mechanisms would be absent in a more phenotypically 
mature animal, thus leading to the increase in follicle number reported elsewhere (334, 335). 
 
It may be that the increase in follicle recruitment a d growing follicle number, opposed to 
the decrease in follicle regression, reported in some human and sheep studies, may 
differentially occur through respective androgenic and estrogenic actions. Indeed, the short 
term treatment of cycling adult Rhesus monkeys with testosterone or DHT, result in 
increased preantral and small antral follicle number and follicular growth, although follicular 
atresia was not affected by either treatment (336). It is clear that the high level of 
heterogeneity characteristic of PCOS could account for some of the differences encountered 
between studies. For example, Maciel et al. reported an increased number of primary 
through to antral follicles in PCOS ovaries however did not find any alterations in primordial 
follicle reserve or in the level of follicular atresia in PCOS (318). 
 
As well as evaluating the intrinsic ovarian features that could alter morphology, the 
steroidogenic potential of the ovary was also examined to determine whether changes 
associated with PCOS were present. Systemically there was no alteration in circulating sex 
steroids, including estradiol, testosterone or androstenedione as a result of prenatal 
androgenisation (Chapter 6). Hyperandrogenaemia is however a cardinal feature of PCOS of 
which the ovary is a contributor. The thecal cells are responsible for androgen biosynthesis 
and synthesise androstenedione when triggered to do so by LH, which is subsequently 
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converted to estradiol by granulosa cells in the prsence of FSH. In the prenatally 
androgenised ewe, this study aimed to assess the local production of androstenedione by the 
thecal cell in vivo and in vitro and to examine whether the steroidogenic capacity is altered 
by changes in thecal cell gene expression. 
 
Androstenedione was measured in vivo to give a physiological assessment of thecal cell 
steroidogenic output. In the largest antral follicles (>4mm) androstenedione concentration, 
measured in the follicular fluid, was increased in both maternally and fetally treated cohorts 
as a result of prenatal androgenisation, although in both cases this followed a non-significant 
trend. Crucially the impact of the fetal injection was apparent: in fetal control follicles there 
was a trend for increased androstenedione output compared to maternal control follicles at all 
sizes assessed and this was significant for follicles >4mm. Therefore the androstenedione 
concentration was in fact increased by 35-fold in these large follicles from fetal TP-exposed 
animals when compared with maternal controls. Similarly, the increased capacity for thecal 
cell androstenedione production in prenatally androgenised animals was demonstrated in 
vitro by measurement of androstenedione in media from thecal cell cultures pre- and post-
LH stimulation. Maternal treatment resulted in an increased drive for androstenedione 
production in large (>4mm) follicles, basally and post LH stimulation. Interestingly in small 
(<3mm) follicles androstenedione secretion was decreased both basally and post LH in TP-
exposed animals compared to controls, the opposite f he effect in >4mm follicles. These 
data are in accordance with increased androstenedione production from cultured thecal cells 
from women with PCOS, before and after LH stimulation (344, 345), and may indicate 
changes in ovarian steroid production that are not yet identifiable systemically. In the fetally 
treated cohort there was, like the in vivo assessment, a universal enhancement of 
androstenedione concentration in media collected from cultured thecal cells at all follicle 
sizes assessed. The thecal cell response to LH was more limited than the maternal treatment 
groups and there was no added effect of prenatal androgenisation.  
 
While there was some evidence in the maternally androgenised cohort that increased 
androstenedione levels are a consequence of reduced conversion to estradiol, these studies 
have demonstrated a clear thecal cell phenotype that would promote increased steroidogenic 
drive. Previous research that has assessed the factors that might lead to increased steroid 
production in human PCOS thecal cells have identifid alterations in gene expression related 
to the steroidogenic biosynthesis pathway. These include the up-regulation of StAR (598), 
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CYP11A and CYP17 (345, 598) as well as increased enzymatic activity of 17α-hydroxylase, 
3β-HSD and 17β-HSD (345). Assessment of the prenatally androgenised ovine model via the 
maternal route of TP administration identified the up-regulation of many genes involved in 
steroid biosynthesis including StAR, CYP11A (trend), HSD3B1 and CYP17. Furthermore 
thecal LHR gene expression was increased in maternal TP-exposd animals, a finding that 
has also been reported in human thecal cells from PCOS patients (598). These data imply 
that the enhanced androstenedione secretion could also be mediated through both increased 
sensitivity to LH and increased activity of the steroidogenic pathway. 
 
In the maternal TP exposed young adult ewe, thecal expression of the inhibin subunit INHBB 
was significantly increased in 3-4mm follicles compared with controls. This is in contrast to 
reports by West et al. 2001 who found a non-significant downward trend for INHBB mRNA 
expression by in situ hybridisation in follicles from d30-90 prenatally androgenised 5-week 
lambs. However, aside from the differences between these studies in terms of prenatal 
treatment period and the age of animals assessed, INHBB expression in the study by West et 
al. included the granulosa cells which are the predominant producer of activin and inhibin. In 
this study the increase in the INHBB subunit in thecal cells could lead to an increase in 
activin AB or activin B (not inhibin B which is not produced in sheep). Also the increase, 
albeit non-significant, in INHA and INHBA subunit expression could potentially lead to 
increased activin A or inhibin A protein expression. The fact that activin is known to 
suppress androstenedione expression, while inhibin enhances it (120-122), makes these 
findings difficult to reconcile. Nevertheless it is possible to speculate that the increase in 
inhibin A could contribute to the enhanced androstenedione synthesis that occurs in the 
prenatally androgenised sheep, although inhibin subunit changes were found in the 3-4mm 
follicle and androstenedione was not raised until the >4mm size. 
 
The role of the Id genes as novel candidates for the regulation of thecal cell function was 
also assessed in the ovine model of prenatal androgenisation. The Id genes have roles in 
proliferation, apoptosis and differentiation and are regulated by members of the transforming 
TGFβ superfamily, including the BMPs and activin. Although the Id genes are generally 
described in either development or in cancer, we hav  shown that they are also present in the 
adult ovary and can be regulated by TGFβ members (Chapter 5). Due to the role in inhibition 
of differentiation and promotion of proliferation, the Id genes are potential candidates for the 
dysregulation of folliculogenesis observed in PCOS. In fact, we have shown that in the ovine 
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prenatal androgenisation model there are alterations in Id1 and Id3 protein expression in the 
fetal ovary. Id1 and Id3 were up-regulated in the d70 and d90 fetal ovary following maternal 
exposure to androgens and Id3 was up-regulated at d70 in the fetally exposed group (Chapter 
4). In the prenatally androgenised adult the thecal xpression of Id2 was unaltered. Id1 was 
down-regulated as a result of fetal TP-exposure; however, the control group in this cohort 
presented a phenotype in which Id1 was elevated in the first instance. Since activin ca
regulate the Ids, changes in Id expression may have been reflected in the local activin 
production however no changes were observed in the expression of the inhibin subunits 
INHBA or INHBB. Furthermore, the finding that Id protein expression is down-regulated in 
the thecal layer of atretic follicles in the adult ovary (Chapter 5) might predict a down-
regulation of the Id genes in the thecal cells of non-estrogenic follicles; however this 
correlation was not observed. Therefore the effect of the Id1 gene expression change in the 
fetally exposed cohort is not easily reconciled, but further indicates a global dysregulation of 
gene expression in the thecal cells of this cohort. 
 
This chapter has highlighted a number of interesting pathways that are influenced by prenatal 
androgenisation and may provide insight into the mechanisms involved in PCOS. There was 
evidence for subtle alterations in follicular dynamics as a result of increased in utero 
androgens that were present in an otherwise normal ovarian morphology. Interestingly, there 
was variation in the amount of ovarian activity, observed by the number of antral follicles 
present in ovaries from different individuals; however, these morphologies were not linked 
to treatment. Two explanations for the lack of an ovarian morphological phenotype may be 
the shorter period of prenatal androgenisation compared to other studies in the sheep and 
also the assessment of these parameters in the young sheep in the first breeding season 
opposed to more mature animals in their second breeding season. Much of the changes 
observed in sheep studies have occurred in the second breeding season. This provided a 
unique model in which it was possible to dissect out intrinsic ovarian changes that were 
present in the absence of an altered hormonal environment and, at this stage, disrupted 
folliculogenesis. 
 
Indeed, it was demonstrated that there are intrinsic ovarian abnormalities that are 
programmed by prenatal exposure to androgens, which are not associated with an altered 
steroid or gonadotrophin hormone environment. This study has for the first time 
characterised thecal cell androgen production and steroidogenic gene expression in the ovine 
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prenatal androgenisation model and revealed a considerable increase in the amount of 
androgens produced by thecal cells which is likely driven by a universal up-regulation of 
genes involved in steroid biosynthesis. Moreover, an up-regulation of LHR in these same 
cells is an additional pathway in which androgen sythesis may be augmented. 
 
Finally, injecting the fetus in utero can also lead to ovarian irregularities, paralleling some of 
the findings in the maternally TP exposed cohort. These included the increased expression of 
steroidogenic genes and also a vast enhancement of thecal cell androgen output far 
exceeding that of the maternal TP phenotype. While t e mechanisms resulting in this are not 
clear it implies that the reproductive anomalies apparent in the maternally treated cohorts 
may not entirely be programmed by the effects of androgens and/or estrogen. Also the 
finding that Id1 is increased in the thecal control cohort might provide insight into an 
alternative mechanism for the programming of follicle dysregulation that is not influenced 
by exposure to sex steroids. 
 
In conclusion, mid-gestation prenatal androgenisation does not result in PCO, perturbed 
ovulatory cycles, or an altered hormonal environment in young adult ewes. Despite this, 
there are phenotypic differences present in the adult ovary that are likely programmed in 
fetal life to result in a pre-PCOS phenotype, observed at this stage. Therefore the thecal cell 
phenotype that is similar to that in women with PCOS may be inherent and not secondary to 
systemic environmental changes that are typical of PCOS. This is particularly remarkable 
given that thecal cells are not present at the timeof prenatal treatment, so androgens must act 
on other cell types such as a thecal stem cell, somatic pre-granulosa cell or germ cell. 
Alternatively the developing thecal cell may be influenced by other environmental factors in 
the adult. Women with PCOS may also have increased drenal gland androgen secretion. 
Therefore prenatal androgen exposure may have a similar effect in the adult adrenal gland as 
the ovary, to pre-dispose enhanced androgen producti n. In the following chapter, the effects 
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In addition to the ovary, the adrenal gland is a major source of steroids including androgens 
and glucocorticoids, which are released upon stimulation by ACTH secreted by the pituitary 
gland. In females, approximately 50% of androgens are synthesised by the adrenal which 
produces, in order of abundance, DHEA, DHEAS, androstenedione and testosterone (393). 
This is of importance for women with PCOS, in which hyperandrogenaemia is thought to be 
a result of the increased secretion of androgens from both the ovary and the adrenal gland 
(408, 409, 411, 413, 414). Evidence for the increased adrenal expression of steroidogenic 
enzymes in these women suggests intrinsic changes to the adrenal to drive steroid 
production. In fact daughters of women with PCOS, that were therefore exposed to a 
androgenic maternal environment, were assessed peri-pubertally and had increased serum 
androgens and 17α-OH progesterone post-ACTH stimulation that would suggest increased 
activity of the enzyme 17α-hydroxylase (412). Accordingly, studies in the prenatally 
androgenised Rhesus monkey have demonstrated increased b sal levels of DHEA (297, 415) 
and ACTH-stimulated production of DHEA and androstenedione (415), although in this 
instance there was no reciprocal increase in the level of 17α-OH progesterone (415). Given 
the increase in the ovarian capability to produce androgens in this ovine model, androgen 
output in the stimulated adult adrenal gland was also ssessed. 
 
The adrenal gland is also responsible for regulating the body’s response to stressful stimuli, 
whether that is physical or emotional (386, 387, 390). In this way, the stimulation of 
glucocorticoids from the adrenal gland is crucial for maintaining physiological homeostasis 
and they can act directly on a variety of tissues including liver, muscle, fat, bone, the brain 
and the kidneys (31). It is therefore imperative that t is system is controlled and triggered in 
an appropriate manner to maintain homeostatic equilibri m and normal body function. Adult 
diseases in which this does not happen, such as Cushing’s syndrome in which there is over-
production of cortisol, lead to obesity, altered fat distribution, muscle weakness and other 
metabolic irregularities that arise as result of the crucial role that cortisol has in maintaining 
these systems (31). In other syndromes, including PCOS, it is suggested that there is an 
enhanced response of the HPA axis to stressful stimuli and increased cortisol output (426) 
which, given some of the metabolic disturbances comm n to PCOS, may identify a pathway 
that contributes to this phenotype. These observations have also been extended to an animal 
model of PCOS, where prenatally androgenised non-human primates have been shown to 
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have increased ACTH-stimulated corticosterone production (but not cortisol) compared to 
control animals (415). The effect of prenatal androgens on HPA function in the adult sheep 
is not published but there are some indications that cortisol production is not affected in this 
model (427). 
 
In the ovine fetus it is the maturation of the HPA axis that is crucial to the initiation of 
parturition and maturation of organs including the lungs, which is essential for survival 
(601). The adrenal glands are visible in the ovine fetus by gestational d25 and by d60 two 
morphologically distinct cortical zones are present (602). The zona glomerulosa is present at 
d80 and by d90 the inner cortical zone begins to resemble that of the zona fasciculata that 
becomes fully formed by d120 (602). The HPA axis matures at approximately d125 in the 
sheep fetus and with that there is a steady increase in cortisol levels due to increased adrenal 
steroidogenesis. This activation of fetal adrenal hormone production is stimulated by the 
pituitary hormone ACTH (603). 
 
The ovine fetal adrenal secretes large amounts of cortisol between d40-90 and d120 to term, 
but during d90-120 cortisol production is low (604). In fact any cortisol present in the fetal 
circulation between d90-120 is thought to mainly come from the placental transfer from 
mother to fetus (605). The expression of adrenal steroidogenic genes reflects this triphasic 
pattern of cortisol production. Both CYP11A and CYP17 are strongly expressed in the fetal 
adrenal between d40-60 and d120 to term but are down-regulated in between these times 
(398). Conversely, CYP21 mRNA expression steadily increases throughout gestation, 
suggesting that the production of cortisol is also limited by enzymatic steps at the beginning 
of the pathway (398). In fact infusion of ACTH into the fetus at ~d100 stimulates cortisol 
secretion through the up-regulation of CYP11A and CYP17, and this treatment does not 
affect the expression of CYP21 (603). Therefore ACTH directly controls adrenal steroid 
production by mediating specific adrenal gene expression and it is the availability of this 
pituitary hormone that controls the pattern of glucocorticoid production in the fetus. 
 
The aim of this chapter is to assess the function of the adult adrenal gland in relation to 
steroid hormone output and adrenal gene expression in the ovine prenatal androgenisation 
model. The lamb adrenal is also assessed to determin  the timing of manifestation of a 
phenotype. In addition to studying the post-natal effects of prenatal androgens, the fetal 
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adrenal gland was also assessed to determine whether arly alterations during adrenal 
development might be reflected in the adult animal or whether fetal adrenal development 
was normal and any affects in the adult develop post-natally. In the lamb and adult prenatally 
androgenised offspring, the steroidogenic potential of the adrenal gland was examined by 
measuring: A) the ACTH-stimulated production of cortisol and adrenal androgens including 
androstenedione and testosterone, and B) the adrenal st roidogenic gene expression. In the 
fetus, the objectives were to: A) assess the effect of maternal androgenisation for either 10 or 
30 days (commencing at d60), in the d70 and d90 fetal adrenal respectively, by measuring 
the expression of steroidogenic genes, and B) compare this with the effect of directly 
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8.2 Materials and Methods 
 
8.2.1 Experimental animals 
 
The female animals assessed in this chapter are detaile  in Table 8.1. 
 
Study Treatment Sample number (n) 
Fetal 
Fetal Treatment Injection at d60, assessed at d70 C = 4, TP 20mg = 8 
Treatment from d60-70, assessed at d70 C = 3, TP = 6 
Maternal Treatment 
Treatment from d60-90. assessed at d90 C = 6, TP = 8 
Lamb 
Maternal Treatment Treatment from d62-102 C = 9, TP = 7 
Adult 
Injection at d62 and 72 C = 4, TP 20mg = 8 
Fetal Treatment 
Injection at d62 and 82 
C = 4, TP 1mg = 5, 4mg = 5, 
20mg = 7 
Maternal Treatment Treatment from d62-102 C = 5, TP = 9 
Table 8.1  The experimental animals included in the assessment of the adrenal gland, 
treatment regime and corresponding sample numbers. 
 
 
8.2.2 Quantitative real time -PCR 
 
The expression of a range of genes was investigated in the fetal, lamb and adult sheep 
adrenal gland. The methodology used for these experiments are as described in Section 2.8 
of the Materials and Methods chapter, which details RNA extraction, cDNA synthesis, 
primer validation and SYBR Green qRT-PCR protocols that were utilised for assessment of 
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Table 8.2  Adrenal gland gene analysis using SYBR
 
Green qRT-PCR. Gene names and 
accession numbers, forward and reverse primer sequences (5’-3’) and PCR product sizes are 
listed. 
 
8.2.3 Determination of adrenal function 
 
To assess adrenal function a synacthen test was perform d at approximately 10 weeks and 
10.5 months of age. Synacthen is a synthetic chemical equivalent to the endogenous pituitary 
secreted ACTH and is routinely used to investigate adrenal insufficiency. Animals were 
fasted on the day of the test, which was carried during late morning and early afternoon in 
groups of 8-10 animals at a time. The animals within treatment cohorts were randomly 
mixed in these test groups to avoid variability due to diurnal rhythms. A basal blood sample 
was drawn from the jugular vein prior to administration of a 2ml intravascular dose of 
synacthen (50µg/ml in saline; Alliance Pharmaceuticals Ltd., Wiltshire, UK) and subsequent 
sampling occurred 15 and 30 min post-stimulation. Blood was decanted into heparin-











CAACGTCCCTCCAGAACTGT CAGGAGGCAGTAGAGGATGC 172 
HSD3B1 
(NM_001135932) 
GGAGACATTCTGGATGAGCAG TCTATGGTGCTGGTGTGGA 200 
StAR 
(NM_001009243) 
GCATCCTCAAAGACCAGGAG CTTGACACTGGGGTTCCACT 194 
CYP17  
(NM_001009483) 
AGACATATTCCCTGCGCTGA GCAGCTTTGAATCCTGCTCT 215 
AR   
(XM_001253942) 
GCCCATCTTTCTGAATGTCC CAAACACCATAAGCCCCATC 233 
ERα                          
(NM_001001443) 
GAATCTGCCAAGGAGACTCG CCTGACAGCTCTTCCTCCTG 187 
CYP11B 
(NM_174638) 
AGAAGTACACGCCCTTGGTG AGCGCGTGGATAAAGTTCAG 217 
CYP21  
(NM_174639) 
CACATGTCTGTGGTGGACCT AAGTGACTCGGGAGCATGAG 163 
POMC 
(NM_001009266) 
GAGAGCAGCCAGTGTCAGG GAAATGGCCCATGACGTACT   159 
GAPDH 
(NM_001034034) 
GGCGTGAACCACGAGAAGTATAA AAGCAGGGATGATGTTCTGG 229 
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Hormonal analysis was carried out by RIA pre- and post-ACTH stimulation, and included 
assays for androstenedione, testosterone and cortisol. For the testosterone and 
androstenedione measurements, serum was extracted prior to the assay as described in 
Section 2.5.1. The general RIA protocol is detailed n Section 2.5.2 and specific information 
for each hormone assay is described in Appendix A. The reagent information and CVs are 
listed in Table 8.3.  
 
Hormone Primary antibody 













Rabbit  anti-Androstenedione (07-
109216; MP Biomedicals,  Illkirch, 
France) 
Andro-







Rabbit anti- Testosterone (R3S07-








Rabbit anti-Cortisol (20-CR5; 
Fitzgerald, MA, USA) 





Table 8.3  The hormones measured in plasma by RIA during a synacthen test. Listed are the 
primary antibodies, tracers and standards employed for each RIA. Radiolabelled tracer was 
supplied by MP Biochemicals, Illkirch, France and the standards by Sigma-Aldrich. 
 
 
8.2.4 Statistical analyses 
 
Where the differences between two means were assessed, including the gene expression and 
hormonal analysis following the synacthen test at each time point (0, 15 and 30 min), data 
were statistically analysed using a student’s unpaired t-test assuming equal variances. If the 
data were not normally distributed (unequal variance) a non-parametric Mann Whitney test 
was alternatively employed. For the d62/82 experimental cohort in which there were 
numerous treatment groups, statisitcal analyses were conducted so that each TP-treated 
group (shaded bar) was compared to the control group (white bar). The values are presented 
as the mean ± sem. P values of P<0.05 were considered statistically significant.  
 
Chapter 8                                                                            Prenatal androgens and the adrenal gland




8.3.1 Adult adrenal function in the prenatally androgenised sheep 
model 
 
In order to determine whether the adrenal gland of prenatally androgenised animals might 
function differently upon stimulation, ewes were delivered a large dose of a synthetic form 
of the pituitary hormone, ACTH, and the subsequent production of hormones monitored 15 
and 30 min later. Cortisol, androstenedione and testosterone were assayed to determine how 
steroidogenic pathways might be affected by prenatal androgenisation. Those animals that 
were exposed to androgens via the maternal route did not show any differences in cortisol 
(Fig. 8.1.A) or androstenedione (Fig. 8.1.B) response to ACTH, however, they did have an 
exaggerated testosterone response to adrenal stimulation after 30 min (P<0.05; Fig. 8.1.C). 
Fetal androgenisation had no effect on adrenal steroidogenic output following stimulation 
with ACTH. Like the maternal treated cohort, the fetal treatment paradigm had no effect on 
the adrenal response to ACTH, for either glucocortiid or androstenedione secretion (Fig. 
8.1-3). The output of cortisol and androstenedione (d62/72; Fig 8.2.A and B, respectively, 
and d62/82; Fig. 8.3.A and B, respectively) were not changed between C and TP cohorts. 
However, unlike the maternal TP-treated cohort, the p ripheral concentrations of 
testosterone were not significantly different after stimulation in those animals that were 
fetally androgenised at either d62 and 72 (Fig. 8.2.C), or at d62 and 82 (Fig.8.3.C), compared 
to controls. Therefore these data suggest that like the adult thecal cell, adrenal androgen 
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Figure 8.1 The hormonal secretion following adrenal stimulation in maternally 
androgenised adult sheep. Blood was sampled at a basal time point (0 min) and 15 and 30 
min post-ACTH stimulation. Cortisol (A), androstenedione (B) and testosterone (C) were 
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Figure 8.2 The hormonal secretion following adrenal stimulation in fetally d62/72 
androgenised adult sheep. Blood was sampled at a basal time point (0 min) and 15 and 30 
min post-ACTH stimulation. Cortisol (A), androstenedione (B) and testosterone (C) were 
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Figure 8.3 The hormonal secretion following adrenal stimulation in fetally d62/82 
androgenised adult sheep. Blood was sampled at a basal time point (0 min) and 15 and 30 
min post-ACTH stimulation. Cortisol (A), androstenedione (B) and testosterone (C) were 
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8.3.2 Expression of steroidogenic enzymes in the adult adrenal 
 
The adrenal gene expression in the adult sheep was studied to detect any functional 
molecular alterations that may alter the steroid biosynthesis as a consequence of in utero 
exposure to androgens. Adrenal gene expression was studied in the maternal and fetal treated 
cohorts with regard to StAR, CYP11A, HSD3B1, CYP17, CYP21 and CYP11B1 expression. 
The expression of steroid receptors in the adrenal, i cluding AR and ERα, was also assessed. 
In addition, to determine whether adrenal gene expression might be regulated by changes in 
ACTH, the expression of pro-opiomelanocortin (POMC), the gene pre-cursor of ACTH, was 
measured in the adult pituitary. 
 
Maternal androgenisation resulted in alterations in the expression of steroidogenic genes in 
the adult adrenal. The rate-limiting enzymes of the steroid biosynthesis, StAR and CYP11A 
were both up-regulated as a result of maternal TP (P<0.05; Fig. 8.4.A and B, respectively). 
The intermediaries, HSD3B1 and CYP17 were also increased in this cohort (P<0.05; Fig. 
8.4.C and D, respectively). Additionally, the enzymes involved in the glucocorticoid 
pathway were altered with CYP21 expression showing a non-significant increase (Fig. 8.4.E) 
and CYP11B1 was significantly up-regulated (P<0.01; Fig. 8.4.F). These data reveal a 
mechanism for increased testosterone synthesis in the s imulated adult adrenal from 
maternally androgenised offspring. Furthermore, the increased adrenal steroidogenic gene 
expression changes are parallel with the findings ob erved in the adult thecal cell. In 
agreement with the results of the synacthen test, there was no effect of fetal androgenisation 
on the steroidogenic gene expression in the adult aren l for either fetal treatment cohort 
(StAR, CYP11A, HSD3B1, CYP17, CYP21 and CYP11B1; d62/72 Fig. 8.5.A-F and d62/82 
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Figure 8.4 The steroidogenic gene expression in the adrenal of the maternally androgenised 
adult sheep. Genes analysed were StAR (A), CYP11A (B), HSD3B1 (C), CYP17 (D), CYP21 (E) 
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Figure 8.5 The steroidogenic gene expression in the adrenal of the fetally d62/72 
androgenised adult sheep. Genes analysed were StAR (A), CYP11A (B), HSD3B1 (C), CYP17 
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Figure 8.6 The steroidogenic gene expression in the adrenal of the fetally d62/82 
androgenised adult sheep. Genes analysed were StAR (A), CYP11A (B), HSD3B1 (C), CYP17 
(D), CYP21 (E) and CYP11B1 (F). 
 
 
Additional genes that were studied included the receptors for androgens and estrogens. 
Maternal androgenisation did not effect the expression of AR (Fig. 8.7.A) or ERα (Fig. 
8.7.B). In the fetally injected cohorts there was an effect of early TP injection (d62/72) on 
AR which was up-regulated (Fig. 8.7.D), however, ERα was unaffected (Fig. 8.7.E). Fetal 
injection at d62 and d82 had no effect on AR (Fig. 8.7.G) or ERα (Fig. 8.7.H) expression. To 
assess whether the increase in adrenal steroidogenic e expression in the maternally 
treated cohort could be linked to stimulation by pituitary hormones, POMC was measured. 
There was no change in POMC gene expression in the adult pituitary (Fig. 8.7.C) suggesting 
that increased ACTH is not responsible for the increased adrenal gene expression in these 
animals. Similarly, the expression of pituitary POMC was not altered in either fetally TP 
treated adult cohorts (Fig. 8.7.F and Fig. 8.7.I). Finally, the route of treatment did not alter 
the expression of these sets of genes in the adrenal or pituitary when the control cohorts were 
compared (Figs. 8.4-7). 
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Figure 8.7 Other gene expression in the adrenal and pituitary of the prenatally 
androgenised adult sheep. Respectively, genes analysed were AR, ERα and POMC in the 
maternally (A-C), fetal d62/72 (D-F) and fetal d62/82 (G-I) treatment cohorts. * P<0.05 
 
 
8.3.3 The effect of maternal prenatal androgenisation in the lamb 
adrenal 
 
The maternal administration of androgens to the mid-gestation fetus results in increased 
stimulated adrenal testosterone synthesis in the adult, and there is a global enhancement of 
steroidogenic genes that are likely to play a role in this. To investigate the developmental 
period in which this phenotype might arise, adrenal function and gene expression was also 
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assessed at 10-12 weeks of age (Fig. 8.8). While no significant changes were observed at 10-
12 weeks in female maternally androgenised offspring, there were trends that might indicate 
early effects that would develop into the changes observed in the adult cohort. Testosterone 
secretion following adrenal stimulation was variable, and tended to be increased in the TP-
exposed group (Fig. 8.8.A), although not reaching statistical significance. Likewise, the 
suggestion of small increases in the lamb adrenal expression of StAR (Fig. 8.8.B), CYP11A 
(Fig. 8.8.C) and CYP17 mRNA (Fig. 8.8.E), did not reach statistical significance. The 
expression of HSD3B1 in the lamb adrenal gland (Fig. 8.8.D), was clearly not altered by 




Figure 8.8  Adrenal function in the maternally androgenised lamb. Testosterone was 
measured by RIA at a basal time point (0 min) and 15 and 30 min post-ACTH stimulation (A). 
Steroidogenic gene expression was measured in the lamb adrenal including StAR (B), 
CYP11A (C), HSD3B1 (D) and CYP17 (E). 
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8.3.4 Fetal adrenal function in the prenatally androgenised sheep 
model 
 
Since there were changes present in adult adrenal gene expression, and possible subtle 
alterations in the lamb, in androgenised offspring, the expression of steroidogenic genes was 
also assessed in the fetal adrenal to determine if there are functional programming effects 
during development. Adrenal StAR, CYP11A, HSD3B1, CYP17, CYP21 and CYP11B1 
mRNA expression was studied. There was no effect of maternal TP exposure on the fetal 
adrenal expression of StAR by d70 or d90 of gestation (Fig. 8.9.A). CYP17 tended to rise 
(not-significant; Fig. 8.9.D) and CYP21 (P<0.05; Fig. 8.9.E) increased with gestational age 
but neither was affected by maternal androgenisation. In contrast, CYP11A (P<0.05; Fig. 
8.9.B) and HSD3B1 (P<0.01; Fig. 8.9.C) were both significantly up-regulated after 30 days 
of TP exposure in the d90 fetal adrenal. The expression of CYP11B1 on the other hand was 
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Figure 8.9 The steroidogenic gene expression in the adrenal of the maternally androgenised 
fetus at d70 and d90. Genes analysed were StAR (A), CYP11A (B), HSD3B1 (C), CYP17 (D), 
CYP21 (E) and CYP11B1 (F). * P<0.05 and ** P<0.01. 
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The effect of direct fetal exposure on fetal adrenal gene expression was also assessed. In 
contrast to maternal androgenisation, in the fetal injected cohort that had received one 
injection of TP (20mg) on d60, CYP17 was significantly up-regulated (P<0.05; Fig. 8.10.D) 
and CYP21 showed an increased trend (Fig. 8.10.E). There wasno effect of fetal 
androgenisation on the expression of adrenal StAR, CYP11A, HSD3B1 or CYP11B1 (Fig. 
8.10.A, B, C and F, respectively) in the d70 fetus.  
  
 
Figure 8.10  The steroidogenic gene expression in the adrenal of the fetally androgenised 
fetus at d70. Genes analysed were StAR (A), CYP11A (B), HSD3B1 (C), CYP17 (D), CYP21 (E) 
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Androgens can directly target the ovine fetal adrenal during mid-gestation (Fig. 8.11). 
Between gestational d70 and 90 the expression of AR tended to decrease (white bars, 
P=0.06; Fig. 8.7.A). Maternal TP exposure for ten days down-regulated adrenal AR in the 
d70 fetus, to that found at d90 (P<0.01; Fig. 8.11.A). No effects were found at d90 due to 
androgenisation. It is possible that the down-regulation of androgen receptivity and likely 
activity at d70, results in the changes in expression of the steroidogenic genes, observed at 
d90. Directly injecting the fetus with TP had no effect on the expression of adrenal AR by 
d70 (Fig. 8.11.B). However, comparison of the d70 maternally and fetally treated control 
cohorts revealed that there was a significant down-regulation of AR in the fetally injected 
control group (P<0.01; Fig. 8.11.C). In fact, when similar comparison  are made between 
steroidogenic gene expression, down-regulated AR in the fetal injection group is also 
associated with a non-significant increase in CYP17 (P=0.13) and down-regulation of 
HSD3B1 (P<0.05), when compared to the maternal control cohort (Figs. 8.9 and 8.10). These 
data imply that altered androgen signalling may be associated with changes in the 
steroidogenic potential of the fetal adrenal gland. 
 
 
Figure 8.11  AR gene expression in the prenatally androgenised fetus. AR was measured in 
the maternally androgenised fetus at d70 and d90 (A) and in the fetally androgenised fetus 
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The effect of prenatal androgens in the developing adrenal, the pre-pubertal lamb, and adult 
were assessed to ascertain whether there was a programming effect of androgens or 
estrogens that were identifiable in an animal model in which the peripheral hormonal 
environment was normal, and to distinguish at what time-point any changes are observable. 
There was a clear effect of prenatal androgens in the adult adrenal as a consequence of 
maternal TP exposure. While androstenedione secretion was not enhanced following ACTH 
stimulation in the maternally TP-exposed cohort, serum testosterone concentration was 
significantly increased in this group 30 min post-ACTH. In addition, gene expression 
analysis revealed the up-regulation of StAR, CYP11A, CYP17 and HSD3B1 that might shunt 
steroid precursors in the direction of androgen biosynthesis. In the absence of changes in 
basal or ACTH-stimulated cortisol secretion, adrenal CYP11B1 gene expression was 
significantly up-regulated in the maternally TP-treated animals compared to controls. 
CYP11B1 is required for the final step in the glucocorticoid biosynthesis pathway converting 
deoxycortisol into cortisol (134). Peripheral cortisol concentration was not altered in these 
animals; nevertheless, it may be that the increase in CYP11B1 is not sufficient to drive 
increased cortisol production in the absence of increased substrate. Unlike the changes 
observed in the maternally treated cohort, there did not appear to be any alteration in adult 
adrenal function in the fetally treated cohort in response to either the fetal injection or to TP 
exposure. 
 
The effects of maternal TP in the adult adrenal may be mediated through the actions of 
estrogens that reach the fetus via placental aromatisation (377), since long-term effects of 
direct fetal TP on adrenal hormonal production and steroidogenic gene expression were not 
observed. In these cohorts basal concentrations of circulating androgens, testosterone and 
androstenedione and the estrogen, estradiol, were not altered in any of the treatment groups 
(Chapter 6) implying that the changes in the adrenal are not affected by an altered sex steroid 
environment. With the exception of the d62/72 fetally TP-treated cohort, the expression of 
adrenal AR and ERα mRNA was also not affected by prenatal androgenisation suggesting 
that the alterations in steroidogenic signalling are independent of androgen or estrogen 
signalling in the adult adrenal. In addition, there was no change in the amount of POMC 
expressed by the pituitary, indicating that the altr tions in steroidogenic gene expression are 
likely intrinsic and not a result of altered pituitary ACTH stimulation. The consequence of 
Chapter 8                                                                            Prenatal androgens and the adrenal gland
                                                          
 245 
increased AR gene expression in the d62/72 fetal TP cohort is not k own, and no other genes 
in this group were altered. 
 
To investigate whether the adult adrenal phenotype hat was observed in the maternally 
androgenised cohort might be a result of long-term changes in the adrenal, or, progressively 
develops as the animal matures, adrenal function in the 10-12 week lamb was also assessed. 
While no definitive changes in function were observed, there did appear to be an increased 
propensity for enhanced steroidogenesis that could translate into the significant alterations in 
the adult adrenal, suggesting that there were programming effects inherent to this tissue. 
 
Subsequent examination of the fetal adrenal did ident fy alterations in steroidogenic gene 
expression during the time of testosterone exposure. In maternally TP exposed fetuses, by 
d90, but not d70, the expression of CYP11A and HSD3B1 was increased; however, exposure 
to increased androgens did not effect the expression of other steroidogenic genes. In the 
control maternal cohorts, AR showed a non-significant trend for down-regulation between 
gestational d70 and d90. At d70, the maternal exposure of the fetus to androgens for ten days 
led to the down-regulation of adrenal AR mRNA to the same level observed in the d90 
control cohort. At d90 prenatal androgens had no effect on AR expression. It is possible that 
increased circulating levels of androgens resulted in the down-regulation of adrenal AR by 
d70 to act in a negative manner to dampen further t adrenal androgen output. While the 
steroidogenic genes are not affected at d70, by d90 the increase in CYP11A and HSD3B1 
may reflect a programming affect of a moderate lossin adrenal androgen signalling. It is also 
possible that estrogens may have a role in regulating AR expression at this time since there 
was no change in AR mRNA in the adrenals of animals directly exposed to TP. It was noted 
however that the expression of AR was down-regulated as a result of the fetal injection, 
suggesting that alternative programming pathways may be at play.  
 
In the fetus, the adrenal gland produces cortisol in a triphasic pattern over gestation. In this 
study the assessment of the fetal adrenal coincided with the gestational period in which the 
adrenals are producing steroids before cortisol secretion declines from around d90-120 
(604). Interestingly the levels of CYP17 and CYP21 were increased at d90 compared to d70 
in control animals which does not marry very well with the fact that adrenal steroidogenesis 
declines at this stage, however these genes may increase throughout development and it is 
the drop in ACTH from d90-120 that leads to a transie t down-regulation in these enzymes 
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after d90. In this regard, Tangalakis et al. demonstrated a direct relationship with ACTH 
stimulation and CYP17 gene expression although they did not find this relationship with the 
expression of CYP21 (603). 
 
In the fetal TP injected cohort CYP17 was significantly up-regulated in the d70 adrenal 
which represented a 2-fold increase from fetal injection controls and a 4-fold increase from 
maternal controls. Also while HSD3B1 mRNA expression in the d70 adrenal of fetally TP 
exposed animals was not different to controls, it was significantly down-regulated compared 
to maternal controls. The overall adrenal phenotype of the TP-exposed fetally injected fetus 
is therefore a combination of lowered AR that is associated with an increase in CYP17 and a 
decrease of HSD3B1. Speculatively this may suggest that the loss of androgen signalling in 
this model could result in the modulation of the expr ssion of steroidogenic genes that might 
favour the androgenic biosynthesis pathway. 
 
In conclusion, both the adult and fetal adrenal glands are affected by prenatal 
androgenisation, with possible subtle differences ob erved in the lamb. It appears that the 
changes in the fetal adrenal, in response to maternal and fetal TP exposure, may occur via 
independent pathways and have alternative long-term effects. The phenotype observed in the 
fetally injected control and TP d70 adrenals may be transient as there was no adult adrenal 
phenotype present in these animals with regards to the parameters assessed. The long-term 
effects of the d70 fetally injected adrenal phenotype are not known, but there may be a role 
for the programming of other systems in the fetus through the androgenic actions of TP 
and/or elevated levels of cortisol (Chapter 3). On the other hand, maternal TP-exposure, 
possibly through the programming actions of estrogen, may exert developmental effects on 
the fetal adrenal that lead to the changes in the adult drenal. 
 
In the adult prenatally androgenised sheep, not only is there an enhanced drive for the ovary 
to secrete androgens, but steroidogenic gene expression is increased in the adrenal, which 
can also excessively produce testosterone when stimula ed in vivo. This occurs in the 
absence of an altered hormonal environment such as LH and androgens. It is however 
possible that these changes are affected by alternative f ctors that are present in the adult, 
which include metabolic function, and that such features may contribute the development of 
an ovarian and/or adrenal phenotype that is not present in younger animals. The following 
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chapter investigates the effect of prenatal androgenisation on metabolic homeostasis and 
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An abnormal or altered fetal environment is emerging as a likely aetiological factor for a 
host of adult diseases (274, 517, 606). The maternal nvironment can influence epigenetic 
processes in the placenta and fetus that programme lasting developmental changes associated 
with cardiovascular disease, hypertension, obesity and type II diabetes (517, 519, 606, 607), 
all of which are prevalent in Westernised societies (428, 429). Women with PCOS often 
present with these metabolic perturbances in addition to the reproductive and endocrine 
characteristics of the syndrome (166). More than one third of obese women with PCOS are 
insulin resistant (167) and these women are more likely to develop type II diabetes than 
weight-matched controls (449, 450). However, while PCOS women are hyperandrogenaemic 
(162), and androgens are linked with the development of central obesity and insulin 
resistance (608, 609) some women with PCOS are lean and have normal BMIs. These 
women do however retain the hyperinsulinaemic featur  of PCOS regardless of their weight, 
indicating a pancreatic defect that is likely augmented by obesity (434, 452). Metabolic 
parameters such as hyperinsulinaemia, insulin resistance and increased adiposity are also 
reported in animal models of PCOS in which the fetus is exposed to elevated androgens 
(298, 365, 477-479).  
 
In this chapter the metabolic effects of prenatal androgenisation of the ovine fetus were 
assessed with particular focus on the liver. Women with PCOS are more likely to have 
abnormal liver function tests (610, 611) including raised aminotransferases (alanine 
aminotransferase [ALT] and aspartate aminotransferae [AST]). Elevated aminotransferases 
are linked with obesity, increased triglycerides, insulin resistance and are often an indicator 
of non-alcoholic fatty liver disease (NAFLD) (611-63), which has also been associated with 
PCOS (614-616). NAFLD occurs through liver damage leading to steatosis and in severe 
cases hepatic inflammation, liver fibrosis or cirrhosis (613). The metabolic features of PCOS 
therefore seem to involve a complex interplay betwen increased androgen concentrations, 
insulin signalling, central obesity and NAFLD (162, 168). 
 
An assessment of NAFLD in young adult ewes exposed to increased androgen 
concentrations in utero, and investigation of the metabolic and synthetic function of the liver 
at a molecular level, was carried out. The relationship between findings in the liver, insulin 
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resistance and central obesity was determined to provide novel insights into possible early 
hepatic alterations associated with a PCOS-like conditi . The aims of this chapter were to 
establish: A) whether prenatal androgenisation is as ociated with the development of 
NAFLD or clinical determinants of liver damage. This included measurements of ALT and 
AST as well as other analytes including alkaline phosphatase (ALP) and gamma 
glutamyltransferase (GGT) of which elevated levels would indicate liver dysfunction such as 
bile duct blockage (617). B) If in utero exposure to androgens is linked to the development 
of central obesity by the measurement of omental fa as well as other metabolic parameters 
including plasma triglycerides, leptin and cholesterol concentrations. C) Whether treatment 
results in a metabolic phenotype affecting glucose and insulin homeostasis as determined by 
glucose tolerance testing. The effect of prenatal androgenisation on adult liver function was 
investigated by examining D) the expression of hepatic steroid receptors, E) liver metabolic 
activity, by assessing expression of the gluconeogenic enzyme PEPCK, and F) growth factor 
secretion by analysing the hepatic expression of IGF1. These experiments were conducted in 
animals that were maternally exposed to androgens from d62-102 of gestation and those that 
were fetally injected with TP at d62 and d82. A final aim of this chapter was to characterise 
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9.2 Materials and Methods 
 
9.2.1 Experimental animals 
 
The female animals assessed in this chapter are detaile  in Table 9.1. 
 
Study Treatment Sample number (n) 
Adult 
Fetal Treatment Injection at d62 and 82 C = 4, TP 20mg = 7 
Maternal Treatment Treatment from d62-102 C = 5, TP = 9 
Table 9.1  The experimental animals included in the assessment of metabolic parameters, 
treatment regime and corresponding sample numbers. 
 
Animals were fasted and a GTT performed on the day of sacrifice. Bolus glucose (500mg/ml 
in 20ml) was administered intravenously following collection of a peripheral basal blood 
sample. Blood was re-sampled after 15 min and the animal immediately euthanised and 
tissue collected. Equivalent liver samples were snap frozen and stored at -80°C, or embedded 
in cassettes containing OCT compound (VWR International) and snap frozen. Alternatively 
tissue was stored in Bouins fixative for 24 h, transferred to 70% ethanol and embedded in 
paraffin wax. In addition, the omental fat was removed and weighed. Blood was decanted 
into a heparinised test-tube for hormonal/metabolite measurements or S-Monovettes 
containing sodium fluoride combined with anti-coagul nt (Sarstedt Ltd, Nümbrecht, 
Germany) for glucose measurement. Tubes were centrifuged at 3000 rpm for 15 min at 4°C 
and the plasma collected and stored at -20°C. 
 
9.2.2 Measurement of glucose and insulin 
 
Glucose concentrations were measured with a colourimet ic glucose assay kit (Alpha 
Laboratories Ltd., Eastleigh, UK), using a Cobas Fara centrifugal analyser (Roche 
Diagnostics Ltd.). Glucose is oxidised by glucose oxidase into gluconic acid and hydrogen 
peroxide, which, in the presence of peroxidase reacts with 4-aminoantipyrine and 
hydroxybenzoic acid, forming a red compound. Colour intensity monitored at 500nm is 
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proportional to the concentration of glucose in the sample. Assay sensitivity was 0.2mmol/l 
and intra- and inter-assay CVs were <2% and <3%, respectively. Insulin was measured using 
an ovine insulin ELISA kit (80-INSOV-E01, ALPCO Diagnostics, Salem, NH, USA) as per 
the manufacturer’s instructions. Absorbance was measur d colourimetrically on a 
ThermoMax Microplate Reader (Molecular Devices, CA, USA) at 450nm with a reference 
wavelength of 650nm. A standard curve comprising a cubic spline fit was generated and 
insulin concentrations calculated using SoftMax Prosoftware (Molecular Devices). Assay 
sensitivity was 5.0pg/ml and intra- and inter-assay CVs were <5% and <6%, respectively7. 
 
9.2.3 Measurement of other plasma analytes 
 
To measure the concentration of cholesterol, free fatty acids (FFA), triglycerides, ALT, AST, 
ALP and GGT, commercial assay kits were employed (Alpha Laboratories Ltd., Eastleigh, 
UK) as per the manufacturer’s protocols, using a Cobas Fara centrifugal analyser (Roche 
Diagnostics Ltd.) to obtain analyte concentration. Assay sensitivities for cholesterol, FFA, 
triglycerides, ALT, AST, ALP and GGT were 0.1mmol/l, 0.05mmol/l, 0.02mmol/l, 4U/l, 
6U/l, 20U/l and 5U/l, respectively, and the overall CVs were all <3%8. Serum leptin 
concentrations were obtained using a Multi-Species Leptin RIA kit with an antibody against 
human leptin (XL-85K, Millipore, Missouri, USA). Specific leptin RIA details are listed in 
Appendix A. Assay sensitivity was 1ng/ml and intra- and inter-assay CVs were <4% and 
<7%, respectively. 
 
9.2.4 Oil Red O Lipid Staining and Analysis 
 
Frozen 5µm sections from OCT embedded liver samples w re cut (Leica Cryostat 
Microtome 1900, Leica Biosystems Nussloch GmbH, Heidelberger, Germany) at -20°C, 
mounted onto glass slides and air-dried. Tissue was fixed in 10% formalin for 10 min, rinsed 
in dH20 and air-dried before a further rinse in 60% isopropanol. Sections were stained with 
Oil Red O dissolved in 60% isopropanol for 15 min at room temperature and rinsed in 60% 
                                                
7 The measurement of plasma glucose and insulin was carried out by Charlotte Wood, under 
supervision by KH 
8 The measurement of plasma analytes was performed by Dr Forbes Howie. 
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isopropanol followed by washing in dH20. Tissue was counterstained in haematoxylin, 
washed thoroughly in dH20 and mounted in Aqua-Mount media (Fisher Scientific Ltd.). 
Unsaturated hydrophobic lipids were identified microscopically by the presence of a red 
stain and was subsequently quantified blindly by two independent investigators by 
classification into negative (-), possible early (-/+) and positive (+) fatty liver categories by 
comparison to pre-agreed reference sections. 
 
9.2.5 Quantitative real time -PCR 
 
The extraction of mRNA from tissues containing a high blood, lipid or fibre content 
necessitates the use of the TRI-reagent method instead of the on-column method as column 
blockage would result in low a RNA yield. Adult liver was extracted using the TRI-reagent 
protocol. This method combines the lysis and purification of samples with guanidine-
thiocyanate and that of phenol and chloroform to achieve RNA, DNA and protein isolation. 
RNA was extracted from a representative ~50mg frozen liver sample. Tissue was 
homogenised in 1ml TRI-reagent using a Qiagen TissueLyser (Qiagen Ltd.), rested for 5 min 
and phase separated with the addition of 0.2ml chloroform and vigorous shaking for 15 sec. 
Samples were incubated for 5 min at room temperature and centrifuged at 12,000 g at 4°C 
for 20 min. The upper aqueous phase containing RNA was collected, mixed with 0.5ml 
isopropanol, and incubated for 10 min at room temperature. Samples were centrifuged at 
12,000 g at 4°C for 15 min and the RNA pellet washed in 1ml 75% ethanol prior to 
centrifugation at 7,500 g and 4°C for a further 10 min. The pellet was subsequently air-dried 
before elution in 50µl nuclease-free water and stored at -80°C. Measurement of RNA 
concentration, cDNA synthesis and qRT-PCR were performed in adult liver as described in 
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Table 9.2  Liver gene analysis using SYBR
 
Green qRT-PCR. Gene names and accession 




A portion of liver was processed for histology using the standard method (Section 2.4.1), and 
immunohistochemistry (Section 2.4.3.1) was carried out using antibodies to AR and PEPCK. 
For negative controls an AR-specific blocking peptide was available and for PEPCK 
immunostaining negative controls consisted of omission of the primary antibody and 
substitution with non-specific IgGs. Antibody details and optimised working concentrations 
are listed in Table 9.3. 
 




Polyclonal Rabbit (N20; sc-816) Santa Cruz 
Biotechnology Inc., Santa Cruz, USA 
1:100 GARB 
PEPCK 
Polyclonal Rabbit (H300, sc-32879) Santa Cruz 
Biotechnology Inc. 
1:100 GARB 
Table 9.3  List of antibodies used for immunohistochemistry in the adult liver.  The antibody 
suppliers, working concentrations and appropriate secondary antibodies are detailed.  
 
Gene        
(Accession No.) 




AR   
(XM_001253942) 
GCCCATCTTTCTGAATGTCC CAAACACCATAAGCCCCATC 233 
ERα                          
(NM_001001443) 
GAATCTGCCAAGGAGACTCG CCTGACAGCTCTTCCTCCTG 187 
GR  
(NM_001114186) 
AAGTCATTGAACCCGAGGTG ATGCCATGAGGAACATCCAT 207 
IGF1 
(NM_001009774) 
CATCCTCCTCGCATCTCTTC CTCCAGCCTCCTCAGATCAC 239 
IGF1R 
(XM_002696504) 
CCAAAACCGAAGCTGAGAAG TCCGGGTCTGTGATGTTGTA 199 
IGFBP1 
(NM_001145177) 
TCCCCAGAGAGCTCAGAGAT CTGCTCCCTGGCTAATCTGT 207 
PEPCK 
(NM_174737) 
AAAGAGATACGGTGCCCATC ATGCCAATCTTGGACAGAGG 178 
GAPDH 
(NM_001034034) 
GGCGTGAACCACGAGAAGTATAA AAGCAGGGATGATGTTCTGG 229 
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To confirm that the staining for PEPCK in the liver was specific a Western blot was 
performed (Section 2.7) using adult control liver homogenates. A single band for PEPCK 
was visualised at 62kDa (Fig. 9.1). 
 
 
Figure 9.1  Validation of PEPCK immunohistochemical staining specificity by Western blot.  
In each lane 20µg of protein was loaded. Primary antibodies applied were β-actin as an 
internal control (1:40,000; AC-15 mouse monoclonal, A5441, Sigma-Aldrich) or PEPCK 
(1:6000; H-300 rabbit polyclonal, sc-32879, Santa Cruz Biotechnology Inc.). 
 
 
9.2.7 Statistical analyses 
 
An unpaired Student’s t-test or a Mann Whitney non-parametric test was applied when group 
variances were not equal or the data were not normally distributed, to compare the means of 
two groups including analyte and hormonal assessment and gene expression analysis. Values 
are presented as mean ± sem. A chi-squared test was employed when analysing differences 
between the proportions of animals classified into liver phenotype groups and values are 
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9.3.1 Maternal prenatal androgenisation is associated with subclinical 
fatty liver in adults that is not related to central obesity 
 
To determine whether prenatal androgenisation is associated with the development of fatty 
liver in young adult sheep, liver tissue was examined for signs of lipid accumulation and 
plasma was analysed for clinical features of liver damage. An Oil red O histological lipid 
stain was performed on frozen liver sections and staining was classified into negative (-), 
possible early (+/-), or positive (+) for fatty liver (Fig. 9.2.A), as determined by the presence 
of red lipid globules. Androgenisation of female fetuses by maternal TP treatment from d62-
102 of gestation resulted in the presence of fatty liver in offspring at 11 months of age 
(P<0.05; Fig. 9.2.B). These early signs of liver damage were not however detectable at a 
clinical level as there was no change in serum determinants of liver function including 
circulating AST (Fig. 9.2.C), GGT (Fig. 9.2.D), ALT or ALP (Appendix C) concentrations. 
While fat accumulation was present in the liver, prenatal testosterone exposure did not lead 
to central obesity (omental fat; Fig. 9.2.E) in adult sheep. These findings were consistent 
with the lack of change in circulating leptin concetrations (Fig. 9.2.F). Other metabolic 
parameters including plasma FFA, triglycerides (Appendix C) and cholesterol (Fig. 9.2.G) 
were not altered. 
 
9.3.2 Insulin homeostasis in maternally treated adult offspring 
 
The presence of fatty liver without central obesity in adults from androgenised mothers 
indicates early metabolic disruption that might be further manifested systemically. Glucose 
tolerance tests were carried out just prior to sacrifice to determine pancreatic response to 
glucose. Following bolus glucose administration, initial glucose dynamics between control 
and TP-exposed animals were not altered (Fig. 9.2.H), however the insulin response to 
glucose stimulation was significantly greater in the treatment group (P<0.05; Fig. 9.2.I), 
suggesting a perturbed pancreatic response. Additionally, basal circulating insulin levels 
were ~3-fold higher in adults maternally exposed to TP (Fig. 9.2.I), though this did not reach 
statistical significance (P=0.071). 
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Figure 9.2  The effect of maternal prenatal androgenisation on adult liver lipid content and 
other metabolic parameters. A) representative Oil red O histological stains for lipids in 
ovine adult liver sections illustrating negative (-), possible early (+/-) or positive (+) fatty 
liver (scale bars = 50µm) and B) analysis of fatty liver in C and TP cohorts. Effect of maternal 
prenatal TP treatment on liver analytes including AST (C) and GGT (D), weight of omental 
fat (E), plasma leptin (F) and cholesterol levels (G). Plasma glucose (H) and insulin (I) 
concentrations at basal levels and 15 min after i.v. glucose bolus. * P<0.05. 
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9.3.3 Alterations in the expression of hepatic steroid receptors  
 
As subclinical fatty liver and insulin resistance can be associated with increased androgens, 
the responsiveness of the adult liver to androgens, in the absence of increased circulating 
testosterone concentrations (Chapter 6), was examined. AR protein was found to be 
expressed in the nuclei, and more weakly in the cytoplasm, of hepatocytes across the 
parenchymal region (Fig. 9.3.A), as well as in the nuclei of cells associated with portal veins 
(arrow; Fig. 9.3.A). Interestingly, while a strong nuclear stain was observed in many 
hepatocytes, a large proportion of cell nuclei were also negative for AR (arrow; Fig. 9.3.B). 
This pattern did not appear to be altered by prenatal androgens. QRT-PCR analysis revealed 
an up-regulation of AR in the livers of prenatally TP-exposed adult sheep (P<0.05; Fig. 
9.3.C), suggesting an increased receptivity to thissteroid. There was no difference in 
expression of genomic ERα (Fig. 9.3.D) but there was an increase in the hepatic expression 
of GR (P<0.05; Fig. 9.3.E). 
 
9.3.4 Functional changes in the adult liver  
 
To determine whether there were functional changes in the liver itself that may be associated 
with metabolic dysregulation the effect of prenatal androgens on hepatic gluconeogenesis 
was examined by assessing liver PEPCK expression. Immunolocalisation of PEPCK (Fig. 
9.4.A) revealed widespread protein expression through t parenchymal liver tissue with 
positive staining visualised within the cytoplasm and membrane of hepatocytes particularly 
in the peri-portal region. The liver capsule, comprising connective tissue, was negative for 
PEPCK (arrow; Fig. 9.4.A) as were the non-hepatocyte ells surrounding the hepatic portal 
vein (HPV and arrow; Fig. 9.4.B). However, there were no changes in adult hepatic PEPCK 
expression in maternally TP-treated animals (Fig. 9.4.C). There were transcriptional 
differences in the components of hepatic IGF system in prenatal TP-exposed adults, where 
IGF1 was up-regulated ~3-fold (P<0.01; Fig. 9.4.D) without any change inIGFBP1 
expression (Fig. 9.4.E). There was a non-significant trend for hepatic IGF1 receptor (IGF1R) 
to be increased after maternal TP-exposure (P=0.068l; Fig 9.4.F). 
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Figure 9.3  The effect of maternal prenatal androgenisation on adult liver steroid receptor 
expression. A) and B) Immunohistochemistry showing androgen receptor (AR) localisation 
in control adult ovine liver sections (A, scale bar = 100µm; arrow indicating staining in blood 
vessels and B, scale bar = 20µm; arrow indicating negatively stained hepatocyte nucleus).  
Inset in A) is negative control, scale bar = 50µm. QRT-PCR showing the effect of prenatal 
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Figure 9.4  The effect of maternal prenatal androgenisation on hepatic metabolic and 
signalling pathways. A-B) Immunohistochemistry for PEPCK (brown) in control adult liver 
sections. Scale bars in A and B are 100µm and 20µm, respectively. Inset in B is a negative 
control, scale bar = 50µm. QRT-PCR showing the effect of prenatal maternal 
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9.3.5 Fetal exposure to testosterone per se might not be responsible 
for the subclinical fatty liver change  
 
To assess the effects of prenatal androgenisation without the contribution of placental 
metabolism of TP, the metabolic and liver outcomes w re also investigated in adult offspring 
that were directly treated with TP in utero. Fetuses were directly exposed to TP or vehicle 
control by ultrasound-guided injection at d62 and d82 of gestation. There was no difference 
in the proportion of adult animals histologically categorised for fatty liver between TP 
treatment and control (Fig. 9.5.A). In fact, and unexpectedly, all animals showed signs of 
possible, or actual fatty liver (Fig. 9.5.A) and the prevalence of fatty liver was similar to 
maternal TP exposed animals rather than maternal control injection animals. Nevertheless, 
like the maternal treated cohorts, liver function determinants including serum AST (Fig. 
9.5.B), GGT (Fig. 9.5.C), ALT and ALP (Appendix C) were not altered by direct fetal 
androgenisation. In addition there were no differences in central obesity (omental fat; Fig. 
9.5.D), circulating leptin (Fig. 9.5.E), FFA, triglyceride (Appendix C) or cholesterol (Fig. 
9.5.F) concentrations. 
 
9.3.6 Insulin homeostasis in direct fetally treated adult offspring 
 
There were no significant differences between direct f tal control and TP animals when 
glucose (Fig. 9.5.G) and insulin (Fig. 9.5.H) levels were determined by GTT in adult 
animals. This suggests that fetal TP exposure does n t directly affect insulin homeostasis. 
However, like the changes in hepatic lipid content, the direct fetal intervention alone also 
affected insulin secretion in response to glucose lad. Although baseline glucose was similar 
in the fetal and maternal treatment groups, 15 min after a glucose bolus the serum glucose 
concentrations in the fetal treatment group were approximately double those of the maternal 
treatment group (Fig. 9.5.G and Fig 9.2.H; Maternal control vs. Fetal control P=0.064). In 
addition, the fetal control insulin concentrations after 15 min were midway between the 
maternal control and TP treatments (Fig. 9.5.H and Fig. 9.2.I). Like the fatty liver findings, 
this implies that the fetal injection per se has a metabolic phenotype that is not changed by 
the presence of testosterone and may effect glucose and insulin regulation.  
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Figure 9.5  The effect of direct fetal androgenisation on metabolic parameters in adult 
offspring. A) Classification of fatty liver in directly androgenised C and TP cohorts. The effect 
of fetal prenatal TP treatment on adult liver analytes, including AST (B) and GGT (C), the 
weight of omental fat (D), plasma leptin concentrations (E), and cholesterol levels (F). 
Plasma glucose (G) and insulin (H) concentrations at basal levels and 15 min after i.v. 
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9.3.7 Alterations in the expression of hepatic steroid receptors 
 
Unlike the maternal TP-treatment cohort, hepatic AR gene expression was not increased (Fig. 
9.6.A), in fact it showed a tendency to be reduced, although this did not reach statistical 
significance (P=0.085). In addition, in contrast to the maternal trea ment, direct fetal-TP 
treatment led to the up-regulation of ERα gene expression in adult livers (P<0.05; Fig. 
9.6.B). No change in hepatic GR mRNA expression was observed in these animals (Fig.
9.6.C).  
 
9.3.8 Functional changes in the adult liver  
 
Adult liver PEPCK mRNA expression was down-regulated following direct fetal TP 
exposure (P<0.05; Fig. 9.6.D), in contrast to findings in the androgenised maternal cohort. 
However the phenotypic effect of in utero injection was once more highlighted by a 
significant up-regulation of PEPCK mRNA levels in fetal control compared to maternal 
control (P<0.05). In contrast to maternal treatment, direct prenatal androgen exposure did not 
lead to significant alterations in the hepatic IGF system. There were no changes in IGF1 
(Fig. 9.6.E), IGFBP1 (Fig. 9.6.F) or IGF1R (Appendix C) gene expression. 
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Figure 9.6  The effect of direct fetal androgenisation on molecular liver function in adult 
offspring. QRT-PCR data showing the effect of direct prenatal fetal androgenisation on 
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This chapter focussed on the fetal programming effects of androgens on the adult liver, a key 
organ in regulating metabolic homeostasis, and alsothe physiological effect of prenatal 
treatments on insulin secretion and response to glucose load. Maternal prenatal 
androgenisation led to subclinical hepatic steatosis in young animals. Importantly this fatty 
liver was not a general reflection of central fat accumulation as it was not associated with an 
increase in omental fat. In addition, overall fat mass as assessed by body weight (Chapter 3) 
and plasma leptin concentrations were unchanged. Clinical y, liver damage was not 
discernable as standard liver function tests remained ormal. If these findings inform us 
about PCOS this suggests that liver abnormalities ar  evident at an early stage before any 
obesity or hyperandrogenism is manifest.  
 
While fatty liver has not been previously reported in studies of prenatal androgenisation, 
NAFLD is associated with PCOS. Women with PCOS have increased prevalence of fatty 
liver that is associated with elevated aminotransfera s, hyperandrogenaemia and central 
obesity (614-616, 618, 619). It is therefore plausible that early hepatic metabolic disturbance 
may in fact precede weight gain that would act to enhance liver damage and that subclinical 
fatty liver is a feature that worsens with obesity and hyperandrogenaemia. Interestingly, one 
study observed that a significant proportion of lean PCOS women also developed fatty liver 
(618) and another study failed to confirm significant central fat accumulation in obese 
women with PCOS (620). As these sheep showed evidence of pancreatic dysregulation it 
remains unclear whether there is a temporal relationship or association between the 
development of fatty liver and insulin resistance (621). 
 
Although the development of fatty liver in young adults may be programmed in the fetus, the 
causative role of prenatal androgens is not clear. Direct fetal exposure to TP also led to 
hepatic lipid accumulation; however, control animals so presented physical signs of fatty 
liver, indicating a phenotype arising solely from the fetal treatment intervention that could 
have a stress, inflammatory or metabolic origin. It is clear however that high concentrations 
of fetal androgens (Chapter 3) did not programme additional fatty liver changes. This finding 
implies that the changes observed in the maternal te ted cohort may not necessarily be 
attributed to the actions of androgens and confirms that not all of the features seen in 
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prenatal androgenisation animal models of PCOS are directly related to androgen exposure 
(335). 
 
Insulin resistance and hyperinsulinaemia are common features of PCOS that are augmented 
by the associated obesity, but are also intrinsic without the requirement for increased central 
fat or BMI (167, 168). In this regard, maternal TP-exposed young adult sheep exhibited 
increased basal serum insulin levels that although were not significantly altered, may 
indicate early signs of pancreatic β-cell hypersecretion, known to be a cause of 
hyperinsulinaemia in PCOS (167, 622). Moreover, insul  response to glucose load was 
significantly increased in maternally androgenised animals. Subsequent glucose clearance 
was not affected in these animals suggesting that wile early signs of insulin resistance may 
be present, these animals are not glucose intolerant. Although for technical reasons we were 
unable to conduct a euglycaemic clamp on these animals this finding further underlines 
intrinsic changes that occur before any alterations in body weight, fat distribution or 
circulating androgen concentrations (Chapter 6). 
 
Previous studies have shown that prenatal TP from d30-90 and/or d60-90 lead to reduced 
insulin sensitivity in 5 week (478) and 11 week (479) old lambs and that the critical 
developmental programming period for insulin signalli g is during d60-90 (479). 
Additionally, these studies reveal the parallel effects of prenatal TP and non-aromatisable 
DHT indicating an androgenic mode of programming (479). In this study however, basal 
insulin secretion as well as glucose clearance and insulin secretion following a GTT, were 
not affected by direct fetal TP treatment. The similarity of maternal TP and DHT effects in 
other studies, imply that fetal estrogen is not involved in the development of insulin 
resistance. However the lack of an effect by the dir ct fetal injection of TP, that massively 
increases fetal TP exposure (Chapter 3), questions he role of androgens. Of course it is 
possible that the changes that occur in response to the injection itself may mask or alter any 
further alterations induced by androgenic programming and therefore it is difficult to draw 
robust conclusions in this regard.  
 
The finding of altered adult liver tissue composition prompted the investigation of its role in 
metabolism and glucose homeostasis. Hepatic cytosolic PEPCK catalyses the conversion of 
oxaloacetate into phosphoenolpyruvate and is the rat -limiting step of gluconeogenesis 
(421). Gluconeogenesis is an essential hepatic process that maintains normal blood glucose 
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concentrations. PEPCK undergoes tight transcriptional control so that glucose production is 
appropriately managed and can be regulated by hormones, including insulin that has an 
inhibitory role and glucagon and glucocorticoids that stimulate its expression (422). It is 
therefore a prudent candidate molecule for dysregulation associated with the metabolic 
phenotype of prenatal androgenisation. 
 
Although fetal androgenisation through the maternal route was associated with insulin 
resistance, there was no effect on hepatic PEPCK expression in the adult ewe. However, 
direct in utero treatment led to differential changes in PEPCK gene expression with a 
significant up-regulation in fetal control compared to maternal control animals, but a down-
regulation in fetal TP compared to fetal control cohorts. In this instance the fetal injection 
phenotype was altered by direct exposure to androgens. In mice, the over-expression of 
PEPCK leads to a type II diabetic phenotype (623), which would be expected given the role 
of PEPCK in regulating glucose synthesis. However li r-specific knock-out of this gene did 
not, unexpectedly, affect blood glucose and remarkably did result in the development of fatty 
liver (624), suggesting a role in liver lipid metabolism distinct from gluconeogenesis. This 
has subsequently been explained by the hepatic role of PEPCK in cataplerosis, a metabolic 
pathway involving the removal of intermediary unoxidisable citric acid cycle anions from 
the Krebs cycle (625). Mice with a liver-specific deletion of cytosolic PEPCK developed 
fatty livers on postnatal day 1, thought to be due to the reduced ability of the liver to oxidize 
fatty acids resulting in an increase in triglycerid synthesis and hepatic fat accumulation 
(626). The role and regulation of liver PEPCK after fetal programming is complex and 
requires further work but it can be altered by fetal injection and modified by androgen 
exposure in the fetus.  
 
The effect of prenatal androgenisation on liver pathw ys involved in growth, development 
and metabolism were also examined. The expression of hepatic IGF1, IGFBP1 and IGFR1 
was studied in young adults. IGFBP1 sequesters IGF1 reducing bioavailability, thus 
controlling ligand-receptor binding potential (627). An increased IGF1:IGFBP1 ratio (628) 
and reduced IGFBP1 (629) in serum is associated with obesity, hyperinsulinaemia and 
insulin resistance in human studies. Reduced circulating IGFBP1 has also been linked to 
PCOS in women, although this is likely attributed to the metabolic, rather than reproductive, 
aspects of the syndrome (630, 631). In this study, hepatic IGF1 mRNA was significantly 
increased in indirectly androgenised offspring suggesting that alterations in the hepatic 
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expression of IGF1 may be involved in the phenotype associated with ovine prenatal 
androgenisation (380, 478, 479).  
 
There was no alteration in adult hepatic IGF1 gene expression after direct fetal injection of 
TP. This implies that androgens might not be involved directly in this programming and 
highlights that placental androgen metabolites, such as estrogen, may be involved. It is likely 
that steroids have a role in the modulation of liver IGF1 expression. The human IGF1 gene is 
known to contain androgen responsive elements in the upstream promoter region that bind 
AR and stimulate IGF1 transcription (632). Although circulating testosterone is not altered 
in these sheep, liver AR is increased after prenatal androgen exposure by maternal TP 
administration, suggesting that this organ is more responsive to androgens. Speculatively, the 
increase in IGF1 expression and up-regulation of AR in the maternal treated ovine liver may 
be associated. Unfortunately because of the recognised technical limitations of Western 
blotting for IGF1 or AR in ovine tissues it was not possible to convincingly and robustly 
analyse expression at the protein level.  
 
As alluded to, the up-regulation of liver AR in adult sheep seems to originate from the 
estrogenic fetal programming effects of TP since this effect does not occur after direct fetal 
TP exposure. Conversely, analysis of liver ERα gene expression revealed an up-regulation in 
directly, but not indirectly TP-exposed adults. Consequently, it is testosterone that may 
programme the expression of the liver estrogen receptor. It is not known what the 
significance of these changes in hepatic receptivity to these steroid hormones is, but 
illustrates intrinsic perturbations in liver function and signalling as a consequence of prenatal 
androgenisation. 
 
Exposure of an adult to increased glucocorticoid concentrations is associated with insulin 
resistance, hyperglycaemia and central obesity (633). Interestingly hepatic GR shows a small 
but significant up-regulation after maternal androgenisation of the fetus. This does not occur 
following direct exposure to androgens. Overall this implies that fetal steroids can 
permanently programme liver steroid reception. If this were the case our data suggest that the 
effects on hepatic AR and GR may be mediated by estrogen while androgens have a direct 
effect on the adult liver expression of ER, although these results must be treated with caution 
given the underlying liver phenotype present in the dir ct fetally treated animals. 
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For the first time, the occurrence of hepatic steatosis and early indications of liver damage in 
an ovine model of prenatal androgens is reported. These changes are independent of central 
obesity and may be the culmination of disturbances to hepatic metabolic homeostasis 
predisposed by exposure to in utero factors, including androgens, estrogens and/or physical 
stress. In addition indirect maternal TP exposure results in increased hepatic receptivity to 
androgens, in the absence of hyperandrogenaemia, and is also associated with the up-
regulation of liver GR and IGF1 mRNA expression as well as early indications of insulin 
resistance. Direct prenatal androgenisation leads to increased receptivity to estrogens. In 
addition, the changes observed in liver PEPCK transcription following direct prenatal 
vehicle or TP administration, may indicate altered liver glucose pathways that could be 
associated with the occurrence of fatty liver that arise through impairment of alternate 
hepatic metabolic pathways. These animals also appear to have metabolic disturbances 
relating to glucose clearance and insulin response.  
 
It is clear that the pathways involved in programming metabolic dysregulation in the adult 
are complex and not easily dissected, nevertheless th  early modifications to liver function 
present in these young adults may precede weight gain and hyperandrogenaemia that are 
common in women with PCOS. It seems that the hormonal r peripheral phenotype of the 
maternally androgenised ewe may not, in fact, be entirely normal in these young adults. It is 
therefore possible that the enhanced environmental factors such as insulin or IGF signalling 
may be linked to the effects of augmented androgen secretion by the ovary and the adrenal 
gland, however this is not known. Furthermore, it is clear that there is a fetal injection 
phenotype that mirrors some of the effects of matern l androgenisation, in the absence of 
androgens. The findings from these studies, how they add to the literature, and how they can 
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The clinical features of PCOS have been recognised in women for many years (161), and 
have become more defined over recent times as medicin  searches for the answers to the 
aetiology and the appropriate lines of therapy (163). Ovulatory dysfunction is common in the 
modern woman and this is confounded by environmental factors such as lifestyle. The high 
prevalence of obesity in women with PCOS only acts to worsen the overall milieu of 
hormonal, ovarian and metabolic disturbances (163). In addition, the high levels of 
circulating androgens, which promote the accumulation of fat in a male-like central 
distribution, also have superficial manifestations i cluding severe acne and hirsutism. These 
features, in combination with reproductive elements, are particularly distressing and are 
known to lead to lowered self-esteem, anxiety and depression in some women (634, 635) and 
therefore have a major social impact on their quality of life.   
 
Medical and scientific observations have unravelled many of the pathways that are 
associated with PCOS demonstrating the multifactorial and complex nature of the disorder, 
yet the underlying cause(s) remain unknown. Within the last twenty years standard 
guidelines have been set down to provide clinicians with a framework to diagnose PCOS 
(173, 174), however, even with these in hand it is clear that PCOS is not a clear-cut disorder 
and there are many diversities of this syndrome in women. While there have been numerous 
candidate genes for linkage to PCOS (225), none have been robustly and reproducibly 
correlated to all of the main features of PCOS and genetic influences remain unsolved. The 
most promising research into PCOS has involved the modelling of a PCOS-like phenotype in 
non-human primates, rodents and sheep that indicate an early programmable developmental 
origin of this disorder (304). Such models are established through the fetal programming 
effects of steroid hormones that are likely to induce epigenetic modifications to the genome. 
 
10.1 The ovine model of mid-gestation prenatal androgenisation 
 
The exposure of an ovine fetus to increased concentrations of androgens during development 
leads to multiple reproductive, neuroendocrine and metabolic aberrancies that are 
reminiscent of PCOS in women. The timing of prenatal exposure does however appear to be 
key to the development and severity of some of these traits. Those female animals that are 
exposed from early to mid-gestation (d30-90), spanning the period of sexual differentiation 
of the reproductive tract and brain, develop the most severe reproductive and endocrine 
effects (352, 372-374, 378, 379). Furthermore, femal  offspring are born with ambiguous 
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genitalia, possessing empty scrotal sacs and a penis y t retaining ovarian development (370, 
373, 495). In the later model of prenatal androgenisation, which spans mid-gestation in the 
sheep (d60-90), the reproductive/endocrine effects appear to be less severe (299); however, 
certain metabolic effects of prenatal androgens are still prominent (479). The crucial 
difference between this early and late model of prenatal androgenisation in the sheep is the 
absence of external masculinisation in the later exposed female, born without male-features 
and possessing normal AGDs (Chapter 3) (370). The lack of virilisation in this model makes 
it more relevant to the normal anatomical arrangement of the genital tract present in women 
with PCOS. 
 
The major reprogramming of the brain that is present in the ovine d30-90 androgenisation 
model makes it difficult to dissect out subtle changes that contribute to an overall phenotype, 
with those of the prominent masculinisation effects that perturb adult reproductive function 
in the female. In these animals there is severe hormonal imbalance and endocrine function is 
disturbed (352, 379, 380), and while these are featur s of PCOS they have not necessarily 
arisen in the same manner. The assessment of mid-gestation prenatal androgen exposure, 
from d62-102, in this thesis, revealed that in young adult female offspring, circulating sex 
steroids and gonadotrophin dynamics were normal, ovrian cyclicity was not altered between 
control and treatment groups and PCO was not present in TP-exposed ewes during the first 
breeding season (Fig. 10.1). Abnormal vaginal development, as well as a male urinating 
posture, as biomarkers of testosterone/estrogen activity during development, does however 
clearly demonstrate the occurrence of prenatal exposure to sex steroids in these offspring.  
 
The mid-gestation exposure of an ovine fetus to increased androgens generates a model that 
does not fulfil the major diagnostic criteria for PCOS in young animals, and therefore the 
animals studied here do not yet have experimentally-induced PCOS. This provides a unique 
opportunity to study the effects of prenatal androgens without the influence of confounding 
factors such as hyperandrogenaemia, LH hypersecretion and polyfollicular ovaries, with the 
possible exception of slightly raised peripheral insulin concentrations. A thorough 
assessment of ovarian follicular, adrenal and liver function as well as glucose/insulin 
homeostasis revealed that changes are apparent as a con equence of prenatal androgenisation 













   
  
   
  
  
   
  
   
  







   
  
   
  
  
   
  
   
  
  
   
  
   
  




   
 
  
   
  
   
  
  
   
  
















   
  
   
  
  
   
  
   
  
  
   
  
   
  
  
   





   
  
   
  
  
   
  
   
  
  
   
  
   
  
  
   








































































Figure 10.1  Summary of the 
main findings in animals that 
were indirectly maternally 
androgenised in utero. The 
effects of mid-gestation 
maternal TP treatment are 
compared with control 
animals. Exposure to TP 
resulted in certain fetal and 
adult physiological aspects 
which were normal and 
others that were abnormal.  
C: control, E2: estradiol,          
T: testosterone,                      
A4: androstenedione. 
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In PCOS, hyperandrogenaemia arises through excessive androgen production by both the 
ovary (344) and the adrenal gland (414). In the mid-gestation ovine model of prenatal 
androgenisation, it has been demonstrated for the first time that there is programming of a 
follicular phenotype that is independent of androgen and gonadotrophin signalling in the 
adult. The thecal cells from such animals have an uneq ivocal pre-disposition to secrete 
increased concentrations of the androgen, androstenedione, and do so with and without 
exogenous stimulation with LH. This drive for enhanced steroidogenesis is identified at a 
molecular level in which there is a global up-regulation of genes that are crucial components 
of the steroidogenic pathway, including StAR, CYP11A, HSD3B1 and CYP17. In addition, 
there is up-regulation of thecal cell LHR, which renders the thecal cell more responsive to 
the steroidogenic effects of LH and a concomitant increase in pituitary LHB subunit 
expression, although this does not reflect changes in peripheral LH concentrations at this 
stage. These novel data from an animal study of PCOS are in line with observations in thecal 
cells that are collected from the ovaries of women with PCOS, in which the findings are 
remarkably similar. The women in these studies are however hyperandrogenic, have 
distorted gonadotrophin profiles and PCO, making it difficult to determine the primary 
effects of PCOS on the ovary, from the secondary effects of hormonal imbalance. The 
studies outlined in this thesis provide evidence for an intrinsic programming event in ovarian 
cells, which could include the pre-thecal cells that are present in the developing ovary. 
 
In fact, study of the ovine fetal ovary after ~10 and ~30 days of androgen exposure does 
indicate direct programming effects on this tissue during this time. Perturbations to the 
steroidogenic biosynthesis capacity with a general down-regulation of many of the genes 
involved in this pathway were observed. It is not known in which cell type(s) these changes 
occur, how this might affect the fetal ovary and whether the local production of steroid 
hormones is negatively affected by the large periphral levels of exogenous testosterone and 
a subsequent increase in estradiol, during this time. The alterations in gene expression may 
be important and lead to altered autocrine or paracrine signalling between somatic cells that 
programme permanent functional changes. In addition, it was demonstrated for the first time 
that the Ids are expressed, and may have important functional roles, in the fetal ovine ovary. 
Furthermore, differential expression of the Ids in the TP-exposed ovary compared to controls 
was observed, with the up-regulation of Id1 protein in the androgenised cohort. This may 
indicate the presence of complex pathways that could also contribute to the setting down of 
an adult ovarian phenotype. It is also possible that ere is some involvement of the 
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gonadotrophins in the development of the female gonad as both LHR and FSHR are 
expressed in the mid-gestation ovary and it was found that pituitary secretion of both LH and 
FSH were dampened in these fetuses. 
 
In the adrenal gland of prenatally androgenised adults, there was enhanced production of 
testosterone, after stimulation with ACTH, implying that the adrenal gland is also 
predisposed to excessively secrete androgens under certain circumstances. In women with 
PCOS, hyperandrogenism occurs in part through enhanced stimulation of adrenal androgen 
secretion, including DHEA/S and androstenedione (408, 414) and this has also been 
demonstrated in the Rhesus monkey prenatal androgenisatio  model (415).  Secretion of one 
adrenal androgen, androstenedione, was not altered in our sheep model, which might explain 
why there was no detectable alteration in peripheral l vels of this hormone in the young adult 
ewe. Cortisol secretion was also unaffected by prenatal treatment, implying shunting of 
hormone biosynthesis towards the testosterone pathway. Indeed, molecular analysis of the 
adult adrenal gland revealed that steroidogenic gene xpression was up-regulated, 
resembling the findings in the ovarian thecal cell. These changes were also independent of 
alterations in pituitary POMC expression, implying that these are also intrinsically 
programmed changes that are not influenced by other factors, such as endogenous ACTH. 
The ACTH receptor was not measured in the adrenal however, and would be useful to study 
to determine whether increased stimulation by ACTH could occur at the adrenal level. In the 
fetus, prenatal androgenisation for ~30 days resultd in the up-regulation of both CYP11A 
and HSD3B1 in the d90 adrenal and therefore the adult phenotype may be linked to 
programming effects of androgens or estrogens during development. 
 
In addition to the intrinsic effects of mid-gestation androgenisation on the endocrine glands 
of adults, there were also metabolic features present in these young animals. Basal insulin 
concentrations were slightly, but not-significantly raised in the TP-exposed cohort and when 
these animals received bolus glucose, insulin levels w re significantly enhanced compared to 
controls. At the same time, glucose clearance was un ffected, implying that while there may 
be early signs of a hyperinsulinaemic response to glucose, peripheral glucose uptake is 
normal. It is therefore likely that these animals are exhibiting early signs of pancreatic β-cell 
dysfunction, an area that is ripe for future study. Abnormalities of pancreatic insulin 
secretion are proposed to occur in women with PCOS, leading to hyperinsulinaemia, 
independent of obesity (167, 168). Augmentation of this phenotype occurs through weight 
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gain and can culminate in insulin resistance (168, 452). In our sheep model, it is likely that 
this phenotype will develop further as the animal mtures, as the ewes in this study were 
very young and metabolic dysfunction is not a marked f ature at this stage of ongoing 
development. These sheep were reared on a normal caloric diet and therefore were not likely 
to gain weight inappropriately. Indeed, over-feeding sheep that have been prenatally 
androgenised from d30-90 considerably exacerbates th  reproductive (482) as well as the 
metabolic aspects (479) of the PCOS-like phenotype, wh n compared to over-fed and normal 
weight controls. This is therefore another example of changes that may be inherently present 
but surface fully when hypercaloric environmental conditions are present. 
 
In the d62-102 prenatal androgenisation model, sheep were not fat and they were not at this 
stage glucose intolerant. Nevertheless, examination of other metabolic tissues, such as the 
liver, did reveal stark physiological perturbations that could affect tissue function. There 
were early signs of fatty liver in the livers of TP-exposed adult ewes, an observation that has 
not yet been made in other animal models of prenatal androgenisation. This is relevant in 
that NAFLD is associated with insulin resistance and hyperandrogenaemia (613, 614) and is 
prevalent in women with PCOS (611, 614-616). Furthermore, the hepatic expression of IGF1 
was increased, which could impact on ovarian steroidogenesis (434), particularly as thecal 
cell IGF1R was concomitantly up-regulated. The fact that this phenotype was present 
without the accumulation of central fat or hyperandrogenaemia further demonstrates an 
independent modification of a physiological system that may reflect early overall aspects of 
a multifactorial disorder.  
 
A hypothetical model of how mid-gestation prenatal androgenisation might affect different 
physiological systems in the adult ewe, with the ovary at the centre, is presented in Figure 
10.2. It illustrates the establishment of a pre-PCOS model, in which there are a multitude of 
inherent tissue-specific changes that are present in the young adult ewe. In the ovary and 
adrenal at least, there are functional changes during development that occur through the 
direct actions of testosterone and/or estrogen. The propensity for androgen secretion by both 
the ovary and adrenal gland are increased and imply that the cellular machinery to promote 
this is in place before clinical manifestations arep sent. In addition, possible enhancement 
of insulin and/or IGF1 signalling may also directly act on the ovary, in an additive way to 
either affect ovarian steroidogenesis and/or follicular growth. Furthermore, there may be an 
effect of prenatal androgens on pituitary synthesis of LH that in the circumstances of 
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perturbed steroid or GnRH signalling, could contribute to the LH hyper-secretion or 
increased pulse amplitude that is observed in women with PCOS (164, 165) and animal 
models of PCOS (351, 352). It is possible that assessing the animals at this particular age (11 
months) has allowed for the capture of these early changes that represent underlying 
mechanisms that are involved in the aetiology of PCOS-like characteristics that will develop 
further in this subtle mid-gestation model of prenatal ndrogenisation. For example, if the 
ovarian and adrenal defect were to develop further and result in increased peripheral 
concentrations of androgens, then it is likely that a hyperandrogenic state would act to 
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Figure 10.2  A pre-PCOS model is present in young adult sheep following mid-gestation 
prenatal androgenisation. Tissue-specific intrinsic gene expression and hormonal changes, 
and hepatic fat accumulation, are present in the maternally androgenised adult ewe, 
independently of severe ovarian, metabolic and endocrine features of PCOS. The dotted 
lines represent possible enhancement of signalling pathways. In the presence 
hyperandrogenaemia, increased androgens could negatively impact on the overall 





Chapter 10                                                                                                        General Discussion  
                                                                                                  
 279 
10.2 The direct model of prenatal androgenisation 
 
The direct delivery of TP to the ovine fetus was undertaken for 3 key reasons: 1) to bypass 
placental conversion of testosterone into estrogen m tabolites, 2) to avoid any confounding 
effects of androgens on the mother that might indirectly affect the fetus, and 3) to control the 
dose of androgens to which each fetus is exposed. Hormonal analysis of fetal blood at the 
time of sacrifice confirmed that there were no increases in peripheral estradiol concentrations 
in TP treated fetuses, as were reported later in the maternally TP exposed cohort. A major 
inference from these studies was the remarkable resistance that the developing female fetus 
showed to frankly supraphysiological testosterone concentrations. Like the maternal cohort, 
these animals were exposed to androgens after the timing of sexual differentiation and 
masculinisation that would occur in male fetuses. Very few of these female animals 
exhibited abnormal vaginal development in adulthood, implying that such programming 
effects are mediated by estrogens. Conversely, all TP-exposed animals from fetal and 
maternal treated cohorts, exhibited male-like urination postures, a clear androgenic 
programming effect of which the critical period occurs during mid-gestation.  
 
Like the maternally exposed cohort, directly androgenised adult ewes had not developed the 
definable features of PCOS that are described in women or animal studies, by 11 months of 
age (Fig. 10.3). The hormonal profile, ovarian cyclicity, LH secretion and pulsatility and 
ovarian morphology were not changed in comparison to controls or to the findings in the 
maternally exposed group. In parallel to the maternal cohort, direct prenatal androgenisation 
did exert some effect on ovarian androstenedione secretion and thecal cell steroidogenic 
gene expression. There were also direct effects of androgens on the developing ovary and 
adrenal gland. These changes could therefore be attributed to programming by either 
testosterone and/or estrogen. Unlike the maternal cohort, the fetal TP-exposed animals had 
possible dysregulation of hepatic gluconeogenesis due to down-regulated PEPCK 
expression. This differential finding might imply an ndrogenic mode of programming in the 
liver. Conversely, the up-regulation of IGF1 gene expression, exclusively in the livers of the 
maternal TP-exposed adult ewe, suggests direct estrog nic programming. However, accurate 
delineation of the differential effects of androgens and estrogens in this model is confounded 
by the presence of a third steroidal hormone that may be raised during these fetal treatments, 












   
  
   
  
  
   
  
   
  







   
  
   
  
  
   
  
   
  
  
   
  
   
  




   
 
  
   
  
   
  
  
   
  
















   
  
   
  
  
   
  
   
  
  
   
  
   
  
  
   





   
  
   
  
  
   
  
   
  
  
   
  
   
  
  
   





































































    
Figure 10.3  Summary of the 
main findings in animals that 
were directly fetally 
androgenised in utero. The 
effects of mid-gestation TP 
delivered directly to the fetus 
are compared with fetal 
vehicle control injections. 
Exposure to TP resulted in 
certain fetal and adult 
physiological aspects which 
were normal and others that 
were abnormal.  C: control, 
E2: estradiol,                                             
T: testosterone,                     
A4: androstenedione. 
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10.3 A non-androgenised model of PCOS 
 
The comparison of circulating fetal cortisol levels at d70, between control and treated 
cohorts in the fetal injection group, did not reveal any differences (Fig. 10.3). However, 
comparison of the fetal injection control cohort with the maternal treated control group 
revealed that there was a trend for increased cortisol in the fetally treated groups (Fig. 10.4). 
As this measurement was carried out 10 days post treatment it is possible that initial 
activation of either the fetal and/or maternal HPA axis at this time, responsible for elevated 
peripheral cortisol concentrations, is dampened by 70. Nonetheless, this finding highlights 
an additional variable that is present in the fetal injection cohort and could confound the 
conclusions reached concerning androgenic and estrog nic programming effects. 
 
Numerous features of the mid-gestation ovine maternl a drogenisation model were also 
observed in the fetal injection control and TP cohorts, and were significantly altered 
compared to the maternal control animals (Fig. 10.4). One of the most considerable effects of 
the fetal injection paradigm was the excessive biosynthesis of androstenedione by the 
ovarian thecal cell, in which secretion was enhanced compared to both maternal control and 
TP animals in vivo and in vitro. In addition, the thecal cell expression of StAR and CYP17 
was up-regulated in this cohort pointing to perturbed intrinsic steroidogenic activity that, like 
the maternally androgenised cohort, is not influenced by alterations in the peripheral 
hormonal environment. The fetal injection model of steroid delivery also resulted in the 
development of a metabolic phenotype. All of the contr l (and TP) animals in the fetal 
injection cohort presented signs of possible or positive fatty liver. Furthermore, while direct 
fetal testosterone did not programme enhanced glucose-stimulated insulin secretion, 
comparison of fetal control and TP cohorts with maternal control and TP cohorts, revealed 
that in fetally injected cohorts, insulin secretion post glucose was in fact mid-way between 












   
  
   
  
  
   
  
   
  







   
  
   
  
  
   
  
   
  
  
   
  
   
  




   
 
  
   
  
   
  
  
   
  
















   
  
   
  
  
   
  
   
  
  
   
  
   
  
  
   





   
  
   
  
  
   
  
   
  
  
   
  
   
  
  
   













































































Figure 10.4  Summary of the 
phenotypic aspects of the 
fetal injection model in 
control animals. The effects of 
mid-gestation TP delivered 
directly to the fetus are 
compared with fetal vehicle 
control injections. Exposure to 
TP resulted in certain fetal and 
adult physiological aspects 
which were normal and others 
that were abnormal.                 
C: control, E2: estradiol,                
T: testosterone,                      
A4: androstenedione. 
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The fact that these changes are generally present in both fetal control and TP cohorts 
presents a major caveat to this method of delineation of androgenic from estrogenic actions. 
It is not possible to robustly conclude whether it is the effects of glucocorticoids or 
androgens during mid-gestation might be responsible for these programming outcomes. In 
some cases it appears that the effects of fetal TP are additive to changes in the fetal control 
cohort, which might include in vivo thecal cell androstenedione production, suggesting that 
different pathways could programme an analogous adult ovarian phenotype. Conversely, 
differential hepatic gene expression of the gluconeogenic enzyme, PEPCK, in the fetal 
control and TP cohorts could point to separate programming effects of steroid hormones on 
liver glucose metabolism.   
 
10.3.1 Potential sources of elevated fetal cortisol 
 
Given the known role of glucocorticoid programming of fetal growth (286) and the 
development of obesity and related metabolic disorders in adult life (277, 278), cortisol is a 
promising candidate for the programming of some of the metabolic, and also ovarian, traits 
that are observed in the mid-gestation direct fetal injection cohort. Further evidence to 
support this is the elevated concentration of cortis l present in fetal blood ten days post-
injection. It is possible that the physical injection to the fetal flank triggers a stress response 
and activation of the fetal HPA axis leading to increased biosynthesis and secretion of 
cortisol. This could involve an immunological reaction to piercing fetal tissue that triggers 
wound repair or a reaction to the vehicle carrier, in this case vegetable oil. 
 
It is also feasible that the increase in fetal cortis l is a result of enhanced activation of the 
maternal HPA axis and glucocorticoids pass from the maternal circulation to the fetus via the 
placenta. Measurement of cortisol in maternal blood, sampled at d90, demonstrated that there 
was significantly more circulating cortisol in mothers that were subjected to anaesthesia and 
fetal injections, twice, twenty days apart (C; P<0.05, TP; P<0.01), compared to mothers that 
received an intramuscular treatment (Fig. 10.5.A). lthough fetal injection cohorts were 
assessed at d70 and not d90, the findings that maternal cortisol is increased by d90, 
following two injections, provide a mechanism for increased fetal cortisol that may well be 
measurable in the d90 fetus. 
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Figure 10.5  Cortisol measurements and adrenal function in pregnant ewes during the 
prenatal treatment period. Serum collected from pregnant mothers studied in this thesis at 
d90 was assayed for cortisol by RIA (A). MI: maternal injection; d62-102 C = 5, TP = 9, FI: 
fetal injection; d62/82 C = 4, TP = 7. A synacthen test was performed in pregnant ewes at 
d90 in a separate cohort of sheep, in which the treatments differed from those studied in 
this thesis, and cortisol measured in serum by RIA. Maternal TP treatments from d30-90 of 
gestation (n = 12) were compared with fetal injection treatments (n = 12) that included 
control, dexamethasone (synthetic glucocorticoid), diethylstilbestrol (synthetic estrogen), 
dehydrotestosterone (non-aromatisable androgen). Data are presented as mean ± sem and 
t-tests were applied between groups as indicated by bars in A) and at each time point in B).   
* P<0.05, ** P<0.01, *** P<0.001. 
 
 
To test whether the increased maternal cortisol could be a result of exaggerated activation of 
the maternal HPA axis, a synacthen test was subsequently performed on a different set of 
experimental animals that were undergoing gestationl treatments and are not included in 
this thesis. Pregnant ewes were assessed at d90. Maternal controls were not available to test, 
and fetal injections were performed at d62 and 82 and consisted of varying treatments (Fig. 
10.5 legend). Nevertheless, the findings were remarkable. Similar to the observations in the 
cohorts described in this thesis, basal cortisol concentrations were elevated in the fetal 
injection group compared to the maternal treatment cohort (P<0.01), and considerably higher 
15 min (P<0.001) and 30 min (P<0.001) after adrenal stimulation with ACTH (Fig. 10.5.B). 
It is not likely that maternal androgens lower cortisol output given that TP does not affect 
cortisol secretion compared to controls in the d62-10  treated cohort (Fig. 10.5.A). Fetal TP 
also had no effect on circulating fetal cortisol (Fig. 10.5.A) and it does not appear that the 
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varied treatments analysed in the fetal cohort in Figure 10.5.B affect cortisol secretion either 
since the controls animals within that group exhibited the same enhancement of cortisol 
secretion as observed in the other treatments. 
 
These data are therefore good evidence that maternal cortisol concentrations are significantly 
raised as a consequence of the direct fetal method of treatment delivery. In addition, it is 
possible that the placental transfer of this steroid t  the fetus is also enhanced in the fetally 
injected cohort. The placental expression of HSD11B1, which encodes 11βHSD1, was up-
regulated in the fetal compared to the maternal control cohorts (Chapter 3). Since 11βHSD1 
converts inactive forms of cortisol into active metabolites (424), this may allow greater 
amounts of cortisol to cross the placental barrier than normal. Unlike animal models of 
prenatal glucocorticoid exposure (286), birth weight was not affected in the fetally injected 
cohort, which might suggest that the endogenously raised cortisol concentrations were not in 
the region of exogenous cortisol concentrations administered to animals, and may have 
exerted more subtle effects. Nevertheless, the fetally injected offspring in this study did show 
possible signs of exaggerated insulin secretion in response to glucose, when compared to 
maternally treated control offspring. These animals also had fatty livers. Therefore there may 
be some indication of the presence of a metabolic phenotype that is associated with the 
prenatal exposure to increased cortisol, which would fit with previous research that finds 
adverse metabolic outcome in cases of maternal administration of glucocorticoids (277, 278, 
280).    
 
10.3.2 Implications of raised maternal cortisol and subsequent fetal 
phenotype 
 
In the sheep, it is clear that injecting the fetus and/or anaesthetising the mother, during mid-
gestation, results in an increase in circulating fetal and maternal cortisol. Whether or not this 
increase is causative, or merely associated, with the development of ovarian and metabolic 
anomalies in offspring is not known. These findings do however raise the point that any 
intervention to the mother or fetus during pregnancy, albeit small and uninvasive, may itself 
induce epigenetic programming that negatively impact on the fetus, without the 
administration of treatment. The findings generated from studies that involve fetal surgery 
and/or anaesthesia of the mother may therefore be confounded by the underlying effects of 
technical aspects of the experiment. Furthermore, these findings might have implications for 
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some routine procedures that are performed in pregnant women. It is not uncommon for 
pregnant women to receive amniocentesis mid-way through pregnancy, involving insertion 
of a needle through the womb and into the amniotic cavity. Chronic villus sampling is 
another method of fetal chromosomal diagnosis that is more invasive than amniocentesis as a 
biopsy of placenta is collected. Both procedures can involve the administration of a local 
anaesthetic, although this is not likely to have a major impact on maternal stress, rather the 
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10.4 Future work 
 
The studies outlined in this thesis examine the effcts of prenatal androgens immediately 
post-treatment in fetal life, and also in the young adult animals during the first breeding 
season. The changes in the adult ovary, adrenal gland and liver appear to be independent of 
the secondary effects of an abnormal endocrine enviro ment and therefore provide good 
evidence that prenatal androgens and/or estrogens directly programme intrinsic changes in a 
multitude of fetal tissues. These findings have gone some way to characterise the primary 
origins of an adult disorder that may develop into a more clinically recognisable syndrome 
such as PCOS. To assess the potential contribution to the overall phenotype that might occur 
if the syndrome developed further there are a number of areas that would be pertinent to 
examine in this maternal model of androgenisation in particular. 
 
1) Do the recognised features of PCOS arise in mid-gestation maternally androgenised 
offspring by the second or even third breeding season? The mid-gestation model of 
androgenisation is, as discussed, a more subtle model f adult reproductive and 
metabolic dysfunction (299, 479) and therefore may not be apparent until the animal is 
more mature. In addition, while PCOS can be diagnosed in the adolescent (637), the 
features are often confounded by environmental enhancement of the phenotype, such as 
obesity (638-640). In the ovine model, without such additive input, it is possible that the 
animals are too healthy and lean at this age to exhibit many of the features of PCOS. 
 
2) With this in mind, it would be valuable to consider the effects of weight gain on the 
metabolic and reproductive features present in the 11 month maternally androgenised 
ewe. Studies that over-feed prenatally androgenised animals post-natally have 
successfully demonstrated worsening of the reproductive and metabolic phenotype (479, 
482), and it would therefore be of interest to study the effects of obesity on the specific 
findings presented in this study. 
 
3) In both non-obese and obese prenatally androgenised ew s, it would be useful to study 
whether more mature animals display hyperandrogenaemia, increased LH secretion 
and/or hyperinsulinaemia. At 11 months, lean animals h d the potential or predisposition 
to have raised basal peripheral concentrations of all three hormones, however this was 
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not yet realised. The main questions would be whether alterations to the hormonal 
environment are additive or alter some of the phenotypes described in this study, such as 
thecal cell, liver and adrenal function. It is realistic to hypothesise that it is the 
combination of all of these environmental factors with the intrinsic features studied in 
this project that will lead to the development of an animal that fulfils the diagnostic and 
anatomical features that are present in PCOS women. 
 
It is clear from the studies presented in this thesis, that the programming effects of prenatal 
androgens on the adverse outcomes in the adult, might not be an effect of androgens per se, 
and that there are multiple ways that this programming could occur. The effects of various 
physiological stressors during pregnancy are well documented to have deleterious effects in 
infants and adult progeny in both humans and animals (262, 274). These include over and 
undernutrition, dietary composition changes, emotional stress and the fetal/maternal 
exposure to toxins and steroid hormones (265, 278, 80 284, 286, 518, 520, 641-646). It is 
demonstrated in this thesis that the fetal injection method results in increased exposure of the 
mother, and potentially the fetus, to elevated levels of cortisol, and this is associated with an 
adult phenotype including reproductive and metabolic anomalies similar to the maternal 
model of prenatal androgenisation. It is therefore important to dissect out the underlying 
mechanisms that have led to this phenotype in the adult sheep and whether cortisol exposure 
can be directly linked to this. 
 
1) One of the major unknowns emerging from this study is whether it is the physical effect 
of injecting the fetus, or the impact of maternal anaesthesia that could influence maternal 
and/or fetal homeostasis to trigger a stress response. I deed, particularly high levels of 
cortisol are observed in the mothers that received this treatment. One way to investigate 
this would be to sedate the pregnant ewe twice during gestation at d62 and again at d82, 
without performing any fetal injections and assess the effect of this relatively 
unobtrusive intervention on maternal cortisol secretion, the immediate effect on fetal 
developmental parameters and the long-term effect in he adult offspring of these 
mothers.  
 
2) In order to dissect whether it is a fetal or maternal source of cortisol that confers these 
effects, a set of subtraction experiments could be performed. To determine if it is 
maternal cortisol that is associated with this phenotype, endogenous cortisol could be 
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initially controlled by immunising the animal against ACTH and then constantly 
replacing cortisol exogenously, so that the physiological levels are maintained. The 
pregnant ewe would then be anaesthetised at d62 and d82 and receive a control fetal 
injection simultaneously. This would prevent endogenous activation of the maternal 
HPA axis as a consequence of the physical interventions. If the adult phenotype is 
reversed through inhibition of the maternal HPA axis in this manner, then this would 
confirm that the phenotype is associated with secondary effects in the mother that may 
be mediated at the level of the placenta (647). If the phenotype is present in adult 
offspring then this is likely mediated through the activation of the fetal HPA axis.  
 
Alternatively, this could be studied directly in the fetus, by anaesthetising the mother and 
directly injecting the fetus with an inhibitor of cortisol synthesis such as metyrapone. 
This would identify if the phenotype arises from the exposure of the fetus to cortisol 
(that could come from the fetus or mother), if the phenotype was subsequently not 
observed in the fetal injection group plus cortisol inhibitor. By inducing raised 
endogenous cortisol through these treatment interventions and not exposing the mother 
to exogenous glucocorticoids such as dexamethasone, this would generate a model that 
examines the effects of physiological levels of this stress hormone on fetal development 
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The findings presented and discussed in this thesis highlight the remarkable plasticity and 
therefore vulnerability of the fetus to changes in the maternal and/or fetal environment. The 
Barker hypothesis highlights just how susceptible th  developing conceptus is to in utero 
programming effects which can lead to adult pathophysiologies (261, 262), including 
reproductive and metabolic anomalies that are associated with PCOS. The main findings 
from this study suggest that there are multiple effects of in utero programming on the 
developing fetus that pre-dispose offspring to develop the adult characteristics of PCOS. 
These features are likely to manifest in a clinical sense, either passively as the animal 
matures, or in circumstances in which the external e vironment influences such traits. This is 
of particular significance given the widespread incidence of poor lifestyle and obesity that is 
common today. Furthermore, it is evident that the underlying causes of disorders such as 
PCOS are not exclusively an effect of increased in utero exposure to sex steroids but could 
include a range of adverse fetal environments, including inappropriate exposure to the stress 
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To    100 
NSB  
290 (+10 stripped 
plasma [SP]) 
 100 
Bo  190 (+10 SP) 100 100 
Standards 
4-1000pg/100µl 
50 140 (+10 SP) 100 100 













To    100 
NSB  200 + 90 (+10 SP)  100 
Bo  100 + 90 (+10 SP) 100 100 
Standards 
1-2000pg/100µl 
100 90 (+10 SP) 100 100 













To    100 
NSB  300  100 
Bo  200 100 100 
Standards 
0.25-500pg/100µl 
100 100 100 100 













To    100 
NSB  300  100 
Bo  200 100 100 
Standards 
0.25-500pg/100µl 
100 100 100 100 
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Tracer  (µl) 
~20,000 cpm 
To    100 
NSB  300  100 
Bo  200 100 100 
Standards 
10-5000pg/100µl 
100 100 100 100 
QCs 100 100 100 100 











Tracer  (µl) 
~20,000 cpm 
To    100 
NSB  300  100 
Bo  200 100 100 
Standards 
5-2500pg/100µl 
100 100 100 100 











Tracer  (µl) 
~12,000 cpm 
To    100 
NSB  300  100 
Bo  200 100 100 
Standards 
0.06-64pg/100µl 
100 100 100 100 





Sample  or 
STD (µl) 
Buffer Supplied (µl) 
Antibody (µl) 
ready to use 
Tracer (µl) 
~14,000 cpm 
To    100 
NSB  300  100 
Bo  200 100 100 
Standards 
100-5000pg/100µl 
100 100 100 100 
QCs 100 200 100 100 
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Appendix B: ‘Data not shown’ from Chapter 4 
 
 
Figure AB.1  Immunohistochemistry for ER antibodies in sheep tissues. ERα antibody was 
strongly localised to the nuclei in cells of the adult sheep pituitary (A; 1:100, no tyramide 
enhancement required). However, ERα appeared to be non-specifically expressed 
throughout the ovarian stroma of the fetal ovary and this staining was not nuclear (B; 1:30, 
tyramide). Control sections for ERα  immunolocalisation were not completely negative (C, 
tyramide). Similarly, ERβ staining was demonstrated in the nucleus of granulosa cells of a 
small follicle in an adult sheep ovary (D; 1:50, no tyramide), and was strongly (E; 1/30, 
tyramide) but not specifically (F, tyramide) immunolocalised in fetal ovaries. Scale bars are 
all 50µm, except D) which is 200µm. 
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Figure AB.2  Gene expression in the d90 ovary of maternally androgenised fetuses. There 
was no change in the ovarian expression of FSHR (A), SLIT2 (B), SLIT3 (C), ROBO1 (D), 
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Figure AB.3  Id gene and protein expression in the d90 ovary of maternally androgenised 
fetuses. There was no change in Id2 (A), Id3 (B) or Id4 (C) mRNA expression, or Id2 (D), Id3 
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Figure AB.4  Gene expression in the d70 ovary of maternally androgenised fetuses. There 
was no change in the ovarian expression of AR (A), StAR (B), HSD3B1 (C), LHR (D), FSHR (E) 
ROBO2 (F) or ROBO4 (G). 
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Figure AB. 5  Gene expression in the d70 ovary of fetally androgenised fetuses. There was 
no change in the ovarian expression of AR (A), StAR (B), HSD3B1 (C), LHR (D), FSHR (E) 
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Figure AB.6  Id gene and protein expression in the d70 ovary of androgenised fetuses. In 
maternally and fetally treated fetuses, there was no change in Id1 (A and G), Id2 (B and H) 
or Id4 (C and I) mRNA expression, or Id1 (D and J), Id2 (E and K) or Id4 (F and L) protein 
expression in these ovaries. 
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Figure AC. 1 Data not shown from Chapter 9. Peripheral plasma analytes are shown for 
maternal (A-D) and fetal (E-H) androgenised cohorts for ALT, ALP, FFA and triglycerides, 
respectively. I) mRNA expression for IGF1R in livers from the fetally injected cohort.  
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